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Abstract 
 
Osteoarthritis (OA) is the most prevalent form of degenerative joint diseases 
and affects about 13% of the world’s population with patients over 65 years of 
age reflecting the largest group of patients (Matthews and Hunter 2011). OA 
is characterized by a progressive degeneration of joint cartilage and results in 
impaired function of affected joints, pain and negatively affects quality of life of 
patients. Several biomarkers for the detection of early OA were already 
described (Mobasheri 2013), but none of them is reliable and quantifiable. 
Therefore, a need for novel biomarkers for OA exists to improve diagnosis 
when overt changes in cartilage are not yet detectable. 
The aim of my thesis was to identify novel biomarkers for OA which can be 
used for early diagnosis. I focused on changes in the glycosylation of 
proteoglycans, especially on chondroitin sulphate (CS) glycosaminoglycan 
(GAG) chains. Using human chondrocyte progenitor cells, a novel 3D cartilage 
model was developed and characterized. The resulting cartilage constructs 
showed similar biochemical, histological and mechanical properties like native 
articular cartilage. To investigate the effects of inflammatory cytokines, which 
are also present in OA, on changes in expression of glycosylation-related 
genes, treated and untreated constructs were analyzed using microarrays. 
Analysis showed that although genes for GAG chain synthesis were down-
regulated, the sulphotransferase GalNAc4S-6ST was significantly up-
regulated. This enzyme catalyzes the formation of GalNAc4,6diS, which has 
high biological activity (Mikami and Kitagawa 2013). In addition, the expression 
of serglycin was strongly increased after inflammatory stimulation. These 
results show that novel epitopes containing GalNAc4,6diS or serglycin could 
be potential biomarkers for OA. 
Besides the experiments with cartilage constructs, analysis of the CS chain of 
decorin isolated from human skin fibroblasts showed that inflammatory 
stimulation alters the length and composition of CS chains. 
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1 Introduction 
 Arthritis 
Arthritis is a collective term for degenerative joint diseases, which can be 
subdivided by their cause. The most common forms of arthritis are 
osteoarthritis, rheumatoid arthritis and gout, but also lupus and psoriasis. In 
contrast to osteoarthritis, which is mainly caused by progressive joint 
deterioration through use, rheumatoid arthritis is a major autoimmune disease, 
characterized by active destruction of cartilage and bone (Abdel-Nasser et al. 
1997). The following paragraphs will focus on osteoarthritis and describe the 
disease in more detail. 
 
 Osteoarthritis 
Osteoarthritis (OA) is the most common form of arthritis and characterized by 
the degeneration of articular cartilage in joints. In Europe, one OA-damaged 
joint is replaced every 1.5 minutes (WHO Scientific Group 2003) and an 
estimated 1 million joints are replaced each year (Wood et al. 2013). In the 
Unites States it is predicted that 19 million people will be suffering from arthritis 
between 1995 and 2020 (Iorio et al. 2008). Mostly the weight-bearing joints of 
knee, hip, and lower spine are affected by OA, and to a lower extent feet and 
hands. It occurs when the dynamic equilibrium of breakdown and regeneration 
of joint tissue becomes unbalanced by outside influences, for example when 
the load-bearing capacity of a joint is exceeded (Eyre 2004). During the 
progression of the disease, the articular cartilage becomes more and more 
eroded, and this ultimately leads to complete loss of cartilage in weight bearing 
areas of the joint. This results in loss of motility of the affected person and can 
be very painful. 
In an early stage of OA, chondrocytes from the articular cartilage form clusters 
through clonal expansion at the damaged site and the concentration of 
angiogenic growth factors in the extracellular matrix increases (Goldring 2000; 
Aurich et al. 2005). Repair fails and leads to an imbalance in the matrix, which 
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results in degradation. Increasing concentrations of matrix destructive 
proteases like matrix-metalloproteases (e.g. MMP-13) and aggrecanases 
(ADAMTS-4 & -5) (Karsenty 2005; Burrage et al. 2006), increasing apoptosis 
of chondrocytes and altered synthesis of matrix components lead to the 
formation of a matrix that is unable to bear normal mechanical stresses. As a 
result, the tissue enters a vicious cycle where matrix breakdown outweighs 
synthesis and regeneration. Because of the aneural nature of cartilage, 
patients have no symptoms until surrounding neural tissue of the bone 
becomes affected (Bijlsma et al. 2011). However, recent evidence shows that 
OA is not only cartilage-driven, but that also synovial tissue and bone play an 
important role. Synovial inflammation is evident in OA (Sellam and Berenbaum 
2010) and may lead to generation of neurotransmitters and ultimately pain. 
In synovial inflammation, proinflammatory and catabolic mediators are 
produced by synovial macrophages and negatively alter the balance between 
degradation and generation of cartilage matrix, leading to an excessive 
production of proteolytic enzymes that degrade cartilage matrix. Due to this, 
synovial inflammation in turn is amplified (Bondeson et al., 2006). Synovial 
inflammation can occur in early and late stages of OA and contributes to the 
vicious cycle of progressive joint degeneration (Bijlsma et al. 2011). 
The main factors for the development of OA are excessive loading of joints 
due to obesity, aberrant joint alignment, peak forces and joint injury in sport, 
as well as wear and tear of joints during a lifetime. Age is therefore considered 
to be a main factor. It has been shown that the prevalence of OA affects a 
large proportion of all people above the age of 65 (Badley and Wang 1998). 
However, injuries and the presence of a genetic predisposition can promote 
the development of OA (Balint and Szebenyi 2000). Moreover, women are 
more often affected than men, which indicates a sex-specific predisposition. 
OA is commonly associated with changes in the subchondral bone of the 
affected joint. This can be the formation of osteophytes, bone remodeling, 
subchondral sclerosis and attrition. These are all important features for the 
radiographic diagnosis of the disease. Due to the fact that some of these 
changes not only occur in the later stages of OA, but also even before cartilage 
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degradation, it is suggested that subchondral bone changes could be an 
initiating or major contributing factor for OA (Intema, Hazewinkel, et al. 2010; 
Intema, Sniekers, et al. 2010).  
Usually patients see a doctor when they have symptoms like joint pain and 
loss of movement and function. These are typically experienced by patients 
with well-established disease and hence, substantial cartilage damage may 
already have occurred. Pain occurs occasionally, but is typically worst during 
and after a period of weight-bearing activities. Stiffness in the morning and 
evening is another symptom often experienced by patients suffering of OA. It 
occurs after longer inactivity of the joint, e.g. in the morning after sleep and in 
the evening and usually resolves in a couple of minutes. Additional features 
that can be associated with OA are psychological in nature like depression and 
unsound sleep, which worsen the quality of a patient’s life (Bijlsma et al. 2011). 
Differences between a healthy and osteoarthritic knee joint are illustrated in 
figure 1.1. 
 
Figure 1.1 Comparison of a healthy and osteoarthritic (OA) knee joint. The OA joint is 
characterized by inflamed synovium, degraded cartilage and formation of osteophytes. 
Reprinted by permission from Macmillan Publishers Ltd: [Nature reviews. Drug discovery.] 
(Wieland H, Michaelis M, Kirschbaum B, Rudolphi K “Osteoarthritis - an untreatable disease?” 
Volume 4, Issue 4, Pages 331-344), copyright (2005). Link to the journal.  
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 Diagnosis of OA 
Diagnosis of OA must be carried out carefully to exclude pain and functional 
symptoms of other origins. Therefore, the site of joint pain has to be carefully 
evaluated. For example, patients with hip OA often feel pain in the 
corresponding knee. Based on this, spine and neurological examination is 
often required. To identify the source of pain, serological tests that screen for 
the presence of anti-cyclic citrullinated peptide antibodies or uric acid can be 
used to exclude rheumatoid arthritis and gout (Majithia and Geraci 2007). It is 
very difficult to correctly assess the severity of joint damage in OA without 
using imaging techniques. The use of biopsies for histological and biochemical 
analysis of cartilage, and bone is not feasible, since the tissue changes that 
occur are often focal and could be missed by taking random biopsies. 
Moreover, taking a biopsy would in itself cause irreversible damage to the joint 
cartilage. Imaging of the joint cartilage is rarely used to confirm the diagnosis 
of OA, but is a useful tool to establish the severity of the joint damage and 
monitor the progression of the disease (Bijlsma et al. 2011).  
Imaging of OA currently relies on conventional radiography. This technique is 
cheap, fast and easy to perform with minimal risk for the patient. However, 
restrictions are that only calcified bone can be visualized, giving an indirect 
measurement of cartilage thickness, and without providing any information on 
the synovial tissue (Bijlsma et al. 2011). Several classification models based 
on radiography have been developed (Kellgren and Lawrence 1957; Altman 
and Gold 2007), which are used to grade the progression of OA in several 
joints. The grading systems are based on the formation of osteophytes, joint-
space narrowing and bone sclerosis. Other than radiography, more advanced 
imaging techniques are available for a more detailed visualization of 
osteoarthritic joints. These are magnetic resonance imaging (MRI), computer 
tomography (CT) and ultrasound (Bijlsma et al. 2011). CT provides a three-
dimensional image and uses contrast agents, which allows visualizing 
cartilage next to bone. Nevertheless, the high radiation exposure of the tissue 
is a major disadvantage. By using ultrasound, even soft tissues such as 
synovial tissue can be visualized in several planes without contrast agents. 
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However, limitations of this technique are the depth rapid loss of resolution 
with increasing depth of tissue penetration. MRI allows the quantitative 
assessment of morphology (volume, and thickness) and integrity of cartilage 
(Eckstein et al. 2005; Eckstein et al. 2006). By providing a large number of 
different imaging sequences and scoring systems, it is a very valuable 
technique to monitor the state of joint damage. Nonetheless, high costs and 
time consuming image acquisition and analysis of the data are limiting factors 
for its applicability. Various different specialized imaging modes for MRI have 
been developed which give a more complex view into cartilage quality. T2 MRI 
relaxation time for example allows determining the collagen orientation and 
density of cartilage (Dunn et al. 2004; Regatte et al. 2006). In addition, T1ρ 
MRI can be used to map proteoglycan distribution in cartilage (Menezes et al. 
2004; Borthakur et al. 2006). The difference between T1 and T2 MRI is that 
different aspects of the proton spins are measured. Therefore, some tissues 
can be visualized with a higher or lower resolution, which is strongly influenced 
by the individual water content. 
 
 Biological markers for osteoarthritis 
Biochemical markers might help to understand the pathophysiology of OA and 
help in diagnosing OA. They are generally molecules or catabolic products 
released by the joint into body fluids (blood, urine and synovial fluid): for 
example, remnants from extracellular matrix turnover (collagen and 
proteoglycan fragments) and changes in cellular metabolism (collagen 
synthesis byproducts, proteases, cytokines) derived from articular cartilage, 
synovial tissue and subchondral bone (Mobasheri 2012). To date, MMP-3 in 
serum and collagen II C-telopeptide (CTX-II) in urine are the best 
characterized commercially available biomarkers (Kraus et al. 2011). They 
have been tested extensively and show expected relations to radiological and 
clinical findings in OA. Additional markers, which are still under investigation, 
include further collagen synthesis byproducts (CPII and PIICP in serum) or 
degradation products (C2C, Col2-1 and Col2-1NO2 in serum and urine), 
proteoglycans (cartilage oligomeric matrix protein in serum, aggrecan CS846 
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epitope in serum), glycosaminoglycans (hyaluronic acid and keratan sulphate 
content in serum) and finally markers of bone resorption (CTX-1 and NTX-1). 
However, none of the so far available biomarkers is indicative on its own for 
the prognosis and diagnosis of OA. Especially in an aged population, changes 
in protein turnover can have many different reasons which leads to a relatively 
low specificity of a single marker. It is suggested that for a correct diagnosis of 
the stadium of disease progression, a combination of several biomarkers 
together with imaging techniques will be needed (Goldring and Goldring 2007). 
For all biomarkers, substantial variations in baseline levels exist between 
individuals. Furthermore, there is a lack of adequate knowledge about 
systemic origin, metabolism and kinetics for many markers (Bijlsma et al. 
2011). Given the age profile of the population in many western countries, there 
is a pressing need for reliable, simple to attain and cost effective biomarkers 
for OA (Kraus et al. 2011), especially for the diagnosis and patient stratification 
in an early stage, when overt changes in the joint have not occurred, and 
therefore the disease may be modified through intervention. 
 
 Current treatment of osteoarthritis 
There is no cure for OA. However, many different surgical procedures, and cell 
and tissue transplantation methods have been proposed to promote the 
regeneration or repair of the articular cartilage in situ (Buckwalter 1997; Dewan 
et al. 2014). For the management of OA, there are three treatment modalities 
available: non-pharmacological, pharmacological and surgical. For most 
patients, a combination of these options is used, tailored to the individual 
needs of the patient. Regarding non-pharmacological options, physiotherapy 
and exercise, joint protection, weight loss and other modalities for reducing the 
weight on the damaged joint have shown a positive effect (W. Zhang et al. 
2007; Zhang et al. 2008). Paracetamol is the first choice analgesic to reduce 
joint pain. However, if this does not prove to be efficient, non-steroidal anti-
inflammatory drugs (NSAIDs) are another option (Hunter 2011a). In recent 
years, a new drug type called DMOADS (disease-modifying OA drugs) has 
emerged (Hunter 2011b). DMOADS are modifying the progression of OA by 
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slowing down or preventing cartilage degradation or synovial inflammation. To 
give a few examples, inhibitors of IL-1, nitric oxide synthase or matrix 
metalloproteases (Hunter 2011b) belong to the group of DMOADS. 
Surgical options of OA treatment are the intra-articular injection of bioactive 
compounds such as glucocorticoids, which are an effective tool for treating 
inflammatory flares of OA (Bellamy et al. 2006). Principal surgical treatments 
are osteotomy to correct the joint alignment, micro fracture, cartilage 
transplantation, and autologous chondrocyte transplantation (ACI). ACI 
describes the removal of a small amount of intact cartilage from a non-load-
bearing region of articular cartilage for the extraction of intact chondrocytes. 
The cells are expanded ex vivo and transferred back into the patient once a 
sufficient number of cells was generated (Dewan et al. 2014). The expanded 
chondrocytes are then transferred into the cartilage lesion of the patient.  
To date, severely damaged cartilage cannot be repaired using the above 
described techniques. The only possible way to restore mobility of the patient 
is total knee arthroplasty (Buckwalter 1997). The replacement of the affected 
joint has proved to be very effective, but can only be carried out beyond a 
certain age due to the limited life span of the joint prosthesis. Young patients 
will require a replacement prosthesis after several years, but this may be less 
successful because the prosthesis can be replaced only about two times in 
total for each joint due to changes in the underlying bone structure. 
 
 Chondrocytes and cartilage 
Chondrocytes are the sole cell-type present in cartilage. As a consequence, 
cells are at a considerable distance to neighboring cells and the tissue lacks a 
vascular and neural connection. Therefore, the main nutrition/waste exchange 
is achieved by diffusion and fluid movement, when cartilage is compressed 
and expanded during joint movement. To overcome the resulting low oxygen 
tension inside cartilage (10% at the surface layer and <1% in deep layers), 
chondrocytes cover their energy requirements by glycolysis and therefore, 
they normally contain comparably small numbers of mitochondria (Archer and 
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Francis-West 2003). Chondrocytes are generally round cells, except at tissue 
boundaries where they have a discoid or flattened shape, like at the surface of 
articular cartilage. The main functions of chondrocytes is synthesis and 
maintenance of the extracellular matrix of supporting structures like articular, 
tracheal and nasal cartilage in order to resist mechanical strain (Archer and 
Francis-West 2003). During development, chondrocytes form cartilage and 
subsequently epiphyseal growth plates that allow for longitudinal growth of 
bones during postnatal development. This is achieved by chondrocytes in 
three different ways: through rapid proliferation and differentiation of cells, 
through secretion of matrix proteins, matrix mineralization and regulation of 
angiogenesis and through programmed cell death (Goldring 2012).  
The extracellular matrix surrounding chondrocytes can be divided into three 
distinct areas (Fig. 1.2). Firstly, the pericellular zone that directly surrounds the 
cell, and contains molecules that directly interact with cell surface receptors, 
for example hyaluronic acid binding to CD44. It is also rich in proteoglycans 
(predominantly aggrecan, but also SLRPs like decorin, biglycan, lumican and 
fibromodulin to a lower extent) and non-collagenous proteins like the cell 
membrane associated molecule anchorin CII and microfibril-forming collagens 
like collagen type VI (Mollenhauer et al. 1984; Hagiwara et al. 1993). Moreover, 
it contains little to no fibrillar collagen. Next is the territorial zone, which 
surrounds the pericellular zone. Collagen fibers situated at various angles form 
a fibrillar basket around the chondrocytes, which may provide mechanical 
protection (Buckwalter and Mankin 1998). Finally, the interterritorial zone has 
the furthest distance to the cell. It fills out most of the space in cartilage and 
contains collagen fibrils of large diameter as well as large aggregates of 
aggrecan and hyaluronic acid (Heinegård and Saxne 2011). 
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Figure 1.2 Composition of the chondrocyte extracellular matrix (ECM). The ECM is 
divided into the pericellular, territorial and interterritorial zone. Each zone has a distinct protein 
composition which results in specific functions in the ECM. Proteins involved in cell attachment 
to ECM (fibronectin, syndecan and CD44) are found in the pericellular zone. Aggrecan and 
other proteoglycans (decorin, biglycan, fibromodulin) are present in all three zones. Matrilins 
(1 and 3), and collagen molecules (type II, VI, IX, XI) can be found predominantly in the 
territorial and interterritorial zone.  
Reprinted by permission from Macmillan Publishers Ltd: [Nature reviews. Rheumatology.] 
(Heinegård D, Saxne T “The role of the cartilage matrix in osteoarthritis” Volume 7, Issue 11, 
Pages 50-56), copyright (2011). Link to the journal. 
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Cartilage found at different body sites is distinct, both due to differences in 
embryonic origin of the cells as well as environmental conditions. Articular 
cartilage covers the bone surface in synovial joints and is biochemically 
different from other cartilage. It has a low cell to matrix ratio: in humans 
cartilage contains approx. 1% cells (Stockwell 1967). It is responsible for the 
weight-bearing abilities of articular joints and therefore a painless movement. 
Articular cartilage is comprised of several zones (Fig. 1.3). Starting from the 
surface, there is the superficial zone which contains discoid chondrocytes and 
well-ordered collagen fibers. It is also the thinnest zone, consisting of two 
layers: a sheet of fine fibrils, which is also called lamina splendens, and the 
cell-containing layer. Relative to other layers, the matrix composition of the 
superficial layer shows high fibrillar content and little proteoglycan content. In 
addition, water and fibronectin concentrations are also highest in this layer. 
The collagen fibrils are arranged parallel to the joint surface, providing more 
tensile stiffness and strength than deeper zones. It has also been suggested 
that the superficial layer protects the cartilage matrix from the immune system 
due to its function as a barrier for large molecules from synovial fluid 
(Buckwalter and Mankin 1998). Below the superficial zone lies the middle 
zone. It has several times the volume of its overlying layer and contains 
chondrocytes of spheroidal shape, which produce a matrix rich in collagen 
fibrils with large diameters. Moreover, a higher concentration of proteoglycans 
and lower concentration of water than in the superficial zone can be found 
(Buckwalter and Mankin 1998). The zone below the middle zone is called deep 
zone and contains spherical chondrocytes, which accumulate together vertical 
to the joint axis. This zone contains the largest collagen fibrils and highest 
concentration of proteoglycans. This is followed by the zone of calcified matrix, 
which is directly on top of subchondral bone (Hayes et al. 2007). The 
chondrocytes of this zone have a smaller volume and appear to be completely 
surrounded by calcified cartilage (Buckwalter and Mankin 1998). 
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Figure 1.3 Cellular organization of articular cartilage. Articular cartilage is organized in four 
different zones, starting with the superficial zone at the top, followed by the middle zone, deep 
zone and finally the calcified zone. Each zone is characterized by a unique organization of 
collagen fibers and chondrocytes. The subchondral and cancellous bone provides a strong 
base for articular cartilage.  
Reprinted from Advanced Materials, Volume 24, Issue 36, Pages 4995 – 5013, Authors: Fong 
E., Watson B., Kasper F., Mikos A.; “Building bridges: leveraging interdisciplinary 
collaborations in the development of biomaterials to meet clinical needs.”, Copyright (2012), 
with permission from John Wiley and Sons. 
 
(Fong et al. 2012) 
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 Chondrocyte progenitor cells 
Chondrocyte progenitor cells are a population of adult mesenchymal stem 
cells, residing in the superficial zone of articular cartilage. They are capable of 
differentiating into a chondrogenic, osteogenic or adipogenic lineage, 
becoming chondrocytes, bone cells or adipocytes, respectively. This cell 
population was initially discovered and isolated by Dowthwaite et al. (2004), 
using differential fibronectin adhesion. The principle of this method is that the 
progenitor cells are more rapidly and strongly adhering to a fibronectin-coated 
surface due to high levels of expression of 51 integrin (Jones and Watt 
1993). In contrast to normal full-depth chondrocytes which lose their 
chondrogenic potential after 8 population doublings (PD) (Dell’Accio et al. 
2001; Schnabel et al. 2002; Cournil-Henrionnet et al. 2008), chondrocyte 
progenitor cells keep their chondrogenicity even after extensive culture in 
monolayers and a high number of PD, without losing the chondrocyte specific 
transcription factor SOX9 (Williams et al. 2010).  
 
 Cartilage extracellular matrix 
The extracellular matrix (ECM) found in cartilage is a complex composite of 
macromolecules, which are capable of self-assembly, mostly by non-covalent 
bonds. The major components are collagens, elastin, hyaluronic acid, non-
collagenous glycoproteins and proteoglycans (Gentili and Cancedda 2009; 
Heinegård and Saxne 2011). The ECM surrounds the cells and serves as a 
scaffold. The organization of collagen fibrils into a fibrillar meshwork provides 
elasticity and mechanical strength and provides a substrate for cell migration 
and adhesion. In addition, it creates a barrier for cell penetration and filtration 
of macromolecules (Hocking et al. 1998; Kresse and Schönherr 2001). The 
ECM is also a reservoir of growth factors and modulates their activity. By 
interacting with matrix molecules, growth factors become sequestered from 
their signaling receptors, potentially activated by proteolytic processing and 
presented to the cells in a specific conformation or in the context of ECM 
components. There is evidence that ECM molecules can also exhibit a potent 
direct signaling function by interacting with matrix receptors like integrins or 
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through growth factor receptors themselves (Ornitz 2000; Schönherr and 
Hausser 2000; Kresse and Schönherr 2001). 
 
 Collagen 
Collagens are an essential component of ECM in many tissues. They provide 
stability to the matrix and are important for the mechanical properties and 
stiffness of the tissue (Hulmes 2008). Collagen molecules are trimeric, being 
composed of three alpha chains. Roman numerals are used to classify 
collagens based on the order of discovery and structural homology (Birk and 
Bruckner 2011). The chains form a triple helical structure, which can be up to 
300 nm long in the case of fibril forming collagens type I, II and III. The 
individual chains are characterized by a repeating (Gly-X-Y)n motif, with X and 
Y being any amino acid but often proline and hydroxyproline (Birk and 
Bruckner 2011). In addition to hydroxyproline, hydroxylysine is also found in 
collagens. Both unique amino acids are important for triple helix stability. One 
turn of the alpha chain helix is composed by only three amino acids. It has the 
shape of a left handed helix, whereas the triple helix has a right handed twist.  
Collagens are synthesized as procollagens, containing N- and C-terminal 
propeptides. This was assumed to prevent the formation of collagen fibrils 
inside the cell although recent data from Kadler and colleagues suggest that 
fibrillogenesis may occur in specialized intracellular compartments (Canty-
Laird et al. 2012). After translation at the ribosomes, the procollagen alpha 
chains are post-translationally modified in the endoplasmic reticulum (Hulmes 
2008). Prolyl- and lysyl-hydroxylases form hydroxyproline (mostly to proline at 
the Y position) and hydroxylysine (only to lysine in the Y position), respectively. 
Hydroxylysine can be modified through addition of monosaccharides. After 
these modifications, folding of the triple helix starts from the C-terminal 
propeptides to the N-terminal part of the molecules. By passaging through the 
Golgi system, the triple helix is further modified through addition of 
oligosaccharides. Finally, N- and C-terminal propeptides are cleaved off by 
proteases (for example ADAMTS-2/-3/-14, BMP-1), and the collagen 
molecules assemble into fibrils. The resulting supramolecular structures are 
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further cross-linked by lysyl oxidases, which provides additional mechanical 
stability. Interestingly, a recent paper by Bruckner and colleagues 
demonstrated transglutaminase crosslinks in mature collagen fibrils (Wang et 
al. 2014). The fibrils can contain many different types of collagen molecules. 
In cartilage, collagen type II is the predominant fibril forming collagen (Eyre 
2002). These collagen fibrils also contain collagen type IX and XI (Mendler et 
al. 1989; Bruckner et al. 1985). Furthermore, several non-collagenous proteins 
like COMP and the SLRPs decorin, biglycan and fibromodulin are involved in 
regulation and organization of fibrillar growth (Birk and Bruckner 2011). An 
additional type of collagen only found in cartilage is type X collagen. It belongs 
to the group of network-forming collagens and is associated with chondrocyte 
hypertrophy and mineralization (Birk and Bruckner 2011). 
 
 Proteoglycans 
Proteoglycans are proteins that contain one or more glycosaminoglycan chain 
attached to their core protein (Esko et al. 2009). Most proteoglycans also 
contain N-linked oligosaccharide branches. Cartilage contains two major 
classes of proteoglycans. On the one hand there are large aggregating 
proteoglycans with >100 GAG chains like aggrecan, on the other hand small 
leucine-rich proteoglycans (SLRPs) like decorin, biglycan, lumican and 
fibromodulin, which contain only a small number of GAG chains (Buckwalter 
and Mankin 1998). About 90 percent of total cartilage proteoglycans are made 
up by aggrecan, filling most of the interfibrillar space. Aggrecan contains GAG 
chains made from chondroitin sulphate and keratan sulphate, whereas SLRPs 
are variably glycanated in a tissue specific manner with either chondroitin 
sulphate or dermatan sulphate (decorin, biglycan) or keratan sulphate 
(lumican, fibromodulin). 
 
 Aggrecan 
The predominant large proteoglycan found in cartilage is aggrecan. Next to 
collagen type II, it is one of the major components of articular cartilage ECM. 
15 
 
The core protein is composed of 3 globular domains (G1-G3), an interglobular 
domain (IGD) and attachment sites for chondroitin sulphate and keratan 
sulphate chains. The fully processed protein contains about 100 chondroitin 
sulphate chains and about 50 keratan sulphate chains (Wight et al. 2011). Its 
name relates to its ability to form large aggregates through binding to 
hyaluronic acid chains within the extracellular matrix. Aggrecan binds non-
covalently to hyaluronic acid through its N-terminal G1 domain in combination 
with link protein, forming large proteoglycan aggregates (Buckwalter and 
Rosenberg 1982; Buckwalter and Rosenberg 1983). Link protein is an 
important factor involved in the binding of aggrecan to hyaluronic acid. Mouse 
studies have shown that knock-down of link protein results in deformed limbs 
and early postnatal death (Czipri et al. 2003), probably because of insufficient 
ECM organization. The large aggregates comprised of aggrecan and 
hyaluronic acid are compressed within the collagen type II network to about a 
third of their normal volume. This leads to an enormous charge density 
resulting from the sulphate esters and carboxyl groups within chondroitin 
sulphate and to a smaller extent keratan sulphate. The attracted water 
molecules together with the constrained GAG chains create a large swelling 
pressure on the collagen network (Wight et al. 2011). This leads to 
compressibility of the tissue and excellent resilience to load of the cartilage 
ECM, which is ultimately the major function of the tissue. 
 
 Small Leucine-Rich Proteoglycans 
The group of small leucine rich proteoglycans (SLRP) is part of the LRR 
(leucine-rich repeat proteins) superfamily. In general they are defined by a 
degenerate consensus sequence which is characterized by leucins in 
conserved positions: x Lx x N ± x a x x ± a ± ± ± ± a ± ± x ± ±, where L is 
leucine or isoleucine, N is asparagine (but can also be substituted with 
threonine or cysteine), x is any amino acid, ± indicates a loose requirement for 
an amino acid and “a” indicates an aliphatic amino acid (Kobe and Deisenhofer 
1994). Repeats can have a length between 20-29 amino acids, but most 
common are 24 amino acids. SLRPs additionally possess a unique N-terminal 
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domain, which is flanked by cysteine clusters and contains four similarly 
spaced cysteine residues within a 20 amino acid stretch at its N-terminal end, 
forming disulphide bonds. At its C-terminal end, two cysteine residues are 
forming an intra-chain disulphide bond. Every member of the SLRP family has 
a terminal LRR domain, which runs through the C-terminus of the individual 
protein, and therefore does not satisfy the requirements of a true repeat. 
However, it has been suggested that the repeats that reside between the 
cysteine clusters are the ones that are functionally and structurally important 
(Hocking et al. 1998). 
The SLRP gene family has expanded over the last decades and includes 17 
proteins (Iozzo 1997; Hocking et al. 1998; Iozzo 1999). Even though not all of 
them contain at least one GAG chain, they all share a common functionality. 
They are classified into five distinct groups based on homology and 
conservation at the genomic and protein level and their specific N-terminal 
cysteine-rich clusters (Table 1.1) (Schaefer and Iozzo 2008). 
An additional typical structural feature of SLRPs is the so-called “ear repeat” 
motif. Decorin, for instance, contains this structure, which is made of the 11th 
LRR that extends laterally from the main body at the C-terminal end, where a 
cysteine forms a disulphide bond with a second cysteine in the 12th LRR 
(McEwan et al. 2006). All class I-III SLRPs contain the ear-repeat, but not class 
IV and V. Therefore, it was suggested that this specific feature is an indicator 
for the “true” SLRP family. Nevertheless, this is true only on a structural, but 
not functional level. For example, tsukushi (class IV) is like biglycan (class I) a 
potent modulator of bone morphogenic protein (BMP) (Chen et al. 2004; Ohta 
et al. 2004; Moreno et al. 2005). Podocan (class V) inhibits cell growth and 
binds to collagen type I like some of the class I-III proteins (Shimizu-Hirota et 
al. 2004). 
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Table 1.1 Overview of small leucine-rich proteoglycans (SLRP). Members of the same class 
share the cysteine-rich cluster consensus sequence. Adapted from Schaefer et al. (2008). 
SLRP class Proteins 
Cysteine-rich 
cluster consensus 
I Decorin, Biglycan, Asporin Cx3CxCx6C 
II 
Fibromodulin, Lumican, PRELP, Keratocan, 
Osteoadherin 
Cx3CxCx9C 
III Epiphycan, Opticin, Osteoglycin Cx2CxCx9C 
IV Chondroadherin, Nyctalopin, Tsukushi Cx3CxCx6-17C 
V Podocan, Podocan-like protein 1 Cx3-4CxCx9C 
 
1.9.2.1 SLRP class I proteins 
The group of class I SLRPs consist of decorin, biglycan and asporin. Their N-
terminal cysteine cluster forms 2 disulphide bonds. Decorin and biglycan 
contain one and two chondroitin / dermatan sulphate chains, respectively, in 
contrast to asporin, which lacks the xylosyltransferase consensus sequence 
and therefore harbours no GAG chain. That is why it is not a proteoglycan. 
One general feature of all class I SLRPs is the similar exonic organization of 
the eight exons with conserved intron/exon junctions (Schaefer and Iozzo 
2008). The amino acid sequence of asporin contains a stretch of asparagine 
residues, which forms a negatively charged acidic domain that can also be 
found in osteoadherin (class II), epiphycan (class III) and podocan (class V). 
Decorin, biglycan, and asporin are commonly expressed in cartilage. 
 
1.9.2.2 Decorin 
Decorin is a biologically active component of the ECM and not just a structural 
protein (Merline et al. 2009). It is ubiquitously expressed throughout tissues 
but is post-translationally modified in a tissue specific manner and was first 
cloned from a human embryonic fibroblast cell-line (Oikarinen et al. 1989). 
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There are various names for it like PG40 (due to the mass of its core protein, 
~40 kDa), PG-S2, bone proteoglycan-II, small leucine-rich-proteoglycan-1B, 
dermatan sulphate proteoglycan-II, but many of them are not used anymore 
(Chen and Birk 2011). Its molecular size is about 100 kDa, which includes the 
attached GAG chain and the core protein. Human decorin consists of 359 
amino acids that fold into 12 tandem leucine-rich repeat (LRR) domains, which 
are flanked by cysteine-rich loops (Fig. 1.4, 1.5). The twelve LRRs are what 
give decorin a curved solenoid, horseshoe-like shape with a parallel β-sheet 
on the inner concave surface (Fig. 1.5). In addition, decorin contains a 
structural feature called “ear repeat”, as described above. This is thought to 
contribute to the folding of the 12th LRR and may also be involved in ligand 
recognition (Chen and Birk 2011). Its pre-propeptide contains a 16 amino acid 
signal sequence, which leads the translating protein into the ER where it is 
cleaved co-translationally. Next, the propeptide, which is composed of 14 
amino acids, regulates the attachment of the GAG chain. Both core protein 
and GAG chain contribute to the biological function of decorin (Seidler and 
Dreier 2008). Decorin can be substituted with two GAG chains in some 
species, but only one is found in decorin of mammals. One chain, either of 
chondroitin sulphate or dermatan sulphate type, depending on the tissue, is 
covalently attached to a serine-residue (Ser34) in the N-terminal part of the 
human protein (Seidler and Dreier 2008). Traditionally, dermatan sulphate is 
found in soft tissues (e.g. skin) and chondroitin sulphate in musculoskeletal 
tissue (e.g. bone and cartilage), although dermatan sulphate is also found 
during the early stages of bone and predentine formation (Waddington et al. 
2003). In addition, three N-glycosylation sites are present (Glössl et al. 1984). 
It is thought that N-glycosylation contributes to folding and secretion of the 
protein (McEwan et al. 2006). In its function as a matrix proteoglycan, decorin 
regulates lateral growth and therefore diameter of collagen fibrils. It 
“decorates” the collagen I fibrils by binding to their “d” or “e” bands (Scott and 
Parry 1992). Decorin slows down assembly of collagen fibrils, resulting in a 
reduction in fibril diameter, at least in vitro (Vogel et al. 1984). Decorin also 
binds to other collagens, e.g. type I, II, III, IV, VI, and XIV (Bidanset et al. 1992; 
Ehnis et al. 1997; Santra et al. 2002). In vivo, decorin was detected in the 
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interterritorial region around chondrocytes in articular cartilage, being 
preferentially associated with thicker fibrils, whereas it was absent on the 
thinner fibrils in the territorial region (Hagg et al. 1998). Besides its regulatory 
function in fibril formation, decorin also acts as a bridging molecule between 
collagen types I and VI, where it interacts with both collagens via different 
binding sites (Nareyeck et al. 2004). Furthermore, it was shown that a complex 
of decorin and matrilin-1 can act as a bridge between collagen type II and VI 
fibrils, whereby decorin binds to the globular N-terminal domain of collagen 
type VI (Wiberg et al. 2001). 
Decorin not only serves as a structural element in the ECM, but its core protein 
also serves as a signalling molecule. It is a ligand for the insulin-like growth 
factor receptor (ILGFR) (Schönherr et al. 2005) and the epidermal growth 
factor receptor (EGFR) (Seidler et al. 2006). While decorin activates the IGFR-
Akt signalling axis, it has been reported to block the EGF-R signalling in 
cancer. Therefore it has been proposed as a potential therapeutic agent in 
cancer treatment (Seidler et al. 2006; Neill et al. 2012).  
It has long been known that decorin regulates cellular growth (Yamaguchi et 
al. 1990). This is mediated by its ability to engage the above receptors, 
influencing regulation at certain checkpoints in the cell cycle (Merline et al. 
2009). A TGF-β-dependent inhibition of Chinese hamster ovary (CHO) cells 
(Yamaguchi et al. 1990), arterial smooth muscle cells (Fischer et al. 2001), 
human hepatic stellate cells (Shi et al. 2006) and fibroblasts (Zhang et al. 2007) 
were also observed. 
It was reported that some SLRPs dimerize with high affinity (Scott et al. 2004; 
McEwan et al. 2006), but this may be true only in vitro and not in vivo. They 
are more likely to be monomeric with regards to their biological function 
(Goldoni et al. 2004). For instance, the binding site for collagen type I in the 
concave shape of decorin’s LRR6 (Kalamajski et al. 2007) would not be 
accessible in a dimeric decorin. Moreover, in regards of the dimensions of the 
decorin core protein (Scott et al. 2004), a decorin dimer would not fit into the 
EGFR binding groove. However, a detailed understanding of monomer-dimer 
transition and its regulation is outstanding to fully answer this question. A 
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possible situation for SLRPs undergoing monomer-dimer transitions is the 
exposure of their specific binding sites. As a result, the functional activity of a 
SLRP would be regulated by the intrinsic affinity for its cognate receptor and 
this could contribute to specialization and functional differentiation (Santra et 
al. 2002; McEwan et al. 2006; Schaefer and Iozzo 2008).  
In the decorin-knockout mouse, collagen type I fibrils are irregular, showing a 
cross-sectional contour presenting notches and frequent protuberances 
(Danielson et al. 1997; Corsi et al. 2002; McEwan et al. 2006; Schaefer and 
Iozzo 2008). As a consequence, the skin is fragile, has a markedly reduced 
tensile strength and the dermis is thinner compared to the wild type. This 
phenotype is similar to the fragile skin observed in humans suffering from 
Ehlers-Danlos syndrome (EDS) (Danielson et al. 1997). EDS is a 
heterogeneous syndrome, which involves skin hyperflexibility, joint 
hypermobility and tissue fragility of different severity depending on the 
underlying genetic defect / EDS type (Mao and Bristow 2001). The decorin-
knockout mouse also shows a random orientation of collagen fibrils in the 
periodontal ligament (Hakkinen et al. 2000), which underlines the regulatory 
role of decorin in collagen fibril organization. 
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Figure 1.4 Schematic structure of the class I SLRP decorin. It contains a signal peptide (SP, 
cyan), propeptide (PP, pink), and two cysteine rich domains (yellow) flanking the 12 leucine-
rich repeat domains (blue and yellow, respectively). Signal- and propeptide are removed prior 
to secretion. One GAG chain of the chondroitin / dermatan sulphate type is attached to a serine 
residue in the N-terminal part. In addition, three N-linked oligosaccharides can be found on 
leucine-rich repeat domains. Based on Chen et al. (2001). 
 
 
Figure 1.5 Crystal structure of decorin (PDB #1XKU). Leucine-rich repeat domains (LRRs, 
green) are flanked by N- and C-terminal cysteine-rich domains (red). Decorin adapts a curved 
shape that has been described as horseshoe-like in some literature, but the actual structure 
is too rigid to undergo bending to such an extent. The figure was prepared using Pymol 
software package (Schrödinger 2010) and data set #1XKU from the PDB (www.pdb.org) 
created by Scott et al. (2004).(Schrödinger 2010) 
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1.9.2.3 SLRP class II proteins 
The class of type II SLRPs consist of 5 proteins: fibromodulin, lumican, PRELP, 
keratocan and osteoadherin. Apart from osteoadherin, all proteins are 
expressed in cartilage. One feature that distinguishes this class from others is 
the presence of sulphated tyrosine residues in their N-terminal domain, which 
could contribute to the polyanionic character of SLRPs (Ameye and Young 
2002; Corsi et al. 2002; Goldberg et al. 2003). They mostly contain KS and 
polylactosamine, a non-sulphated variant of KS. The genes of class II SLRPs 
have a similar exonic organization of 3 exons, and a large exon that encodes 
most of the LRRs (Schaefer and Iozzo 2008).  
 
1.9.2.4 SLRP class III proteins 
Epiphycan, opticin and osteoglycin embody the group of class III SLRPs. 
These proteins are characterized by a genomic organization of seven exons 
and a number of six LRRs (Schaefer and Iozzo 2008). Like class II SLRPs, 
their N-terminal domain contains sulphated tyrosine residues (Ameye and 
Young 2002). All three proteins are expressed in cartilage. 
 
1.9.2.5 SLRP class IV proteins 
To the novel class of type IV SLRPs belong tsukushi, chondroadherin, and 
nyctalopin (Bech-Hansen et al. 2000; Pusch et al. 2000; Ohta et al. 2004). 
Nyctalopin is the first described glycosylphosphatidyl-anchored SLRP and the 
second that is linked to the X chromosome. Together with tsukishi it contains 
eleven homologous LRRs, which are flanked by N-terminal cysteine-rich 
regions. Like some class I SLRPs (Chen et al. 2004; Moreno et al. 2005), 
tsukushi is a BMP inhibitor, which forms a complex with chordin and BMP 
(Ohta et al. 2004; Ohta et al. 2006). Unlike tsukushi and nyctalopin, 
chondroadherin is expressed by chondrocytes. 
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1.9.2.6 SLRP class V proteins 
Class V SLRPs are a new non-canonical class of SLRPs (Schaefer and Iozzo 
2008). This class is composed of two genes: podocan, which is located on 
chromosome 1 (Ross et al. 2003) and podocan-like protein 1, which can be 
found on chromosome 19. Although the proteins contain different C-terminal 
cysteine-rich clusters compared to other SLRP classes, they have 20 LRRs, 
which are homologous to some class I and II SLRPs (Schaefer and Iozzo 
2008). However, podocan is able to bind collagen type I and inhibits cell growth 
by inducing p21 expression (Shimizu-Hirota et al. 2004). None of the class V 
proteins is expressed in cartilage. 
 
 Glycosaminoglycans 
Glycosaminoglycan (GAG) chains consist of a linear, unbranched chain of 
disaccharide units, which are made of a composition of a hexosamine (N-
acetylgalactosamine or N-acetylglucosamine), and a hexuronic acid (HexA, 
glucuronic acid or iduronic acid) or hexose (galactose) (Esko et al. 2009). Due 
to the carboxyl-group of the hexuronic acid and the potential sulphate esters, 
which can be attached to the hexuronic acid and the amino sugar, GAG chains 
are strongly negatively charged. As a result, they have a very large binding 
capacity for water molecules, which imparts osmotic pressure and elasticity on 
the tissue, an important feature of cartilage as already discussed. Several 
different GAG chain types can be distinguished, depending on its composition: 
hyaluronic acid, heparin/heparan sulphate, chondroitin sulphate, dermatan 
sulphate, and keratan sulphate (Table 1.2).  
Hyaluronic acid (HA) consists of GlcA-β-1,3-GlcNAc disaccharide units, which 
are β-1,4 linked to each other. The length can reach up to 1 x 105 units in one 
chain (Esko et al. 2009). The disaccharide units are not sulphated. Unlike all 
other GAG types, it is synthesized by enzymes, HA synthases, at the cell 
surface. HA is an amphipathic helix and is not attached to a core protein.  
Heparin and heparan sulphate (HS) consist of GlcA-β-1,4-glucosamine or 
IdoA-α-1,4-glucosamine disaccharide units, which are α-1,4 linked to each 
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other (Esko et al. 2009). Heparin is only produced in mast cells, whereas HS 
is produced throughout all tissues. Heparin differs from HS by the amount of 
modifications of the sugar residues. Its disaccharide units are more sulphated 
and contain a significantly higher amount of iduronic acid compared to HS. 
Moreover, heparin is also a strong anticoagulant because of its ability to bind 
to antithrombin-III due to its negative charge.  
The disaccharide units of keratan sulphate (KS) consist of Gal-β-1,4-GlcNAc, 
which are β-1,3 linked to each other. Both sugars can be sulphated at their C-
6 atom, but Gal is rarely found to be sulphated (A. Plaas et al. 2001). The two 
types of KS (KS I and KS II) can be distinguished by their linkage to the protein 
core. KS I is predominantly found in cornea and N-linked to an asparagine 
residue of the core protein. KS II in contrast is O-linked to a serine/threonine 
residue via GalNAc. 
Chondroitin sulphate (CS) and dermatan sulphate (DS) consist of GlcA-β-1,3-
GalNAc units and IdoA-β-1,3-GalNAc, respectively. The subunits are β-1,4 
linked to each other (Esko et al. 2009). The hexuronic acids can be sulphated 
at the C-2 position and the GalNAc at the C-4 and C-6 position. DS is derived 
from CS. The enzyme C5-epimerase uses GlcA as a substrate to epimerize 
the carboxyl group at its C-5 atom, which then becomes IdoA. The reverse 
reaction that prevents the “flip-back” of the carboxyl group is blocked by the 
sulphation of the hydroxyl group at the C-4 atom of GalNAc (Kusche-Gullberg 
and Kjellen 2003). If the epimerization and sulphation reactions are coupled, 
the two involved enzymes may interact and form a complex with each other. 
Since not all GlcA-residues in CS are epimerized to IdoA, DS GAG-chains 
usually contain a mixture of CS and DS. 
The biological function of GAG chains is strongly influenced by its composition 
and also post-translational modification. A large body of investigation was 
performed on the function of HS chains found attached on cell surface 
proteoglycans like syndecans or glypicans (Zako et al. 2003; Multhaupt and 
Couchman 2012; Gallagher 2006). The biological function of these HS-
proteoglycans partly depends on the variety of posttranslational modifications 
of the HS chains, e.g. sulphation and epimerization. These modifications lead 
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to the ability of the HS chain to bind growth factors or regulate the activation of 
cell surface receptors, which was shown for FGFs, TGF- superfamily, Wnt, 
and others (Zako et al. 2003). This example shows that the structural patterns 
generated during GAG chain synthesis and modification are very important in 
the overall biological context and may also be influenced in the pathogenesis 
of degenerative joint diseases like osteoarthritis.  
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Table 1.2 Overview of GAG chains. Each type consists of different disaccharide subunits, 
which are repeatedly connected with each other. They can also be specifically modified 
through the addition of sulphate groups at designated hydroxyl groups of the hexuronic acid 
and the hexosamine. 
Chondroitin sulphate 
GlcA--1,3-GalNAc--1,4 
Modifications: 
Sulphation on C-4 and/or C-6 of 
GalNAc and on C-2 of GlcA 
 
 
Dermatan sulphate 
IdoA--1,3-GalNAc--1,4 
Modifications: 
Sulphation on C-4 and/or C-6 of 
GalNAc (must be present) and on 
C-2 of IdoA 
 
 
Hyaluronic acid 
GlcA--1,3-GlcNAc--1,4 
No modifications 
 
 
Keratan sulphate 
Gal--1,4-GlcNAc--1,3 
Modifications: 
Sulphation on both C-6 of Gal and 
GlcNAc 
 
 
Heparin / Heparan sulphate 
GlcA--1,4-GlcNAc--1,4 (top) 
IdoA--1,4-GlcNAc--1,4 (bottom) 
Modifications: 
Sulphation on C-2 and C-6 of 
Glucosamine and on C-2 of IdoA or 
GlcA 
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 Synthesis of chondroitin sulphate 
CS/DS chains consist like all other GAGs (except HA) of three distinct 
structural regions: a linkage region which connects the reducing end of the 
chain to the core protein, a large region between the reducing and non-
reducing end which contains the repetitive disaccharide units, and a non-
reducing end terminal region (Midura et al. 1994). CS/DS and heparin/HS 
share the same tetrasaccharide linkage sequence Xyl-Gal-Gal-GlcA. Xyl is 
connected by an O-glycosidic linkage to a serine residue in the core protein 
sequence. This reaction is catalyzed by a xylosyl transferase (XylT). No single 
consensus recognition pattern of XylT for setting a starting point for GAG chain 
synthesis onto the core protein sequence has been identified yet. However, in 
general a glycine follows a substituted serine, and the Gly-Ser pair is led by 
acidic amino acid residues (Kjellen and Lindahl 1991). Alignment of sequences 
of over 50 CS attachment sites from 19 proteoglycans identified a potential 
consensus sequence of a-a-a-a-Gly-Ser-Gly-a-b-a, where “a” is a Glu or Asp 
and “b” is a Gly, Glu or Asp. However, this does not explain why often potential 
Gly-Ser pairs are not substituted. Therefore, other factors like proximity to 
other substituted sites, downstream sequences, or secondary structures may 
be important. Other sequences and structural features may contribute to the 
specification of the type of GAG, for example CS/DS or heparin/HS chains on 
the mutual linkage region (Silbert and Sugumaran 2002). 
The basic building blocks of GAGs are disaccharide units, which originate from 
sugar nucleotide precursors like UDP-Xyl, UDP-Gal, UDP-GlcA, UDP-GalNAc, 
and UDP-GlcNAc. The main precursor for their synthesis is glucose, whereas 
galactose derived from lactose can be the precursor for UDP-Gal, UDP-GlcA 
and UDP-Xyl. They serve as substrate for the various glycosyltransferases 
involved in chain formation (Table 1.3) (Silbert and Sugumaran 2002). The 
sugar nucleotides are directly added to the appropriate acceptor sites without 
the formation of any intermediates. The synthesis of the linkage region and the 
disaccharide polymer is segregated within the endoplasmic reticulum (ER), 
transfer vesicles and Golgi system. However, unlike N-glycosylation of 
glycoproteins which occurs co-translationally, GAG chain synthesis occurs on 
the folded core proteins. 
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The initial addition of xylose by XylT (Table 1.3) starts in the ER and continues 
in the early Golgi (Silbert and Sugumaran 2002). The following additions of the 
two galactoses are catalyzed by two different galactose transferases (GalT-1 
and GalT-2) (Kearns et al. 1993). They reside in different parts of the cis/medial 
Golgi (Sugumaran et al. 1992). Next, the first GlcA residue is added by GlcA 1 
transferase (GlcAT-1) in the medial/trans Golgi regions, where also CS 
polymerization takes place (Sugumaran et al. 1998). The attachment of the 
first GalNAc residue by GalNAc 1 transferase (GalNAcT-1) determines the fate 
of the forming GAG-chain in becoming a CS/DS polymer. This transferase is 
also responsible for further polymerization of the chain by adding GalNAc 
(Uyama et al. 2002). When the first added hexosamine is a GlcNAc, the GAG 
chain becomes heparin/HS. Despite all that, the GalNAcT-1 must be able to 
differentiate between the primers for CS and heparin/HS in some way. This 
might be regulated by the capping of undesired primers. The enzymes involved 
may also recognize structures or sequences of the core protein which appear 
as transient modifications of the linkage region (Kitagawa et al. 1999; 
Nadanaka et al. 1999). CS is the predominant GAG on cartilage 
proteoglycans. 
Recent studies with mice deficient of GalNAcT-1 showed that their cartilage 
was smaller and contained only half of the CS amount of the respective wild 
type or heterozygous mice. In addition, CS in collagen type II fibres (collagen 
IX associated with fibre surface) were abnormally arranged. Despite the fact 
that GalNAcT-2 is also able to attach a GalNAc residue to the polymerizing CS 
chain and to the linkage tetrasaccharide, it was apparently not able to 
compensate for the loss of GalNAcT-1. This indicates that GalNAcT-1 plays 
an important role in CS synthesis in developing cartilage (Watanabe et al. 
2010).  
The polymerization of the GAG chain takes place in a highly organized manner 
with GlcAT-2 and GalNAcT-2 acting in concert adding sugar monomers to the 
non-reducing end of the forming chain, which can be as large as 70 kDa 
(Silbert and Sugumaran 2002). It is notable that each sugar unit is added 
independently and the addition of the following sugar is delayed until the 
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concentration of the activated binding block with the required sugar is high 
enough. As a reason for this, it is thought that the GalNAc transferase activity 
and GlcA transferase activity are on two different enzymes (Silbert and 
Reppucci 1976). However, a protein, which has both transferase activities was 
isolated and has been denoted as chondroitin synthase 1 (ChSy-1). This 
protein is unable to add a GalNAc to the GlcA residue in the linkage region, 
which separates it from the GalNAcT-1. However, ChSy-1 shows both β1,3-
GlcA transferase and β1,4-GalNAc transferase activities (Kitagawa et al. 
2001). Interestingly, the chondroitin polymerizing activity could not be 
demonstrated by recombinantly expressed ChSy-1, indicating a more complex 
mechanism for this enzyme. Kitagawa and colleagues discovered, that the 
presence of another protein denoted as chondroitin polymerizing factor 
(ChPF), was required for full ChSy-1 activity (Kitagawa et al. 2003). 
Furthermore, two more chondroitin polymerases (ChSy-2 and ChSy-3) were 
cloned (Yada, Gotoh, et al. 2003; Yada, Sato, et al. 2003). Remarkably, all 
chondroitin polymerases and ChPF on their own show only very little enzyme 
activity, but distinct chondroitin polymerization was achieved when any two of 
these enzymes were combined. Two additional enzymes with both GalNAcT-
1 and GalNAcT-2 activity were more recently discovered. They are called 
ChGn-1 and ChGn-2 and are thought to be able to catalyse the initiation and 
also polymerization of the CS chain (Uyama et al. 2002; Gotoh et al. 2002; 
Sato et al. 2003; Uyama et al. 2003). A schematic representation of all the 
steps in the biosynthesis of CS chains is given in Fig. 1.6. 
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Table 1.3 Summary of enzymes involved in synthesis of CS/DS GAG chains with their 
corresponding abbreviation used in literature and respective substrate (underlined). Partially 
adapted from Fransson et al. (2000) and Mikami et al. (2013). 
Enzyme Abbreviation Substrate 
xylosyl-transferase XylT ..D/E..SG..(D/E) 
galactosyl-transferase 1 GalT-I Xyl-Ser 
galactosyl-transferase 2 GalT-II Gal-Xyl-Ser 
glucuronyl-transferase 1 GlcAT-I Gal-Gal-Xyl-Ser 
glucuronyl-transferase 2 GlcAT-II GalNAc-β1,4-GlcA 
chondroitin N-acetylgalactosaminyl-
transferase 1 
 
GalNAcT-I GlcA-Gal-Gal-Xyl-Ser; GlcA-
β1,3-GalNAc 
chondroitin N-acetylgalactosaminyl-
transferase 2 
 
GalNAcT-II GlcA-Gal-Gal-Xyl-Ser; GlcA-
β1,3-GalNAc 
chondroitin synthase 1 ChSy-1 GlcA-β1,3-GalNAc; GalNAc-
β1,4-GlcA 
chondroitin synthase 2 ChSy-2 GlcA-β1,3-GalNAc; GalNAc-
β1,4-GlcA 
chondroitin synthase 3 ChSy-3 GlcA-β1,3-GalNAc; GalNAc-
β1,4-GlcA 
chondroitin polymerizing factor ChPF GlcA-β1,3-GalNAc 
chondroitin GalNac transferase 1 ChGn 1 GlcA-Gal-Gal-Xyl-Ser; GlcA-
β1,3-GalNAc 
chondroitin GalNac transferase 2 ChGn 2 GlcA-Gal-Gal-Xyl-Ser; GlcA-
β1,3-GalNAc 
dermatan sulphate/C-5 epimerase DS-epi GlcA-GalNAc 
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Figure 1.6 Schematic overview of the CS synthesis. Initially, the tetrasaccharide linkage region 
is synthesized, followed by the assembly of repeating disaccharide subunits forming the CS 
chain. It can be further modified by specific sulphotransferases and epimerases. XylT: xylosyl-
transferase, GalT-I: galactosyl-transferase 1; GalT-II: galactosyl-transferase 2; GlcAT-I: 
glucuronyl-transferase 1; GlcAT-II: glucuronyl-transferase 2; GalNAcT-I: Chondroitin N-
acetylgalactosaminyl-transferase 1; GalNAcT-II: Chondroitin N-acetylgalactosaminyl-
transferase 2; ChSy: chondroitin synthase; ChPF: chondroitin polymerizing factor; ChGn: 
chondroitin GalNAc transferase; C4ST: chondroitin 4-O-sulphotransferase; C6ST: chondroitin 
6-O-sulphotransferase; D4ST: dermatan 4-O-sulphotransferase; UST: uronyl 2-O-
sulphotransferase; GalNAc4S-6ST: GalNAc 4-sulphate 6-O-sulphotransferase; DS-epi: GlcA 
C-5 epimerase (DS epimerase). 
Reprinted from Biochimica et Biophysica Acta, Volume 1830, Issue 10, Pages 4719 – 4733, 
Authors: Mikami T., Kitagawa H.; “Biosynthesis and function of chondroitin sulfate.” Copyright 
(2013), with permission from Elsevier. 
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 Post-translational modification of chondroitin sulphate 
CS can be modified by kinases, sulphotransferases and epimerases, which 
takes place in the trans Golgi compartments (Silbert and Sugumaran 2002). 
The sulphation of CS/DS chains can be considered as the most important type 
of posttranslational modification. Here, 3’-phosphoadenosine 5’-
phosphosulphate (PAPS) serves as substrate for sulphotransferases. PAPS is 
derived from ATP by a single enzyme with both ATP sulphurylase and APS 
kinase activity (Lyle et al. 1994). The main proportion of sulphate groups is 
found within the repeating disaccharide subunits of the chain. However, one 
or two Gal residues in the linkage region were found to be sulphated as well. 
Interestingly, Gal 4-sulphate is only found in chondroitin 4-sulphate chains and 
Gal 6-sulphate is only found in chondroitin 6-sulphate chains. Furthermore, no 
Gal sulphotransferase specific for the linkage region was identified, which 
indicates that these modifications are catalyzed by the same transferases that 
sulphate GalNAc residues (Silbert and Sugumaran 2002).  
In general, the sulphation of CS/DS is highly variable. Other than the possible 
sulphation of the linkage region, a diverse range of differently sulphated 
disaccharide units can be found. The possible CS chain permutations consist 
of GalNAc 4-sulphate and GalNAc 6-sulphate only, both 4- and 6- sulphated 
GalNAc in the same GAG chain, GalNAc which is 4,6-sulphated, and also non-
sulphated. Moreover, the GlcA can be 2-sulphated and also rarely 3-sulphated. 
DS usually contains disaccharide units consisting of IdoA 2-sulphate and 
GalNAc 4-sulphate, but was also found containing GalNAc 6-sulphate as the 
hexosamine (Silbert and Sugumaran 2002). Additionally, GlcA 2-sulphate in 
CS is relatively rare. The different forms of CS are listed in Table 1.4. 
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Table 1.4 Different types of CS chains. Each type comprises a different modification of the 
basic disaccharide subunit GlcA-GalNAc 
Chondroitin-type Systematic name Chemical nomenclature 
CS A chondroitin 4-sulphate GlcA-GalNAc4S 
CS B dermatan sulphate IdoA2S-GalNAc4S 
CS C chondroitin 6-sulphate GlcA-GalNAc6S 
CS D chondroitin 2,6-sulphate GlcA2S-GalNAc6S 
CS E chondroitin 4,6-sulphate GlcA-GalNAc4,6diS 
 
Enzymes known as sulphotransferases catalyze the addition of sulphate 
groups to the above mentioned positions on GlcA, IdoA, GalNAc and also Gal 
(Fig. 1.7, Table 1.5). Sulphation of GAG chains appears to occur during the 
polymerization of the chain rather than on the completed chain (Sugumaran 
and Silbert 1990). Sulphotransferases are type II transmembrane proteins with 
an N-terminal cytoplasmic domain, a transmembrane domain and a stem 
region followed by a catalytic domain. So far, little is known about their 
organization in the Golgi system, but they are likely to form complexes with 
other enzymes in the same biosynthetic pathway (Kusche-Gullberg and Kjellen 
2003). 
To date, three different GalNAc-4-O-sulphotransferases (CS4ST1-3) have 
been cloned and characterized (Yamauchi et al. 2000; Hiraoka et al. 2002; 
Kang et al. 2002). Moreover, a GalNAc-4-O-sulphotransferase that adds a 
sulphate group to a GalNAc which is next to an IdoA (D4ST1) has also been 
cloned and characterized (Evers et al. 2001). CS chains modified by these 
sulphotransferases are named CS-A and CS-B, respectively (Table 1.4). 
Pacheco and colleagues showed that there is a close connection between the 
4-O-sulphation of GalNAc and epimerization of GlcA to IdoA by C-5-
epimerase. Down regulation of D4ST-1 led to a substantial reduction of IdoA 
residues, which are located in block structures. However, C-5-epimerase 
activity was not affected (Pacheco et al. 2009). As already mentioned, this may 
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be due to the fact that the 4-O sulphation of GalNAc prevents the back-
epimerization of IdoA to GlcA (Silbert and Sugumaran 2002).  
C6ST is a sulphotransferase that catalyses 6-O sulphation of GalNAc 
(Yamauchi et al. 2000), leading to the generation of CS-C (Fig. 1.7, Table 1.4, 
Table 1.5). A higher degree of sulphation can be achieved by the sequential 
sulphation of C6ST followed by UST, a sulphotransferase specific for 2-O 
sulphation of GlcA/IdoA(Kobayashi et al. 1999). This leads to the formation of 
CS-B and CS-D (Fig. 1.7, Table 1.4, Table 1.5). Moreover, disulphated CS-E 
can be generated through 4-O sulphation by C4ST1 followed by 6-O 
sulphation of GalNAc4S-6ST (Ohtake et al. 2001). This sulphotransferase 
needs 4-O sulphated GalNAc as a substrate (Mikami and Kitagawa 2013). 
 
 
Figure 1.7 Pathways of modifications of CS/DS chains. Based on the substrate specificities of 
CS sulphotransferases, two pathways based on 4-O and 6-O sulphation can be determined. 
DS synthesis is based on the initial formation of IdoA by DS-epi, followed by subsequent 4-O 
sulphation of the adjacent GalNAc.  
Reprinted from Biochimica et Biophysica Acta, Volume 1830, Issue 10, Pages 4719 – 4733, 
Authors: Mikami T., Kitagawa H.; “Biosynthesis and function of chondroitin sulfate.” Copyright 
(2013), with permission from Elsevier.  
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Table 1.5 Summary of mammalian CS/DS sulphotransferases and kinases described in 
literature, including the corresponding abbreviation and substrate (underlined). Adapted from 
Kusche-Gullberg et al. (2003) 
Enzyme Abbreviation Substrate 
chondroitin 4-O-sulphotransferase 1 C4ST1 -GlcA-GalNAc- 
chondroitin 4-O-sulphotransferase 2 C4ST2 -GlcA-GalNAc- 
chondroitin 4-O-sulphotransferase 3 C4ST3 -GlcA-GalNAc- 
dermatan 4-O-sulphotransferase 1 D4ST1 -IdoA-GalNAc- 
chondroitin 6-O-sulphotransferase C6ST -GlcA-GalNAc- 
chondroitin 4-sulphate 6-O-
sulphotransferase 
GalNAc4S-6ST 
-GlcA-GalNAc4S- 
-IdoA-GalNAc4S- 
galactosaminyl uronyl 2-O-
sulphotransferase 
UST 
-GlcA-GalNAc6S- 
-IdoA-GalNAc±4S- 
xylosyl-kinase Fam20B -Gal-Gal-Xyl-Ser 
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It has recently been reported that C4ST-1 regulates GalNAc-4O-sulphation 
and chain length (Klüppel et al. 2005; Uyama et al. 2006). It was demonstrated 
that CS chain elongation is regulated by C4ST-1 in cooperation with ChGn 2 
(Izumikawa et al. 2011). They proposed a model for CS chain polymerization 
as follows (Fig. 1.8 A): when GlcA is at the non-reducing terminus, ChGn 2 
catalyzes the addition of a GalNAc. Next, C4ST-1 facilitates the 4-O-sulphation 
of this residue. Triggered by this, a GlcA is added by ChSy-1 and ChPF 
(polymerase complex) and the chain elongation continues (left column). In the 
case of a GalNAc presented at the non-reducing terminus (right column), it is 
subsequently 4-O-sulphated by C4ST-1. In the next step, a GlcA is added by 
the polymerase complex, and then a GalNAc by ChGn 2, which is again 4-O-
sulphated by C4ST-1 and so on (Izumikawa et al. 2011). In addition to the 
above described conventional pathway of CS chain synthesis, a different 
model was described (Anggraeni et al. 2011). In contrast to the chain 
polymerization starting from the GlcA of the tetrasaccharide linker by the CS 
polymerase complex, the first GalNAc is attached to GlcA by ChGn 1 (Fig. 1.8 
B). This serves as a substrate for C4ST-2, leading to 4-O sulphation of 
GalNAc. From then on, chain synthesis is facilitated by the CS polymerase 
complex (Mikami and Kitagawa 2013). 
An early posttranslational event is the phosphorylation at the C-2 atom of 
xylose in the linker region by Fam20B (Fig. 1.8 C). The modification of xylose 
is stable in aggrecan from cartilage ECM, but only transient in decorin. 
Depending on the length of the forming linkage region, phosphorylation goes 
from 50 to 60% at the Ser-Xyl and Ser-Xyl-Gal stage up to 90% at the Ser-Xyl-
Gal-Gal stage (Mikami and Kitagawa 2013). However, the phosphate group is 
removed during the addition of the first GlcA residue to the linkage region. 
Probably the phosphorylation serves as a signal for intracellular trafficking or 
in regulating other following modifications (Silbert and Sugumaran 2002). In a 
recent study, Wen and colleagues found that phosphorylation of Xyl strongly 
increases the activity of GalT-II, and that the knockout of Fam20B leads to a 
truncated, sialic acid-capped linkage tetrasaccharide that cannot be further 
elongated (Wen et al. 2014). 
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Two modifications that result in the termination of GAG chain synthesis are 
performed by human natural killer cell carbohydrate antigen 1 (HNK-1) 
sulphotransferase and EXTL2, respectively. HNK-1 catalyses the transfer of a 
sulphate group to the C-3 atom of a terminal GlcA in the tetrasaccharide linker 
region (Mikami and Kitagawa 2013), which leads to the inhibition of CS chain 
elongation (Fig. 1.8 D). However, this was only observed so far for the 
proteoglycan thrombomodulin (Nakagawa et al. 2011). EXTL2, a 
glycosyltransferase that catalyses the addition of GlcNAc to the terminal GlcA 
of the linkage region, was found to be able to add -GalNAc or -GlcNAc to 
GlcA, which in return inhibits the further synthesis of CS or HS (Fig. 1.8 D). 
Although this was so far only observed in vitro, it could indicate a possible 
regulatory mechanism for GAG chains (Mikami and Kitagawa 2013). 
Overall, the polymerization of CS/DS chains is a highly sophisticated process, 
which is not yet completely understood. Even the findings from enzyme-
knockouts can be controversial in the light of a possible compensatory effect 
of other CS polymerizing enzymes, which cannot be completely excluded 
(Professor Kazuyuki Sugahara, Hokkaido University, Hokkaido, Japan, 
personal communication).  
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Figure 1.8 Mechanisms of CS synthesis. A: Conventional model of CS chain polymerization 
by ChGN 2 and C4ST-1. ChGn 2 attaches a GalNAc to the terminal GlcA of the linkage region, 
which is then 4-O sulphated by C4ST-1. Followed by this, the chain elongation is taken forward 
by a polymerization complex composed of ChSy-1 and ChPF (left column). If GalNAc is 
present at the terminus, it is first sulphated by C4ST-1 and then serves as a substrate for the 
chain polymerization complex (right column). B: A different mechanism describes the addition 
of the first GalNAc by ChGn 1, followed by 4-O sulphation by C4ST-2. From then on, chain 
elongation is performed by a CS polymerization complex. C: The linkage region xylose can be 
phosphorylated at the C-2 atom by Fam20B. D: Addition of an -GalNAc or -GlcNAc to the 
linkage region GlcA prevents further synthesis of CS and HS. Similar, 3-O sulphation of GlcA 
by HNK-1 supresses CS formation. Reprinted from Biochimica et Biophysica Acta, Volume 
1830, Issue 10, Pages 4719 – 4733, Authors: Mikami T., Kitagawa H.; “Biosynthesis and 
function of chondroitin sulfate.” Copyright (2013), with permission from Elsevier.  
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 Termination of chondroitin sulphate synthesis 
Usually CS/DS chains terminate at their non-reducing end variably with 
nonsulphated GlcA, GalNAc4S, GalNAc6S, GalNAc4,6diS or nonsulphated 
GalNAc (Silbert 1978; Otsu et al. 1985). However, some degree of specificity 
was found showing that GalNAc4S at the non-reducing end (Silbert and 
Freilich 1980) or pre-terminal to GlcA at the non-reducing end (Cogburn and 
Silbert 1986) of a CS chain blocks the further attachment of GlcA or GalNAc. 
Analysis of swarm rat chondrosarcoma aggrecan showed that GalNAc4,6diS 
as the non-reducing terminal disaccharide was 60 times more abundant than 
other disaccharides (Midura et al. 1995; Mikami and Kitagawa 2013). 
Moreover, it was shown that bone marrow derived mast cells isolated from 
GalNAc4S-6ST knockout mice produced larger CS chains compared to normal 
mice (Ohtake-Niimi et al. 2010). Although the mechanism responsible for chain 
termination is not yet fully understood, GalNAc4,6diS seems to be involved in 
a chain termination mechanism. 
 
 Degradation of GAG chains 
In eukaryotes, GAG chain degradation takes place endogenously mostly in 
lysosomes, where chains are broken down initially by endo-glycosidases. The 
resulting oligosaccharides are further degraded by exo-glycosidases, acting 
on the non-reducing end terminus of the sugar, and sulphatases, which 
liberate the individual monosaccharides (Prabhakar and Sasisekharan 2006). 
Two enzymes known to be involved in the degradation of CS chains are 
HYAL1 and HYAL4, which are both endo--N-acetylgalactosaminidases 
specific for CS and HA (Mikami and Kitagawa 2013). 
For a detailed analysis of the GAG disaccharide composition, the long 
polysaccharide chains need to be degraded into their smallest component: the 
disaccharide subunit. This is accomplished by polysaccharide lyases and 
hydrolases of bacterial origin, which specifically attack the glycosidic linkages 
between the disaccharide subunits. Lyases display a degree of specificity for 
heparin, HS, CS and HA and are therefore classified as heparinases, 
chondroitinases and hyaluronidases, respectively (Linhardt et al. 1986). 
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Lyases cleave disaccharides by catalyzing an elimination reaction, where the 
C5-hydrogen of the hexuronic acid part of the disaccharide gets removed, 
forming an unsaturated double-bond between the C4 and C5 atom. Lyases 
can only cleave glycosidic bonds on the non-reducing end of hexuronic acids 
as its carboxyl group is involved in the catalytic mechanism (Ernst et al. 1995). 
Hydrolases are the major class of polysaccharide degrading enzymes in higher 
animals. They are specific for heparin, HS, CS/DS, HA and KS. Unlike lyases, 
these enzymes are catalyzing a hydrolytic cleavage of glycosidic bonds, where 
a proton is donated to the glycosidic bond resulting in forming an oxonium ion 
and therefore cleavage of the bond. Then, a proton donated from H2O is 
neutralizing the oxonium ion. In contrast to lyases, hydrolases are not 
restricted to the glycosidic bond between individual disaccharides, but can also 
cleave within a disaccharide. This feature and also the absence of an 
unsaturated double bond in the hexuronic acid makes hydrolases not 
preferable enzymes for GAG disaccharide analysis. Without the double bond, 
disaccharides are not absorbing UV light (232 nm) or easily undergo labeling 
reactions (Ernst et al. 1995).  
In the following sections, the three types of GAG chain degrading enzymes are 
described in more detail. 
 
 Chondroitinases 
Chondroitinases are specific for GAG chains comprised of CS and DS. Within 
this enzyme family, several chondrotinases are specific for only a certain type 
of CS depending on the sulphation of GalNAc or the position of the carboxyl 
group of the hexuronic acid (Cs vs DS). The substrate specificity is part of the 
enzyme nomenclature. For example, chondroitinase ABC (ChABC) cleaves 
both 4-sulphated CS (CS-A) and 6-sulphated CS (CS-C) as well as DS (CS-
B).  
ChABC utilized for GAG analysis is commonly derived from the bacterium 
Proteus vulgaris, which is used for large scale production and purification 
(Yamagata et al. 1968; Hamai et al. 1997) of this enzyme. Alternatively, it is 
recombinantly expressed in Escherichia coli (Prabhakar et al. 2009; Prabhakar 
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et al. 2005). ChABC does not cleave heparin or HS, but shows some activity 
towards HA (Ernst et al. 1995). It depolymerizes CS/DS chains from the non-
reducing end disaccharide towards the core protein and is therefore denoted 
as an exolytically cleaving chondroitinase. 
ChAC is derived from Arthrobacter aurensis and Flavobacterium heparinum. It 
is specific for CS. In fact, DS inhibits ChAC activity in a competitive way with a 
Ki of 10 – 60 mM. Two different isoforms of ChAC exist depending on the 
expressing organism. ChAC-I (F. heparinum) is degrading CS chains in an 
endolytic fashion by randomly generating oligosaccharides initially and 
disaccharides in the later stages of the reaction. In contrast, ChAC-II (A. 
aurensis) degrades exolytically from the non-reducing end generating primarily 
disaccharides from the outer portions of the CS chain (Hiyama and Okada 
1976).  
ChB is another chondroitinase derived from F. heparinum. It is specific for DS 
chains only (Ernst et al. 1995). Additionally, it only cleaves disaccharides that 
comprise a 4-sulphated GalNAc (Michelacci and Dietrich 1974). In contrast to 
ChAC which is inhibited by DS, ChB is not inhibited by CS chains. 
ChC has a higher catalytic activity towards 6-sulphated CS than towards 4-
sulphated CS. Like ChAC-I and ChB, it is also expressed by F. heparinum. 
Like ChABC, it is also able to depolymerize HA (Ernst et al. 1995). However, 
due to its very selective substrate specificity, it is not commonly used for GAG 
disaccharide analysis. 
 
 Heparinases 
Heparinases are lyases that specifically depolymerize heparin and HS. No 
cross-reactivity with other GAG types have been reported. Heparinases are 
divided into three classes. Class 1 is mainly specific for heparin, class 2 
cleaves heparin as well as HS and class 3 can only cleave HS (McLean et al. 
1985). All the isoforms can be found in F. heparinum, however heparinase 1 
was also found to be expressed in other soil bacteria (Ernst et al. 1995). 
Heparinase 2 is also known as heparitinase 2 and heparinase 3 is also known 
as heparitinase 1. 
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 Hyaluronidases 
Hyaluronidases can be found in bacteria as well as animal tissues. Depending 
on the source, the hyaluronidases have different cross-reactivities towards 
other GAGs and from different depolymerization products. For instance, 
hyaluronidase from Peptostreptococcus sp. shows a low activity towards CS-
A and CS-C, but not CS-B and heparin (Tam and Chan 1985). It completely 
depolymerizes HA into disaccharides, in contrast to the more commonly used 
bovine testicular hyaluronidase, whose cleavage products are mostly hexa- 
and tetrasaccharides (Yamagata et al. 1968). 
 
 Changes in GAG chain structure identified in disease 
states of cartilage 
During the last decades, increasing evidence accumulated regarding the 
alteration of GAG chain fine structure in OA. Early work from Mankin and 
Lipiello (1971) showed that OA hip cartilage contained an increased amount 
of chondroitin-4-sulphate (C-4-S) and decreased amount of KS compared to 
normal cartilage (Mankin and Lippiello 1971), which was subsequently 
confirmed by others (Michelacci et al. 1979). As the ratio of C-4-S to C-6-S is 
higher in fetal and young cartilage than in adult cartilage, chondrocytes in OA 
cartilage seem to produce an immature type of extracellular matrix. Moreover, 
a reduced HA content (Sweet et al. 1977) as well as longer and more CS 
chains per protein (Cox et al. 1985; Carney et al. 1985) were observed in OA 
cartilage. Further studies using specific antibodies raised against GAG chain 
epitopes revealed the re-appearance of epitopes in OA cartilage which are 
normally absent in adult cartilage but present in fetal cartilage (Rizkalla et al. 
1992; Visco et al. 1993; Slater et al. 1995; Cs-Szabó et al. 1995; Carlson et al. 
1995). Taken together, the observed differences in GAG chain structure in OA 
cartilage indicate that changes in the expression of GAG chain synthesizing 
and modifying enzymes take place during OA pathology. 
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    Aims of the thesis 
The overarching aim of the project is to identify potential biomarkers that can 
aid in the diagnosis of joint disease. We speculate that disease processes lead 
to alterations in glycosylation of proteins and that specific carbohydrate 
epitopes constitute highly specific markers for underlying pathological 
processes.  
 
The hypothesis to be tested is: 
Glycosylation of secreted proteoglycans is altered by biochemical processes 
triggered in the joint in response to inflammatory processes in cartilage. 
 
The specific aims to investigate the hypothesis are: 
1. To analyze the composition and fine structure of GAG chains of 
secreted proteoglycans under different conditions, e.g. decorin 
2. Development of a 3D in vitro model of “articular” cartilage 
3. Using the cartilage model for the analysis of tissue-specific expression 
patterns of proteins involved in carbohydrate synthesis and modification 
under inflammatory conditions similar to osteoarthritis using 
microarrays  
4. Investigate changes in carbohydrates on proteins predicted from 
changes in gene expression of enzymes involved in carbohydrate 
synthesis/modification 
 
 
 
 
 
 
 
 
 
 
Chapter 2: 
 
Establishing HPLC disaccharide 
analysis methods and analysis  
of decorin GAG chain composition 
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2 Establishing HPLC disaccharide analysis methods 
and analysis of decorin GAG chain composition 
 
 Introduction 
The basic building blocks of GAG chains are disaccharide units. The gross 
composition of the disaccharides determines the GAG chain type, e.g. CS/DS 
(GlcA/IdoA-GalNAc), heparin / HS (GlcA-GlcNAc), KS (Gal-GlcNAc) or HA 
(GlcA-GlcNAc). Except for HA, all disaccharides can be modified by the 
attachment of sulphate groups on the hydroxyl groups attached to carbon 
atoms 2, 4, and 6 on the glucopyranose sugar ring. This modification is 
performed by sulphotransferases during GAG chain synthesis in the 
endoplasmic reticulum/Golgi complex (Mikami and Kitagawa 2013). To be able 
to analyze the composition of differentially sulphated disaccharide units, the 
GAG chain is first depolymerized, which is achieved by specific lyases or 
hydrolases (Ernst et al. 1995). For example, chondroitinases are lyases 
specific for CS, DS and also HA to a lesser extent. They catalyze the 
elimination of the 1,4-glycosidic bond between the hexosamine of one unit 
and the hexuronic acid of its adjacent unit, introducing a 4,5-unsaturated 
bond in the hexuronic acid. Heparinases, cleaving heparin and HS, belong to 
the same family of polysaccharide lyases. A different mechanism is used by 
hydrolases, which cleave KS and HA. The respective hydrolytic cleavage does 
not introduce an unsaturated bond in the hexuronic acid. In addition, they can 
also cleave within a disaccharide unit in contrast to lyases. 
 
A variety of different methods have been developed to analyze the structure 
and composition of GAG chains, ranging from gel electrophoresis (Yamada et 
al. 1992), fluorescence-assisted carbohydrate electrophoresis (FACE) 
(Calabro et al. 2000; A H Plaas et al. 2001), NMR analysis (Yamada et al. 
1992), mass spectrometry (Linhardt et al. 1992; Zamfir et al. 2009; Sisu et al. 
2011), capillary zone electrophoresis (Kitagawa et al. 1995; Lamari et al. 
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2002), to high performance liquid chromatography (HPLC) (Midura et al. 1994; 
Shibata et al. 1992). HPLC allows for the analysis of the relative composition 
of GAG chains by comparison of the elution profile to a set of disaccharide 
standards, indicating the relative proportion of differentially sulphated 
disaccharide units of a particular type present in the chain. These can be 
separated due to differences in their negative charge and position of the 
negative sulphate groups on the disaccharide. Common methods for HPLC 
analysis are “normal phase” chromatography approaches, which are similar to 
ion exchange chromatography. Here, an increasing concentration of a high 
ionic strength buffer, such as 1 M NaCl, is applied onto the column and 
disaccharides elute in the order from weakly charged (non-sulphated) to highly 
charged (three sulphate groups). Disaccharides can be detected by measuring 
absorbance at 232 nm due to the 4, 5-unsaturated bond introduced by the 
lyase depolymerization reaction. Sensitivity for normal phase HPLC analysis 
can be increased by chemically labeling disaccharides with fluorescent dyes, 
e.g. 2-aminobenzamide (2-AB).  
Alternatively, “reverse phase” chromatography approaches use differences in 
hydrophobicity of the molecules for separation. However, disaccharides are 
highly hydrophilic, which makes it necessary to chemically link them to a highly 
hydrophobic molecule. For example, 2-aminoacridone (AMAC) is a 
hydrophobic fluorescent dye which is used for disaccharide labeling (Plaas et 
al. 2001; Kitagawa et al. 1995; Jackson 1994). The advantage of the 
fluorescent label is a substantial increase in sensitivity. In reversed phase 
HPLC, highly charged disaccharides elute first and weakly charged elute last 
with increasing organic solvent, e.g. methanol.  
In this chapter, several HPLC analysis methods for GAG chains were 
evaluated for disaccharide analysis of CS/DS to establish a method for 
characterization of changes in GAG composition of selected proteoglycans in 
the context of osteoarthritis. These represent the predominant GAG chains 
found conjugated to decorin, a small leucine-rich repeat proteoglycan which is 
found in cartilage and skin (Reed and Iozzo 2003). It is composed of a core 
protein and a single GAG chain which itself is composed of either CS or DS, 
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depending on the tissue. Decorin derived from articular cartilage has a GAG 
chain which consists mostly of CS (70-80 %) and a small amount of DS (20-
30%), whereas skin decorin has a GAG chain consisting mostly of DS (~80%) 
(Tiedemann et al. 2001; Cheng et al. 1994). While decorin may not turn out to 
be suitable as a biomarker for OA, it is used here as a model protein to 
establish relevant methodology as it has been shown to be highly sensitive to 
changes in the biosynthesis machinery in cells subjected to different conditions 
(Jianyun Yan et al. 2011). 
 
 Aims for this chapter: 
1. Establish a sensitive HPLC disaccharide analysis method for the 
determination of GAG chain disaccharide composition. 
2. Purify decorin from human skin fibroblasts and human chondrocyte 
progenitor cells. 
3. Compare the GAG chain composition of decorin purified from different 
sources. 
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 Materials and Methods 
 
 HPLC analysis of disaccharides using CarboPac PA1 column 
A protocol for the HPLC analysis of disaccharide subunits was adapted, which 
describes the separation of chondroitinase-ABC-digested CS/DS disaccharide 
units using a CarboPac PA1 matrix (Dionex, Idstein, Germany) (Midura et al., 
1994). It is based on the principle of ion exchange chromatography. Buffer 
solutions were 0.1 M NaOH (buffer A) and 0.1 M NaOH, 1 M NaCl (buffer B). 
For their preparation, ultrapure H2O (>18 MΩ), HPLC-grade NaCl and NaOH 
(Fisher Scientific, Loughborough, UK) were used. The solutions were filtered 
through a 0.22 μm nitrocellulose membrane (Millipore, Watford, UK) and 
degassed. Due to the use of alkaline buffers, the disaccharides had to be 
reduced prior to analysis, as otherwise, the disaccharides would experience 
degradation from “alkali peeling” reactions (Whistler and Bemiller 1958). For 
this, 1 M NaBH4 in 0.1 mM NaOH was added to the sample to give a final 
concentration of 25 mM NaBH4. The reaction mixtures were incubated at 38°C 
for 30 min and then acidified by adding 25 μl of 1 M acetic acid per 100 μl 
reaction mixture. Samples were subsequently incubated on ice for 10 min, 
filtered through a 0.45 μm syringe filter (Millex®-HV, Millipore, Watford, UK) 
and transferred to 1.5 ml glass vials for HPLC analysis. For the separation of 
reduced disaccharides, the following linear buffer gradient (buffer A (%): buffer 
B (%)) was used: 0 min (98:2), 12 min (98:2), 62 min (40:60), 70 min (0:100), 
85 min (0:100). Due to the introduction of a 4,5-unsaturated double bond at 
the hexuronic acid unit of the disaccharides by chondroitinases, elution could 
be monitored at a wavelength of 232 nm. The column was regenerated with 
100% buffer A. Disaccharide standards (Sigma Aldrich, Gillingham, UK and 
Dextra, Reading, UK) were used to determine the elution position of the 
individual disaccharides. Data analysis was performed using Dionex 
Chromeleon software (Dionex, Idstein, Germany). 
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 Labeling of chondroitin/dermatan sulphate disaccharides with 2-
aminobenzamide (2-AB) 
For labeling with 2-AB, 10 µl 2-AB labeling mix (0.35 M 2-AB/1.0 M NaBH3CN/ 
30% acetic acid (v/v) in DMSO) were added to the dried sample and incubated 
for 2 h at 65°C (Kinoshita and Sugahara 1999). The labeling mix needs to be 
prepared fresh and in a defined order of steps. Firstly, a solution of 30% acetic 
acid (v/v) in DMSO is prepared (solution A). Secondly, crystalline 2-AB is 
added to solution A to give a final concentration of 0.35 M 2-AB (solution B). 
Subsequently, NaCNBH4 can directly be dissolved in solution B to a final 
concentration of 1.0 M. Labeled disaccharides were analyzed immediately or 
stored at -20°C. 
 
 Removal of excess 2-AB from the labeled disaccharide sample 
Since 2-AB was added in excess over the disaccharides in the labeling 
reaction, free 2-AB needed to be removed to reduce background signal to 
improve detection of small amounts of labeled disaccharides. Two methods 
are described for the removal of excess 2-AB in the literature: paper 
chromatography and chloroform extraction (Mizumoto and Sugahara 2012). 
Paper chromatography was performed by applying the labeling mixture (10 µl) 
on a Whatman 3MM filter paper strip. The running phase was 
butanol/ethanol/water, 4:1:1 (v/v). After separation, the strip was dried and the 
original position as well as areas from the middle of the strip harbouring the 2-
AB labeled disaccharides were cut out under UV-light. The cut out paper slices 
were placed into Mini Bio-Spin™ chromatography columns (BioRad) and 
washed four times with 300 µl distilled H2O to elute the disaccharides. The 
eluates were pooled and dried in a vacuum concentrator (Christ RVC 2-25 CD 
plus and Christ CT 02-50 SR, Osterode am Harz, Germany) for about 5 h at 
30°C.  
Chloroform extraction was performed by adding 500 µl distilled H2O to a 
disaccharide sample, followed by an equal amount of chloroform. The solution 
was vigorously mixed and then centrifuged for 15 sec at 1000 x g to establish 
phase separation. The chloroform phase was carefully removed and discarded 
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and this step repeated for 5 to 10 more times. The resulting aqueous solution 
was finally dried using the vacuum concentrator. 
 
 HPLC analysis of 2-AB labeled disaccharides using YMC Pack 
Polyamine II column 
Analysis of 2-AB labeled disaccharides was performed using a Dionex ICS-
3000 system in combination with a YMC Pack Polyamine II ion exchange 
column (5 µm particle size, 12 nm pore size, 250 x 4.6 mm, YMC Europe 
GmbH, Dinslaken, Germany) as described (Kinoshita and Sugahara 1999). 
Buffer solutions were 16 mM NaH2PO4 (buffer A) and 1 M NaH2PO4 (buffer B). 
The solutions were filtered through a 0.22 µm nitrocellulose membrane and 
degassed as before. Dried samples of 2-AB labeled disaccharides were 
dissolved in buffer A to a final volume of 500 µl. To remove any residual 
particles, samples were filtered (0.45 µm filter) before applying them into 1.5 ml 
glass vials for HPLC analysis. The column was heated to 30°C. For the 
separation of 2-AB-labeled disaccharides, 100% buffer A was applied for the 
first 10 min, followed by a linear gradient up to 40% buffer B / 60% buffer A 
over 60 min at a flow rate of 1 ml/min. Emission of labeled disaccharides at 
420 nm was recorded by a RF 2000 fluorescence detector (Dionex, Idstein, 
Germany) while exciting at 330 nm. The column was regenerated with 2 
column volumes of 100% buffer B. Disaccharide standards (Sigma Aldrich and 
Dextra, Reading, UK) were labeled with 2-AB prior to use to determine specific 
elution times of the differentially sulphated disaccharide units. Data analysis 
was performed using Chromeleon software package (Dionex) as described. 
 
 Labeling of chondroitin/dermatan sulphate disaccharides with 2-
aminoacridone (AMAC) 
Labeling of disaccharides was carried out essentially as described (Jackson 
1994; Kitagawa et al. 1995; Deakin and Lyon 2008). All samples were freeze-
dried prior to labeling. The dried sample was reconstituted in 10 l of 0.1 M 
repurified AMAC (see below) in DMSO/acetic acid (85:15, v/v) and incubated 
for 15 min at room temperature. Subsequently, 10 l of freshly prepared 1 M 
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NaBH3CN were added and the labeling reaction was carried out at 37C for 
18 h. Samples were either subjected to HPLC analysis immediately or stored 
at -20C. 
 
 Repurification of AMAC using hydrophobic interaction 
chromatography 
Repurification of AMAC was carried out as described (Deakin and Lyon 2008). 
10 mg of AMAC were dissolved in 1 ml DMSO/acetic acid (85:15, v/v) and 
made up to 5 ml with H2O. The solution was applied to a column packed with 
Macro-prep tert-butyl HIC media (2 ml bed volume, Bio-Rad), which was 
equilibrated in H2O. The resin was washed with 20 ml of 20% methanol to 
remove any contaminants. Pure AMAC was subsequently eluted with 100% 
methanol. Repurified AMAC appeared as a bright yellow solution. Methanol 
was removed by evaporation. 
 
 HPLC analysis of AMAC-labeled disaccharides using Kinetex C-18 
column 
For HPLC analysis, a Dionex ICS-3000 system was used in combination with 
a Kinetex C-18 column (2.6 µm particle size, 100 Ǻ pore size, 100 x 4.6 mm, 
Phenomenex, Macclesfield, UK). Buffer solutions were 0.1 M ammonium 
acetate (buffer A) and methanol (buffer B). AMAC-labeled samples (20 µl) 
were diluted to a volume of 500 µl in buffer A, centrifuged at 18,000 x g for 5 
min, filtered through a 0.45 µm syringe filter (Millex®-HV, Millipore, Watford, 
UK) and applied to 1.5 ml glass vials. The column was heated to 40°C. For the 
separation of AMAC-labeled disaccharides, the following buffer gradient 
(buffer A (%): buffer B (%)) at a flow rate of 1 ml/min was used: 0 min (100:0), 
5 min (90:10), 20 min (75:25), 25 min (0:100). Emission of labeled 
disaccharides was recorded by the RF 2000 fluorescence detector at 520 nm 
while exciting at 427 nm. The column was regenerated with 2 column volumes 
of 100% buffer B. Disaccharide standards (Sigma Aldrich and Dextra) were 
AMAC-labeled and subsequently used to determine the elution times of the 
differentially sulphated disaccharide units. Data analysis was performed using 
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Chromeleon software package (Dionex) as described. Deakin et al. (2008) 
pointed out that some disaccharides are more readily labeled with AMAC than 
others. Therefore, correction factors were determined to compensate for the 
differential labeling rates (Table 2.1) (Deakin and Lyon 2008). Those were 
used in all calculations of AMAC-labeled disaccharides in this study. 
 
Table 2.1 Correction factors for AMAC-labeled disaccharides (Deakin and Lyon 2008) 
Disaccharide Correction factor 
2,4,6triS 1.91 
2,4diS 2.28 
2,6diS 1.00 
4,6diS 1.37 
2S 1.05 
4S 1.47 
6S 1.26 
0S 1.52 
 
 
 Cell culture 
Human skin fibroblasts (Bonacker cells) (Glössl et al. 1984) were cultured in 
minimal essential medium (MEM) containing 10% heat-inactivated fetal calf 
serum (FCS), non-essential amino acids (NEAA), 2 mM L-glutamine, 100 U/ml 
penicillin and 100 μg/ml streptomycin (Life Technologies, Paisley, UK). Human 
chondrocyte progenitor cells were cultured as described in chapter 3 (section 
3.2.2). These cells originate from primary human skin fibroblasts obtained from 
a skin biopsy. 
For passaging, the cells were washed with PBS before addition of 
trypsin/EDTA (0.05% v/v, Gibco, Cat. No. 25300-062), and incubation for 5 min 
at 37°C. Trypsination was stopped through addition of a 4-fold volume of 
serum-containing medium. Cells were collected by centrifugation at 1,500 x g 
for 5 min and resuspended in fresh medium. Cells were seeded at a density of 
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1.3 x 105 cells/cm2 into a new tissue culture flask (T-75, Sarstedt, Leicester, 
UK).  
For collection of conditioned medium, cells were cultured to approximately 
70% confluency in medium containing 10% heat-inactivated FCS and then 
switched to low serum medium (4% FCS). The cells were cultured for 3 more 
days, and then the medium was collected and supplemented with a Tris-HCl 
pH 7.5 stock solution to a final concentration of 5 mM and also protease 
inhibitors (10 mM 6-aminohexanoic acid, 1 mM ethylenediaminetetraacetic 
acid (EDTA), 0.1 mM phenylmethylsulphonylfluoride (PMSF), 0.5 mM 
benzamidine, from a 10x stock solution) and stored at -20°C. Decreasing the 
serum concentration in the medium reduces the contamination from serum 
proteins while maintaining sufficient growth factor activity not to cause changes 
in GAG structure (Fiedler, 2007). Just before anion exchange chromatography, 
Triton X-100 was added to a final concentration of 0.1%. 
 
 Purification of decorin by anion exchange chromatography 
In order to partially purify the proteoglycan decorin from conditioned medium 
of human skin fibroblasts, 1 liter of conditioned medium was filtered through a 
Whatman filter paper (No. 4, Whatman, Maidstone, UK) and applied overnight 
to an anion-exchange column containing DEAE-Cellulose DE52 matrix (weak 
anion exchanger; column 1.6 cm x 11 cm, Whatman Biosystems, Maidstone, 
UK) at a flow rate of 1 ml/min. The column had been pre-equilibrated with 
20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Triton X-100 and protease 
inhibitor cocktail (see 2.2.8). After sample application, the column was washed 
with 12 column volumes using the above described buffer prior to step elution 
as follows: By applying 36 column volumes of the same buffer, but containing 
400 mM NaCl, weakly bound proteins were eluted. Tightly bound proteins, 
including proteoglycans, were subsequently eluted with the same buffer 
containing 1 M NaCl (Fiedler 2007). During this step, 7 fractions of 14 ml were 
collected and subsequently protein containing fractions were pooled. To 
reduce the NaCl-concentration and to remove Triton X-100, the pooled sample 
was dialyzed (Spectra/Por MWCO: 12-14.000, Spectrum Laboratories, 
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Rancho Dominguez, USA) extensively against 20 mM Tris-HCl, pH 7.4, 
400 mM NaCl at 4°C. To purify decorin further, the sample pool was applied to 
a column containing Source 15Q matrix (strong anion exchanger; column 1 cm 
x 9.5 cm, GE Healthcare, Buckinghamshire, UK), which had been pre-
equilibrated in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl. The flow rate was 
1 ml/min. After sample application, the column was washed with the same 
buffer containing 400 mM NaCl until a baseline of absorbance at 280 nm was 
reached. Then the column was eluted with a linear gradient of 400 mM to 
600 mM NaCl over 2 column volumes. The NaCl concentration was then 
increased to 1 M and 14 fractions of 14 ml each were collected. Decorin 
containing fractions were pooled and stored at -20°C for further analysis. 
 
 Digestion of decorin with chondroitinase ABC, AC-I and B 
To depolymerize CS/DS chains, samples were incubated with 5 mU 
chondroitinase ABC (chABC, protease free, derived from Proteus vulgaris, ICN 
Biomedicals, Aurora, UK) per 1 µg decorin in 50 mM Tris-acetate, 60 mM 
sodium acetate, pH 8.0, for 2 h at 37°C. To specifically depolymerize DS, 
samples were incubated with 5 mU chondroitinase B (chB, Iduron, 
Manchester, UK) per 1 µg of decorin in 50 mM Tris-HCl, pH 8.0, 2 mM CaCl2 
for 2 h at 37°C. Specific cleavage of CS was performed by addition of 5 mU 
chondroitinase AC-I (chAC-I, Sigma Aldrich) per 1 µg of decorin in 50 mM Tris-
HCl, pH 7.3 and incubation for 2 h at 37°C. The specificity of lyases is outlined 
in Table 2.2. 
 
Table 2.2 Chondroitinases used in this study and their substrate specificity 
Enzyme Organism Substrate 
chondroitinase ABC P. vulgaris CS, DS, HA (low) 
chondroitinase AC-I F. heparinum CS, HA (low) 
chondroitinase B F. heparinum DS 
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 Protein concentration determination 
In order to determine the protein concentration of a sample, the Pierce BCA 
Protein Assay (Thermo Scientific, USA) was used. This assay works on the 
basis of the quantitative reduction of Cu2+ to Cu+ by proteins and the chelation 
of Cu+ with two molecules of bicinchoninic acid (BCA), of which the absorbance 
can be detected at 562nm. 25 μl of a sample of unknown concentration was 
mixed with 200 μl BCA working solution in a 96 well plate. At the same time, a 
dilution series of bovine serum albumin (BSA, 25 µg/ml to 2.0 mg/ml) was also 
mixed with working solution. The mixtures were incubated at 37°C for 30 min. 
The protein concentration of the unknown sample was calculated from the BSA 
calibration curve using non-linear regression using Microsoft Excel®. 
 
 Ethanol precipitation of proteins 
The precipitation of proteins for SDS-PAGE analysis was achieved by adding 
9 volumes of ice cold ethanol (Sigma Aldrich) to 1 volume of sample solution, 
followed by incubation for 2 hours at -20°C or overnight at 4°C. The 
precipitated protein was collected by centrifugation at 13,200 x g for 20 min at 
4°C. The supernatant was carefully removed and the pellet dried to remove 
the remaining ethanol. Then, the pellet was resuspended in a 1:1 mixture of 
8 M Urea and 2x SDS-sample buffer (see below). The samples were 
extensively mixed and boiled for 2 min prior to separation by SDS-PAGE. 
 
 SDS-Polyacrylamide-gel electrophoresis 
For SDS-PAGE, Novex Tris-Glycine gels with a linear gradient of 4-20% 
polyacrylamide (Invitrogen) were used. After rinsing the gel with H2O, it was 
placed into an XCellTM Surelock gel chamber (Invitrogen). Protein samples 
were mixed with an equal amount of 2x sample buffer (126 mM Tris-HCl, pH 
6.8, 20% glycerol (v/v), 4% SDS (w/v), 0.02 % bromophenol blue; for reducing 
conditions, 2% 2-mercaptoethanol was added), boiled for 2 min, mixed and 
centrifuged for 1 min at 13,200 x g immediately before loading onto the gel to 
remove aggregates. The gel was run at 125V constant voltage (~ 35 mA) for 
2 h in running buffer (25 mM Tris, pH 8.8, 192 mM glycine, 1% (w/v) SDS). 
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Gels were calibrated with low molecular weight standards (GE Healthcare Life 
Sciences, Little Chalfont, UK). 
  
 Silver staining of polyacrylamide gels 
Silver staining of SDS-PAGE gels is a very sensitive method to visualize 
proteins. The level of sensitivity approaches ~5-30 ng per protein band (Blum 
et al. 1987). The method developed by Blum et al. (1987) uses Ag+-ions, which 
are complexing with Glu, Asp and Cys- residues in the polypeptide chain. After 
addition of formaldehyde, the Ag+ -ions are reduced to Ag0 and precipitate as 
pure silver. The SDS-PAGE gel was fixed for at least 1 h in fixing solution (50% 
ethanol (v/v) and 12% acetic acid (v/v) in H2O). After washing three times with 
50% ethanol (v/v), the gel was incubated in 0.8 mM Na2S2O3 pentahydrate for 
1 min. Next, the gel was washed extensively in H2O, incubated in staining 
solution (12 mM AgNO3, 0.015% formaldehyde (v/v)) and again washed with 
H2O. The bands were made visible through incubation in developing solution 
(380 mM Na2CO3, 0.015% formaldehyde (v/v)). The reaction was stopped by 
adding fixing solution. 
 
 Western blotting 
Western blotting involves the transfer of proteins from a gel onto a membrane 
for detection of proteins by specific antibodies. After separating a protein 
sample in a SDS-PAGE gel, the gel was equilibrated in transfer buffer (12 mM 
Tris, 96 mM glycine, 20% methanol (v/v)). After that, a sandwich free of air was 
prepared that contained the components in the following order starting from 
the cathode-side of the blotting chamber: 3x sponges, 2x filter paper, gel, 
Protran nitrocellulose membrane (Whatman, Maidstone, UK), 2x filter paper, 
3x sponges. The transfer was performed at a constant current of 125 mA 
(~25 V) for 2h in transfer buffer. After transfer, the membrane was washed in 
Tris-buffered saline (TBS, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl). To visualize 
proteins and mark the migration of non-prestained protein markers, the 
membrane was incubated in a Ponceau S staining solution (0.1% Ponceau S 
(w/v), 5% acetic acid (v/v), Sigma Aldrich) for 5 min. The molecular weight 
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marker bands and position of lanes were marked with a pencil and the 
membrane subsequently washed in TBS until the bands were fully destained. 
In order to block non-specific binding sites of the membrane, it was incubated 
in 5% skimmed milk (Sigma Aldrich) in TBS (blocking buffer) for 1 h. A primary 
antibody against a protein of interest (Table 2.3) was diluted to the desired 
concentration in blocking buffer. The incubation time of the membrane with 
primary antibody depended on the nature of the antibody used and varied 
between 1 h at room temperature and overnight at 4°C. The membrane was 
washed three times for 5 min with TBS-T (0.01% Tween 20 in TBS) while 
shaking. An appropriate secondary antibody conjugated to horseradish 
peroxidase (HRP) made up in blocking buffer was added and the membrane 
incubated for 1 h at room temperature. The membrane was again washed 
three times for 5 min with TBS-T, followed by a 5 min wash step in TBS. Bound 
antibodies were visualized by chemiluminescence using a solution containing 
ECL Plus (GE Healthcare) and subsequent exposure of the membrane to a 
photographic film (Hyperfilm ECL, GE Healthcare) for different times to 
optimize the signal. 
 
Table 2.3 Antibodies used in this chapter for Western blotting 
Antibody Dilution 
factor 
Source 
Rabbit polyclonal anti-decorin 
 
1:500 
 
Dr Elke Schönherr, Cardiff University 
Rabbit polyclonal anti-biglycan 
 
1:500 
 
Dr Elke Schönherr, Cardiff University 
Swine anti-rabbit IgG/HRP conjugate 1:1000 
 
P0399, Dako, Cambridgeshire, UK 
 
 Stripping of nitrocellulose membrane 
For re-probing, the membrane was transferred into a roller bottle and stripped 
in 10 ml stripping buffer (62.5 mM Tris-HCl, pH 6.8, 0.5% SDS (w/v), 90 mM 
2-mercaptoethanol, all from Sigma Aldrich) at 50°C for 30 min while agitating 
in a PersonalHyb hybridization oven (Stratagene, La Jolla, USA). Afterwards, 
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the membrane was washed three times with TBS-T for 5 min. Finally, the 
membrane was blocked again with 5% skimmed milk in TBS for 1 h prior to 
incubation with antibodies as described above.  
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 Results 
 HPLC disaccharide analysis using anion exchange 
chromatography of unlabeled disaccharides 
For the qualitative and quantitative analysis of CS/DS chain composition, a 
protocol used by Midura et al. (1994) was adapted. A program for disaccharide 
analysis on the Dionex ICS-3000 HPLC machine equipped with a CarboPac 
PA1 column (Dionex) was developed. Although high sensitivity with a detection 
limit of 50 ng CS/DS disaccharides by UV detection was described by Midura 
et al. (1994), it had to be tested if this was achievable with our system. In 
addition, the exact retention times for the different expected CS/DS 
disaccharides needed to be determined. For this, 100 μl of 1 mg/ml solutions 
of ΔHexA-GalNAc (Δ0S), ΔHexA-GalNAc2S (Δ2S), ΔHexA-GalNAc4S (Δ4S), 
ΔHexA-GalNAc6S (Δ4S), ΔHexA-GalNAc2,4diS (Δ2,4diS), ΔHexA-
GalNAc2,6diS (Δ2,6diS), and ΔHexA-GalNAc4,6diS (Δ4,6diS) (Δ indicates an 
unsaturated double bond between C4 and C5 of the hexuronic acid) were 
subjected to reduction with NaBH4 as described in section 2.2.1. The 
standards were applied to the CarboPac PA1 column either individually or as 
a mixture and absorbance at 232 nm was measured. The reduced CS/DS 
disaccharides eluted in the following order: Δ0S (7.7 min), Δ4S (27.6 min), Δ2S 
(32.0 min), Δ6S (34.0 min), Δ4,6diS (51.6 min), Δ2,4diS (52.7 min), and 
Δ2,6diS (59.3 min) (Fig. 2.1). Peaks observed between 17 and 25 min were a 
result of buffer contaminants as shown previously (Midura et al. 1994). The 
elution times in the mixed sample were consistent with those of each standard 
run separately. For the determination of the detection limit, lower 
concentrations of disaccharide standards (1.1 µg and 0.11 µg of each 
standard) were separated. Analysis of the resulting chromatograms showed, 
that 1.1 µg of each disaccharide was still more than sufficient for identifying 
clear peaks (not shown). When analyzing 0.11 µg of each disaccharide, 
absorbance was markedly reduced to <10 mAU, although peaks could still be 
identified (Fig. 2.1 B). Therefore, the sensitivity of this method in combination 
with the available HPLC system was around 100 ng, which is in line with 
published data (Midura et al. 1994). 
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Figure 2.1 Disaccharide analysis using CarboPac PA1 column 
A: Chromatogram of the HPLC analysis of reduced CS/DS disaccharide standards (~11 µg 
each) on a CarboPac PA1 column. Absorbance was detected at 232 nm and a buffer gradient 
with increasing NaCl-concentration applied to the column (dotted line). Disaccharides eluted 
in accordance of their apparent charge density due to attached sulphate groups. The blue 
spectrum shows the absorbance of disaccharide standards and the red spectrum the 
absorbance detected when only buffer was applied to the column.  
B: Determination of the detection limit for disaccharide analysis. The amount of standard 
applied was reduced to ~0.11 μg each to confirm the expected sensitivity of the method. The 
small peak indicating the elution of Δ0S is marked with a circle.   
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 HPLC disaccharide analysis using 2-aminobenzamide labeling 
and anion exchange chromatography 
Due to very small GAG amounts expected in the present biological samples, 
a detection limit of about 100 ng per disaccharide achieved by detecting 
unlabeled disaccharides was considered to be not sensitive enough. 
Therefore, a modified method using fluorescence-labeled disaccharides was 
established. The fluorescent dye 2-aminobenzamide (2-AB) was used to label 
disaccharides (Kinoshita and Sugahara 1999). Labeling was performed by 
reductive amination of the sugar aldehyde (Fig. 2.2). Separation was achieved 
using an increasing concentration of NaH2PO4 on a Pack Polyamine II column 
(YMC) under normal phase HPLC conditions. The retention time of each 
disaccharide standard was individually determined using 1 ng per 
disaccharide. The labeled CS/DS disaccharides eluted in the following order 
(Fig. 2.3A): Δ0S (11.6 min), Δ2S (32.4 min), Δ4S (33.8 min), Δ6S (34.2 min), 
Δ2,6diS (49.6 min), Δ2,4diS (51.4 min), Δ4,6diS (55.7 min), Δ2,4,6triS (71.5 
min). For the labeling reaction, 350 mM 2-AB were used, which was in large 
excess over disaccharide. The high concentration of 2-AB was nevertheless 
necessary to ensure complete labeling of all disaccharides in the sample. The 
remaining free 2-AB interferes with the HPLC disaccharide analysis 
(overlapping elution), hence removal is imperative. To remove free 2-AB from 
the labeled disaccharides, several methods have been described: e.g. 
chloroform extraction and paper chromatography (Mizumoto and Sugahara 
2012). Both methods were assessed on their applicability and efficacy. Both 
chloroform extraction (Fig. 2.3B) and paper chromatography (Fig. 2.3C) were 
effective in removing free 2-AB, which eluted within the first 10 minutes of the 
HPLC analysis as indicated (red frame). However, paper chromatography was 
more effective than chloroform extraction, and was therefore adapted for 
further analysis. This difference could be particularly important for the 
detection of small amounts of Δ0S, which eluted around 11.6 min and therefore 
close to free 2-AB. 
Using this approach, a detection limit of 100 pg was determined (not shown). 
However, the necessity of a post-labeling cleanup could be disadvantageous 
due to variations in the recovery of labeled disaccharides from filter paper. 
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Despite the high sensitivity, a major problem of this method was the elution 
times of 4S and 6S disaccharides. Those were eluting very close to each 
other (Fig. 2.3), and therefore may not be sufficiently separated to ensure the 
correct analysis of the integrated area from each peak. Better separation of 
the two peaks could have only been achieved by significantly decreasing the 
slope of the NaH2PO4 gradient, which would have resulted in a much longer 
overall running time per sample. Apart from this, labeling of disaccharides with 
2-AB and the analysis using normal phase HPLC with a Polyamine II column 
in combination with increasing concentrations of NaH2PO4 is a very sensitive 
method to detect even very small quantities of CS/DS disaccharides in 
biological samples. 
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Figure 2.2 Labeling of disaccharides using fluorescent dyes. 
To increase the sensitivity of detecting sulphated HexA-GalNAc disaccharides generated as 
a product from chondroitin-lyase enzymes using HPLC, they were labeled with the fluorophore 
2-aminobenzamide (2-AB) or 2-aminoacridone (AMAC). Sugar molecules in solution are in an 
equilibrium between a closed conformation (pyranose) and open form (aldehyde). By applying 
acidic conditions, the equilibrium shifts towards the open form. The NH2-group of 2-AB and 
AMAC attacks the sugars’ aldehyde group via nucleophilic addition, forming a Schiff base. 
Through addition of a reducing agent (NaCNBH3), the final stable reaction product is formed 
by reductive amination. The samples are stable for several months at -20°C. Reproduced with 
modifications from Plaas et al (2001).  
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Figure 2.3 Analysis of 2-AB labeled disaccharides using YMC polyamine II column. 
Chromatogram of the analysis of 2-AB labeled CS/DS disaccharide standards (~ 1 ng each) 
using an YMC polyamine II column (A). Fluorescence emission was detected at 420 nm. 
Labeled disaccharides eluted according to their apparent charge with increasing NaH2PO4 
concentration (dotted line). The analysis was performed at a constant temperature of 30°C. 
To remove excess 2-AB dye from the sample containing disaccharide units, two methods are 
described: chloroform precipitation (B) and paper chromatography (C). A mix of differentially 
sulphated HexA-GalNAc disaccharides were labeled with 2-AB and excess dye removed 
using the two methods. Paper chromatography proved to be more effective for 2-AB removal 
(red box) compared to chloroform extraction. Free 2-AB eluted around 5 min, whereas all 
labeled disaccharides eluted after 10 min.   
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 HPLC disaccharide analysis using 2-aminoacridone labeling and 
reversed phase chromatography 
An additional method was established where a different fluorophore, 2-
aminoacridone (AMAC), was used to label disaccharides using the same 
principal mechanism of reductive amination (Fig. 2.2). 2-AB and AMAC differ 
strongly in their properties, with AMAC being more hydrophobic due to its 
cyclical ring structure. As a result, AMAC-labeled disaccharides can be 
separated using reversed phase HPLC (Deakin and Lyon 2008). Here, a linear 
gradient of increasing methanol concentration was applied to separate AMAC-
labeled disaccharides on a C-18 column. An advantage of using AMAC to label 
disaccharides compared to 2-AB is that there is no post-labeling cleanup step 
necessary, because free AMAC is eluting later than all disaccharides at 
approximately 20 min. However, crystalline AMAC powder supplied by Sigma 
Aldrich needed to be repurified by hydrophobic interaction chromatography as 
described in section 2.2.6 before use, because it contained impurities that 
eluted in the same region as the labeled disaccharides (Fig. 2.4 B). A 
repurification method described by Deakin et al. (2008) proved to be very 
effective in removing a compound eluting around 12 min from the AMAC 
preparation. The purified AMAC preparation was then used for all further 
labeling reactions.  
 
The retention time of each labeled disaccharide standard was individually 
determined using 1 ng disaccharide and eluted in the following order (Fig. 2.4 
A): Δ2,4,6triS (12.8 min), Δ2,4diS (14.6 min), Δ4,6diS (16.6 min), Δ2,6diS 
(17.0 min), Δ2S (18.7 min), Δ4S (19.2 min), Δ6S (20.7 min), Δ0S (23.6 min). 
The detection limit of AMAC-labeled disaccharides was determined to be 
around 10 pg. Because of the superior sensitivity and the excellent separation 
of the free dye from the labeled disaccharides using the Kinetex C-18 column, 
AMAC-labeling of disaccharides was used for all further GAG chain 
disaccharide analyses in this study. 
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Figure 2.4 Analysis of AMAC-labeled disaccharides using a Kinetex C-18 column 
A: Chromatogram of the analysis of AMAC labeled CS/DS disaccharide standards (~ 1 ng 
each) using a Kinetex C-18 column. Fluorescence emission was detected at 520 nm. Labeled 
disaccharides eluted according to their hydrophobicity with increasing methanol concentration 
(dotted line). Highly charged disaccharides eluted first and weakly charged last. The analysis 
was performed at a constant temperature of 40°C. 
B: Repurification of AMAC. To remove a contaminant within the AMAC reagent supplied by 
Sigma Aldrich, a solution of AMAC was purified using a MacroPrep tert-butyl HIC matrix. 
Subsequent analysis on Kinetex C-18 column showed that the contaminant eluting at around 
12.5 min (black line) was effectively removed from the reagent solution (red line). 
Commercially supplied AMAC and purified AMAC are shown as a black and red line, 
respectively.  
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 Decorin purification from human skin fibroblast conditioned 
medium 
After establishing a highly sensitive HPLC method for CS/DS disaccharide 
analysis, decorin was purified from human skin fibroblast and human 
chondrocyte progenitor cell conditioned media. The aim was to use the purified 
proteins for the analysis of their respective CS/DS chain composition.  
 
Firstly, decorin was purified from conditioned medium derived from human skin 
fibroblasts essentially as previously described (Fiedler 2007). The purification 
process involved a two-stage ion exchange chromatography (IEC) procedure. 
One liter of conditioned medium was initially applied to a DEAE-Cellulose 
matrix to remove the majority of serum proteins. After washing the column with 
a buffer containing 400 mM NaCl, an ionic strength sufficient to elute most 
glycoproteins, proteins with a strong negative charge, including proteoglycans, 
were eluted with 1 M NaCl (Fig. 2.5 A).  
The pooled and dialyzed (20 mM Tris-HCl pH 7.4, 400 mM NaCl) fractions (X7, 
X8) from the first IEC step were applied to a column containing Source-15Q 
matrix. This is a strong anion exchanger and allows for more high resolution 
separation of proteins eluting at different NaCl concentrations. The column 
was washed with up to 600 mM NaCl and decorin was eluted with 1 M NaCl 
(Fig. 2.5B). Fractions containing the respective protein peak (fraction 26 and 
27, total volume after pooling was 2 ml) were pooled for further analysis.  
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Figure 2.5 Purification of decorin from human skin fibroblast conditioned media 
A: Conditioned media (1 liter) was applied on a column containing DEAE 52 cellulose (15 ml 
column volume) equilibrated in buffer containing 150 mM NaCl. Weakly bound proteins were 
removed by washing the column with 400 mM NaCl. Strongly negatively charged proteins, e.g. 
proteoglycans like decorin, were eluted from the column using 1 M NaCl. The fractions (X7, 
X8) were pooled and extensively dialyzed against 20 mM Tris-HCl, pH 7.4, 400 mM NaCl. 
B: The dialyzed sample was applied to a column containing Source 15Q matrix (6 ml column 
volume), which was equilibrated in Tris buffer containing 400 mM NaCl (not shown). The salt 
concentration was gradually increased to 600 mM NaCl over 20 min to remove contaminating 
proteins. Decorin was eluted by increasing the concentration to 1 M NaCl, represented by a 
sharp peak with absorbance at 280 nm. Fractions collected during the peak elution were 
pooled.  
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 Analysis of purified decorin 
The protein concentration in the pooled fractions was ~43 µg/ml, as 
determined by BCA assay. Therefore, ~86 µg total protein was isolated from 
one liter of conditioned medium. This is in line with data from others who have 
purified decorin from fibroblast-conditioned medium (Schönherr et al. 1995; 
Fiedler 2007). For analysis of the purified decorin by SDS-PAGE and Western 
blotting, a sample was digested with chABC to analyze the size of the 
proteoglycan core protein. For SDS-PAGE and subsequent silver staining, 
4 μg decorin was digested with 10 mU chABC. For Western blotting, 2 μg 
decorin was digested with 5 mU chABC. An equal amount of undigested 
decorin and also chABC were separated alongside chABC-treated samples. 
In order to collect decorin core protein from the dilute samples after chABC 
digest, it was ethanol precipitated. All samples were reduced for analysis.  
In the lane of undigested decorin in the silver stained SDS-PAGE gel (Fig. 2.6 
A), a smear of 70-100 kDa is visible. This smear could be resolved into distinct 
bands through digestion with chABC and therefore belonged to a 
proteoglycan. Two major bands of approximately 43 and 45 kDa became 
visible after enzymatic processing and also a band of 97 kDa, which belonged 
to chABC. Two faint bands of about 90 kDa (marked with arrowhead) and 38 
kDa, respectively, were also visible. The latter one corresponds to one of the 
units of chABC.  
The presence of decorin was further confirmed by Western blotting with 
decorin-specific antibodies (Fig. 2.6 B). For detection of decorin, a polyclonal 
antibody against human decorin was used which was raised against chABC 
digested human decorin (Glössl et al. 1984). This antibody also recognizes 
dermatan stubs which still reside on the core protein (Voss et al. 1986). In the 
lane containing the undigested decorin, a smear with a size of 70-100 kDa was 
detected. The chABC digested decorin showed two distinct bands with sizes 
of about 43 and 45 kDa. These bands correspond to core proteins with either 
2 or 3 N-linked glycans (Glössl et al. 1984). Again, a band of about 90 kDa was 
visible. It corresponds to a dimer of covalently cross-linked decorin core protein 
as shown previously using mass spectrometry (Fiedler, 2007). The membrane 
was subsequently reprobed with an antibody raised against biglycan. Biglycan 
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has been reported to be synthesized by fibroblasts and has similar 
physicochemical properties (Schönherr et al. 1995). No band could be 
detected, indicating that there was no contamination with biglycan (Fig. 2.6 C). 
Therefore, decorin was purified from conditioned media from human skin 
fibroblasts to a high degree of purity. 
 
To ensure that the purified decorin was exclusively derived from the cells and 
not from serum used in culture media, 2 μg decorin were analyzed by mass 
spectrometry (MS). For this purpose, decorin was digested with chABC as 
described above, separated on a SDS-PAGE gel, and stained with Coomassie 
Brilliant Blue R-250. The bands of 43 and 45 kDa were cut out, reduced and 
alkylated, and digested with trypsin. Tryptic digests were subjected to MALDI-
TOF (matrix-assisted laser desorption ionization - time of flight) and MS/MS 
analysis (Cardiff Biotechnology Service). The data gave a Mascot score of 93 
for human decorin, with three peptides being identified (Fig. 2.7). Alignment of 
the amino acid sequence of human and bovine decorin using the ClustalW 
software suite (Larkin et al. 2007) showed that the identified peptides are only 
present in human decorin. Therefore, contamination of the decorin preparation 
with bovine decorin or biglycan could be excluded. 
 
  
70 
 
 
Figure 2.6 Analysis of purified decorin from human skin fibroblast conditioned media 
A: SDS-PAGE analysis followed by silver staining of decorin purified from conditioned medium 
of human skin fibroblasts. 4 μg decorin before or after digestion with chABC was separated in 
4-20% SDS-PAGE gels under reducing conditions. Left-hand lane shows native decorin with 
intact GAG-chain as a smear of about 70-100 kDa in size. Enzymatic cleavage of the GAG-
chain by chABC resolved the smear into two bands of about 43 and 45 kDa (middle lane). 
These constitute decorin core protein with either 2 or 3 attached N-glycans (Glössl 1984). The 
arrowhead points to an additional faint band of ~90 kDa. chABC alone shows a band of 97 kDa 
in size (middle and right-hand lane). Migration of molecular weight marker is indicated on the 
right. 
B: Western blotting using a polyclonal antibody raised against decorin confirmed the 
successful purification of decorin. A smear of ~70-100 kDa with the undigested decorin and 
two bands of 43 and 45 kDa, respectively, with chABC-digested sample confirm that the silver-
stained proteins correspond to decorin. The band at around 90 kDa is recognized by the anti-
decorin antibody. Previous work revealed that this band constitutes a stable decorin-dimer 
(Fiedler, 2007).  
C: Western blotting using a polyclonal antibody raised against biglycan. No signal could be 
detected even after prolonged exposure to the photographic film. 
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Figure 2.7 Analysis of decorin peptide sequence using MALDI-TOF 
A: To verify the purification of human and to rule out any cross-contamination with bovine 
decorin from FCS, decorin core protein was subjected to trypsin cleavage followed by tandem 
mass spectrometry analysis. Identified peptides are shaded in yellow. The identified peptides 
are consistent with the human but not bovine decorin sequence.  
B: Summary of the ion scores and expect values for the identified decorin peptides. The ion 
score is a measure for the matching of the stated peptide with the observed peak in the MS/MS 
spectrum. A value of >46 is considered to be significant. The expect value is a measure of the 
probability of the peak observed matching the peptide sequence by chance. A value <0.1 is 
considered to be confident (Takegawa et al. 2006). 
 
  
72 
 
 Decorin purification from human chondrocyte progenitor 
conditioned media 
Similar to the purification of decorin from human skin fibroblasts, decorin was 
purified from one liter of conditioned media collected from human chondrocyte 
progenitor cells during culturing and culture expansion. Briefly, these cells 
originate from non-osteoarthritic knee articular cartilage and were collected 
post-mortem from a 56 year old male. The cells were isolated from the 
superficial zone of cartilage using differential fibronectin adhesion (Jones and 
Watt 1993). They are characterized by a high expression of SOX9 and Notch1 
even after extensive expansion in monolayer culture and can be differentiated 
into cartilage when cultured in a 3D environment using appropriate culture 
medium (Williams et al. 2010; Dowthwaite et al. 2004) (see chapter 3, section 
3.2.2 and 3.2.5). 
The medium (containing protease inhibitor cocktail, 5 mM Tris-HCl, 0.1% 
Triton X-100) was applied to a column containing DEAE cellulose to remove 
the majority of serum proteins. Highly charged proteins were eluted using 1 M 
NaCl and collected fractions were pooled for further purification. After 
extensive dialysis against 20 mM Tris-HCl, pH 7.4, 400 mM NaCl, the dialyzed 
sample was applied to a Source 15Q column. Again, the column was washed 
using moderate salt concentrations, before applying a buffer containing 1 M 
NaCl, upon which a sharp peak absorbing at 280 nm was eluting (Fig. 2.8 A). 
Three fractions (13, 14, and 15) of 1 ml were collected and used for further 
analysis. Fraction 13 contained 112 µg, fraction 14 contained 208 µg and 
fraction 15 contained 135 µg protein, as determined by BCA assay. 4 µg 
protein from each faction were used for SDS-PAGE analysis followed by silver 
staining and 2 µg for Western blot analysis. To detect decorin core protein, an 
aliquot of each fraction was digested using chABC.  
In the silver-stained SDS-PAGE gel, several bands were visible in the lanes of 
the undigested samples (Fig. 2.8B). There was no predominant characteristic 
smear as seen before for the intact skin fibroblast decorin (Fig. 2.6 A). 
However, after digestion with chABC, two major bands with a size of 
approximately 45 kDa and 66 kDa appeared. The upper band corresponds to 
BSA which was a component of the chABC preparation used. The lower band 
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appears only after digestion with chABC and therefore corresponds to one or 
more proteoglycan core proteins. This data confirms that the predominant 
component of the sample was a CS/DS-bearing proteoglycan of ~45 kDa. The 
presence of decorin was further confirmed by Western blotting (Fig. 2.8 C). 
Each fraction contained decorin. Undigested samples showed a small smear 
at around 100 kDa, indicative of highly glycanated decorin. The core protein of 
decorin with a size of ~45 kDa was only observed in the digested samples as 
expected. In chABC digested samples of fraction 14 and 15, an additional band 
at around 97 kDa is visible which corresponds to dimeric decorin as previously 
observed in Fig. 2.6 B. The membrane was then reprobed for biglycan. Weak 
bands with a size of ~45 kDa were observed only in the chABC digested 
samples, indicating a contamination of the sample with biglycan (Fig. 2.8D). 
However, this is below the limit of detection for the intact proteoglycan and 
hence present in substantially lower amounts than decorin. It is also possible 
that other SLRPs like fibromodulin or lumican were present. These 
proteoglycans contain a KS chain, and therefore the core proteins would not 
be visible after digestion with chABC. For all further analysis, fraction 13 was 
used because it showed the lowest amount of biglycan contamination from all 
three fractions. 
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Figure 2.8 Purification of decorin from human chondrocyte progenitor cell conditioned 
media.  
Chondrocyte progenitor cells (PRO3 cell line) were grown in the presence of 10% FCS in 
monolayer culture and media was collected when the cells reached about 70% confluency. 
Most serum proteins were removed using DEAE-cellulose ion exchange chromatography. The 
proteoglycan fraction eluted with 1 M NaCl was pooled, dialyzed (400 mM NaCl containing 
buffer) and subjected to Source 15Q ion exchange chromatography. Small proteoglycans 
eluted at 1 M NaCl (A). The fractions collected during elution of the peak were analyzed using 
SDS-PAGE followed by silver staining (B). Western blot analysis of the elution fractions 
showed the presence of decorin (C) and biglycan (D). Samples were digested with 
chondroitinase as indicated (+/- chABC). The lane marked chABC represents the lyase 
preparation itself as a control. 
 
  
75 
 
 Comparison of decorin purified from different cell sources 
In addition to the purified decorin from skin fibroblasts and chondrocyte 
progenitor cells, recombinantly expressed human decorin purified from 
HEK293 cells (EMP Genetech, Ingolstadt, Germany) was used for analysis. 
To compare the different decorin preparations with each other, 2 µg of each 
sample was analyzed using SDS-PAGE, with or without chABC digestion.  
In the silver-stained gel, intact decorin derived from chondrocyte progenitor 
cell medium showed a higher average molecular mass than skin fibroblast or 
HEK293 intact decorin (Fig. 2.9 A). Decorin purified from HEK293 cells 
showed the broadest smear with a size of approximately 80-120 kDa indicating 
a large degree of variation in GAG chain length. After digestion with chABC, 
bands of approximately 43 and 45 kDa corresponding to decorin core protein 
were the predominant components. Interestingly, compared to decorin purified 
from skin fibroblasts, an additional band of about 40 kDa was observed for 
decorin from chondrocyte progenitor cells and HEK293 cells, indicating that 
decorin with reduced N-glycosylation may be present. A band with a size of 
approximately 90 kDa belonged to chABC. 
Western blot analysis (Fig. 2.9 B) showed that the bands for skin fibroblast and 
HEK293 decorin visible after probing the membrane with an anti-decorin 
antibody are matching up with the bands visible in the silver-stained gel as 
expected. In addition, dimeric decorin is visible for the skin fibroblast decorin 
after digestion with chABC. For chondrocyte progenitor cell decorin, the bands 
for decorin are weaker than expected from the silver stained gel and only 
partially overlap. Interestingly, only a single band was detected for the decorin 
core protein, likely corresponding to decorin carrying 3 N-glycans, which was 
not expected given the broad band observed in the silver-stained gel. The 
faster migrating band may be biglycan as shown in Fig. 2.8. In contrast, 
chABC-digested HEK293 decorin showed a broad band with a size of 
approximately 40-45 kDa, indicating that decorin without N-glycosylation may 
be present. Collectively, these data show that both N and O-linked 
glycosylation are cell type specific. 
 
76 
 
 
Figure 2.9 Comparison of decorin purified from different cell types. 
2 µg of decorin from human skin fibroblasts, human chondrocyte progenitor cells (fraction 13) 
and recombinantly expressed in HEK293 cells were separated in 4-20% SDS SDS-PAGE 
under reducing conditions followed by silver staining (A) and Western blotting using an 
antibody raised against human decorin (B). Where indicated, samples were digested with 
chondroitinase (+/- chABC). Lane marked as ‘chAC’ shows the chondroitinase preparation on 
its own as a control.  
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 Disaccharide analysis of decorin from different cell types 
To analyze the disaccharide composition of the CS/DS chain attached to 
decorin purified from skin fibroblast and chondrocyte progenitor cell 
conditioned media as well as from recombinant decorin purified from HEK293 
cells, 4 µg decorin from each sample was digested using 5 mU of chABC, 
chAC-I and chB. The disaccharides were labeled using AMAC and analyzed 
using reversed phase HPLC. Fig. 2.10 shows representative HPLC 
chromatograms of AMAC-labeled disaccharides from skin fibroblast decorin 
after digestion with the respective chondroitinases. Chromatograms for the 
other decorin preparations from chondrocyte progenitor cells and HEK293 
cells after digestion with chondroitinases were of similar quality (not shown). 
After complete depolymerization of the GAG chains with chABC, which 
cleaves both CS and DS, the total disaccharide composition was obtained (Fig. 
2.11 A). The comparison of the disaccharide composition of the respective 
CS/DS chains from the different decorin preparations showed that there are 
substantial differences in the relative amounts of monosulphated 
disaccharides. The most abundant disaccharides were 4S and 6S, and the 
relative levels of these differed significantly between the different decorin GAG 
chains (Fig. 2.11 A). Skin fibroblast decorin contained about 74.8% 4S and 
12.8% 6S whereas chondrocyte progenitor cell decorin contained about 
30.5% 4S and 57.3% 6S and HEK293 decorin contained about 22.9% 4S 
and 50.3% 6S. In addition, 0S was also highly abundant in HEK293 decorin 
(17.0%), whereas it contributed only a small fraction to the composition of the 
GAG chains of the other decorins. After enzymatic digestion using chAC-I, the 
disaccharide composition of the CS type disaccharide within the GAG chains 
could be determined (Fig. 2.11 B). The ratios of the relative amount of 4S to 
6S for chondrocyte progenitor cell and HEK293 decorin were not 
substantially changed (0.53 to 0.63 and 0.46 to 0.5, respectively), whereas it 
changed from 5.8 to 9.4 for skin fibroblast decorin. A much lower relative 
amount of tri- and disulphated disaccharides (0.7 to 1.29% and 1.3 to 1.75%, 
respectively) was observed compared to the chABC digest (0.8 to 1.5% and 
3.3 to 6.0%, respectively), suggesting that these are largely not made of CS 
but DS. 
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Figure 2.10 Reversed phase HPLC analysis of the CS/DS chain disaccharide 
composition of decorin purified from human skin fibroblasts. 
4 µg decorin were digested with chondroitinase ABC (A), AC-1 (B) or B (C). Disaccharides 
were labeled with AMAC and analyzed using reversed phase HPLC as described in Fig. 2.2. 
The elution positions of the disaccharide standards are indicated with arrows. Identified 
disaccharides within the samples are indicated in red. Note, the relative abundance of 
disaccharides in the different digestions requires different levels of sensitivity (scale on y-axis).  
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Digestion of the GAG chains using chB (specifically cleaving only DS 
disaccharides) showed that the major DS disaccharide was 4S (90.1 – 
98.1%), followed by 2,4diS (1.9 – 7.8%) and 2,4,6triS (0-1.5%) (Fig. 2.11 
C). In contrast to digestion with chABC and chAC-I, no 6S and 0S was 
observed. The reason for this is that chB requires a 4-O-sulphated GalNAc 
residue to perform the cleavage of the galactosaminidic bond (Yoshida et al. 
1993). By comparing the relative amounts of each disaccharide species, a 
substantial increase in the relative amount of 2,4diS between the chB and 
chABC digest can be observed for the skin fibroblast decorin. This shows that 
the majority of 2,4diS is made from DS, which is supported by the absence 
of this disaccharide after chAC-I digest. The same is true for 2,4,6triS. 
Conversely, 4,6diS can only be observed after digestion with chABC and 
chAC-I, which suggests that this is mostly made from CS.  
By comparing the relative disaccharide amounts for decorin from chondrocyte 
progenitor cells after digestion with different enzymes, a marked increase of 
2,4,6triS and 2,4diS was observed after chB digest, suggesting that here as 
well the majority of these disaccharides was constituted by DS. Decorin 
produced by HEK293 cells did not have any 2,4,6triS, but 2,4diS appeared 
to be of DS type as well. 
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Figure 2.11 Quantitative analysis of the GAG disaccharide composition from decorin 
isolated of different cell types. 
For each sample, 4 µg protein was digested using chondroitinases ABC (A), AC-I (B) or B (C), 
followed by labeling with AMAC and reversed phase HPLC analysis. Peaks for individual 
disaccharides were integrated and the result expressed at the percentage of the total 
disaccharide content. The data shown in the graphs is representative for one batch of decorin 
of each source, which was analyzed in triplicate. Data is shown as mean ± SEM.   
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 Discussion 
 Establishing a method for disaccharide analysis by HPLC 
Differentially sulphated disaccharides derived from GAG chains can be 
successfully analyzed using strong anion exchange HPLC (Midura et al. 1994). 
In order to set up the method on the Dionex ICS-3000 HPLC system (Dionex, 
Idstein, Germany), several parameters needed to be optimized before 
analyzing GAG samples of unknown disaccharide composition. These 
parameters are the precise retention times and detection limit of individual 
disaccharides.  
For determining the retention times, each disaccharide standard was run 
separately on the system. Comparison between the order in which the different 
non-sulphated, mono- and disulphated CS/DS disaccharides eluted on the 
Dionex HPLC system and CarboPac PA1 column to the data in the literature 
showed almost complete agreement. Only the elution order of Δ4,6diS and 
Δ2,4diS was reversed. Generally, these two disaccharides elute very close to 
each other and therefore minor changes in the column matrix could easily 
account for such a change in affinity.  
In order to assess the detection limit for CS/DS disaccharides, several different 
concentrations were analyzed. It was found that an amount of 110 ng of each 
standard was very close to the detection limit (Fig. 2.1 B), but still allowed the 
resolution into single peaks. This is in good agreement with the proposed 
detection limit of about 50 ng using UV detection (absorbance at 232 nm) as 
described by Midura and colleagues.  
Even though the detection limit of this method was in the 100 nanogram range, 
it was unlikely to be sensitive enough for the analysis of small amounts of 
biological samples. Therefore, the fluorescent labeling of disaccharides using 
2-AB and AMAC was evaluated. This allowed to significantly increase 
sensitivity by a factor of 103 (2-AB) and 104 (AMAC), respectively. Firstly, the 
fluorescent labeling of disaccharides with 2-AB was established (Kinoshita and 
Sugahara 1999). 2-AB is a relatively hydrophilic compound and therefore 
allows for separation of unlabeled disaccharides using an ion exchange HPLC. 
Despite the high sensitivity (picogram range), the method had a substantial 
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disadvantage which was the post-labeling cleanup that was required. Two 
different methods for the cleanup were evaluated, showing that paper 
chromatography was most effective. Nevertheless, an incomplete recovery of 
labeled disaccharides from the filter paper is a concern, especially of low-
abundant disaccharide species. In addition, the 4S and 6S disaccharides 
eluted too close to each other for confident discrimination, even after 
optimization of the buffer gradient. Kinoshita and coworkers did not observe 
this problem. They could fully resolve every disaccharide, even though 4S 
and 6S were also quite close to each other. One reason for this could be the 
column used for separation. In their study, an amine-bound silica PA-03 
column (250 x 4.6 mm, YMC Co., Kyoto, Japan) was used (which is not 
commercially available anymore), that may have slightly different properties 
compared to the column YMC-Pack Polyamine II (250 x 4.6 mm, YMC Europe 
GmbH, Dinslaken, Germany) employed here. 
Another commonly used fluorophore, AMAC, was then used for disaccharide 
labeling (Deakin and Lyon 2008; Volpi 2010; Kitagawa et al. 1995; Jackson 
1994). The separation of AMAC-labeled sugars follows a completely different 
principle. Here, the hydrophobicity of AMAC is exploited and separation of 
disaccharides achieved using reversed phase HPLC with a C-18 column (Fig. 
2.4 A). Post-labeling cleanup was not necessary because free AMAC is more 
hydrophobic than labeled disaccharides and therefore elutes last. After 
establishing the AMAC-labeling and HPLC analysis method, a good separation 
of each disaccharide was achieved.  
In conclusion, sensitive HPLC-based methods for GAG disaccharide analysis 
were compared. The HPLC methods and determined sensitivity are 
summarized in Table 2.4. AMAC-labeling of disaccharides was the most 
sensitive method and showed the best separation of individual disaccharide 
species. 
 
  
83 
 
Table 2.4 Comparison of HPLC disaccharide analysis methods 
 unlabeled 2-AB labeled AMAC labeled 
Detection 
mode 
Absorbance 
(232 nm) 
Fluorescence            
EX: 330 nm              
EM: 420 nm 
Fluorescence            
EX: 427 nm   
EM: 520 nm 
Sensitivity ~100 ng ~100 pg ~10 pg 
Column CarboPAC PA1 
(250 x 4 mm, 
Dionex) 
Polyamine II column     
(250 x 4.6 mm, YMC) 
C-18 column                  
(100 x 4.6 mm, Kinetex) 
Separation 
method 
Normal phase: 
ion exchange 
Normal phase: ion 
exchange 
Reverse phase: 
hydrophobicity 
Gradient Increasing NaCl Increasing NaH2PO4 Increasing methanol 
Labeling 
conditions 
None Reductive amination, 
2h, 65°C 
Reductive amination, 
16h, 37°C 
Post-labeling 
cleanup 
None Paper chromatography, 
chloroform extraction 
None 
 
 Characterization of decorin preparations from different cell types 
Decorin from human skin fibroblast media was purified using a two-step anion 
exchange chromatography method without adding denaturing agents and 
without precipitation of proteins from the media. Purity was assessed through 
SDS-PAGE analysis followed by silver staining and Western blotting and was 
high as described in previous studies (Glössl et al. 1984; Schönherr et al. 2005; 
Fiedler et al. 2008). After chABC digestion, in addition to the core protein at 43 
and 45 kDa, a band at around 90 kDa was also recognized by a decorin-
specific antibody. A previous study in our lab analyzed the band using mass 
spectrometry and provided evidence for it to be a cross-linked decorin-dimer 
(Fiedler 2007). 
Purification of decorin using anion exchange chromatography reported the 
contamination of decorin with biglycan (Pearson and Gibson 1982) and 2HS 
glycoprotein (Sugars et al. 2002). However, the method employed here differs 
and no biglycan contamination was detected using Western blotting with a 
biglycan specific antibody or mass spectrometry of the bands constituting the 
core protein. Furthermore, the skin fibroblast cell line used as a source for 
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decorin was reported to lack an efficient biglycan synthesis (Schönherr et al. 
1995). Also, no contamination with 2HS glycoprotein (59 kDa) was noticed in 
the silver-stained SDS-PAGE gel. It was reported earlier that 2HS 
glycoprotein co-elutes with decorin using anion exchange chromatography. 
However, 2HS glycoprotein was shown to elute at salt concentrations below 
0.35 M NaCl on a strong anion exchange matrix (Sugars et al. 2002), and 
therefore could be separated from decorin which eluted at higher NaCl 
concentrations (from Source 15Q matrix at > 0.7 M NaCl).  
Decorin was also purified from the conditioned media of human chondrocyte 
progenitor cells. For this, the same purification protocol as for the skin 
fibroblast medium was used. The purity of the isolated proteoglycan(s) was 
assessed using SDS-PAGE followed by silver staining and Western blotting. 
After treatment with chABC, a predominant broad band with a molecular mass 
of ~45 kDa appeared, which is the expected size of the decorin core protein, 
and confirmed that the preparation was composed of > 95% CS/DS bearing 
proteoglycan. The presence of decorin was confirmed by probing with an anti-
decorin antibody. However, a weak band of approximately 45 kDa appeared 
as well after reprobing the membrane with an antibody raised against human 
biglycan. Contamination with biglycan was not surprising given that the 
chondrocyte progenitor cells are derived from cartilage and as biglycan like 
decorin is highly abundant in cartilage (Heinegård and Saxne 2011). Biglycan 
and decorin share a high degree of homology and have similar properties. 
Their core proteins have a similar size and since biglycan can have one or two 
GAG chains attached, they elute at similar NaCl concentrations. However, 
unlike decorin, the amount of biglycan seemed to be only a small fraction of 
the total protein content. In order to minimize the effect of biglycan content on 
HPLC disaccharide analysis, the first fraction eluting from the Source Q15 
matrix was used for downstream analysis as the Western blot showed that it 
had the lowest biglycan content. 
The comparison of the different decorin preparations in combination with 
recombinantly expressed decorin isolated from HEK293 cells revealed 
differences in GAG chain length and also in the N-linked glycosylation. This 
might be a result of different tissue specific expression levels of 
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glycosyltransferases (Little et al. 2008). The data showed that the glycosylation 
of decorin depends on the cell type and possibly adapts its biological function 
depending on the tissue. Similar observations were made by Viola and 
coworkers, who found that CS/DS chains of decorin of various different bovine 
tissues have a unique disaccharide composition (Viola et al. 2006). 
 
 GAG analysis of decorin from different cell types 
Decorin has long been subject to detailed disaccharide analysis because of its 
relative simple glycosylation (1 site for O-linked and 3 sites for N-linked 
oligosaccharides) and biological availability, be it purified from animal tissues 
or through recombinant expression. The major feature being that decorin 
comprises only one GAG chain which makes it well suited for developing novel 
GAG analysis methods because the analytical results can be directly related 
to this simple GAG chain structure (Laremore et al. 2010; Zamfir et al. 2011; 
Zhao et al. 2013; Viola et al. 2006). Proteoglycans with multiple GAG chains 
(e.g. aggrecan) could potentially be differentially sulphated on different 
domains of the core protein depending on the biological context. Several 
studies have analyzed the disaccharide composition of decorin, either 
recombinantly expressed in Chinese hamster ovary cells (Kitagawa et al. 
1997), HEK293 cells (Laremore et al. 2010) or purified from skin tissue (Zhao 
et al. 2013). Even though the human skin fibroblast cell line used in this study 
was used in many previous studies on decorin GAG chain structure (Seidler et 
al. 2007; Zamfir et al. 2009; Zamfir et al. 2003; Glössl et al. 1984; Greve et al. 
1990; Hausser et al. 1992; Schönherr et al. 1995; Hausser et al. 1989), none 
of the publications described the total disaccharide composition. In these 
studies, the skin fibroblast decorin GAG chain was mainly used for developing 
mass spectrometry techniques for GAG chain analysis. Interestingly, in one of 
these studies, the composition of a pentasulphated hexasaccharide that 
interacts with FGF2 was identified (Zamfir et al. 2003). More recent work gave 
insights into the architecture of the GAG chain (Zhao et al. 2013). 
The disaccharide composition of the decorin GAG chains analyzed here 
differed greatly between the different cell types in line with observations in 
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previous studies (Jianyun Yan et al. 2011; Koźma et al. 2011; Li et al. 2013). 
Skin fibroblast decorin had 4S as its main component (75%), whereas for the 
other ones, 6S was the main disaccharide followed by 4S. Although 0S 
contributed only a small part to the disaccharide composition of skin fibroblast 
and chondrocyte progenitor cell decorin, it was highly abundant within the 
HEK293 decorin (17%). The high amount of non-sulphated disaccharides was 
not unexpected as decorin expression in these cells is engineered. The 
amount of sulphotransferases located in the Golgi system may not have been 
sufficient to perform complete sulphation of the disaccharides because of the 
artificially high expression level of decorin. Incomplete posttranslational 
processing of decorin when expressed recombinantly has previously been 
reported (Laremore et al. 2010). Laremore and coworkers investigated the 
disaccharide composition of recombinant decorin purified from HEK293 cells 
using native PAGE and LC-MS. Using these techniques combined with 
digestion of the GAG chain with different chondroitinases, they proposed a 
rough map of decorin’s GAG chain. They suggested that it is comprised of CS 
and DS blocks of various lengths and disaccharide compositions. In contrast 
to the results described here, the major disaccharide was 4S (63%), followed 
by 6S (23%) and 0S (12%) after digestion with chABC (Laremore et al. 
2010). Nevertheless, they also made the observation that the relative amount 
of 2,4diS increased when comparing chABC to chB digested GAG, indicating 
that this disaccharide is mostly contributed to by DS, which is in agreement 
with the results obtained here. Given that only one type of decorin from 
HEK293 cells grown in a single condition was used for their study, differences 
in the disaccharide composition compared to HEK293 decorin in the 
experiments described here could be the result of many factors, including 
culture media, expression system, and expression levels. An overview of the 
differences in disaccharide composition of decorin isolated from different cell 
types from this study and from others is shown in Table 2.5. 
 
To conclude, these results show that decorin is a highly versatile proteoglycan, 
which can have substantially different modifications in its glycosylation, be it 
the amount or structure of N-linked glycans or the length and the disaccharide 
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composition of its CS/DS chain, depending on the cell type or biological context 
in which it is expressed. Different disaccharide compositions could have an 
influence on the biological function of decorin within a specific tissue. 
Especially highly sulphated disaccharides, e.g. 2,4,6triS and 2,4diS, can 
have an effect on binding of growth factors or to cell surface receptors 
(Sugahara and Kitagawa 2000). 
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3 Development and optimization of a novel human 3D 
cartilage model 
 
 Introduction  
To investigate the molecular changes taking place in cartilage in developing 
OA, a model system of normal human cartilage would be of great advantage 
for the following reasons:  
- investigating human cartilage and therefore detecting relevant events 
as there may be species specific differences in pathogenesis 
- minimizing variability as a consequence of tissue origin 
- studies conducted in tightly controlled environments 
 
Human cartilage from a non-arthritic joint can only rarely be obtained, as cases 
(accidental death) where such tissue can be harvested are relatively rare and 
therefore are not a reliable source for a steady supply of cartilage for 
meaningful experimental studies. Data obtained from studies on tissue 
harvested from unaffected areas of osteoarthritic joints, e.g. collected from 
total knee arthroplasties, must to be viewed with caution. Even though the 
cartilage may look histologically normal, the chondrocytes nevertheless were 
exposed to the inflammatory conditions within the joint and therefore 
osteoarthritic changes could be imprinted. Hence, tissue engineered human 
cartilage is the obvious choice to analyse chondrocyte metabolism in a 
controlled and defined environment. 
 
To generate cartilage-like tissue in vitro, various techniques using different 
approaches have been developed (Chung and Burdick 2008; Chen et al. 
2014). Tissue scaffolds based on proteins (collagen, fibrin), polysaccharides 
(alginate, chitosan, HA) and synthetic polymers (polylactic acid, poly(lactic-
coglycolic acid)) have been used for cartilage tissue engineering (Chung and 
Burdick 2008; Vinatier et al. 2009). They provide a support to which 
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chondrocytes/chondrogenic cells can adhere and produce extracellular matrix. 
In addition, scaffold-free approaches have also been developed where the 
resulting cartilage construct is the product solely of the extracellular matrix 
secreted by the cells. Because of the absence of artificial compounds, scaffold-
free constructs are probably as close to native cartilage as possible. However, 
it takes considerable time before such constructs develop mechanical integrity 
and resilience to loading. 
 
A typical scaffold-free model are micromass cultures, where cells are collected 
by centrifugation in a conical tube, leading to formation of a small ball-shaped 
cartilaginous tissue (Johnstone et al. 1998). In spite of the formation of 
cartilaginous tissue, a disadvantage of micromass cultures is the 
inhomogeneous differentiation of cells into chondrocytes. Incomplete 
chondrogenic differentiation can occur depending on the location of the cells 
within the pellet and therefore, be influenced by access to medium 
components and growth factors. Such micromass pellet cultures are also size 
limited and cell death may occur in the centre of the construct due to lack of 
sufficient nutrient diffusion. Moreover, mechanical loading experiments are 
difficult to perform since the cells are experiencing different amounts of 
compression depending on their location in the pellet. The use of transwell 
inserts with a semipermeable membrane to generate disc-shaped cartilage 
constructs provides a different approach for micromass cultures (Murdoch et 
al. 2007; Tew et al. 2008). This method has the advantage that the cells have 
access to nutrients from two sides independently, resulting in more 
homogenous chondrogenic differentiation and an overall architecture more 
akin of joint cartilage.  
 
Independent of the culture system employed, the success of cartilage tissue 
engineering ultimately depends to a large extent on the cell type used. 
Chondrocytes harvested from articular cartilage can be expanded in 
monolayer culture but quickly change their phenotype and loose the ability to 
form a cartilaginous matrix (Schnabel et al. 2002; Lin et al. 2008). However, it 
was reported that dedifferentiated primary human chondrocytes are able to re-
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differentiate in a 3D environment, e.g. alginate beads or micromass culture, 
after losing their chondrogenic potential during monolayer expansion 
(Schrobback et al. 2011; Domm et al. 2002). The main problem is the limited 
number of chondrocytes that can be harvested from a single cartilage sample 
of each patient. This considerably limits the number of cartilage constructs that 
can be generated. Therefore, these cells are not suitable for large scale 
cartilage tissue engineering. Consequently, people have looked for alternative 
cell sources. 
Bone marrow derived mesenchymal stem cells (BMSC) are commonly used 
for cartilage tissue engineering (Johnstone et al. 1998; Yoo et al. 1998; 
Solchaga et al. 2011; Murdoch et al. 2007). The cells form a cartilage-like 
matrix in micromass cultures, but show expression of terminal differentiation 
markers after a few weeks in culture (Johnstone et al. 1998). Adipose-tissue 
derived stem cells show mesenchymal cell characteristics and can be 
differentiated into chondrocytes. However, in comparison to BMSCs, these 
cells show a reduced chondrogenic potential, resulting in cartilage constructs 
with a lower collagen type II and GAG content (Huang et al. 2005; Im et al. 
2005). It was also demonstrated that stem cells isolated from synovium (Kurth 
et al. 2007), periosteum (Fukumoto et al. 2003), muscle (Adachi et al. 2002) 
and umbilical cord tissue (Harris 2013) can be differentiated into cartilaginous 
tissue. A cell type that has thus far only rarely been investigated for cartilage 
tissue engineering are chondrocyte progenitor cells. They are a cell population 
showing mesenchymal stem cell properties (Archer et al. 2012), residing in the 
surface zone of articular cartilage (Dowthwaite et al. 2004). They are capable 
of differentiating into chondrocytes, osteoblasts or adipocytes, respectively in 
vitro and in vivo. Chondrocyte progenitor cells were recently isolated from 
human articular cartilage, using selection based on differential fibronectin 
adhesion (Williams et al. 2010). In contrast to normal full-depth chondrocytes 
which loose their chondrogenic potential after 8 population doublings (PD) 
(Dell’Accio et al. 2001; Schnabel et al. 2002; Cournil-Henrionnet et al. 2008), 
these chondrocyte progenitor cells keep their chondrogenicity and maintain 
the expression of the chondrocyte specific transcription factor Sox9 even after 
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extensive expansion in monolayer culture and after high numbers of PD 
(Williams et al. 2010). 
Based on this background it was considered that the chondrocyte progenitor 
cells were the ideal cell-type for establishing an in vitro cartilage model. 
 
 Aims for this chapter: 
1. To establish a methodology that supports chondrogenic differentiation 
of human articular cartilage progenitor cells and subsequent cartilage-
like ECM deposition in in vitro culture. 
 
2. To optimize the medium formulation to yield reliable homogenous and 
maximal cartilage matrix formation. 
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 Materials and methods 
 Materials 
Cell culture media and other cell culture reagents were purchased from Life 
Technologies (Paisley, UK). All other chemical reagents and proteins were 
purchased from Sigma Aldrich (Gillingham, UK) unless otherwise stated. 
Recombinant human transforming growth factor (TGF)-2 and recombinant 
human basic fibroblast growth factor (FGF)-2 were purchased from Peprotech 
(London, UK). Recombinant human BMP-2 was a kind gift from Genetics 
Institute (Cambridge, MA, USA). 
 
 Cell culture 
Human chondrocyte progenitor cells were isolated as described (Williams et 
al. 2010). For monolayer expansion, cells were cultured in a 1:1 mixture of 
Dulbecco’s minimal essential medium and Ham’s F12 (DMEM/F12, without L-
glutamine, Gibco, Cat #21331-046), containing 10% heat-inactivated fetal calf 
serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, 
50 μg/ml L-ascorbic acid-2-phosphate, 1 mg/ml D-glucose, 1 ng/ml TGF-2 
and 5 ng/ml FGF-2. Medium was changed every third day. Cells were 
maintained in a 1:1 mixture of fresh medium and conditioned medium. The 
growth factors were added fresh to the medium on the day when medium was 
changed. Passaging of cells was performed as described in chapter 2, section 
2.2.8. 
 
 Coating of transwell membranes with collagen type II or 
fibronectin 
Collagen type II was isolated from bovine nasal cartilage by acid extraction 
and pepsin digestion, and human serum fibronectin was obtained from Sigma 
(Cat #F1056). Collagen type II was solubilized in 0.5 M acetic acid at a 
concentration of 5 mg/ml. For coating, a solution with a concentration of 
0.5 mg/ml was prepared by diluting the stock solution with sterile filtered 0.5 M 
acetic acid. 70 µl was added directly onto the membrane for each transwell 
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insert, followed by addition of 10 µl 0.2 M Tris-HCl, pH 7.4, to neutralize the 
solution. After incubation overnight at 4°C, the excess solution was carefully 
removed and the transwell membrane dried in a cell culture hood.  
Human fibronectin stock solution was diluted in PBS (137 mM NaCl, 3 mM 
KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.3) to a concentration of 40 µg/ml. 
To each transwell insert, 70 µl of the solution were added and incubated over 
night at 4°C. The solution was then carefully removed and the transwell 
membrane dried.  
 
 Chondrogenic differentiation of human chondrocyte progenitor 
cells 
Cells were cultured as a monolayer in 75 cm2 tissue culture flasks until about 
80% confluency was reached. The cells were passaged using trypsin/EDTA 
solution (0.05% v/v, Gibco) and seeded into Millicell hanging transwell culture 
inserts (PET membrane, 0.4 µm pore size, 6.5 mm diameter, Millipore, 
Watford, UK) pre-coated with human fibronectin. A total cell number of 0.5 to 
14 x 106 was used per construct depending on the experiment. Prior to seeding 
into the transwell inserts, the cells were washed in the respective medium 
formulations to be evaluated (Table 3.2). Cells were finally resuspended in 
500 µl medium containing the respective growth factors (TGF-2, BMP-2, 
bovine insulin) as indicated and seeded into the inserts which were placed into 
24-well cell culture plates (Sarstedt, Nümbrecht, Germany). The plates 
containing the inserts were either placed directly in the incubator or centrifuged 
for 5 min at 250 x g prior to that. 1 ml of the respective medium containing 
growth factors was applied into the wells to immerse the bottom of the transwell 
with medium. The constructs were cultured for 14 to 28 days (depending on 
the experiment) and the medium from inside the transwell insert and bottom 
well was changed every 2 days with fresh medium. 
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Table 3.2 Media formulations described in the literature for the differentiation of 
chondrocytes, chondrocyte progenitor cells, and mesenchymal stem cells in 3D culture 
systems. 
Literature reference Formulation 
Williams et al. (2010) 
 
monolayer expansion 
medium (without FGF-2) 
DMEM/F12 
10% heat-inactivated FCS 
50 µg/ml ascorbate-2-phosphate 
5.5 mM D-glucose 
2 mM L-glutamine 
1 ng/ml TGF-β2 
Hayes et al. (2004) 
DMEM/F12 
20% heat-inactivated FCS 
100 µg/ml L-ascorbic acid-2-phosphate 
5 ng/ml TGF-β2 
Williams et al. (2010) 
 
chondrogenic 
differentiation medium 
DMEM/F12 
2% heat-inactivated FCS 
50 µg/ml L-ascorbic acid-2-phosphate 
5.5 mM D-glucose 
ITS (10 µg/ml insulin, 5.5 µg/ml transferrin, 
5 ng/ml selenium) 
100 nM dexamethasone 
10 ng/ml TGF-β2 
Murdoch et al. (2007) 
DMEM 
25 mM D-glucose 
4 mM L-glutamine 
1 mM sodium pyruvate 
100 U/ml penicillin and 100 μg/ml 
streptomycin 
non-essential amino acid mixture (1x) 
ITS supplement 
100 nM dexamethasone 
50 g/mL L-ascorbic acid-2-phosphate 
10 ng/ml TGF-2 
 
 Immunocytochemistry 
Chondrocyte progenitor cells (1 x 105 cells/well) were seeded into wells of a 
24 well-plate containing circular glass coverslips coated with 40 µg/ml human 
fibronectin. Cells were cultured for 48 h, washed in PBS and either fixed with 
4 % paraformaldehyde (PFA, Sigma Aldrich) in PBS for 30 min for staining with 
anti-Sox9 antibody (Abcam, Ab3697, 4 µg/ml) or ice cold methanol/acetone 
(1:1) for 20 min for staining with anti-Notch-1 antibody (bTAN-20, cell culture 
supernatant, Developmental Studies Hybridoma Bank, Iowa, USA). 
Permeabilization of the cells using 0.1 % Triton X-100 / 0.5 % PFA in PBS for 
5 min was performed in addition for slides stained for Sox9. The coverslips 
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were washed twice in PBS and nonspecific binding sites were blocked with 1% 
BSA in PBS for 30 min at room temperature. Afterwards, the primary antibody 
was diluted in 1% BSA in PBS to the appropriate concentration and added, 
and coverslips incubated overnight at 4°C. Coverslips were washed 3x with 
TBS (50 mM Tris HCl, pH 7.4, 150 mM NaCl) and incubated with a compatible 
AlexaFlour488-conjugated secondary antibody (1 µg/ml in 1%BSA in TBS, Life 
Technologies) for 1 h at room temperature in the dark. Diluted antibodies were 
centrifuged for 5 min at 10,000 x g to remove any aggregated antibodies before 
application to the coverslips. Afterwards, the coverslips were washed 3x with 
TBS and then mounted with Vectashield containing DAPI (Vectorlabs, UK). 
Antibody controls were performed by replacing primary antibodies with non-
specific mouse IgG or rabbit IgG (4 µg/ml, Jackson ImmunoResearch 
Laboratories Inc., West Grove, USA). 
 
 Histological methods 
Cartilage constructs were fixed for 24 h using 4% (w/v) PFA in PBS. After 
extensive washing in PBS, the fixed constructs were paraffin-embedded and 
cut into sections with a thickness of 5 µm. Sections were deparaffinised in 
xylene and rehydrated with a series of decreasing ethanol-concentrations. 
Staining with haematoxylin and eosin was performed using a Leica 
autostaining machine (Oral Pathology Lab, UHW). Haematoxylin and eosin are 
commonly used to assess the tissue and cell morphology. Haematoxylin stains 
nuclei blue to purple and eosin stains cytoplasmic structures pink to red. 
Cartilage ECM structures are stained bluish. Safranin-O and toluidine blue 
(both from Sigma Aldrich) staining were performed as described (Schmitz et 
al. 2010). Briefly, slides were deparaffinised and rehydrated as described 
above. For toluidine blue staining, slides were immersed in staining solution 
(0.04% (w/v) in 200 mM sodium acetate, pH 4) for exactly 5 min and 
immediately washed using tap water afterwards. Afterwards, sections were 
dried, washed once in xylene and subsequently mounted using DPX mounting 
solution (Sigma Aldrich). Nuclei stain dark blue and structures rich in 
negatively charged GAG chains stain violet. Other structures stained in 
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different shades of light blue. Safranin-O staining involved staining of slides 
using Fast green solution (0.001% (w/v) in H2O) for 5 min, followed by a 
washing step in 1% (v/v) acetic acid solution. In the next step, slides were 
stained for 5 min in Safranin-O staining solution (0.1% (w/v) in H2O). After 
several washing steps in pure ethanol, the slide was washed once in xylene 
followed by mounting with DPX. With this staining protocol, cartilage matrix 
stained red to orange and underlying bone stained green. Other cellular 
components stain grey to green (Schmitz et al. 2010). 
 
 Biochemical analysis of 3D constructs 
Constructs were washed in PBS and frozen on dry ice after all residual liquid 
was removed. Until further analysis, the constructs were stored at -80°C. For 
determination of GAG content, the constructs were transferred into a 1.5 ml 
tube. To release the GAG chains, constructs were digested in 200 µl of 
500 g/ml papain (specific activity > 10 units/mg protein, Sigma Aldrich) for 
16 h at 65°C in 2 mM cysteine, 50 mM sodium phosphate, pH 6.5, 10 mM 
EDTA. Afterwards, the sample was mixed with 400 µl 0.1 M NaOH and 
incubated for 20 min at room temperature, followed by addition of 400 µl 
neutralizing buffer (4 M NaCl, 100 mM Na2HPO4, 0.1 M HCl, pH 7.2) as 
described (Solchaga et al. 2011). The mixture was centrifuged for 10 min at 
14,000 x g and the supernatant transferred to a fresh 1.5 ml tube for further 
analysis. 
 
 DMMB assay 
DMMB assay was essentially performed as described (Farndale et al. 1986). 
Briefly, 250 l dimethyl methylene blue (Sigma Aldrich) reagent was mixed 
with 10 l sample in a 96 well plate using a multi-pipette. The absorbance was 
measured instantly (within ~2 min) at 525 nm using a Spectrostar Omega 
(BMG Labtech, Ortenberg, Germany). A standard curve from 10 to 50 µg/ml 
was prepared in parallel using CS from bovine trachea (Sigma Aldrich). The 
curve was fitted by linear regression to derive GAG concentrations in samples. 
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 Mechanical loading of cartilage constructs 
2 x 106 cells/insert were seeded on fibronectin-coated transwell membranes 
and cultured for 28 days to form cartilage constructs in serum-free 
chondrogenic medium containing growth factors. Immediately before 
mechanical loading, the constructs were removed from the transwell insert and 
were kept in a 24 well-plate well in differentiation medium.  
Unconfined mechanical loading was performed using a Bose Electroforce® 
3200 loading rig with a Bose low force axial transducer loading cell (220 N 
force capacity; Bose GmbH, Friedrichsdorf, Germany) attached to it (Fig. 3.1). 
To immobilize the cartilage construct for loading, 200 µl of 1% low melting point 
agarose was added into the well of a 24 well plate and after setting, a hole 
using an 8 mm biopsy punch was made. The agarose plug was then carefully 
removed and the well immersed in 1 ml chondrogenic differentiation medium 
(without growth factors). The cartilage construct was placed in the central 
excised area and was subjected to compression as detailed in the results 
section. Data was analysed using WinTest® software suite (Bose). This 
experiment was done in collaboration with Dr Emma Blain, School of 
Biosciences, Cardiff University. 
Determination of Young’s modulus (a measure for the stiffness of an elastic 
material during unconfined compression) was determined by placing 28 day 
old constructs (removed from the transwell inserts and without being immersed 
in medium) on a metal base and compressing them for several minutes using 
an SMT1-5N load cell (Interface Inc., Scottsdale, AZ, USA) mounted on a 
loading rig (Servocon Systems, Daventry, UK). Constructs were compressed 
with 100 mN and the resistive force generated by the constructs was 
monitored. This experiment was done in collaboration with Professor Sam 
Evans, School of Engineering, Cardiff University. 
  
98 
 
 
Figure 3.1 Setup for mechanical loading of cartilage constructs. Mechanical properties of 
28 day old cartilage constructs were examined using a Bose Electroforce® 3200 loading rig 
(A) together with a Bose low force axial transducer loading cell (A, inside red box; magnified 
in B). The cartilage construct was loaded inside a well of a 24 well plate which contained 
medium (C). 
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 RT-PCR gene expression analysis 
Isolation of total RNA, generation of cDNA and PCR analysis was performed 
as described in chapter 4, sections 4.2.6 and 4.2.7. The primers used for 
experiments in this chapter are described in Table 3.1.  
 
Table 3.1 Primer sequences used for PCR analysis 
Gene name 
Sequence of forward (top) and reverse primers 
(bottom) (5‘ - 3‘) 
Reference 
sequence 
c-fos 
GGCAAGGTGGAACAGTTATCTC 
CTTCTCCTTCAGCAGGTTGG 
NM_005252 
h36B4 
AGATGCAGCAGATCCGCAT  
ATATGAGGCAGCAGTTTCTCCAG  
(Wagener et al. 
2001) 
 
 Statistical analysis 
Statistical analysis was performed using the Prism software suite (Graphpad 
Software Inc., La Jolla, CA, USA). Data was analyzed by one-way analysis of 
variance (ANOVA) with post hoc analysis using Tukey‘s multiple comparison 
test. P values < 0.05 (95% confidence) were considered as significant.  
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 Results 
 Development of cartilage-like tissue in an in vitro 3D culture 
system 
Human knee articular cartilage chondrocyte progenitor cells (PRO2N, post-
mortem derived from a 40 year old male with no evidence of OA pathogenesis) 
were the cell type of choice for developing the tissue model, in order to have a 
well-defined and theoretically at least, unlimited supply of cells. Using 
chondrocytes isolated from full depth articular cartilage would have required a 
regular supply of “normal” human tissue and resulted in having a broad mixture 
of cells in different differentiation stages in the model. Another reason for not 
using chondrocytes was that expected variations between cell isolates would 
likely be a major issue for the planned downstream studies. While having its 
own limitations, using a defined chondrocyte progenitor population and strictly 
controlled conditions for the studies will help in regards to reproducibility of any 
findings. The progenitor cell isolates used in this study were a kind gift by 
Professor C. Archer and Dr R. Williams (School of Biosciences, Cardiff 
University, UK). For expansion of the cells in monolayers, supplementing the 
culture medium with fibroblast growth factor-2 (FGF 2) (5 ng/ml) and 
transforming growth factor-β2 (TGF-β2) (1 ng/ml) was essential to keep the 
cells in their progenitor state (Williams et al., 2010). In monolayer, the cells 
showed a characteristic spindle shaped morphology (Fig. 3.2 A). Cells cultured 
without these growth factors dedifferentiated, adopted a different morphology 
and could not be used for tissue engineering (not shown). 
To analyse whether the chondrocyte progenitor cells expanded in monolayer 
culture still possessed their chondrogenic potential as reported in the literature 
(Williams et al. 2010), cells were fixed, permeabilized and incubated with anti-
Sox9 antibody and anti-Notch1 antibody, respectively (Fig. 3.2 B). The cells 
showed clear staining for the transcription factor Sox9 in the nucleus. Strong 
staining for Notch1 was observed on the cell membrane and also in cytoplasm, 
as previously described and taken as evidence of progenitor status (Hiraoka 
et al. 2006; Dowthwaite et al. 2004; Grogan et al. 2009). The cytoplasmic 
staining of Notch1 is most likely a result from staining of Notch1 being 
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synthesized in the ER/Golgi system at the time of permeabilization/fixation. No 
such labeling could be detected in the negative control, where primary 
antibodies were replaced with rabbit IgG or mouse IgG as appropriate. 
Maintenance of Sox9 expression in monolayer culture is related to a persistent 
chondrogenic potential in monolayer culture (Williams et al., 2010). 
Consequently, the cells displayed the criteria for chondrocyte progenitor and 
could be used for cartilage tissue engineering experiments. 
 
 
Figure 3.2 Characterization of human articular cartilage progenitor cells 
Phase contrast image of human chondrocyte progenitor cells in monolayer culture (A, bar = 
100 µm). Immunocytochemical staining of fixed and permeabilized progenitor cells showed 
expression of Notch1 and Sox9 after expansion in monolayer (B, bar = 50 µm). Control 
antibody showed no staining. Nuclei are stained with DAPI (blue) in control to highlight that 
cells are present.  
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 Comparison of different media formulations for chondrogenic 
differentiation 
A high density insert cell culture system (Fig. 3.3) was chosen to generate 3D 
constructs from the chondrocyte progenitor cells, essentially according to 
Hayes and co-workers who successfully seeded full depth bovine 
chondrocytes into transwell inserts and thereby generated cartilage-like tissue 
(Hayes et al. 2007). Because of the comparatively low proliferation rate of 
PRO2N cells, the cell number was a limiting factor for the experiments which 
was also the reason why some conditions were only tested once in the early 
phase of method development. Further difficulties encountered were the long 
time frame before the outcome of an experiment could be evaluated (3-5 
weeks) and that in the absence of cartilage formation, the constructs were 
difficult to recover from the transwell insert for analysis. 
Initially, PRO2N cells were seeded at a density of 4 x 106 per insert into a 
collagen type II coated transwell insert in the same medium as for the 
expansion of the cells in monolayers except lacking FGF-2 (Williams et al. 
2010). Medium was changed every second day for 28 days in total. Afterwards, 
the construct was fixed, excised from the transwell insert (but still attached to 
the membrane) and analysed using histological staining. Fig. 3.4 shows a 
section of the construct stained with haematoxylin & eosin (H&E) (Fig. 3.4 A) 
and Safranin-O/Fast Green (Fig. 3.4 B). The analysis revealed that the cells 
had formed fibrous tissue, and no evidence of chondrogenesis was apparent. 
Additionally, contraction of the cell construct was observed after 72 h in culture 
(not shown) which is indicative of the presence of myofibroblast-like cells. 
Given that chondrocytes had been differentiated under similar conditions by 
others, the complete lack of differentiation came as a surprise. Therefore, 
chondrogenic media used by Hayes et al. (2007) and Williams et al. (2010) 
(Table 3.2) were evaluated because bovine chondrocytes and human 
chondrocyte progenitor cells, respectively, had been differentiated to 
chondrocytes successfully in 3D culture systems using these conditions. 
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Figure 3.3 Schematic depicting culture system. 
Human articular cartilage chondrocyte progenitor cells were seeded at high density into a 
transwell insert with a coated membrane. The cells were cultured for up to 35 days in 
chondrogenic medium containing various growth and differentiation factors. Medium was 
changed every second day. Differentiation of constructs was analyzed histologically and 
biochemically. Variables that were tested over the course of this work included cell seeding 
density, nature of membrane coating, and medium composition. 
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For inserts cultured with chondrogenic media by Hayes et al. (2007), a 
transwell insert culture was set up with 1.4 x 107 cells and a collagen type II-
coated membrane (Fig. 3.4 C, D). Another insert culture with collagen type II-
coated membrane containing 1.0 x 107 cells was cultured as described by 
Williams et al. (2010) (Fig. 3.4 E, F). Media were changed every second day 
and the cells fixed after 21 days. Sections of the paraffin-embedded construct 
were stained with H&E and Safranin-O and revealed that neither culture 
conditions showed clear evidence of cartilage matrix formation, and therefore 
making it necessary to evaluate individual parameters one by one to find 
conditions that supported chondrogenesis. An important finding was the 
absence of cell contraction in insert cultures with higher cell seeding densities.  
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Figure 3.4 Evaluation of different chondrogenic differentiation media. H&E staining (A, 
C, E) and Safranin-O staining (B, D, F) of 5 µm paraffin sections of 3D constructs cultured in 
different chondrogenic differentiation media formulations. Initial work evaluated conditions 
described in the literature: 1., cells were seeded at a density of 4 x 106 cells/insert and cultured 
for 28 days in monolayer culture medium supplemented with 1 ng/ml TGF-2 (A, B); 2., cells 
were seeded at a density of 1.4 x 107 cells/insert and cultured in chondrogenic medium 
according to Hayes et al. (2007) for 21 days (C, D); 3., cells were seeded at a density of 
1.0 x 107 cells/insert and cultured in chondrogenic media formulation described by Williams et 
al. (2010) for 21 days. Bar = 100 µm. 
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 Effect of serum concentration on in vitro cartilage-formation 
As some factors present in serum may influence chondrogenesis, the effect of 
different serum concentrations on cartilage formation was explored. Insert 
cultures were seeded with a cell density of 1.0 x 107 cells per construct using 
the chondrogenic media formulation by Hayes et al. (2007), but containing 5%, 
10% or 20% FCS. The constructs were cultured for 21 days and subjected to 
histological analysis (Fig. 3.5). By looking at the H&E stained sections, it is 
apparent that the constructs cultured with 5% and 10% serum were thicker 
than the construct cultured with 20% serum. Staining of extracellular matrix 
using Safranin-O showed that the construct with 5% serum showed the 
strongest staining when compared to the others. 20% serum did not lead to 
any meaningful proteoglycan-rich matrix deposition and hence resulted in the 
absence of Safranin-O staining. Taken together, these data suggested that 
high concentrations of serum were detrimental to chondrogenesis, at least 
when differentiating human articular cartilage progenitor cells. 
 
However, even though the chondrogenic media formulation from Hayes and 
co-workers showed some promising results, the constructs were very fragile 
and did not produce a proper extracellular matrix as is found in cartilage which 
was very unsatisfactory. An additional chondrocyte progenitor cell isolate 
(PRO3N) was provided by Dr R. Williams to facilitate the supply of sufficient 
cells for subsequent experiments and to ensure that lack of differentiation was 
not cell strain specific. Like the previously used cell isolate PRO2N, PRO3N 
was isolated post-mortem from normal knee cartilage of a 56 year old male 
using selection by differential fibronectin-adhesion (Williams et al. 2010). 
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Figure 3.5 Effect of serum concentration on chondrogenic differentiation and matrix 
formation. H&E staining (left side) and Safranin-O staining (right side) of 5 µm paraffin 
sections of 3D constructs (1.0 x 107 cells/insert) cultured for 21 days in chondrogenic medium 
according to Hayes et al. (2007), but containing 5% serum (A), 10% serum (B) and 20% serum 
(C). Bar = 100 µm.  
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 Chondrogenic differentiation of progenitor cells using serum free 
media 
Several protocols for the chondrogenic differentiation of mesenchymal stem 
cells in which a serum-free media formulation is used have been described 
(Murdoch et al. 2007; Tew et al. 2008; Solchaga et al. 2011; Johnstone et al. 
1998). Especially BMSCs are a well-established cell model for creating 
cartilage-like tissue in vitro. Serum-free culture media have the advantage of 
not being affected by lot-specific differences in serum and this reduces 
variability. Furthermore, it was reported by Murdoch and co-workers (2007) 
that the creation of a dense cell layer within the transwell culture insert was 
essential for chondrogenic differentiation of BMSCs. This is similar in concept 
to pellet micromass cultures where cells are collected by centrifugation within 
a conical tube, forming a small pellet of cartilaginous tissue when cultured in 
chondrogenic media (Solchaga et al. 2011; Johnstone et al. 1998). It is 
suspected that the formation of a high density cell mass mimics the process of 
mesenchymal condensation in embryonic limb development (Johnstone et al. 
1998). To create a dense cell layer inside the transwell insert, it was 
centrifuged at 250 x g for 5 min immediately after applying a cell suspension 
into it as previously described (Murdoch et al. 2007).  
To investigate the effect of using serum-free culture medium (Table 3.2) for 
chondrogenic differentiation of chondrocyte progenitor cells, it was critical to 
remove any residual serum from the cells before seeding which was achieved 
by washing the cells in serum free medium. Different seeding densities, from 
1 x 106 to 4 x 106 cells per insert, were used to identify a suitable cell density 
for further experiments. In the initial experiment, cells were seeded in a 
transwell insert with an uncoated membrane. Approximately 24 h after 
seeding, the cell layer contracted and peeled off from the membrane. This 
resulted in a construct with a spherical shape. After 14 days in culture, the 
constructs were harvested for histological analysis (Fig. 3.6 A). In the following 
experiments, different membrane coatings were used to see whether this could 
prevent the contraction of the cell layer. For this, the membranes were either 
coated with collagen type II, the major fibrillar collagen found in cartilage ECM, 
or fibronectin. As the chondrocyte progenitor cells were selected based on 
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fibronectin adhesion during the initial isolation (Williams et al. 2010), it was a 
logical choice to use this protein to enhance cell adhesion. The high affinity for 
fibronectin is most likely due to abundant expression of 51 integrin on the 
cell surface (Williams et al. 2010). The constructs were again harvested after 
14 days of culture for histological analysis. 
When using collagen type II, the constructs again contracted about 24 h after 
seeding (Fig. 3.6 B) similar to the constructs seeded on uncoated membranes. 
In contrast, fibronectin-coating of the transwell insert membrane led to the 
formation of a flat disc of tissue (Fig. 3.6 C). H&E staining of sections showed 
that the contracted constructs (Fig. 3.6 A, B) had differentiated into two layers 
similar to what has previously been reported in micromass cultures. This is 
likely reflecting limited diffusion of nutrients and growth factors into the center 
of the construct, particularly in larger constructs. Using fibronectin-coated 
membranes (Fig. 3.6 C), there was no contraction at any of the seeding 
densities, with an increase in thickness when increasing cell numbers from 
1 x 106 to 2 x 106 but not from 2 x 106 to 4 x 106. Therefore, coating with 
fibronectin at a concentration of 40 µg/ml was used with a seeding density of 
2 x 106 cells/insert for all further construct experiments.  
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Figure 3.6 Coating of transwell membrane with fibronectin prevented contraction of 
constructs. H&E staining of 5 µm paraffin sections of 3D constructs cultured in serum-free 
chondrogenic medium supplemented with 10 ng/ml TGF-2 for 14 days. Different cell numbers 
were seeded on uncoated (A) and collagen type II coated (B) membranes, resulting in 
contraction. Coating with fibronectin prevented contraction, resulting in a disc-shaped 3D 
construct (C). Bar = 100 µm. 
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 The combination of TGF-2 and BMP-2 for progenitor cell 
stimulation leads to increased formation of cartilaginous matrix 
To achieve better chondrogenesis, several different growth factor 
combinations were then tested. Constructs were seeded at a density of 2 x 106 
cells per insert and cultured in serum-free chondrogenic medium for 21 days 
with different growth factor combinations as follows: with 10 ng/ml TGF-2 
alone (Fig. 3.7 A, B), 10 ng/ml TGF-2 and 50 µg/ml insulin (in addition to ITS 
supplement) (Fig. 3.7 C, D), 10 ng/ml TGF-2 and 100 ng/ml BMP-2 (Fig. 3.7 
E, F), 10 ng/ml TGF-2, 100 ng/ml BMP-2 and 50 µg/ml insulin (Fig. 3.7 G, H), 
or 10 ng/ml TGF-2, 100 ng/ml BMP-2, 50 µg/ml insulin and 5 % serum. At the 
end of the culture period, the constructs were harvested and processed for 
histological analysis. Toluidine blue staining of the sections from each 
condition showed that there was an increase in proteoglycan content as soon 
as TGF-2 and BMP-2 were used in combination (Fig. 3.7 F, H, J), whereas 
only weak toluidine blue staining was observed for TGF-2 alone or in 
combination with additional insulin (Fig. 3.7 B, D). Interestingly, the increased 
toluidine blue staining was only observed in the top and bottom regions of the 
constructs suggesting that growth factor concentrations may be limiting. 
Moreover, the addition of insulin resulted in a marked increase in construct 
size, but only when TGF-2 and BMP-2 were added at the same time 
suggesting that these growth factors had a synergistic effect on either cell 
proliferation or matrix synthesis. The addition of serum gave no overt 
improvement and resulted in a more variable differentiation. As a result, it was 
decided to stay with a chemically defined chondrogenic medium without 
serum. Therefore, the culture medium for chondrogenic differentiation was 
supplemented with TGF-2, BMP-2 and a high concentration of insulin for all 
further experiments. 
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Figure 3.7 TGF-2 in combination with BMP-2 and insulin resulted in cartilage-like 
matrix formation. H&E and toluidine blue staining of 5 µm paraffin sections of 3D constructs 
cultured for 21 days in serum-free chondrogenic medium supplemented with different growth 
factor combinations. Arrows are pointing to regions with increased toluidine blue staining, 
indicating increased GAG deposition into the matrix. (A, B) 10 ng/ml TGF-2; (C, D) 10 ng/ml 
TGF-2 + 50 µg/ml insulin; (E, F) 10 ng/ml TGF-2 + 100 ng/ml BMP-2; (G, H) 10 ng/ml TGF-
2 + 50 µg/ml insulin + 100 ng/ml BMP-2; (I, J) 10 ng/ml TGF-2 + 50 µg/ml insulin + 100 ng/ml 
BMP-2 + 5% FCS; Note, synergistic action of TGF-2 and BMP-2 promotes chondrogenic 
differentiation, whereas insulin supports growth. Bar = 100 µm. 
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 Optimization of growth factor concentrations for cartilage matrix 
formation 
A serum-free differentiation medium supplemented with TGF-2, BMP-2 and 
a high concentration of insulin was successful in driving the chondrogenic 
differentiation of human chondrocyte progenitor cells, leading to the formation 
of cartilage-like tissue. However, the constructs showed a toluidine blue 
staining intensity characteristic for cartilage only in the top and bottom regions 
which were in direct contact with the culture medium. It was speculated that 
the weakly stained region in the middle of the construct was probably a result 
of a diffusion gradient of the growth factors across the tissue, leading to 
insufficient availability of growth factors in the middle part. To test this 
hypothesis, a series of increasing TGF-2 concentrations (10 – 160 ng/ml) was 
applied to a set of constructs while keeping the BMP-2 concentration constant 
at 100 ng/ml (Fig. 3.8 A). Additionally, another set of constructs was cultured 
in medium containing increasing concentrations of BMP-2 (100 – 1600 ng/ml) 
while keeping the concentration of TGF-2 constant at 10 ng/ml (Fig. 3.8 B). 
The constructs were cultured for 28 days which was considered sufficient for 
cartilage matrix formation based on the previous experiments and as reported 
in the literature (Murdoch et al. 2007; Tew et al. 2008). Staining of sections 
with toluidine blue showed that the weakly stained region in the middle of the 
construct was decreasing with increasing TGF-2 concentrations (Fig. 3.8 A). 
Furthermore, toluidine blue staining intensity substantially increased with 
increasing TGF-2 concentration. The strongest toluidine blue staining and 
most homogenous tissue morphology was achieved with a concentration of 
80 ng/ml TGF-2. Increasing the concentration of BMP-2 had only little effect 
on the construct architecture or toluidine blue staining intensity. It was clear 
from these results, that TGF-2 had the strongest effect on the chondrogenic 
differentiation. Based on these results, the chondrogenic differentiation 
medium was modified to an increased TGF-2 concentration of 80 ng/ml which 
was used for all further experiments with cartilage constructs. 
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Figure 3.8 Titration of effective concentrations of TGF-2 and BMP-2 for cartilage-like 
matrix formation. Toluidine blue staining of 5 µm paraffin sections of cartilage constructs 
grown in serum-free chondrogenic medium containing different concentrations of TGF-2 and 
BMP-2 for 28 days. 2 x 106 cells/insert were seeded into fibronectin coated inserts. One set of 
constructs was cultured in medium containing 100 ng/ml BMP-2 and increasing concentrations 
of TGF-2 (10 – 160 ng/ml) (A), whereas another set of constructs was cultured in 10 ng/ml 
TGF-2 and increasing concentrations of BMP-2 (100 – 1600 ng/ml) (B). A representative set 
of pictures from two independent experiments is shown in this figure. Bar = 100 µm. 
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 Biochemical and histological characterization of the effect of TGF-
2 and BMP-2 on cartilaginous matrix formation 
For a better understanding of the role of the different growth factors in matrix 
formation, constructs were cultured with different growth factor combinations 
and subjected to histological and quantitative biochemical analysis. The 
culture medium contained either no growth factors (control), 80 ng/ml TGF-2 
or 100 ng/ml BMP-2 alone, or both in combination. The wet weights of the 
constructs cultured in different media showed significant differences (Fig. 3.9 
A). While control constructs had an average wet weight of 4.7 mg, the 
presence of 80 ng/ml TGF-2 alone resulted in an increase to 7.4 mg. BMP-2 
alone at a concentration of 100 ng/ml resulted in a doubling in average wet 
weight to 14 mg. The highest wet weight of 23.4 mg was achieved by 
combining TGF-2 and BMP-2, which was nearly twice the weight compared 
to BMP-2 alone. Analysis of the total GAG content of the constructs using the 
DMMB assay showed that the control constructs had very little GAG (~11 µg) 
(Fig. 3.9 B). Addition of TGF-2 resulted in an 8-fold increase to 84 µg, 
whereas BMP-2 addition led to an average of 66 µg GAG per construct (Fig. 
3.9 B). In line with wet weight analysis, the combination of BMP-2 and TGF-2 
resulted in a further substantial increase (~3 fold), with an average GAG 
content of 253 µg. By looking at sections of the different constructs stained 
with toluidine blue, very weak staining was observed in the control construct 
(Fig. 3.9 C). Moreover, it had a morphology akin of fibrous tissue unlike the 
constructs cultured with growth factors which resembled cartilage, particularly 
when TGF-2 and BMP-2 were combined. The strongest staining was 
observed in constructs cultured with TGF-2, either alone or in combination 
with BMP-2 in line with the results of the DMMB assay. Taken together, the 
data show that after optimizing various parameters like transwell insert 
membrane coating, cell seeding density, chondrogenic medium formulation 
and growth factor supplementation, a protocol for successful generation of 
cartilaginous tissue in vitro based on differentiation of human chondrocyte 
progenitor cells was established. 
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Figure 3.9 Combination of TGF-2 and BMP-2 led to increased wet weight, GAG content 
and cartilaginous tissue morphology. Cells were seeded at a density of 2 x 106 cells/insert 
and cartilage constructs grown for 28 days in serum-free chondrogenic differentiation medium 
(including 50 µg/ml additional insulin) containing 80 ng/ml TGF2 only, 100 ng/ml BMP-2 only, 
both in combination, or neither growth factor. Wet weight was determined immediately after 
harvesting of constructs (A). Total GAG content was determined using DMMB assay (B). 
Toluidine blue staining of 5 µm paraffin sections of cartilage constructs grown under the 
described conditions showed abundant GAG deposition with medium supplemented with TGF-
2 alone or TGF-2 + BMP-2, and more modest staining for GAG with medium containing 
BMP-2 alone. (C) Little if any staining was observed in constructs grown in control medium 
without any growth factors. Data is shown as mean ± SEM derived from three independent 
experiments with one sample each. Statistical significance of changes was evaluated with 
one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison test. *P< 0.05, 
**P<0.01. Bar = 100 µm. 
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 Characterization of mechanical properties of 3D cartilage 
constructs 
Cartilage constructs grown for 28 days in the optimized chondrogenic medium 
had a disc shape with an opaque white to beige colour similar to joint cartilage. 
The discs had a diameter of 6 mm and a height of around 1 mm (Fig. 3.10 A). 
The construct comprised of a strong extracellular matrix which allowed for 
elastic deformation without permanently changing the construct shape. To 
demonstrate this, the construct was bent using a forceps and after releasing 
the pressure, regained its flat disc shape immediately (Fig. 3.10 B). This 
showed that the construct had properties of resilience similar to articular 
cartilage. Preliminary experiments were performed to evaluate mechanical 
properties using a Bose Electroforce® 3200 loading rig (Fig. 3.1). A construct 
(height: 0.93 mm) was compressed stepwise by 10, 20, 30 and 40% of its 
height with a frequency of 1 Hz for 1 min each, resulting in pressures from 11 
– 261 kPa (Fig. 3.10 C). A higher relative compression of 50% resulted in 
construct failure. This is similar to pressures observed for newborn bovine 
cartilage, which were from 22 to 84 kPa after compression by 10 to 30%, 
respectively (Klein et al. 2007). To analyze whether the cartilage construct 
responded to loading as expected in cartilage, a construct was loaded with a 
physiologically relevant load of 10% relative compression for 1 min at 1 Hz. 
The construct was immersed in TRIzol 15 min after loading and subsequently 
stored at -20°C until RNA isolation was performed. RT-PCR analysis showed 
that there was an increase in the expression of the mechanosensitive gene c-
fos (Bougault et al. 2012) in the loaded sample compared to the unloaded 
control construct (Fig. 3.10 D). For further characterization of the mechanical 
properties of the cartilage constructs, the Young’s modulus was determined. 
This is a measure of the elasticity of an object. It is often used for the 
characterization of the biomechanical properties of tissues (Abrahamsson et 
al. 2010; Martin et al. 2000; Mauck et al. 2006; Little et al. 2011). Using 
indentation testing, a Young’s modulus of 39.05 ± 2.09 kPa was determined 
for 28 day old cartilage constructs (n=5; mean ± SEM). Based on these results, 
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the cartilage constructs created from human chondrocyte progenitor cells 
could potentially be used for further experiments to analyze the effect of 
mechanical loading on changes in human chondrocyte gene expression. 
 
Figure 3.10 Physical properties of 3D cartilage constructs established from adult human 
articular cartilage progenitor cells. Human chondrocyte progenitor cells were seeded into 
transwell culture inserts (2 x 106 cells/insert) coated with fibronectin and differentiated for 28 
days in chondrogenic differentiation medium containing 80 ng/ml TGF-2, 100 ng/ml BMP-2, 
and 50 µg/ml additional insulin. A: Top view (left) and lateral view (right) of the construct after 
removal from the membrane; B: Bending of the construct held within a forceps to demonstrate 
resilience of the tissue; C: Cartilage constructs were mechanically loaded to 10 ‐ 40% relative 
compression for 60 sec at 1 Hz at each step. D: c‐fos expression was analyzed by RT-PCR in 
unloaded constructs as well as constructs subjected to loading (10% compression, 1Hz, 
60 sec) 45 min after stimulation. Expression of the housekeeping gene h36B4 was analyzed 
in parallel as a control. Data confirmed mechanoresponse of cells. Data is shown from one 
single experiment using one construct. 
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 Discussion 
A major aim of the project was to develop an in vitro articular cartilage-like 
model system which can be used for analysing the carbohydrate synthesis 
machinery in chondrocytes in the context of normal and disease conditions 
such as inflammatory conditions or aberrant mechanical loading, as it occurs 
in osteoarthritis.  
In this chapter, the development of a novel human 3D cartilage model system 
is described. This model is based on human chondrocyte progenitor cells, 
which were isolated post-mortem from normal adult articular knee cartilage. 
These cells have the advantage of maintaining a progenitor differentiation 
status after extensive expansion in monolayer (Williams et al. 2010). The cells 
used for experiments in this study had a high expression of SOX9, a 
transcription factor that is a master regulator for cartilage formation and 
maintaining a chondrogenic phenotype (Bi et al. 1999). In addition, the cells 
also showed a high expression of Notch1, a putative stem cell marker found in 
progenitor cells (Hiraoka et al. 2006; Dowthwaite et al. 2004; Grogan et al. 
2009). These features allow for the use of a cell population isolated from a 
single individual to be used for generating a large number of cartilage 
constructs for experimental studies, without having to consider variation due 
to genetic background. Instead of generating pellet micromass cultures, a 
culture model based on transwell culture inserts was chosen as described by 
Hayes and coworkers (Hayes et al. 2007). Generating comparably thin disc-
shaped cartilage constructs resulted in a more homogenous cell differentiation 
compared to pellet cultures and better reflects the physiological situation 
where articular cartilage sits on a solid support (bone). Furthermore, the use 
of a porous membrane as a support allows for asymmetric stimulation of 
constructs from top and bottom with different supplements, and therefore, for 
stratification of the tissue. It has recently been suggested that epigenetic 
information should be considered in cartilage tissue engineering (Hong and 
Reddi 2012; Polo et al. 2010). Unlike cartilage derived from BMSC’s, target 
tissue derived progenitor cells as used here therefore constitute a suitable cell 
source for tissue engineering–based approaches.  
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In initial experiments, different media formulations for chondrogenic 
differentiation of cells described in the literature were evaluated. A TGF- 
concentration of 5 or 10 ng/ml appears to be sufficient for the formation of 
cartilaginous tissue when using primary chondrocytes (Hayes et al. 2007) or 
BMSCs (Johnstone et al. 1998; Murdoch et al. 2007), respectively. However, 
the chondrocyte progenitor cells did not form cartilaginous tissue when 
cultured in serum-free chondrogenic medium supplemented with 10 ng/ml 
TGF-2. An explanation for this could be a lower responsiveness of the cells 
to TGF-2. In addition, the thickness of the construct resulted in the generation 
of a diffusion gradient across the construct, whereby the cells in the inside of 
the construct were exposed to little or no TGF-2. In order to enhance the 
chondrogenic differentiation of the constructs, several different growth factor 
combinations were tried based on literature evidence for factors regulating 
chondrogenesis. Previous studies have shown that addition of insulin or IGF-
1 to the culture medium can enhance the chondrogenic differentiation and 
cartilage formation of primary bovine chondrocytes (Kellner et al. 2001) and 
human BMSCs (Mueller et al. 2013). IGF-1 is about 100 fold more potent in 
the activation of the IGF-1 receptor than insulin. Both human recombinant IGF-
1 and bovine insulin were evaluated with similar results (not shown). As IGF-1 
is also a much more expensive reagent and when used for the generation of a 
large amount of cartilage constructs associated with a very substantial cost, 
insulin was included in the final formulation of the differentiation medium over 
IGF-1. To compensate for the lower potency, a high insulin concentration was 
used. The induction of chondrogenesis using a combination of IGF-1 and 
BMP-2 in vivo in an ectopic differentiation model was previously reported by 
our laboratory (Bulpitt and Aeschlimann 1999). Chondrogenesis of 
chondroprogenitor cells was indeed achieved when TGF-2 and BMP-2 were 
present at the same time and supplementation with insulin had a pronounced 
synergistic effect. To determine the effective concentration of TGF-2 and 
BMP-2 respectively, two concentration series with either increasing 
concentrations of TGF-2 or BMP-2 were performed. Increasing TGF-2 led 
to an increase in toluidine blue staining and reduction of un-stained middle 
zone in the constructs, whereas increasing BMP-2 had no significant effect, 
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indicating that TGF-2 availability was limiting. Based on these results, the 
concentrations for TGF-2 and BMP-2 were adjusted to 80 ng/ml and 
100 ng/ml, respectively, to achieve homogenous differentiation and maximal 
matrix formation. A major finding in the development of a suitable 
chondrogenic differentiation medium for the chondrocyte progenitor cells was 
that the addition of BMP-2 together with TGF-2 dramatically increased the 
chondrogenic differentiation of the cells (Fig. 3.9).  
Shintani and coworkers described a similar synergistic effect on 
chondrogenesis by culturing fetal bovine synovium explant cultures in a 
medium containing 10 ng/ml TGF-1 and 200 ng/ml BMP-2 (Shintani et al. 
2013). Furthermore, this treatment arrested hypertrophic differentiation of the 
cells at an early stage. This is an important finding, which is also of importance 
for this study where hypertrophic differentiation is undesirable. In contrast to 
this study, Shintani and coworkers reported that BMP-2 alone was sufficient to 
form cartilaginous tissue which however, was not very homogenous and 
terminally differentiated. While BMP-2 alone increased both wet weight and 
GAG content in this study, tissue morphology was not articular cartilage-like, 
indicating incomplete differentiation. 
Since overlapping expression patterns of the TGF- and BMP receptors and 
respective ligands are found in the developing growth plate during skeletal 
development, an interaction between the different signaling pathways could 
take place (Keller et al. 2011). TGF- signaling depends on the receptor 
Smads (R-Smad) 2 and 3, whereas BMP signaling involves R-Smad 1, 5, and 
8. Both have a common downstream target, Smad4 (Miyazono et al. 2001). 
Using the chondrogenic ATCD5 cell line, Keller and coworkers found that TGF-
1 strongly enhanced BMP signaling, while BMP-2 signaling reduced TGF- 
signaling (Keller et al. 2011). Several explanations for this were proposed. For 
example, competition over Smad4 between the pathways could take place. 
Furthermore, BMP signaling could induce inhibitory Smad6 and 7, which 
negatively regulates TGF- signaling. Yet another possibility is an interplay 
between canonical TGF-/BMP signaling depending on Smads and non-
canonical signaling depending on p38, JNK and Erk1/2 signaling pathways 
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(Keller et al. 2011). Considering these results, BMP-2 is expected to be the 
driving force in chondrogenic differentiation. However, the results identify a 
critical role for TGF- signaling as no consistent cartilage formation occurred 
in the presence of BMP-2 alone. It is possible that the respective growth factors 
are required at successive stages in the differentiation program of the cells 
rather than their synergistic simultaneous action. Testing this was 
unfortunately beyond the scope of this project. Therefore, the exact 
mechanism of the synergistic effect of TGF-2 and BMP-2 in chondrogenic 
differentiation remains elusive. After all, the optimal composition of 
chondrogenic differentiation medium strongly depends on the cell type used 
for tissue engineering. 
To further characterize the engineered cartilage-like tissue, the mechanical 
properties of 28 day constructs were determined by measuring the Young’s 
modulus. This is a measure for the stiffness of an elastic object and helps to 
compare cartilage matrices from different species, at different stages of 
development, and different tissue engineering approaches (Little et al. 2011). 
Human adult articular cartilage has a Young’s modulus of 0.45 to 0.8 MPa 
(Mansour 2009; Jurvelin et al. 2003). In contrast, tissue engineered constructs 
mostly have a much lower Young’s modulus and are strongly influenced by the 
scaffold material used (Yamaoka et al. 2006; Hoenig et al. 2013). Few 
literature data are available on the Young’s modulus for scaffold-free cartilage 
constructs. Using porcine chondrocytes, Hoenig and colleagues created 
scaffold-free cartilage constructs over 21 days in culture for mechanical 
stimulation (Hoenig et al. 2011). They determined a modulus of about 35 kPa, 
which is comparable to the value of ~39 kPa determined for the constructs 
used in this study. The extracellular matrix of a 28 day old construct is more 
likely to resemble immature cartilage matrix, which could greatly affect the 
mechanical properties (Klein et al. 2007). Despite of the differences in the 
mechanical properties between native adult cartilage and tissue engineered 
cartilage constructs, mechano-responses seen in cartilage can be replicated 
in this model albeit by applying reduced forces (Fig. 3.9), suggesting that it 
constitutes a good model for the planned downstream studies.  
123 
 
In conclusion, the results presented in this chapter show that human cartilage 
progenitor cells are a good cell type to be used in cartilage tissue engineering. 
The generated cartilage constructs are an ideal model system for furthering 
the overarching aim of this project to investigate the effects of external stimuli 
on changes in GAG chain synthesis and modification related to osteoarthritis. 
 
 
 
 
 
 
 
 
Chapter 4: 
 
Characterization of human  
3D cartilage model system 
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4 Characterization of human 3D cartilage model 
system 
 
 Introduction 
Chondrogenesis describes the differentiation of mesenchymal stem cells into 
chondrocytes. During skeletal development, this leads to the formation of 
cartilage anlagen, which are the precursors of long bones. Initially, 
mesenchymal condensation occurs, where mesenchymal chondroprogenitor 
cells aggregate into precartilage condensations (Fell 1925). The mesenchymal 
cells produce an extracellular matrix rich in HA, fibronectin, collagen type I, 
and collagen type II A variant (Sandell et al. 1994). In case of limb 
development, those cells originate from the lateral plate mesoderm (Olsen et 
al. 2000; Tickle and Münsterberg 2001). Signals for cell-cell and cell-matrix 
interactions are crucial to initiate condensation. Neural cadherin (N-cadherin) 
and neural cell adhesion molecule (N-CAM) play important roles in maintaining 
these interactions and are therefore highly expressed in precartilage 
condensations. Other matrix proteins, such as tenascin C and cartilage 
oligomeric matrix protein (COMP) are also expressed and interact with cell 
adhesion molecules. This leads to the transition of the chondroprogenitor cells 
into fully differentiated chondrocytes through activation of intracellular 
signaling pathways (DeLise et al. 2000).  
Sox9, the master chondrogenic transcription factor, is controlling the 
development of embryonic cartilage and is absolutely essential for cell survival 
and chondrocyte differentiation (Akiyama et al. 2002; Bi et al. 1999; 
Moskalewski et al. 2013). It is also required for the expression of collagen type 
II. Two other members of the Sox family, L-Sox5 and Sox6, are not expressed 
during mesenchymal condensation but during chondrogenic differentiation 
(Lefebvre et al. 1998). They are responsible for the expression of other matrix 
molecules, e.g. collagen type IX, aggrecan, and cartilage link protein, as well 
as collagen type II (Smits et al. 2001). 
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During differentiation, chondrocytes switch from collagen type II A to II B 
expression. Type II B, which lacks exon 2, is solely expressed in mature 
chondrocytes and is therefore a reliable marker for chondrocyte differentiation 
(Zhu et al. 1999). In addition, collagen type I as well as N-CAM and N-cadherin 
expression is lost during chondrogenic differentiation (Oberlender and Tuan 
1994). The chondrocytes are starting to produce other important cartilage 
matrix proteins like aggrecan, link protein, collagen type IX and XI (DeLise et 
al. 2000; Mendler et al. 1989). Eventually the cartilage undergoes 
endochondral ossification to form the long bones. In this process, 
chondrocytes undergo hypertrophy, and this precedes the mineralization of the 
tissue. Collagen type X expression is increasing, whereas collagen type II 
expression decreases. Sox9 expression decreases as well and expression of 
Runx2, a major osteogenic transcription factor, increases. Moreover, 
hypertrophic chondrocytes start to express osteonectin, osteocalcin and 
osteopontin, which are core constituents of bone (van der Kraan and van den 
Berg 2012). Chondrocyte hypertrophy is mechanistically linked to vascular 
invasion which ultimately leads to bone deposition. Hypertrophic differentiation 
and cartilage mineralization moves outward to the distal ends of the developing 
bone, leaving a cartilage growth plate on each end, which is required for 
postnatal long bone growth. This process is regulated by indian hedgehog 
(IHH) and parathyroid hormone-related peptide (PTHrP) (DeLise et al. 2000). 
Finally, expression of VEGF leads to vascularization of the calcified cartilage 
matrix and bone formation. 
In the previous chapter, the development and optimization of a novel human 
3D cartilage model system based on chondrocyte progenitor cells was 
described. To use the cartilage construct for further experiments investigating 
changes in cartilage metabolism in response to external stimuli, the cartilage 
constructs required characterizing in detail to establish a body of information 
at baseline conditions.  
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 Aims for this chapter: 
1. Investigate the chondrogenic differentiation process 
2. Analyse the biochemical composition of the cartilage constructs 
3. Analyse the organization of cells with regards to differentiation stage 
within the constructs 
4. Investigate the capacity for chondrogenic differentiation in relation to 
cell source 
 
 Materials and methods 
 Chondrogenic differentiation of human chondrocyte progenitor 
cells 
Cells were cultured as monolayer in 75 cm2 tissue culture flasks until about 
80% confluency was reached (described in chapter 3, section 3.2.2). The cells 
were passaged using trypsin/EDTA solution (0.05% v/v, Gibco) and seeded 
into Millicell hanging transwell culture inserts (PET membrane, 0.4 µm pore 
size, 6.5 mm diameter, Millipore, Watford, UK) pre-coated with human 
fibronectin (see section 3.2.3). A total cell number of 2 x 106 was used per 
construct. Prior to seeding into the transwell inserts, the cells were washed in 
serum-free chondrogenic differentiation media (DMEM, 25 mM D-glucose, 4 
mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 μg/ml 
streptomycin, non-essential amino acid mixture, ITS supplement (all from 
Gibco), 100 nM dexamethasone, 50 g/mL ascorbic acid-2-phosphate (both 
from Sigma Aldrich)) to remove any residual serum. Cells were finally 
resuspended in 400 µl serum-free chondrogenic media containing growth 
factors (80 ng/ml TGF-2 (Peprotech), 100 ng/ml BMP-2 (Genetics Institute, 
Boston, USA.), 50 µg/ml bovine insulin (Sigma Aldrich)) and seeded into the 
inserts, which were placed into 24-well cell culture plates (Sarstedt, 
Nümbrecht, Germany). The plates containing the inserts were centrifuged for 
5 min at 250 x g. After that, 1 ml of the above medium containing growth factors 
was applied into the respective wells to immerse the bottom of the transwell 
with medium. 500 µl medium were applied inside the transwell. The constructs 
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were cultured for at least 28 days by changing the top and bottom medium 
every 2 days. 
 Immunohistochemical staining 
After tissue fixation, paraffin embedding, deparaffinization and rehydration 
(described in chapter 3, section 3.2.6), sections used for immunohistochemical 
staining were incubated in 1% (v/v) H2O2 in methanol for 40 min to block 
endogenous peroxidase activity. Treatment with 40 mU/ml chondroitinase 
ABC (chABC) for 1 h at 37°C (Seikagaku, Associates of Cape Cod, East 
Falmouth, MA, USA) in 50 mM Tris-HCl, pH 8.0, 60 mM sodium acetate, was 
performed to unmask epitopes for antibodies when appropriate. For antibodies 
binding to collagen type I, II and X, the sections were incubated with 0.1 % 
(w/v) pepsin (Sigma Aldrich) in 0.1 M acetic acid at 37°C for 1 h, followed by 
1 mg/mL bovine testicular hyaluronidase (Sigma Aldrich) in TBS at 37°C for 
1 h. To prevent unspecific antibody binding, sections were blocked with 1% 
BSA (w/v) in TBS for 30 min. Slides were washed three times for 5 min in TBS 
after primary antibody and secondary antibody incubations. Primary antibodies 
were incubated overnight at 4°C, and secondary antibodies for 1 h at room 
temperature. Antibody controls were performed by replacing primary 
antibodies with mouse IgG or rabbit IgG (whole molecule, Jackson 
ImmunoResearch Laboratories Inc., West Grove, USA), respectively. 
Antibodies used for immunohistochemical staining in this chapter are 
described in Table 4.1. 
Immunocytochemical staining of JF012OA cells using an anti-SOX9 antibody 
was performed as described in chapter 3, section 3.2.4.  
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Table 4.1 Antibodies used for immunohistochemical staining of cartilage constructs 
Antibody Dilution Factor Source 
Col-1 (collagen type I), mouse 
monoclonal 
1:2000 Sigma Aldrich 
CIIC1 (collagen type II), mouse 
monoclonal 
1:5 
Developmental studies hybridoma 
bank, University of Indiana, USA 
R220-X (collagen type X), rabbit 
polyclonal 
1:300 
Dr Thomas Schmid, Rush University, 
Chicago, USA 
COMP, rabbit polyclonal 1:100 
Dr Frank Zaucke, University of 
Cologne, Germany 
Aggrecan, rabbit polyclonal 1:300 
Prof Daniel Aeschlimann, Cardiff 
University, UK 
Decorin, rabbit polyclonal 1:100 Dr Elke Schönherr, Cardiff University 
Bs-11175R (lubricin), rabbit 
polyclonal 
1:300 Bioss Inc., Woburn, MA, USA 
1B5 (chondroitin-0-sulphate), mouse 
monoclonal 
1:20 Prof Bruce Caterson, Cardiff University 
2B6 (chondroitin-4-sulphate), mouse 
monoclonal 
1:100 Prof Bruce Caterson, Cardiff University 
3B3(+) (chondroitin-6-sulphate), 
mouse monoclonal 
1:100 Prof Bruce Caterson, Cardiff University 
Rabbit IgG 1 µg/ml 
Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, 
USA 
Mouse IgG 1 µg/ml 
Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, 
USA 
Rabbit anti-mouse IgG/HRP 
conjugate 
1:100 Dako, Cambridgeshire, UK 
Porcine anti-rabbit IgG/HRP 
conjugate 
1:100 Dako, Cambridgeshire, UK 
 
 DNA measurement using Hoechst 33258 dye 
To determine the DNA content of a cartilage sample digested with papain 
(chapter 3, section 3.2.7), 100 l sample were mixed with 100 l Hoechst 
33258 (1 g/ml, Sigma Aldrich) and emission monitored at 460 nm using BMG 
Fluostar Omega with excitation at 320 nm. A standard curve from 0.25 to 
2 µg/ml was prepared using Herring sperm DNA (Sigma Aldrich). 
 
 Hydroxyproline assay 
Hydroxyproline is an amino acid typically found in collagen molecules. From 
the amount of hydroxyproline, the amount of fibrillar collagen can be 
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extrapolated. From papain digested samples (chapter 3, section 3.2.7), 100 µl 
were mixed with 100 µl concentrated HCl in a 2 ml Apex® microcentrifuge tube 
with screw cap (Alpha Laboratories, Eastleigh, UK) and incubated for 16 h at 
110°C. This step was necessary to chemically depolymerize the collagen into 
its single amino acids. The samples were dried in a vacuum concentrator. In 
the next step, the samples were reconstituted in 100 µl H2O. 30 µl sample were 
added into a well of a transparent 96 well plate (Greiner, Bio-One, Stonehouse, 
UK), followed by the addition of 70 µl diluent (2 volumes of propan-2-ol and 1 
volume H2O) to it. Then, 50 µl oxidant solution (0.7 g chloramine T, 10 ml H2O, 
50 ml stock buffer; stock buffer: 28.5 g sodium acetate, 18.75 g sodium citrate 
dihydrate, 2.75 g citric acid, 200 ml propan-2-ol) were added and the plate 
placed on an orbital shaker at room temperature for 5 min. In the last step, 125 
µl color reagent (7.5 g dimethylaminobenzaldehyde, 9.64 ml perchloric acid 
(70%), 62.5 ml propan-2-ol, and 1.61 ml H2O) were added and the plate 
incubated at 70°C for 10 min. Absorbance at 550 nm was measured 
immediately. A standard curve from 10 to 50 µg/ml was prepared using L-
hydroxyproline (Sigma Aldrich). A conversion factor of 10 was applied to 
calculate the amount of collagen, assuming an hydroxyproline content of 10% 
(w/w) per collagen molecule (Murdoch et al. 2007). 
 
 Stimulation of cartilage constructs to induce hypertrophic 
differentiation 
To induce hypertrophic differentiation of chondrocytes, cartilage constructs 
differentiated for 35 days were cultured in a modified chondrogenic 
differentiation medium for a further 14 days. The medium consisted of DMEM, 
25 mM D-glucose, 4 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml 
penicillin and 100 μg/ml streptomycin, non-essential amino acid mixture, 
50 g/mL ascorbic acid-2-phosphate, ITS supplement, 1 nM dexamethasone, 
and 1 nM T3 (3,3’,5-Triiodo-L-thyronine, Sigma Aldrich). No additional growth 
factors were added to the medium. Hypertrophic differentiation medium was 
added inside the transwell and the bottom well. Medium was changed every 
second day. 
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 RNA isolation and generation of cDNA  
Cartilage constructs were washed in PBS and subsequently dissociated with 
500 µl TRIzol® reagent (Life Technologies) per construct. They were snap 
frozen in TRIzol using liquid nitrogen and stored at -80°C. At the time of 
analysis, samples were thawed and homogenized in an RNase free 1.5 ml 
tube (Eppendorf, Hamburg, Germany) using a sterile RNase free pestle. 
Subsequently, 120 µl chloroform was added and the sample mixed to extract 
nucleic acids. The organic and RNA-containing aqueous phase were 
separated using Heavy Phase Lock Gel tubes (5 Prime, Hamburg, Germany). 
The aqueous phase was transferred to a fresh RNase free 1.5 ml tube and 
RNA was precipitated by adding an equal volume of 2-propanol and incubation 
at -20°C for 20 min. The precipitated RNA was collected by centrifugation at 
12,000 x g for 10 min at 4°C. The pellet was washed in 750 μl of 75% ethanol. 
After an additional centrifugation step at 7,500 x g for 5 min at 4°C, the 
supernatant was removed and the pellet briefly air-dried. Finally, the RNA 
pellet was resuspended in 40 µl RNase free H2O (Promega, Southampton, 
UK). cDNA was generated from 1 g total RNA using SuperScript® II Reverse 
Transcriptase (Life Technologies) following the manufacturers protocol using 
oligo(dT) 15 oligonucleotides (Promega) for priming. The PCR reactions were 
carried out on a GeneAmp PCR System 9700 (Applied Biosciences, Paisley, 
UK). cDNA was stored at -20°C until further use. Remaining total RNA was 
precipitated by adding 1 µl glycogen (5 mg/ml, Roche Diagnostics GmbH, 
Mannheim, Germany), followed by one tenth of the sample volume of 3 M 
sodium acetate, pH 5.2, and 2.5 volumes of nuclease-free ethanol. The sample 
was stored at -80°C. To recover the precipitated RNA, it was collected by 
centrifugation at 12,000 x g at 4°C for 20 min, washed in 500 µl 80% ethanol 
and collected again by centrifugation at 4°C for 10 min. The pellet was briefly 
air-dried and subsequently dissolved in nuclease-free water to the desired 
concentration. 
 PCR analysis and Q-PCR analysis 
PCR analysis of collagen type II A/B gene expression was carried out using 
GoTaq® Hot Start Polymerase (Promega), 250 nM forward and reverse primer, 
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200 µM dNTPs, 2 mM MgCl2 and nuclease-free water in a final volume of 50 µl. 
In the first step, the sample was incubated for 2 min at 94°C. The second step 
was comprised of sample denaturation at 94°C for 30 sec, primer annealing at 
60°C for 60 sec and DNA elongation at 72°C for 72 sec. This was repeated for 
40 cycles. In the last step, the sample was incubated at 72°C for 7 min. PCR 
products were analyzed on 1% agarose gels, following ethidium bromide 
staining. 
For quantitative gene expression analysis, 100 ng cDNA were mixed with 
Power SYBR®Green Master Mix (Life Technologies) and 300 nM of forward 
and reverse primer. The primers used for experiments in this chapter are 
described in Table 4.2. Nuclease-free H2O was added to obtain a final volume 
of 25 μl. Analysis was performed using an ABI PRISM® 7000 Sequence 
Detection System and data was analyzed with the provided software suite 
(Applied Biosystems). In the first step of the reaction, the samples were heated 
to 95°C for 10 min to activate the AmpliTaq Gold® DNA polymerase. Following 
this, 40 cycles were performed comprised of 95°C for 10 sec for sample 
denaturation and 60°C for 60 sec for primer annealing and elongation. At the 
end of each analysis run, a dissociation run was carried out to determine the 
melting temperature and homogeneity of the resulting PCR products. Since 
the SYBR Green dye intercalates with any double stranded DNA, also 
unwanted PCR products, e.g. primer dimers, can give a fluorescent signal and 
therefore contribute to the overall result. This could lead to an overestimation 
of the respective gene expression level. The Ct method was used to 
estimate relative transcript levels, while employing H36B4 as housekeeping 
gene for normalization of gene expression between different samples. This 
gene is encoding for the acidic ribosomal phosphoprotein P0 (Laborda 1991) 
and was found to have a more consistent expression level in various tissues 
compared to other commonly used housekeeping genes, e.g. -actin, and 
glyceraldehyde 3-phosphate dehydrogenase (Akamine et al. 2007). However, 
using only one housekeeping gene as reference can implicate the problem  
For calculation of p-values, the respective Ct values were used. Fold 
change in gene expression was determined from the respective 2-Ct values. 
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Table 4.2 Primer sequences used for PCR and Q-PCR analysis of cartilage constructs 
Gene  
Sequence of forward (top) and reverse 
(bottom) primers (5‘ - 3‘) 
Amplicon 
size (bp) 
Reference 
sequence 
Collagen type I 
(COL1A1) 
GTGCTAAAGGTGCCAATGGT 
CTCCTCGCTTTCCTTCCTCT 
228 NM_000088 
Collagen type II 
(COL2A1) 
TGTGAAGACGTGAAAGACTGCC 
TCACCTTTGTCACCACGATCC 
221 NM_001844 
Collagen type II A/B 
CTGCTCGTCGCCGCTGTCCTT 
AAGGGTCCCAGGTTCTCCATC 
432/225 
(Johnstone et al. 
1998) 
Collagen type X 
(COL10A1) 
CACTACCCAACACCAAGACACAG 
CACACCTGGTTTCCCTACAGC 
230 NM_000493 
Aggrecan 
CCTCTGGACAACCAGGTGTT 
AAACCAGGTCAGGGACTCCT 
174 NM_001135 
Versican 
GAGACCCAACCAGCCAGACAG 
TCTTCCATTTCCTAAGCACGG 
283 NM_004385 
Matrilin 3 
GTTCAGCCACTGAGGAAGCAC 
GCTGTCCACATTTTCAGGTGAG 
208 NM_002381 
Chondromodulin-1 
AACTCTGCGGTGACCTTCC 
CTTTCCCCTTCCTGCTGATGAT 
235 NM_007015 
Osteonectin 
CATCTTCCCTGTACACTGGCAG 
GATGTACTTGTCATTGTCCAGGTC 
163 NM_003118 
HAS 2 
CATGTACACAGCCTTCAGAGCAC 
ATCCAATATCTTACACTGCTGAGG 
207 NM_005328 
GDF 5 
GACAGAAAGGGAGGCAACAGC 
CTAATGTCAAACACGTACCTCTGC 
131 NM_000557 
HIF2 
GTCTCTCCACCCCATGTCTCC 
CATCAAATGTGAGGTGCTGCC 
195 NM_001430 
Tenascin C 
GGTACAGTGGGACAGCAGGTG 
ACTGGATTGAGTGTTCGTGGC 
228 NM_002160 
N-cadherin 
ATCATTGCCATCCTGCTCTGC 
TCAGGCTCCACAGTGTCAGGC 
224 NM_001792 
IHH 
AAGCAGTTCAGCCCCAATGT 
CGAGATAGCCAGCGAGTTCA 
204 NM_002181 
MMP13 
GTTAAGAAGATAAGTGCAGCTGTTC  
GCTGTATTCAAACTGTATGGGTC  
225 NM_002427 
IL-8 
CTGAGAGTGATTGAGAGTGGACC 
ATTTGCTTGAAGTTTCACTGGC 
209 NM_000584 
H36B4 
AGATGCAGCAGATCCGCAT  
ATATGAGGCAGCAGTTTCTCCAG  
130 
(Wagener et al. 
2001) 
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 Results 
In the previous chapter, the development of the cartilage model system was 
described. An optimized chondrogenic medium formulation was developed, 
yielding a small disc of cartilaginous tissue. In this chapter, the thorough 
characterization of the human 3D cartilage model system using histological, 
biochemical and molecular biology methods is described. 
 
 Cartilage construct: time course of differentiation 
To investigate the chondrogenic differentiation of human chondrocyte 
progenitor cells, constructs were seeded and cultured for a maximum of 35 
days. This was important to better understand the dynamics of the 
differentiation from progenitor cells to chondrocytes and the production of a 
cartilaginous extracellular matrix. Cultures were analysed at day 1, 7, 14, 21, 
28 and 35 post seeding. From each set of constructs, the wet weight was 
determined immediately after removing the constructs from the transwell 
inserts (Fig 4.1 A). Tissue architecture was analysed after fixing the construct 
and embedding it in paraffin wax. Sections of 5 µm were stained using toluidine 
blue to show the relative GAG content of extracellular matrix, which stained 
violet (Fig. 4.1 B). Toluidine blue is a cationic dye, similar to Safranin-O, which 
binds to the negatively charged sulphate groups within GAG chains and is 
therefore a simple method to identify cartilaginous ECM (Schmitz et al. 2010). 
During culture in chondrogenic media, the wet weight of the constructs steadily 
increased (Fig. 4.1 A). Starting from approx. 6 mg, the weight of the constructs 
slowly doubled to about 12 mg at day 21. From then on, the construct mass 
increased in much bigger steps than before. The increase in wet weight was 
reflected by the staining of the cartilage construct with toluidine blue (Fig. 4.1 
B). This suggests that as a result of increased GAG synthesis by the cells, 
water was attracted due to the resulting negative charge, which increased the 
tissue weight. This is consistent with a substantial volume increase from 6 mg 
to 28 mg in the absence of extensive cell proliferation (see Fig. 4.2 B). To 
determine the dry weight, constructs were frozen on dry ice and subsequently 
placed into a freeze-dryer for 16 h. By comparing the wet and dry weight after 
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35 days in culture, the water content of the constructs was determined to be 
approx. 90%. Toluidine blue staining was weak up to day 14, but increased 
rapidly from day 21 until the whole construct stained strongly at day 35. 
Interestingly, the top half of the construct showed stronger toluidine blue 
staining than the bottom half. Also, cartilage lacunae typical for cartilage tissue 
proper were more apparent in the upper part. However, this was somewhat 
variable between experiments (compare with Fig. 4.3 and Fig. 4.10) and likely 
reflects a gradient of diffusion of growth factors across the constructs. 
Collectively, these data suggest that while chondrogenesis occurs rapidly in 
these cultures, a further 3-4 weeks are required to establish a cartilage-like 
ECM. 
135 
 
 
Figure 4.1 Analysis of human chondrocyte progenitor cell differentiation into 
cartilaginous tissue over 35 days. A: Tissue wet weight of constructs differentiated for 1 to 
35 days. Results are displayed as mean ± SEM of two independent experiments with one 
sample per experiment. B: Paraffin sections of constructs stained with toluidine blue after the 
indicated time in differentiation culture medium. Bar = 100 µm. Statistically significant changes 
to sample from day 1 were determined with one-way ANOVA with post hoc analysis using 
Tukey‘s multiple comparison test. *P< 0.05. 
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 Biochemical analysis of cartilage constructs 
To extend these findings and estimate to what degree this reflects a cartilage 
ECM, biochemical analysis of the constructs was performed by measuring the 
total GAG content, DNA content and collagen content. For this, the constructs 
were completely digested with papain. The GAG content was determined 
using the DMMB assay. DMMB is a cationic dye which binds quantitatively to 
the negatively charged GAG chains. The assay showed that there was a 
steady increase in the GAG content every 7 days (Fig. 4.2 A). Similar to the 
wet weight, a slow increase was observed until day 21. From then on, the GAG 
content nearly doubled each week, showing a final average GAG amount of 
433 µg.  
The DNA content of the constructs was measured using the intercalating 
fluorescent dye Hoechst 33258. No significant difference in the DNA content 
during the time course was observed, showing that the cell proliferation after 
seeding the constructs was very low (Fig. 4.2 B). The average DNA content 
slightly decreased within the first 2 weeks from an average 19 µg to 14 µg and 
then increased until day 35 to 19.5 µg again. By normalizing the GAG amount 
to the DNA content, a substantial increase was observed from day 7 to day 28, 
which then further increased at a lower rate until day 35 (Fig. 4.2 C).  
During the whole culture period, the conditioned medium from the cartilage 
constructs was collected from inside the transwell and bottom well and pooled 
each time. This medium was used to determine the increase of released GAG 
chains during the chondrogenic differentiation (Fig. 4.2 D). A steady increase 
in the GAG content of the medium was observed throughout the whole culture 
period, with the highest average GAG release of 28.5 µg per day at day 35.  
The total collagen content of the constructs was measured using the 
hydroxyproline assay. Because hydroxyproline is mostly present in fibrillar 
collagens, this assay gives a good estimate for amounts of collagens of type I, 
II, IX and XI present. Similar to the increase of GAG chains within the construct, 
the amount of collagen fibrils deposited in the ECM of the constructs only 
slowly increased within the first 21 days (Fig. 4.2 E). After that, the collagen 
amount nearly doubled every 7 days, reaching a maximum of 2 mg on day 35. 
By normalizing the collagen amount to the DNA content, a similar trend was 
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observed with the highest value of 101.8 µg collagen per 1 µg DNA on day 35 
(Fig. 4.2 F). The fact that the rate of increase in both GAG and collagen 
deposition was reducing from 28 to 35 days suggests that the matrix is starting 
to reach a saturation point. However, it is likely that at least 7 to 8 weeks would 
be required to reach this point or possibly substantial longer time periods which 
was not feasible in this project.  
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Figure 4.2 Biochemical composition of cartilage constructs at different stages of 
differentiation. After the indicated time of differentiation, constructs were digested with papain 
to break down the tissue for further analysis. A: Total GAG amount per construct as measured 
by DMMB assay; B: Total DNA per constructs as measured by Hoechst assay; C: Total GAG 
amount normalized to DNA content; D: GAG content of conditioned media collected during 
culturing period (from transwell and bottom well); E: collagen content measured by 
hydroxyproline assay (conversion factor 1:10). Results are displayed as mean ± SEM of three 
independent experiments with one sample each. Statistically significant changes to samples 
from day 1 were determined with one-way ANOVA with post hoc analysis using Tukey‘s 
multiple comparison test. *P< 0.05, **P<0.01, ***P<0.001. 
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 Immunohistochemical analysis 
To investigate the presence of matrix proteins that are characteristic for 
cartilage ECM, paraffin section of 35 day old cartilage constructs were stained 
with antibodies raised against various matrix proteins, i.e. collagen type I, II, 
X, cartilage oligomeric matrix protein (COMP), aggrecan, decorin, lubricin, and 
CS epitopes 0S (C-0-S), 4S (C-4-S), 6S (C-6-S) (Fig. 4.3). Toluidine blue 
staining showed a homogenous violet staining of the whole construct, 
indicating the abundant presence of GAG chains. Staining for collagen type I 
and X showed the absence of collagen type X and that little collagen type I 
was present. The strongest staining was found in the middle part of the 
construct, where tissue transformation may be less complete due to limited 
growth factor diffusion. In contrast, collagen type II, the major collagen found 
in cartilage, was highly abundant throughout the construct, with the highest 
expression in the top region. The absence of collagen type X expression 
confirms the absence of hypertrophic differentiation in line with the 
morphological appearance of the tissue (see H&E section). The cartilage 
matrix proteins COMP, aggrecan and decorin were also highly expressed in 
the constructs. COMP and aggrecan were evenly distributed in the construct 
as expected, whereas decorin showed the strongest staining in the top region. 
Interestingly, lubricin staining was restricted to the surface in the top part of the 
construct. This is in good agreement with the expression pattern of lubricin in 
articular cartilage, where it is expressed in the superficial zone (Schumacher 
et al. 1994). The CS epitopes C-0-S, C-4-S and C-6-S were all evenly 
distributed throughout the cartilage matrix. Staining was strongest for C-4-S, 
followed by C-6-S and weakest for C-0-S. However, the staining intensity is 
not a quantitative measurement for the relative amount of each disaccharide, 
but is indicative of the last disaccharide present just before the GAG chain 
linker region, that cannot be cleaved by chABC. A digest of the section with 
chB followed by probing with an antibody detecting C-4-S did not result in any 
staining, showing that there were no DS stubs present on cartilage 
proteoglycans as expected. Taken together, these data not only confirm the 
presence of typical cartilage matrix constituents but a degree of stratification 
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of the constructs that mimics that of articular cartilage and also the absence of 
hypertrophic differentiation. 
 
 
Figure 4.3 Immunohistochemical staining of a 35 day old cartilage construct.  
5 µm paraffin sections of a 35 day old cartilage construct were stained with H&E and toluidine 
blue to visualize the tissue morphology and ECM deposition. Constructs were stained with 
antibodies raised against cartilage matrix proteins and disaccharide epitopes (Table 4.1). 
Sections stained for collagen type I, II and X were digested with 0.1% pepsin (w/v) for 1 h at 
37°C, followed by 1 mg/ml hyaluronidase for 1 h at 37°C prior to primary antibody incubation. 
Sections stained for COMP, aggrecan, decorin, lubricin, C-0-S, C-4-S, C-6-S, and DS were 
digested with 40 mU chondroitinase ABC for 1 h at 37°C. Primary antibodies were incubated 
for 16 h at 4°C, whereas secondary antibodies were incubated at room temperature for 1 h. 
Rabbit and mouse IgG controls were treated with both pepsin/hyaluronidase and 
chondroitinase pre-treatments and did not show any staining. Bar = 100 µm. 
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 HPLC analysis of total CS chain disaccharide composition of 
cartilage constructs 
The composition of CS chains produced during chondrogenic differentiation of 
cartilage constructs was determined using reversed phase HPLC analysis of 
AMAC-labeled disaccharides. From each time point, 1 µg GAG chains from 
papain-digested samples was digested using chABC in combination with 
chAC-1. No tri-sulphated disaccharides were detected for any sample (Fig. 
4.4 A). 2,6diS and 2,4diS disaccharides were only present on day 1 prior to 
chondrogenic differentiation. The major disaccharide subunits were 4S and 
6S and 0S. The relative amounts of these disaccharides within the CS 
chains from different time points during cartilage differentiation were compared 
(Fig. 4.4 B). On day 1, the proportions of 4S and 6S were nearly equal. 0S 
was only marginally present. However, this ratio changed after 7 days in 
culture and thereafter, the relative amount of 6S increased steadily to 68.8%, 
whereas for 4S it fluctuated between 20.0 – 33.3% and for 0S between 7.9 
– 13.4%. An increase in 6S is consistent with a mature cartilage matrix where 
6S reaches 80% in adult articular cartilage (Bayliss et al. 1999). 
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Figure 4.4 Analysis of GAG chain disaccharide composition of cartilage constructs 
during differentiation. A: 1 µg total GAG (derived from papain digested cartilage constructs) 
was digested with chABC + chAC-I and labeled with AMAC. Analysis was performed using 
reversed phase HPLC with a C-18 column. Chromatograms of day 1 to 35 are overlaid. Arrows 
indicate the elution position of labeled CS disaccharides, B: Comparison of the relative 
amounts of the most abundant disaccharides 4S, 6S, 0S, on each time point during the 
chondrogenic differentiation time course. Data is shown as mean ± SEM from three 
independent experiments with one sample each. Statistical analysis using one-way ANOVA 
with post hoc analysis using Tukey‘s multiple comparison test showed no significance for the 
changes of each respective disaccharide amount from day 7 – 35 compared to day 1. * = 
sample unrelated components derived from AMAC labeling. 
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 Gene expression analysis during cartilage construct 
differentiation 
While the biochemical, immunohistochemical and HPLC analysis confirmed 
that a cartilage-like ECM was formed, this provided little information on the 
state or path of cell differentiation. Therefore, gene expression analysis of 
markers of cell differentiation was carried out at the indicated times during the 
differentiation process. The analysis was performed using SYBRGreen and 
relative quantification derived from the Ct method. The advantage of this is 
that it is relatively easy to perform and economical. However, also undesired 
PCR products, e.g. primer dimer, cause a positive signal. Therefore, besides 
confirming the presence of a single product through melting analysis, samples 
were further analyzed with agarose gel electrophoresis after the Q-PCR run 
was complete to confirm that the products generated were of expected size. 
Firstly, the expression of the major cartilage matrix proteins collagen type II 
and aggrecan during differentiation was analyzed as well as collagen type I 
(Fig. 4.5). Matrilin 3 was also investigated as an example of a non-collagenous 
cartilage matrix protein that is present in permanent cartilage remaining 
throughout life, as opposed to temporary cartilage anlagen formed in 
development and subsequently undergoing joint cavitation (Pullig et al. 2002). 
Collagen type II showed no expression in the monolayer cells before seeding 
into the transwell culture inserts. In contrast, collagen type I was expressed, 
as seen in the agarose gel (Fig. 4.5 A). One day post seeding, collagen type I 
expression was substantially increased (40-fold) which was likely due to the 
culture conditions (3D environment, ascorbic acid-2-phosphate 
supplementation) rather than cell differentiation. No substantial change in 
collagen type I expression was seen thereafter. After 7 days, collagen type II 
expression was increased approx. 1000-fold compared to day 1 and by day 14 
reached a plateau at > 50,000-fold increase (Fig. 4.6 B). The expression of the 
major cartilage proteoglycan aggrecan was increased 6 -fold on day 1 and 
increased further after 7 days to approx. 800-fold (Fig. 4.6 C). The expression 
level slowly reached a plateau with the highest value of 2,720-fold change on 
day 35 compared to monolayer. Matrilin 3, a protein involved in formation of 
filamentous networks in cartilage extracellular matrix (Klatt et al. 2011; Budde 
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et al. 2005), showed increased expression levels during the whole time course. 
Expression was very low in monolayer and on day 1, but then increased about 
10-fold on day 7 (Fig. 4.6 D). This was followed by a gradual increase to about 
200-fold by day 28 where it reached a plateau. 
Taken together, these data indicate that the time period taken to reach a 
steady state level of expression differs between genes, with matrilin 3 requiring 
28 days, suggesting that an extended time period is required for cell 
differentiation and not just for matrix synthesis. 
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Figure 4.5 Constructs expressed cartilage matrix proteins during differentiation. 
Cartilage constructs (2 x 106 cells/construct) were differentiated in chondrogenic medium to 
the indicated time points. Total RNA was isolated and converted into cDNA. 100 ng cDNA per 
sample were used for Q-PCR gene expression analysis using SYBRGreen. Above each 
graph, a representative set of samples was analysed after Q-PCR using agarose gel 
electrophoresis to illustrate the resulting PCR products used for expression analysis. A 
logarithmic scale of the y-axis was applied when the fold changes in expression exceeded a 
value of 1000. Data is shown as mean ± SEM derived from three independent experiments 
(independently grown cartilage constructs). Each sample was measured in duplicate. 
Statistically significant changes compared to monolayer (M) samples were determined with 
one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison test. *P< 0.05, 
**P<0.01, ***P<0.001.  
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During the chondrogenic differentiation of human progenitor cells, several 
genes developmentally associated with the formation of mesenchymal 
condensation, which had a high expression in the monolayer cells were down 
regulated over 35 days.  
The expression level of N-cadherin for example significantly decreased (about 
3.4-fold) within 14 days of culture in chondrogenic differentiation medium (Fig. 
4.6 A). It is known to be involved in cell-adhesion and is highly expressed in 
mesenchymal condensation during skeletal development and disappears in 
differentiated chondrocytes (Oberlender and Tuan 1994; DeLise et al. 2000; 
Goldring et al. 2006). In the agarose gel electrophoresis performed after Q-
PCR analysis, a band of approx. 50 bp appeared in every sample (arrow) in 
addition to the expected product for N-cadherin. These bands were most likely 
the result of primer dimers that formed because of a low amount of N-cadherin 
cDNA. While the Ct values are likely to be minimally affected as template 
amplification precedes primer dimer formation, these results should be 
considered with caution and ideally would require repeating with inclusion of a 
TaqMan probe for confirmation. 
Tenascin C expression also decreased significantly over the course of 
construct differentiation (Fig. 4.6 B). On day 35, it was down regulated 10-fold 
compared to monolayer cells. Tenascin C is also highly expressed during the 
stage of mesenchymal condensation and in cartilage anlagen, but absent in 
mature cartilage (Mackie and Murphy 1998).  
HAS-2, one of the major HA synthases in cartilage (Hiscock et al. 2000), 
showed significant down regulation as well (Fig. 4.6 C). The expression level 
decreased gradually every week and was the lowest at day 35 with an approx. 
30-fold change compared to monolayer. This was somewhat unexpected but 
likely indicates a switch in use of HAS enzymes from HAS-2 to HAS-3. 
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Figure 4.6 Expression of transient cartilage markers decreased during differentiation. 
Cartilage constructs (2 x 106 cells/construct) were differentiated in chondrogenic medium to 
the indicated time points. Total RNA was isolated and converted into cDNA. 100 ng cDNA per 
sample were used for Q-PCR gene expression analysis using SYBRGreen. Above each 
graph, a representative set of samples was analysed after Q-PCR using agarose gel 
electrophoresis to illustrate the resulting PCR products used for expression analysis. Data is 
shown as mean ± SEM derived from three independent experiments. Each sample was 
measured in duplicate. Statistically significant changes compared to monolayer (M) samples 
were determined with one-way ANOVA with post hoc analysis using Tukey‘s multiple 
comparison test. *P< 0.05, **P<0.01, ***P<0.001. 
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As mentioned above, collagen type II is the predominant fibrillar collagen 
present in cartilaginous ECM. However, two different splice variants exist, the 
expression of which is differentially regulated during chondrogenic 
differentiation (Zhu et al. 1999). In precartilage condensations, collagen type II 
A variant is the most abundant form and in mature cartilage, the B variant is 
solely expressed. The difference between the two splice variants is the 
presence of exon 2 which can only be found in the A variant. The amplified 
product covered the end of exon 1 to the beginning of exon 3. Thus, the PCR 
product containing exon 2 is longer (432 bp) than the one without (225 bp). 
Through analysis of the cDNA derived from cartilage constructs at different 
stages of differentiation, the relative expression levels for each splice variant 
could be determined (Fig. 4.7 A). The intensity of the bands was estimated by 
densitometry using the ImageJ software package (Abramoff et al. 2004) to 
derive the relative percentages of variant A and B of the total collagen type II 
expression level. Directly after seeding the chondrocyte progenitor cells at day 
1, neither variant A nor B variant were detectable as expected (see Fig. 4.5 B). 
From day 7 onwards, both variants were detected throughout the last time 
point at day 35. On day 7, variant B was the predominant splice variant with 
approx. 70% compared to variant B with approx. 30%. On day 14, both variants 
were equally expressed. From day 21 to 35, a steady decrease of expression 
of variant A accompanied with the increase of variant B was observed. At day 
35, more than 90% of the expressed collagen type II was variant B. 
GDF-5, a critical signaling molecule for cartilage development, both during 
mesenchymal condensation as well as chondrocyte proliferation in later stages 
of skeletal development (Francis-West et al. 1999), was already expressed in 
monolayer cells. Its expression level stayed constant during the whole 
culturing period (Fig. 4.7 B). Versican expression levels decreased about 2-
fold after seeding cells into the transwells. Again, the expression level stayed 
relatively constant over the culture period (Fig. 4.7 C).  
Chondromodulin-1 was absent in monolayer, but increased rapidly in transwell 
environment, reaching a 100-fold increase by day 7 compared to day 1 and 
approaching a plateau of 5,000 to 10,000-fold from day 14 onwards (Fig. 4.7D). 
Chondromodulin-1 is a cartilage matrix protein with anti-angiogenic properties. 
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It has been suggested that chondromodulin-1 expression is an important factor 
of maintaining the avascularity of cartilage (Hiraki et al. 1997; Hayami et al. 
2003). Moreover, it stimulates chondrocyte proliferation and synthesis of 
cartilage proteoglycans (Hiraki et al. 1991) and is therefore a key component 
of persistent cartilage. 
 
In addition to markers indicating the process of cartilage matrix formation, 
markers indicating chondrocyte hypertrophy were evaluated as well. Collagen 
type X, deposition of which is a hallmark for chondrocyte hypertrophy, could 
not be detected in the ECM (Fig. 4.3). However, it was expressed already in 
monolayer cells (Fig. 4.8 A). Its expression level gradually increased from day 
1 to day 35, a feature which has previously been seen in association with 
chondrogenic differentiation. However, as no protein was detectable, the 
significance of this remains unclear. Hypoxia-inducible factor 2 (HIF2), a 
very important transcription factor involved in terminal differentiation of 
chondrocytes and transactivation of collagen type X and MMP13 (Saito et al. 
2010), was transiently increased to about 10-fold on day 1 and decreased 
thereafter. It is likely that this change was a result of the change in culture 
conditions as this gene is known to respond rapidly to environmental changes 
(Fig. 4.8 B). Differences in the expression level of MMP13, a member of the 
matrix metalloproteinase family and highly expressed in hypertrophic cartilage, 
were also observed during the time course. It was expressed in monolayer 
cells and up regulated on day 1 (Fig. 4.8 C). Expression decreased on day 7 
and was very low on both day 14 and 21, but increased moderately thereafter. 
Although the changes did not reach significance, it is possible that MMP13 
contributed to matrix remodeling at these later stages of tissue formation. 
Osteonectin, a protein present in bone as well as in terminally differentiated 
cartilage (Goyal et al. 2010; van der Kraan and van den Berg 2012), showed 
a gradual increase in expression. Notably, the expression level was relatively 
high already in monolayer cells, as seen in the agarose gel analysis of the Q-
PCR products (Fig. 4.8 D). Neither the immunohistochemical analysis nor the 
gene expression analysis provided evidence for hypertrophic differentiation of 
the cartilage constructs.  
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Figure 4.7 Constructs expressed maturation related variant of collagen type II and 
markers associated with permanent joint cartilage. Cartilage constructs (2 x 106 
cells/construct) were differentiated in chondrogenic medium to the indicated time points. Total 
RNA was isolated and converted into cDNA. 100 ng cDNA per sample were used for PCR 
analysis of collagen type II A/B gene expression (A). Densitometrical analysis of PCR bands 
was performed using the ImageJ software package. 100 ng cDNA per sample were used for 
Q-PCR gene expression analysis of GDF 5, versican, and chondromodulin 1 using 
SYBRGreen (B, C, D). Above each graph, a representative set of samples was analysed after 
Q-PCR using agarose gel electrophoresis to illustrate the resulting PCR products used for 
expression analysis. A logarithmic scale of the y-axis was applied when the fold changes in 
expression exceeded a value of 1000. Data is shown as mean ± SEM derived from three 
independent experiments. Each sample was measured in duplicate. Statistically significant 
changes compared to day 7 for collagen type II A/B analysis and monolayer (M) samples for 
GDF 5, versican and chondromodulin 1 were determined with one-way ANOVA with post hoc 
analysis using Tukey‘s multiple comparison test. *P< 0.05, ***P<0.001. n.d. = not detectable.  
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Figure 4.8 Analysis of expression of cartilage hypertrophy markers. Cartilage constructs 
(2 x 106 cells/construct) were differentiated in chondrogenic medium to the indicated time 
points. Total RNA was isolated and converted into cDNA. 100 ng cDNA per sample were used 
for Q-PCR gene expression analysis using SYBRGreen. Above each graph, a representative 
set of samples was analysed after Q-PCR using agarose gel electrophoresis to illustrate the 
resulting PCR products used for expression analysis. A logarithmic scale of the y-axis was 
applied when the fold changes in expression exceeded a value of 1000. Data is shown as 
mean ± SEM derived from three independent experiments. Each sample was measured in 
duplicate. Statistically significant changes to monolayer (M) samples were determined with 
one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison test. *P< 0.05, 
**P<0.01; ***P<0.001.  
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In summary, while many cartilage matrix proteins are already expressed in 
monolayer cells including aggrecan, these are highly up regulated over the first 
14 days of culture. Significantly, neither collagen type II nor chondromodulin 
were present in monolayer cells and the up regulation of their expression 
correlates with signs of tissue transformation as evidenced by morphological 
changes and toluidine blue staining of ECM visible by day 14 (Fig. 4.1). This 
suggests that collagen type II and chondromodulin play a critical role in matrix 
assembly. However, a mature chondrocyte phenotype was not reached until 
at least day 28 as evidenced by the switch in collagen type II isoform 
expression and altered expression of matrilin 3. 
 
 Induction of hypertrophy in cartilage constructs 
Hypertrophic differentiation is a well-known issue in cartilage tissue 
engineering (Johnstone et al. 1998; Murdoch et al. 2007). It is commonly 
observed that cartilaginous tissue made from mesenchymal stem cells derived 
from bone marrow aspirate, for example, undergoes terminal differentiation 
spontaneously (Johnstone et al. 1998; Abrahamsson et al. 2010). Staining for 
collagen type X, a hallmark for chondrocyte hypertrophy, did not show any 
collagen type X deposition in the matrix of the cartilage constructs produced 
here after 35 days in culture (Fig. 4.3), even though there was a substantial 
increase of collagen type X mRNA expression observed over the 35 day 
culture period (Fig. 4.8A). To answer the question of whether the cells and 
culture conditions used in this study prevented hypertrophic differentiation or 
the absence of collagen type X deposition was for unknown reasons not 
reflecting cell differentiation, fully differentiated 35 day old cartilage constructs 
were cultured further in medium which is expected to stimulate hypertrophic 
differentiation of cartilage (Mueller and Tuan 2008; Böhme et al. 1995). This 
medium was based on the standard serum-free chondrogenic differentiation 
medium but did not contain any of the growth factors (TGF-, BMP-2, 
additional insulin), had a reduced amount of dexamethasone and contained 
thyroid hormone T3. T3 hormone regulates chondrocyte terminal 
differentiation through the Wnt/-catenin signaling pathway by activation of 
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Wnt-4 expression (Wang et al. 2010). Control constructs were cultured in 
normal chondrogenic medium containing growth factors. The constructs were 
cultured for an additional 14 days, with medium change every 2 days. Staining 
of sections with an antibody against collagen type X showed a marked 
difference between the control construct (Fig. 4.9 A, C) and the construct 
cultured in hypertrophic medium (Fig. 4.9 B, D). In the latter one, strong 
staining for collagen type X was evident in the area directly adjacent to the 
transwell membrane (arrow). Magnification of this part showed an increased 
size of the cartilage lacunae (Fig. 4.9 D) indicative of hypertrophic 
differentiation of cells. 
Analysis of gene expression (Fig. 4.9 E) showed that Runx2, an osteogenic 
differentiation marker, was surprisingly down regulated. Collagen type X 
expression levels were unchanged. The biggest difference in gene expression 
was observed for MMP13, with an average fold change of 7.4. Other 
hypertrophy markers, HIF2 and IHH, were slightly up regulated compared to 
control. Osteonectin expression was down regulated, which was again not 
expected, as it is typically up regulated in hypertrophic and OA-cartilage (Goyal 
et al. 2010). However, localized changes in expression in the cell layer near 
the filter membrane may be underestimated or masked by the fact that gene 
expression of the entire construct rather than the hypertrophic layer was 
examined. 
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Figure 4.9 Stimulation of hypertrophic differentiation with T3 induced increased matrix 
deposition of collagen type X and significantly increased MMP13 gene expression. 
Cartilage constructs (2 x 106 cells/construct) were differentiated for 35 days using 
chondrogenic differentiation medium. Hypertrophy was induced by culturing constructs in 
medium without growth factors, but containing thyroid hormone T3 for a further 14 days. 
Control constructs were cultured in chondrogenic medium containing growth factors. 
Afterwards, constructs were fixed and embedded in paraffin. 5 µm sections of control 
constructs (A) and hypertrophic culture constructs (B) were stained with an antibody against 
collagen type X. The arrow points to the region with enhanced collagen type X staining. 
Magnified parts of the sections (red box) are shown in C & D, respectively. 100 ng cDNA were 
used for Q-PCR analysis of marker genes for hypertrophic differentiation (E). Data is shown 
as mean ± SEM from two independent experiments with one sample each. Each sample was 
measured in duplicate. Statistical significance of changes to control samples (dotted line) were 
determined with one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison 
test. *P< 0.05, **P<0.01, ***P<0.001. Bar = 100 µm.  
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 Chondrogenic differentiation of chondrocyte progenitor cell 
strains established from different individuals 
To demonstrate that the protocol used for the chondrogenic differentiation of 
the PRO3 human chondrocyte progenitor cell strain also worked for progenitor 
cells generated from different donors under similar conditions, the PRO2 and 
PRO5 cell line were used for chondrogenic differentiation. These were a kind 
gift from Dr Rebecca Williams (School of Biosciences, Cardiff University). 
PRO2 cells were post mortem derived from the normal knee articular cartilage 
of a 56 year old male and PRO5 from a 75 year old male. The provided cell 
aliquots were at a similar population doubling (around 25) and cultured using 
the same monolayer expansion medium as the PRO3 cells. The cells were 
seeded at a density of 2 x 106 cells per insert and cultured for 28 days in serum-
free chondrogenic medium containing 50 µg/ml bovine insulin, 80 ng/ml TGF-
2 and 100 ng/ml BMP2 as before. At the end of the culture period, the 
constructs were embedded in paraffin and 5 µm sections were prepared. The 
sections were stained with H&E and toluidine blue to assess the chondrogenic 
tissue morphology and deposition of ECM. This confirmed the capacity for 
chondrogenic differentiation of both the PRO2 and PRO5 cell strains under 
these conditions (Fig. 4.10, left pictures). This showed that the differentiation 
protocol and medium developed and used in this study can be used to 
differentiate human chondrocyte progenitor cells into cartilage-like tissue 
independent of the age and genetic background of the donor. This could be 
potentially useful for future applications of cartilage tissue engineering using 
this particular cell type. 
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Figure 4.10 Chondrogenic differentiation of other human chondrocyte progenitor cell 
clones. Cartilage constructs (2 x 106 cells/construct) from each progenitor cell line were 
differentiated for 28 days using an identical chondrogenic differentiation medium formulation. 
5 µm sections from each construct were stained with H&E (left) and toluidine blue (right). Bar 
= 100 µm.  
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 Chondrogenic differentiation of OA-cartilage derived progenitor 
cells 
In addition to the chondrogenic differentiation of human chondrocyte 
progenitor cells isolated from normal knee cartilage, the chondrogenic 
differentiation of a progenitor cell line isolated from OA-cartilage was 
investigated. This cell line, JF012 OA, was derived from knee cartilage of a 65 
year old male undergoing total knee arthroplasty. Again, the cells were a kind 
gift from Dr Rebecca Williams. The provided cell aliquot was expanded in 
monolayer culture the same way as the “normal” human progenitor cell strains 
PRO2, PRO3, and PRO5.  
The expression of Sox9 was investigated by immunocytochemistry. Cells were 
seeded onto a fibronectin-coated glass cover slip and stained with a rabbit 
polyclonal antibody against Sox9 as described (chapter 3, section 3.2.4). 
JF012OA cells showed strong staining for Sox9 in the nucleus (Fig. 4.11 A). 
Based on this result, it was expected that the cells were capable of 
differentiating into cartilage similar to the other cell lines as shown in the 
previous paragraph.  
Constructs were seeded with a seeding density of 2 x 106 cells per construct 
and cultured for 28 days in serum-free chondrogenic medium containing the 
same growth factor cocktail and concentrations as used for the other cell lines. 
Constructs were fixed in 4% PFA/PBS for histological analysis and 
immunohistochemical staining of matrix components. At the time of harvest, it 
was obvious that the resulting construct was much smaller and less rigid than 
constructs made from non-OA cartilage derived progenitor cells. By comparing 
the JF012OA-construct with a 28 day old PRO3-construct, it was clearly visible 
that the PRO3-construct (left) was more than twice the size of the JF012OA 
construct (right) (Fig. 4.11 C). H&E and toluidine blue staining (Fig. 4.11 D, E) 
showed that the tissue had a more fibrous morphology for the OA cell construct 
but some toluidine blue staining of the ECM was evident. 
Immunohistochemical staining using antibodies against collagen type I, II and 
X (Fig. 4.11 F, G, H, respectively) showed that collagen type I was more 
abundant and present throughout compared to PRO3 derived constructs (Fig. 
4.3). Interestingly, staining for collagen type II was much reduced and staining 
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for collagen type X was evident. The significance of collagen type X deposition 
is unclear as tissue morphology showed neither typical features of cartilage 
nor hypertrophy. However, as induction of hypertrophy in articular 
chondrocytes is a feature of OA it is possible that the progenitor cells have 
acquired properties of terminally differentiated chondrocytes and are therefore 
unable to synthesize a cartilage matrix proper. 
Analysis of the wet weight at the time of tissue collection showed that the 
JF012OA constructs were 2.3 times lighter than the PRO3 constructs (Fig. 
4.11 K). Interestingly, the average wet weight of 9 mg was almost as low as 
for the PRO3 constructs at day 1, which was around 6 mg. Given that the same 
cell seeding density was used, this indicates that the weight did not increase 
much during the course of differentiation. The average total GAG content of 
the JF012OA constructs (83.2 µg) was significantly lower than that of the 
corresponding PRO3 constructs (250.3 µg) (Fig. 4.11 L) but at the same time 
higher than PRO3 constructs after 7 days in culture, suggesting that some 
matrix deposition did occur. 
The analysis of the gene expression levels showed that collagen type II 
expression was about 10-fold lower than control (PRO3 constructs at day 28) 
(Fig. 4.11 M). In contrast, an almost identical expression level of aggrecan was 
observed. Furthermore, collagen type X expression was much lower, as was 
MMP13. This could indicate that there is a feedback loop that connects matrix 
deposition of collagen type X to gene regulation. Interestingly, the expression 
of the pro-inflammatory cytokine IL-8 was significantly up regulated with an 
average fold change of > 1,000 fold (Fig, 4.11 M). This suggests that an 
inflammatory state had been imprinted into OA-derived cells prior to their 
isolation.  
  
159 
 
Figure 4.11 Human chondrocyte progenitor cells isolated from OA cartilage (JF012OA 
cell strain) showed a decreased ability of chondrogenic differentiation and changes in 
behavior akin of inflammation associated cell differentiation. Sox9 expression in 
JF012OA cells was analyzed using immunocytochemistry of monolayer cells seeded on 
fibronectin-coated glass cover slides (A, bar = 40 µm). Control with non-specific IgG is also 
shown (B). H&E staining of 5 µm paraffin sections of PRO3 (left) and JF012OA constructs (2 
x 106 cells/construct) cultured for 28 days with the same chondrogenic medium formulation 
revealed substantial difference in tissue height (C). Staining of sections with H&E (D) and 
toluidine blue (E) showed fibrocartilaginous nature of tissue. Immunohistochemical staining 
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showed the presence of collagen type I (F), type II (G) and type X (H). Controls using rabbit 
IgG (I) or mouse IgG (J) showed no staining. Bar = 100 µm. Analysis of wet weight (K) and 
total GAG content with DMMB assay (L) of the constructs substantiated differences seen in 
histology. Gene expression analysis using SYBRGreen Q-PCR of selected cartilage matrix 
proteins and OA markers (M) was carried out with 100 ng cDNA. Data is expressed relative to 
expression levels determined for PRO3 constructs. Data is shown as mean ± SEM from two 
independent experiments with one sample each. Each sample was measured in duplicate. 
Statistical significance of changes to PRO3 day 28 control were determined using two-tailed 
Student’s t-test (K, L) and one-way ANOVA with post hoc analysis using Tukey‘s multiple 
comparison test (M). *P< 0.05, **P<0.01, ***P<0.001. Bar = 100 µm. 
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 Discussion 
Following the development and optimization of the human 3D model of 
articular cartilage in the previous chapter, the resulting cartilage construct 
needed to be thoroughly characterized with regards to cell differentiation and 
biochemical composition. The best way to characterize the cartilage constructs 
was to carefully investigate the changes associated with tissue formation. An 
extracellular matrix which showed cartilaginous tissue morphology and 
characteristic staining with toluidine blue was established over a 35 day period. 
In parallel to the increase in tissue height, the wet weight was increasing which 
was presumably a result of the increased water content of the constructs.  
 
Examination of the total GAG and collagen content using DMMB assay and 
hydroxyproline assay revealed that those two major cartilage components 
gradually increased over 35 days. Over the first 2 weeks, the increases were 
only slow. But then after day 21, the GAG and collagen amounts deposited in 
the ECM doubled each week. In contrast, the DNA content did not significantly 
change during the differentiation process. This indicated that the cell number 
stayed relatively constant. Murdoch and coworkers (2007) used a similar 
approach for the generation of cartilage constructs. In their model, human 
bone marrow mesenchymal stem cells (MSCs) were seeded into transwell 
culture inserts and cultured for 28 days. They observed an eight-fold increase 
of DNA within the first 7 days, corresponding to three cycles of cell division. 
This could be explained by a much more proliferative activity of MSCs 
compared to chondrocyte progenitor cells. Analysis of the released GAG 
chains into the conditioned medium showed that there was a gradual increase 
in rate of release over time in our system. In contrast, cartilage constructs 
based on MSCs showed an increase in rate of release of GAG chains up to 
day 7 in culture, after which release was constant. This could indicate that at 
day 7, the collagen and aggrecan network was fully established and therefore 
a state of homeostasis reached with matching rates of synthesis and 
catabolism (Professor Tim Hardingham, Manchester University, personal 
communication). Relating this to the results in this study, chondrogenesis of 
the articular progenitor cells appears to proceed at a slower rate and therefore, 
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building the ECM meshwork is progressing slower as well. Articular cartilage 
was reported to have a water content of about 70-80% of its total weight. The 
dry weight is comprised of about 60% collagen and 10% GAG chains (McDevitt 
1973). In comparison, the water content of the cartilage constructs was slightly 
higher with 90%, as well as collagen (~70%) and GAG (~15%) content of the 
dry weight. This indicates that the overall biochemical composition of the 
cartilage constructs was similar compared to articular joint cartilage. 
 
Immunohistochemical staining of fully differentiated cartilage constructs 
showed the presence of the major cartilage components collagen type II and 
aggrecan, as well as non-collagenous glycoproteins including COMP, decorin, 
fibronectin and lubricin. Lubricin, also known as superficial zone protein and 
proteoglycan 4, is expressed in the superficial layer of cartilage and has been 
proposed to be part of the lubricant of the joint surface (Schumacher et al. 
1994). It was very encouraging that lubricin was predominantly expressed in 
the “surface” layer of the cartilage constructs. Since the cells originate from the 
superficial zone of the donor cartilage (Dowthwaite et al. 2004; Williams et al. 
2010), one would have not been surprised if lubricin would be homogenously 
expressed in the constructs. This shows that the chondrocytes within the 
construct are influenced by other factors independent from the growth factors 
supplied in the medium, and are attempting to re-establish the tissue 
architecture seen in joint cartilage. One of these factors could be hydrostatic 
pressure, which is induced by culturing the cells in the transwell and adding 
excess medium on top of them. Moreover, given the size of the constructs, 
concentration gradients of supplements will be established across the tissue. 
Since lubricin is only produced by superficial zone chondrocytes, it could 
indicate that a stratification within the cartilage construct took place with 
chondrocyte progenitor cells at the surface and normal chondrocytes in the 
remaining parts of the constructs. Specific sulphation patterns have been 
reported for the cartilage stem cell niche (Hayes et al. 2008). The monoclonal 
antibodies 3B3 (-), 7D4, and 4C3 were used because they were reported to 
bind CS motifs present in the niche, but no specific staining was observed 
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(data not shown). Therefore, it remains to be seen whether the chondrocyte 
progenitor cells are restricted to the superficial layer of the constructs. 
Staining of the constructs with antibodies against disaccharide epitopes 
generated after chABC digest showed strong staining for 4S and 6S and 
weak staining for 0S. Digestion with chB followed by staining for 4S resulted 
in no staining, indicating the absence of DS in the construct as expected. 
However, the staining was no indication for the relative content of these 
disaccharides in the GAG chains, since the antibodies only recognize the 
“stubs” of the GAG chains on the core proteins. 
 
HPLC analysis of AMAC labeled disaccharides generated after exhaustive 
cleavage of the cartilage construct GAG chains revealed that the disaccharide 
composition changed during differentiation. Initially at day 1, the GAG chains 
comprised an approx. equal amount of 4S (51.4%) and 6S (46.3%) and a 
small amount of 0S (2.4%). Within the first week of differentiation, the 
disaccharide composition of the constructs changed substantially and then 
gradually thereafter. The GAG composition was characterized by 6S being 
the most abundant disaccharide, followed by 4S and 0S, reaching 69%, 
20% and 11% by day 35.  
 
Bayliss and coworkers (1999) investigated the disaccharide composition of 
total GAG chains from human cartilage explants with different donor age. They 
observed that the amounts of 4S and 6S within the GAG chains were very 
similar at young age, but then changed in adulthood to 6S being the main 
disaccharide (~80%), followed by 4S (~15%). Only about 5% of the 
disaccharides were non-sulphated (Bayliss et al. 1999). They also observed 
di- and trisulphated disaccharides, which contributed less than 1% to the total 
amount. This change in the ratio of 6S:4S is similar to the changes observed 
in the differentiation of the cartilage construct in this study. However, the time 
scale is of course not comparable. The cartilage constructs cultured for up to 
5 weeks could not possibly undergo the spectrum of matrix maturation 
observed during postnatal development and growth in humans over decades. 
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Using aggrecan purified from the cartilage explants for Western blotting 
analysis, Bayliss and coworkers (1999) showed increased staining of the 
membrane after sample digest with chABC using the antibody 3B3 
(recognizing 6S stubs) with increasing patient age. This indicates that 
aggrecan was probably the main source for the increased 6S content. 
 
To gain further insight on cell differentiation, the expression of marker proteins 
during chondrogenic tissue formation was analyzed using Q-PCR. As 
expected, the expression of collagen type II and aggrecan increased over the 
time course very substantially. Matrilin-3 expression also increased over 35 
days, but much later than the other matrix proteins with maximal expression 
not seen until day 28. Matrilins play a role as adapters between collagen fibrils 
and aggrecan. They help to form the ECM meshwork predominantly made 
from these matrix proteins (Klatt et al. 2011). One reason why it took about 28 
days to form the proper cartilaginous ECM, even though collagen type II and 
aggrecan were already highly expressed from day 7, could have been the 
relatively late increase in matrilin-3 expression. 
In contrast to collagen type II, collagen type I was expressed in monolayer 
culture. Interestingly, collagen type I expression was seen throughout the time 
course, although it may not have been expressed by all cells as indicated by 
regional restriction of collagen type I staining to the centre of the constructs by 
immunohistochemistry. Expression of collagen type I was also observed 
during chondrogenic differentiation of MSCs by others (Murdoch et al. 2007). 
 
During the time course of differentiation of the cartilage constructs, a switch 
from collagen type II A to type II B was observed. Type II A is the isoform 
expressed by chondrocyte progenitor cells during mesenchymal condensation 
(Sandell et al. 1994; Goldring et al. 2006). The type II B splice variant lacks 
exon 2, which encodes a von Willebrand factor type C domain in the N-terminal 
propeptide that was shown to interact with TGF- and BMP-2 in vitro (Zhu et 
al. 1999). This growth factor binding property of type II A collagen might be 
particularly important for chondrogenesis. After 35 days in culture, PCR 
analysis showed that > 90% of the total collagen type II was the B isoform, 
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indicating that the vast majority of progenitor cells had differentiated into 
mature chondrocytes. Overall, the analysis showed that the switch from II A to 
II B progressed gradually over 4 weeks, which was relatively slow compared 
to the chondrogenesis of MSCs. Murdoch and coworkers showed that in their 
cartilage model, the switch from collagen type II A to B occurred within 4 to 5 
days after seeding (Murdoch et al. 2007). As discussed above, this showed 
again that MSCs much more readily differentiated into mature chondrocytes 
than human knee cartilage derived progenitor cells. 
 
By evaluating the gene expression levels of hypertrophic markers, an increase 
in the expression of collagen type X was observed. However, no collagen type 
X deposition in the cartilage construct was detected after 35 days in culture. In 
normal healthy articular cartilage, no collagen type X expression is detected 
(van der Kraan and van den Berg 2012), but it is commonly observed in tissue 
engineered cartilage constructs and linked to spontaneous hypertrophic 
differentiation of cells in such engineered tissue constructs (Johnstone et al. 
1998; Murdoch et al. 2007; Yoo et al. 1998; Barry et al. 2001).  
 
Mueller and Tuan (2008) investigated the effects of known hypertrophy 
inducing factors, e.g. decreasing dexamethasone concentration, adding 
thyroid hormone and removing TGF- from the culture medium, on 
chondrogenic differentiation of MSCs. They observed that while in control 
constructs the expression levels of collagen type X mRNA and protein were 
much higher than in constructs stimulated to undergo hypertrophy, there was 
no collagen type X deposition in the matrix of control constructs. Collagen type 
X deposition was strictly associated with chondrocyte hypertrophy (Mueller 
and Tuan 2008). This very interesting observation made it clear that a high 
level of collagen type X expression by itself does not inevitably lead to 
chondrocyte hypertrophy. In a similar experiment in this study, fully 
differentiated constructs were stimulated with a medium promoting 
hypertrophy for 14 days. T3 hormone was added into the medium to stimulate 
hypertrophic differentiation (Wang et al. 2010). This treatment led to collagen 
type X deposition in the bottom most part of the construct next to the supporting 
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filter, a tissue zone which also showed morphological changes akin of 
hypertrophy. Gene expression analysis showed that the mRNA levels of 
collagen type X were unchanged, but the expression of MMP13 was about 7 
fold increased. In addition, HIF2 and indian hedgehog (IHH) were also slightly 
up regulated. However, the expression of Runx2 and osteonectin was higher 
in the control constructs. In a recent study, Yang and colleagues found that 
matrilin 3 is a novel binding partner for BMP-2 and may prevent premature 
chondrocyte hypertrophy through suppression of BMP-2/Smad1 activity (Yang 
et al. 2014). In the cartilage constructs, matrilin 3 expression was strongly 
increased on day 28 and 35 (Fig. 4.5 D). The resulting increased presence of 
matrilin 3 could have therefore resulted in the sequestration of BMP-2 in the 
ECM and inhibited the hypertrophic differentiation of cartilage constructs. 
Taken together, these results indicate that the cartilage constructs derived 
from chondrocyte progenitor cells formed stable cartilage without terminal 
differentiation under normal culture conditions and when induced to undergo 
terminal differentiation, display an architecture mimicking that of joint cartilage 
with a superficial zone at the top and hypertrophic zone at the bottom. 
 
Using progenitor cells established from different individuals (PRO3, PRO2 and 
PRO5), the efficacy of the developed chondrogenic differentiation protocol was 
demonstrated. The successful differentiation of two additional cell strains 
showed that the protocol can be applied to progenitor cells in general, 
independent of patient age. In contrast, differentiation of a progenitor cell strain 
isolated from OA-knee cartilage resulted in a fibrocartilaginous tissue with a 
significantly reduced size, wet weight and GAG content compared to our 
standard PRO3 cell strain. Furthermore, extensive deposition collagen type X 
in the matrix was revealed by immunolocalization. This indicates a 
hypertrophic-like phenotype of the chondrocytes. Up regulation of MMP13 or 
collagen type X was not observed, which would be expected for terminally 
differentiated chondrocytes. In fact, expression levels were lower than control. 
Interestingly, IL-8 was highly up regulated. IL-8 is a pro-inflammatory cytokine 
and produced by chondrocytes upon stimulation with IL-1 and TNF- (Lotz, 
Terkeltaub, et al. 1992). It is also present in the synovial fluid of patients with 
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knee osteoarthritis (Pierzchala et al. 2011). Given that culture conditions for 
PRO3 control cells and JF012OA cells were identical, it is suspected that the 
OA cells had an intrinsically high expression level of proinflammatory 
cytokines. Since the cells were derived from OA knee cartilage, they must have 
been exposed to an inflammatory environment present during OA 
development. Epigenetic modifications of a number of genes in chondrocytes 
from OA cartilage have been described (Barter and Young 2013; Moazedi-
Fuerst et al. 2014). This environment could have caused epigenetic changes 
in these cells, affecting gene expression long after isolation from the tissue and 
extensive expansion in monolayer culture. This further highlights epigenetic 
information as an important factor in cartilage tissue engineering. 
 
In conclusion, the results presented in this chapter show that cartilaginous 
tissue generated with progenitor cells had similar biochemical and histological 
features as articular cartilage and could be used for further investigation of 
cartilage metabolism. Although chondrogenesis of these cells was slower 
compared to MSCs widely used for cartilage tissue engineering, the 
advantages were that the cells did not undergo terminal differentiation and 
formed stable cartilage. In addition, a single cell strain was used to generate 
an enormous amount of cartilage constructs, whereas MSCs can only be 
expanded in monolayer to a limited extend.  
 
 
 
 
 
 
 
 
Chapter 5: 
 
Changes in carbohydrate 
biosynthesis associated with 
exposure of cartilage to an  
OA-like inflammatory stimulus 
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5 Changes in carbohydrate biosynthesis associated 
with exposure of cartilage to an OA-like 
inflammatory stimulus 
 
 Introduction  
The perception of OA being solely caused by wear induced degeneration of 
joint cartilage has changed in recent years. Increasingly, evidence indicates 
that inflammation of the synovium (synovitis) plays an important role in the 
development of OA (Berenbaum 2012; Goldring and Otero 2011). Upon 
induction of inflammation, the synovial membrane gets infiltrated by 
mononuclear cells and inflammatory factors are secreted into the synovial 
fluid. These factors include interleukin 1 (IL-1), tumor necrosis factor  
(TNF-) and various chemokines (Sellam and Berenbaum 2010). Although the 
origin of synovitis is not entirely clear, several theories have been put forward. 
One reason for the development of synovitis could be the release of cartilage 
fragments into the synovium which leads to activation of synovial cells and 
production of inflammatory factors. These factors can induce the expression 
of catabolic enzymes, e.g. matrix metalloproteases (MMPs) and a disintegrin 
and metalloproteinase with thrombospondin motifs (ADAMTS), in the 
superficial layer of joint cartilage leading to matrix break-down. Moreover, 
these factors can promote synovial angiogenesis and induce an increased 
expression of inflammatory factors by the synovial fibroblasts themselves and 
thereby drive a catabolic cycle (Sellam and Berenbaum 2010). Another theory 
describes synovial tissue as the initiator of OA development. In a mouse model 
of OA, depletion of synovial macrophages before inducing collagenase-
mediated joint instability prevented the generation of MMP-generated neo-
epitopes (Blom et al. 2007; Blom et al. 2004). The important role of these cells 
was further underlined by a decreased incident of osteophyte formation (Blom 
et al. 2004). Furthermore, an increased interleukin 17 (IL-17) level in human 
OA synovial tissue could be related to increased IL-17 expression in synovial 
mast cells (Suurmond et al. 2011).  
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IL-1, a member of the interleukin cytokine superfamily, is one of the 
predominant inflammatory cytokines involved in inflammatory joint disease 
(Goldring and Otero 2011). It is a key pro-inflammatory cytokine secreted by 
innate immune cells but can also be produced by many other cells including 
synovial fibroblasts and chondrocytes. Upon binding to its receptor (IL-1R1), it 
can initiate several signaling pathways, leading to activation NF-B, Erk1/2, 
p38, and JNK (Fig. 5.1) (Weber et al. 2010; Daheshia and Yao 2008). This 
results in increased expression of several catabolic enzymes, including MMP1, 
MMP3, and MMP13 (Fan et al. 2005; Inoue et al. 2005; Kobayashi et al. 2005; 
Mix et al. 2001; Tetlow et al. 2001), as well as ADAMTS-4 and ADAMTS-5 
(Fan et al. 2005; Cortial et al. 2006). Furthermore, chondrocytes also increase 
expression and secretion of IL-1 and another inflammatory cytokine, IL-6, 
resulting in an autocrine-positive feedback loop (Fan et al. 2007) driving 
catabolic activity. IL-1 (and TNF-) signaling leads to the suppression of 
expression of proteins responsible for maintaining the chondrocyte phenotype, 
e.g. aggrecan and collagen type II (Goldring and Otero 2011).  
 
Oncostatin M (OSM), a member of the interleukin-6 protein family, was 
reported to be involved in inflammatory joint disease (Cawston et al. 1995; 
Langdon et al. 2000). It is secreted by monocytes, activated T cells and 
neutrophils (Tanaka and Miyajima 2003). OSM alone causes mild catabolic 
responses in chondrocytes (Goldring and Otero 2011). However, it signals 
synergistically together with IL-1, leading to enhanced collagen (Cawston et 
al. 1995) and aggrecan (Cawston et al. 1998; Durigova et al. 2011) 
degradation through the up-regulation of MMPs (Blain et al. 2010; Hui et al. 
2003) and ADAMTSs (Hui et al. 2003; M Durigova et al. 2008; Durigova et al. 
2011). In particular, OSM is a potent inducer of MMP13 in articular cartilage 
(Blain et al. 2010; Fearon et al. 2006; El Mabrouk et al. 2007), and therefore 
plays an important part in the pathological process of cartilage degeneration 
(Goldring and Goldring 2007). OSM binds to its plasma membrane receptor 
which is composed of a heterodimer of the signal transducer receptor chain 
gp130 (glycoprotein 130) and OSMR (OSM-receptor ) (Heinrich et al. 2003). 
OSM can also bind to a receptor heterodimer composed of gp130 and LIFR 
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(leukemia inhibitory factor receptor ). Signal transduction is primarily 
mediated through the JAK/STAT signaling pathway (Fig. 5.1) (Tanaka and 
Miyajima 2003; Heinrich et al. 2003). Alternatively, in some contexts signaling 
can also be transduced through the MAPK (mitogen activated protein kinase) 
pathway, leading to phosphorylation of Erk1/2 (extracellular regulated kinase 
1/2), p38, and JNK (c-Jun N-terminal kinase) (Heinrich et al. 2003). Recently, 
Gilbert and coworkers found that in primary bovine articular chondrocytes, co-
stimulation of IL-1 and OSM leads to increased expression of MMP9, 
ADAMTS-4, and ADAMTS-5 through activation of protein kinase R (Gilbert et 
al. 2012).  
 
Proposed biochemical biomarkers for pre-radiographic OA are mostly cartilage 
matrix turnover and degradation products as already detailed in the 
introduction to this thesis. However, it is not yet established whether any of 
these markers for disease currently available are reliable for clinical diagnostic 
(Mobasheri and Henrotin 2011; Kraus et al. 2011). Moreover, the baseline 
level for some of the markers has a large variability between patients which 
makes it difficult to establish diagnostic thresholds. Identification of one or 
more qualitative markers for early OA, for example an epitope specific for OA, 
should prove to be a more reliable indicator of disease than simply assessing 
the quantity of a certain metabolic product.  
 
Using the novel human cartilage model based on chondrocyte progenitor cells 
(described in chapter 3 and 4), global changes in gene expression of enzymes 
involved in glycan synthesis and modification associated with inflammatory 
stimulation can be analyzed using microarray technology. Such an approach 
might provide clues from which disease-associated biosynthetic changes in 
glycosylation patterns can be predicted, and subsequently tested in follow-up 
biochemical studies. In addition to inflammatory stimulation of cartilage 
constructs, dermal equivalents were generated and stimulated with the same 
inflammatory regimen. The purpose of this was to use a reference model, 
helping to identify changes in gene expression which are chondrocyte specific 
and those that are a general tissue response to the cytokine treatment.  
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 Aims for this chapter: 
1. Identify relevant concentrations for inflammatory insult in cartilage 
model system and verify that expected catabolic changes take place, 
i.e. establish an in vitro model of osteoarthritis. 
 
2. Identify changes in gene expression using microarray technology in 
combination with a robust experimental design likely to provide answers 
to central questions concerning cartilage-specific changes in protein 
glycosylation mediated by an inflammatory environment 
 
3. Select genes of interest from microarray data and verify changes in 
gene expression using Q-PCR to validate data set and identify 
candidate genes of interest for further studies 
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Figure 5.1 Overview of signalling pathways of IL-1 and OSM that play a major role in 
OA. IL-1 binds to the IL1R1 receptor, leading to activation of NFB, Erk1/2, p38 MAPK, and 
JNK signalling. OSM can bind to two different receptor subtypes which are either composed 
of a dimer of gp130 / OSMR or gp130 / LIFR. Signalling mainly occurs through the 
JAK/STAT pathway, but may also involve other pathways including Erk1/2, p38 MAPK, and 
JNK signalling. Both, IL-1 and OSM signalling lead to an increase in the expression of 
catabolic enzymes and inflammatory mediators which are found in OA cartilage. The 
information presented in this schematic diagram was obtained from Weber et al. (2010), 
Heinrich et al. (2003), and Dey et al. (2013). 
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 Materials and methods 
 Inflammatory stimulation of cartilage constructs 
Cartilage constructs were developed for 35 days in chondrogenic 
differentiation medium as described in chapter 4, section 4.2.1. Before 
inflammatory stimulation, the constructs were cultured for 72 h in chondrogenic 
basal medium (chondrogenic differentiation medium without dexamethasone, 
bovine insulin, TGF-2, and BMP-2). The medium was changed in both the 
bottom (1 ml) and top (500 µl) of the transwell insert at all steps. This was done 
to remove any anabolic growth factors endogenously synthesized by the 
constructs which could potentially influence the chondrocyte response to the 
inflammatory cytokines. In the next step, cartilage constructs were cultured in 
basal medium (control), basal medium containing 1 ng/ml IL-1 or basal 
medium containing 1 ng/ml IL-1 and 10 ng/ml OSM. For each condition, three 
constructs were cultured at the same time for 48 h while replacing the medium 
after 24 h. Subsequently, the cartilage constructs were washed twice with PBS 
before being removed from the transwell insert and transferred into a 1.5 ml 
tube containing 500 µl TRIzol. The tubes were frozen immediately in liquid 
nitrogen and stored at -80°C until RNA extraction was performed. Analysis of 
the GAG content in the conditioned medium was determined by DMMB assay 
(described in chapter 3, section 3.2.8). 
 
 Inflammatory stimulation of dermal constructs 
To determine the effective dose of IL-1 for Bonacker fibroblasts, 1 x 104 cells 
were seeded per well of a 24 well plate and cultured in 2 ml medium per well 
containing 10% serum (chapter 2, section 2.2.8). After reaching approximately 
70% confluency, the serum concentration in the medium was reduced to 4%. 
Different concentrations of IL-1 from 0.1 to 30 ng/ml were added to the 
medium and the cells cultured for 72 h without medium change. At the end of 
the incubation period, the medium was removed and the cells were washed 
with PBS. 35 µl cell lysis buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 2% glycerol, 1% Triton X-100, containing protease inhibitor cocktail 
(Sigma Aldrich, Cat. No. P8340; final concentrations: 1.04 mM AEBSF, 0.8 µM 
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aprotinin, 40 mM bestatin, 14 mM E-64, 20 µM leupeptin, 15 µM pepstatin A) 
were added to each well and the cells lysed on ice while shaking for 30 min. 
Subsequently, the remaining cells were scraped from the well. The suspension 
was centrifuged for 10 min at 14,000 x g and 4°C and the supernatant collected 
and stored at -20°C. The protein concentration in the cell extracts was 
determined using the Pierce BCA assay kit. For Western blot analysis, 15 µg 
protein were loaded per lane on a 4-20% Tris-glycine PA gel. SDS-PAGE and 
Western blotting were performed as described (chapter 2, sections 2.2.13 and 
2.2.15). The membrane was initially probed with an antibody raised against 
cyclooxygenase 2 (COX2), and afterwards with an antibody against -tubulin 
as a loading control (Table 5.1). The ratio between the amount of COX2 and 
-tubulin for every condition was calculated from densitometric analysis using 
the ImageJ software package (Abramoff et al. 2004). 
 
For microarray analysis, hyperconfluent cultures of Bonacker fibroblasts were 
prepared and grown in the presence of ascorbate-2-phosphate. Under these 
conditions, fibroblasts are known to establish an endogenous extracellular 
matrix containing collagen and fibrillin fibrils (Kielty et al. 1994). Cells were 
seeded with a density of 1.5 x 105 cells/well into 24 well plates, and after 24 h 
switched to minimal essential medium (MEM) containing 10% heat-inactivated 
fetal bovine serum, non-essential amino acids, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 μg/ml streptomycin, and 50 µg/ml ascorbic acid-2-
phosphate. The medium (1 ml per well) was changed every 2 days. After 22 
days in culture, the ECM layer was washed with PBS, and the serum 
concentration in the culture medium reduced to 4% and cytokines added. For 
each condition, three constructs were cultured in parallel for 48 h in either 
control medium, medium containing 1 ng/ml IL-1 or medium containing 1 
ng/ml IL-1 and 10 ng/ml OSM. Medium was replaced after 24h. At the end of 
the inflammatory stimulation, cells were washed in PBS twice. Subsequently, 
500 µl TRIzol were added per well and cells lysed at room temperature for 10 
min, and the ECM eventually dislodged from the plastic surface using a cell 
scraper. The resulting suspension was frozen on dry ice and stored at -80°C 
until RNA extraction was performed. 
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 Purification of total RNA for microarray analysis 
Total RNA was purified using TRIzol as previously described (chapter 4, 
section 4.2.6). Because highly pure RNA is required for microarray analysis, 
the purified RNA was further processed to remove any remaining genomic 
DNA contamination as well as proteins. The precipitated total RNA pellet from 
the initial purification was reconstituted in 70 µl RNase-free H2O and digested 
with 4 µl (4 units) recombinant RNase-free DNAse I (Promega) in a total 
volume of 100 µl for 30 min at 37°C. To remove DNA fragments generated by 
the DNAse digest as well as aggrecan which co-purifies with RNA during 
TRIzol extraction (McKenna et al. 2000), the samples were applied to RNEasy 
mini spin columns (Qiagen). The total RNA was purified using the RNEasy Mini 
kit according to the manufacturer’s instructions. Afterwards, the RNA was 
precipitated in ethanol as described (chapter 4, section 4.2.6) and stored at -
80°C until further use. 
 
 RNA quality control 
The quality of the purified total RNA from cartilage and dermal constructs was 
assessed using an Agilent 2100 Bioanalyzer (Agilent). This was performed by 
Dr Claudia Consoli at Central Biotechnology Services (CBS, School of 
Medicine, Cardiff University). Briefly, approx. 250 ng of total RNA were applied 
to Eukaryote Total RNA Nano assay chips (Agilent). The RNA quality was 
assessed based on the amount of 18S rRNA and 28S rRNA in the sample, as 
well as the overall electrophoretic sample profile expressed as the RIN score 
(RNA Integrity Number) which gives a verified measure of the degree of RNA 
degradation. The RIN score range is from 1 to 10, whereby 1 is very poor RNA 
quality with a high degree of degradation and 10 is very good RNA with 
essentially no degradation. The recommended threshold for a good quality 
RNA preparation is a RIN score of 6 or higher. In addition, RNA purity was also 
assessed spectrophotometrically as the absorbance at 260 nm to 280 nm ratio 
using a NanoVue™ Plus Spectrophotometer (GE Healthcare). A value higher 
than 1.8 was considered to be acceptable. Any samples that did not meet 
either of these criteria were excluded from the analysis. 
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 RNA storage using RNAstable tubes 
For shipping of RNA to the Scripps Research Institute (La Jolla, CA, USA), 
3 µg total RNA were applied to RNAstable tubes (Biomatrica, San Diego, CA, 
USA) and dried using a vacuum concentrator. The RNAstable tubes allow 
storage of RNA at ambient temperatures without increasing the degree of 
degradation over extended time periods. This was considered to be more 
suitable for shipping of RNA samples than on dry ice, because unexpected 
delay in the shipping of dry ice samples may compromise RNA quality. To 
recover the RNA from the tubes, RNase-free H2O was added to give the 
desired RNA concentration, and a good yield of recovery (> 90%) 
experimentally verified.  
 Microarray analysis of gene expression 
The gene expression of cartilage and dermal samples was analysed using 
GLYCO v4 gene chips which are custom-designed Affymetrix chips 
(Affymetrix, Santa Clara, CA, USA) made for the Consortium of Functional 
Glycomics (CFG, www.functionalgenomics.org). It contains probes for 1260 
human transcripts related to glycosylation. For each of the three conditions, 
cartilage constructs or dermal equivalents were prepared in three independent 
experiments. Synthesis of labelled cRNA and hybridization of the microarrays 
was performed by Dr Steven Head and his colleagues at the DNA Array Core 
Facility at the Scripps Research Institute (La Jolla, CA, USA). For this, the total 
RNA was recovered from RNAstable tubes and transcribed into DNA in a two-
step process. In the first step, cDNA was generated using Superscript II 
reverse transcriptase at 42°C for 1h. In the second step, the cDNA was added 
to a mixture of E .coli DNA ligase, E. coli DNA polymerase I, E. coli RNase H 
and incubated at 16°C for 2 h, followed by addition of T4 DNA polymerase and 
incubation for another 5 min at 16°C. To purify the cDNA from the 
cDNA/protein mixture, phenol/chloroform extraction was used. The aqueous 
phase containing the cDNA was separated using phase lock gels and 
concentration of the cDNA was performed using ethanol precipitation. The 
generation of biotinylated cRNA from cDNA was performed using in vitro 
transcription using the MessageAmp™ II Biotin Enhanced aRNA Amplification 
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Kit (Ambion/Life Technologies) according to the manufacturer’s instructions. 
After sample clean-up using the RNeasy mini kit (Qiagen), cRNA was 
fragmented using fragmentation buffer containing MgOAc and KOAc. 
Hybridization and analysis of the chip was performed on a GeneChip Scanner 
3000 7G (Affymetrix) using standard Affymetrix protocols based on methods 
originally described by Lockhart et al. (Lockhart et al. 1996). 
The initial microarray data analysis was performed by Suzanne Papp and Lana 
Schaffer at the DNA Array Core Facility (Scripps Research Institute). Quality 
control of microarray chips was performed using Bioconductor routines 
(Gentleman et al. 2004). The data obtained from the chips was normalized 
separately for cartilage and dermal samples, resulting in 755 annotated probe 
sets (Bolstad et al. 2003; Irizarry 2003; Carvalho and Irizarry 2010). Before 
comparison of the data sets, the 40% variable transcripts with lowest signal 
intensity were excluded from the data set. The fold changes and standard 
errors were calculated using the LIMMA (Linear Models for Microarray Data) 
package (Smyth 2004) by fitting a linear model for each gene. The fold 
changes are expressed as the average log2 of the array signal raw data. This 
was done because the log scale is the relevant scale for microarray analysis 
starting with log transformed data, taking into account the distribution of noise 
in the intensity measurements as well as the transformation to a normal 
distribution. Smoothing of standard errors was performed with empirical Bayes 
methods. The changes in gene expression between the different experimental 
conditions within each tissue model are presented as fold change, p-value (not 
shown), and adjusted p-value. The adjusted p-value is derived from the p-
value after adjustment for multiple testing with the Benjamini and Hochberg’s 
method of controlling the false discovery rate of 0.15 or less (Benjamini and 
Hochberg 2009). The threshold for a transcript to be recognized as 
differentially expressed was set as a fold change > 1.4 and an adjusted p-value 
< 0.15. Heat maps of the chips were generated using the dChip software 
package (Li and Wong 2001). Shades of red reflect increased and blue 
decreased fold change levels relative to the mean expression of the control 
group for each transcript, respectively.  
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 Verification of microarray results using Q-PCR 
Verification of changes in expression of the genes of interest identified from 
the microarray data was performed as described (chapter 4, sections 4.2.6 and 
4.2.7). The primers used for this analysis are described in Table 5.2. Statistical 
analysis was performed as described (chapter 3, section 3.2.11). For 
calculation of p-values, the respective Ct values were used. The fold change 
in gene expression was determined from the respective 2-Ct values. 
 
Table 5.1 Antibodies used in this chapter for Western blotting 
Antibody Dilution factor Source 
Goat polyclonal anti-COX2 (C-20), 
sc-1745 
1:1000 
 
Santa Cruz Biotechnology 
Mouse monoclonal anti--tubulin 
(TUB 2.1) 
1:1000 
 
Sigma Aldrich 
Rabbit anti-mouse IgG/HRP 
conjugate 
1:1000 Dako, Cambridgeshire, UK 
   
Rabbit anti-goat IgG/HRP 
conjugate 
1:1000 Dako, Cambridgeshire, UK 
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Table 5.2 Sequence of primers used for PCR and Q-PCR analysis 
 
  
Gene name 
Sequence of forward (top) and 
reverse (bottom) primers (5‘ - 3‘) 
Amplicon 
size (bp) 
Reference 
sequence 
IL8 
CTGAGAGTGATTGAGAGTGGACC 
ATTTGCTTGAAGTTTCACTGGC 
209 NM_000584 
CCL20 
GCGAATCAGAAGCAGCAAGC 
CCAACCCCAGCAAGGTTCTT 
294 NM_004591 
SRGN 
AAGATCCCCCGTCTGAGGAC 
CTGAGGGCAGATTCCTGTCA 
232 NM_002727 
ST3GAL1 
CCCACACCCCTGTATTCTCC 
ATAGGCTGAGTGACCGTCCA 
222 NM_003033 
LUM 
GTCCTGACAGAGTTCACAGCA 
GCACTTGGGTAGCTTTCAGG 
261 NM_002345 
CHST15 
GCCGCACACCAGATCCATCAAGG 
GTACAACCTCTCCACAGGGTCC 
240 NM_015892 
GALNT4 
GAGGAAGTAGGGAGAGAGGAGT 
CCACTGTTAAAAACGCCAGC 
279 NM_003774 
XYLT1 
GGACTTCCACCGCTTCCAG 
CCGTCAGGCTCATCGTAGAC 
174 NM_022166 
ALG14 
CACCGAATTCCAAGAAGCCG 
CCCAAGGAGAAGGGCAGATAC 
174 NM_144988 
CHST11 
TATGTTGCACCCAGTCATGCG 
GTCCTCATCCACCACCAAGT 
241 NM_018413 
SLC35D1 
GCAGTTCACCCTCTCCTGTG 
AGCCTCTGACTGTTTGCTCA 
259 NM_015139 
CHSY3 
GGGAGGACCTGGCATGATCT 
GTCTTGGATGTAACCCTTCCGA 
214 NM_175856 
CHPF2 
TTGGACGCTGCCTCATTGAC 
GGGTCAGCACGGTCAGGTTC 
267 NM_019015 
ADAMTS-4 
GTGTGCTGCCTACAACCACCG 
CTGGACACAGACCGAGGAGC 
205 NM_005099 
ADAMTS-5 
GTGAGAACTGGCTGTGACGGC  
CCTTCAGGAATCCTCACCACGTC 
152 NM_007038 
MMP1 
GCTTACGAATTTGCCGACAGAG 
CAATTCCAGGAAAGTCATGTGC 
277 NM_002421 
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 Results 
 Inflammatory stimulation of cartilage and dermal constructs 
In the previous chapter it was shown that the human chondrocyte progenitor 
cells fully differentiated into chondrocytes in the developed cartilage model 
system. Using this model system, the effects of inflammatory stimulation on 
gene expression should be investigated, using the cytokines IL-1 and OSM. 
These cytokines are leading to the up-regulation/activation of key catabolic 
enzymes, including MMP1, MMP13, ADAMTS-4, and ADAMTS-5 which are 
responsible for degradation of the cartilage extracellular matrix in 
osteoarthritis. It was shown before that combined treatment with IL-1 and 
OSM has an even stronger catabolic effect on cartilage than IL-1 alone 
(Barksby et al. 2006; M. Durigova et al. 2008; Pelletier and Martel-Pelletier 
2003). For that reason, it was decided to have a group stimulated with IL-1 
alone and another group stimulated with IL-1 and OSM in combination. From 
previous studies looking at the effects of cytokines on cartilage, it was known 
that treatment with OSM alone had little effect in terms of driving cartilage 
degradation (Barksby et al. 2006; Hui et al. 2003; Cawston et al. 1998). 
Therefore, the treatment with OSM alone was excluded from the experimental 
setup in the following experiments. In addition to the inflammatory stimulation 
of the cartilage model, a dermal model consisting of a 3D matrix generated by 
skin fibroblasts was subjected to the same conditions. A comparison of 
fibroblast and chondrocyte responses to cytokine stimulation will facilitate 
identification of changes in gene expression that may be tissue specific. 
Initially, the effective dose of IL-1 for stimulation of fibroblasts was 
determined. As a readout, the expression of COX-2 was determined using 
Western blotting (Fig. 5.2 A). COX-2 expression is induced by IL-1 through 
NFB signaling (Weber et al. 2010). For analysis, densitometry was used 
whereby the signal intensity of COX-2 was normalized to the signal intensity 
of the loading control -tubulin (Fig. 5.2 B). COX-2 expression showed a 
classic dose-response behavior. At a concentration of 1 ng/ml IL-1, COX-2 
expression was increased about 60-fold compared to control. Higher 
concentrations of IL-1 up to 30 ng/ml did not further increase COX-2 
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expression substantially (Fig. 5.2 B). 1 ng/ml was considered a physiologically 
relevant concentration, and was chosen for further evaluation in the cartilage 
model. 
 
 
Figure 5.2 Analysis of IL-1 regulated COX-2 expression in human dermal fibroblasts. 
To identify the effective dose of IL-1 for regulation of expression, Bonacker cells were 
stimulated with different concentrations of IL-1. Cells were incubated for 72 h and expression 
levels of COX-2 and -tubulin were analyzed using Western blotting (A). Densitometrical 
analysis of Western blot bands was performed using the ImageJ software package (B). Data 
is presented as the fold increase in COX-2 signal intensity relative to the corresponding -
tubulin loading control signal intensity compared to untreated cells. Results are displayed as 
mean ± SEM of two independent experiments with one sample set each. Data was fitted with 
a dose response curve. Statistical significance of changes relative to untreated control were 
determined with one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison 
test. *P< 0.05.  
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Identification of an effective concentration of OSM was attempted using a cell 
proliferation assay, as OSM had been suggested to have a mitogenic effect on 
fibroblasts (Ihn and Tamaki 2000). However, it was not possible to stimulate 
proliferation with OSM in the range of 0.1 to 30 ng/ml in Bonacker cells. 
For inflammatory stimulation of cartilage constructs, an IL-1 concentration of 
1 ng/ml and an OSM concentration of 10 ng/ml was used. The OSM 
concentration was derived from the literature, where 10 ng/ml had proven 
effective in previous studies (Barksby et al. 2006; Gilbert et al. 2012; Blain et 
al. 2010; M. Durigova et al. 2008). To ensure that the cytokines had the 
expected effect on cartilage and dermal constructs, RT-PCR was performed 
using primers for MMP13, ADAMTS-4, and ADAMTS-5 (cartilage constructs) 
and MMP1 (dermal constructs) (Fig. 5.3). The housekeeping gene h36B4 was 
used as a control for the quantity/quality of the cDNA. In the unstimulated 
control cartilage constructs, MMP13, ADAMTS-4 and ADAMTS-5 were barely 
detectable, whereas upon addition of IL-1 for 48 h, strong bands for each of 
the genes could be observed. This was also observed for the combined 
treatment with IL-1 and OSM. For the dermal constructs, MMP1 expression 
was analyzed after inflammatory stimulation. In the control constructs, weak 
expression was observed. After addition of IL-1 alone and in combination with 
OSM, a strong up-regulation of expression was observed. Analysis of the GAG 
released from the cartilage constructs into culture supernatant during 
inflammatory stimulation using the DMMB assay further substantiated these 
findings and showed that the amount of GAG chains released was 7-fold 
higher on day 1 and about 5-fold higher on day 2 compared to control when 
treated with IL-1 alone (Fig. 5.4). Combination of OSM and IL-1 resulted in 
an even stronger GAG chain release which was 19-fold higher on day 1 and 
11-fold higher on day 2 compared to unstimulated control. 
In conclusion, this showed that the cells were responding to the inflammatory 
stimulation as expected and the respective cytokine concentrations were 
therefore chosen for the microarray gene expression profiling. 
183 
 
 
Figure 5.3 Cytokine treatment of cartilage constructs and dermal equivalents resulted 
in up-regulation of matrix degrading enzymes. Cartilage constructs were grown in 
differentiation medium for 35 days and then maintained in medium without TGF-2, BMP-2, 
additional insulin and dexamethasone for a further 3 days prior to stimulation (A). A confluent 
fibroblast layer was grown in ascorbate-2-phosphate for 22 days to establish a dermal tissue 
like 3D extracellular matrix (B). Cytokines (1ng/ml IL-1, 10 ng/ml OSM) were added to the 
culture media every day for 2 days. Afterwards, total RNA was purified from cartilage 
constructs and dermal-like tissue. The expression of known target genes up-regulated by IL-
1 and OSM was investigated using PCR. Addition of IL-1 alone and in combination with 
OSM to cartilage constructs resulted in an increase of MMP-13, ADAMTS-4 and ADAMTS-5 
expression (A). In dermal fibroblast cultures, up-regulation of MMP-1 by cytokines was 
confirmed (B). Each figure shows a representative analysis from three independent 
experiments with 3 repeats each. 
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Figure 5.4 GAG chain release from cartilage constructs upon stimulation with 
inflammatory cytokines. Fully differentiated cartilage constructs were cultured in medium 
without cytokines, or supplemented with IL-1 (1 ng/ml) alone or in combination with OSM (10 
ng/ml) for a total of 2 days. Medium was replaced every day and fresh cytokines were added. 
Released GAG accumulating in the conditioned medium was measured using the DMMB 
assay. Data is shown as the mean ± SEM of three independent measurements. 
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 Preparation of RNA for microarray analysis and evaluation of RNA 
quality 
Cartilage constructs were grown in differentiation medium for 35 days and 
were then cultured in medium without TGF-2, BMP-2, additional insulin, and 
dexamethasone for 3 days prior to stimulation with IL-1 alone or IL-1 in 
combination with OSM for 48 h. Dermal equivalents were obtained by growing 
hyperconfluent fibroblast cultures for 22 days in the presence of ascrobate-2-
phosphate and were subsequently exposed to the same cytokine regimen. 
Total RNA was extracted using TRIzol and purified over several stages as 
outlined in Materials and Methods. RNA was isolated from 3 pooled constructs, 
and the samples for an n = 3 were grown independently.  
The quality and quantity of the isolated RNA was evaluated. The amount of 
RNA was determined spectrophotometrically using absorbance at 260 nm. 
Cartilage samples contained between 4.3 and 11.3 µg RNA, and dermal 
samples between 6.2 and 20.9 µg RNA. Analysis of RNA integrity using the 
Agilent Bioanalyzer showed that there was very little RNA degradation in the 
samples (Fig. 5.5). The peaks representing 18S rRNA and 28S rRNA were the 
biggest peaks observed in the density plots created from the micro agarose 
gel electrophoresis on the chips. By integration of the area under the curve 
from each peak, the RNA integrity number (RIN) can be derived resulting in 
the RIN score. This score is not simply based on 28S/18S rRNA ratio but 
considers a wider range of elements of the electropherogram within the 
calculations for assessing RNA quality (Schroeder et al. 2006). It is generally 
accepted that RNA samples used for microarray analysis should have a RIN 
score not lower than 6, because otherwise RNA fragmentation by RNases 
could negatively affect the results. The RIN scores determined for the cartilage 
and dermal construct samples were all above 6 and are shown in table 5.3. 
From each sample, 3 µg total RNA were dried into RNAstable tubes 
(Biomatrica) using a vacuum concentrator and shipped to the Scripps 
Research Institute, San Diego, USA, for preparation of labeled cRNA and 
hybridization. 
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Table 5.3 RIN scores of total RNA samples 
Sample name RIN score 
cartilage 1 control 8.8 
cartilage 1 IL-1 only 9.0 
cartilage 1 IL-1/OSM 8.0 
cartilage 2 control 7.2 
cartilage 2 IL-1 only 6.4 
cartilage 2 IL-1/OSM 7.3 
cartilage 3 control 6.8 
cartilage 3 IL-1 only 7.3 
cartilage 3 IL-1/OSM 8.0 
skin 1 control 9.4 
skin 1 IL-1 only 9.2 
skin 1 IL-1/OSM 9.3 
skin 2 control 9.6 
skin 2 IL-1 only 9.2 
skin 2 IL-1/OSM 8.3 
skin 3 control 8.5 
skin 3 IL-1 only 7.8 
skin 3 IL-1/OSM 7.8 
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Figure 5.5 Analysis of RNA integrity after isolation from cartilage (A, C, E) and dermal 
(B, D, F) constructs. Total RNA samples isolated from cartilage and dermal control constructs 
(A, B), IL-1 only treated cartilage and dermal constructs (C, D), and IL-1/OSM treated 
cartilage and dermal constructs (E, F) were analysed using Agilent 2100 Bioanalyzer chips. 
Density plots of the gel electrophoresis analysis (right hand side next to respective plot) 
showed sharp peaks for 18S rRNA (1874 nucleotides) and 28S rRNA (4718 nucleotides). A 
representative set of samples from each treatment group is shown in this figure. 
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 Microarray analysis and chip data quality control 
The total RNA was processed for microarray analysis at the DNA Array core 
facility at the Scripps Research Institute. Initially, the quality parameters for the 
chip data were determined. The chip diagnostics recommended by Affymetrix 
were performed using the Bioconductor software suite (Gentleman et al. 2004; 
Kauffmann et al. 2009). 
In order to assess the efficiency of cDNA synthesis by the reverse 
transcriptase and the degree of RNA degradation, the ratio of 3’ and 5’ human 
GAPDH control probes was analyzed. A ratio of less than 1.8 between the 3’ 
and 5’ probe sets on the arrays was considered to be acceptable. The ratios 
for all cartilage and dermal samples were below this threshold. Most samples 
including all cartilage samples had a ratio close to 1 which is excellent (Table 
5.4, 5.5). A high ratio was measured for only one sample which was the second 
repeat of the IL-1/OSM-treated dermal sample with 1.75 (Table 5.5).  
 
 
Table 5.4 GAPDH 3’/5’ ratios for cartilage microarray samples 
Sample GAPDH (3'/5') 
cartilage 1 control 0.95 
cartilage 1 IL-1 only 0.92 
cartilage 1 IL-1/OSM 1.00 
cartilage 2 control 0.93 
cartilage 2 IL-1 only 1.04 
cartilage 2 IL-1/OSM 0.95 
cartilage 3 control 0.93 
cartilage 3 IL-1 only 0.95 
cartilage 3 IL-1/OSM 0.95 
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Table 5.5 GAPDH 3’/5’ ratios for dermal microarray samples 
Sample GAPDH (3'/5') 
skin 1 control 1.08 
skin 1 IL-1 only 1.18 
skin 1 IL-1/OSM 1.13 
skin 2 control 1.10 
skin 2 IL-1 only 1.18 
skin 2 IL-1/OSM 1.75 
skin 3 control 1.23 
skin 3 IL-1 only 1.34 
skin 3 IL-1/OSM 1.32 
 
Furthermore, the raw hybridisation intensity values for all genes of the chips 
were compared to identify chips which are substantially different from others 
in the same data set. Density profile plots showed that there were no outlier 
chips within these data set (Fig. 5.6). Additional quality checks of the chip data 
included analyzing the expression values and the respective residuals from 
the fitting procedures using the relative log expression (RLE) and the 
normalized unscaled standard error (NUSE). The RLE was determined by 
calculating the ratio between the expression of a probe set and the median 
expression of this probe set across all chips of the experiment for each single 
probe. Assuming that the majority of the genes are not differentially expressed 
across the arrays, the log ratios should all be centered near zero and have a 
similar spread. For the cartilage and dermal construct samples, only the 
spread of the first cartilage sample treated with IL-1 alone (Cart_Treat1_1) 
and the second dermal sample treated with IL-1/OSM (Skin_Treat2_2) were 
marginally larger than the other samples within the respective groups (Fig. 
5.7). 
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Figure 5.6 Density plots of raw hybridization intensity values. Superimposition of densities 
from cartilage arrays (A) and dermal equivalent arrays (B) show that all chips had a similar 
density and distribution of signals. Plots were created using the Bioconductor software 
package together with the R software suite by Suzanne Papp and Lana Schaffer, Scripps 
Research Institute, La Jolla, CA, USA. Samples are named as follows: Cart_Ctrl_1-3 = 
cartilage control samples 1-3, Cart_Treat1_1-3 cartilage IL-1 alone samples 1-3, 
Cart_Treat2_1-3 = cartilage IL-1 + OSM samples 1-3, Skin_Ctrl_1-3 = skin control samples 
1-3, Skin_Treat1_1-3 = skin IL-1 alone samples 1-3, Skin_Treat2_1-3 = skin IL-1 + OSM 
samples 1-3 
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The NUSE is based on the standard error estimates obtained for each gene 
from the normalized fit. The standard error estimates are then normalized by 
dividing with the median standard error so that the median of the box is at 1.0. 
The medians of all samples were similar except for cartilage IL-1 sample 1 
(Cart_Treat1_1) and skin IL-1/OSM sample 2 (Skin_Treat2_2) (Fig. 5.7 C, 
D). Taken together, none of the samples showed consistent deviation from the 
expected quality thresholds and therefore all chips were considered valid data 
sets for further analysis. 
Finally, similarity in gene expression between the individual chips within the 
cartilage and dermal sample sets was calculated from the centered correlation 
and average linkage of the expression data from each chip. The resulting 
cluster dendrograms (Fig. 5.8) showed that for the cartilage samples, the 
treated groups clustered separately from the control group, but not discretely 
from each other. This indicates an overlap in gene expression between the IL-
1 alone and IL-1/OSM treatment. This suggests that while having a 
synergistic effect on cartilage breakdown (Fig. 5.4), OSM does not 
substantially alter the gene expression profile from that induced by IL-1. In 
contrast, the dermal samples were instead clustering discretely between each 
group without any overlap. 
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Figure 5.7 Analysis of probe-set homogeneity. RLE (relative log expression) plots of 
cartilage constructs (A) and dermal equivalent (B) samples show the relative gene expression 
values to the mean expression values as a box plot. NUSE (normalized unscaled standard 
error) plots of cartilage (C) and dermal (D) construct samples show the standard error 
estimates obtained for each gene from the normalized fit divided by the median standard error 
as a box plot. RLE and NUSE plots were created using the Bioconductor software package 
together with the R software suite by Suzanne Papp and Lana Schaffer, Scripps Research 
Institute, La Jolla, CA, USA. Samples are named as follows: Cart_Ctrl_1-3 = cartilage control 
samples 1-3, Cart_Treat1_1-3 cartilage IL-1 alone samples 1-3, Cart_Treat2_1-3 = cartilage 
IL-1 + OSM samples 1-3, Skin_Ctrl_1-3 = skin control samples 1-3, Skin_Treat1_1-3 = skin 
IL-1 alone samples 1-3, Skin_Treat2_1-3 = skin IL-1 + OSM samples 1-3 
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Figure 5.8 Cluster dendrograms of array data. Hierarchical clustering is calculated from the 
centered correlation and average linkage of the expression data between the arrays which is 
then transformed into a tree. It gives information on the similarity in gene expression between 
the different arrays. A: Arrays from cartilage construct samples; B: Arrays from dermal 
equivalent samples; Samples are named as follows: Cart_Ctrl_1-3 = cartilage control samples 
1-3, Cart_Treat1_1-3 cartilage = IL-1 alone samples 1-3, Cart_Treat2_1-3 = cartilage IL-1 
+ OSM samples 1-3, Skin_Ctrl_1-3 = skin control samples 1-3, Skin_Treat1_1-3 = skin IL-1 
alone samples 1-3, Skin_Treat2_1-3 = skin IL-1 + OSM samples 1-3. Plots were created 
using the Bioconductor software package together with the R software suite by Suzanne Papp 
and Lana Schaffer, Scripps Research Institute, La Jolla, CA, USA.  
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 Analysis of microarray data for experimental groups 
After the chip quality controls showed that all samples used for each set of 
experiments were within acceptable range, the changes in gene expression 
between the treatment groups and respective controls were analyzed. 
Bioconductor analysis transformed the raw gene expression data into fold 
change and associated adjusted p-values. Genes were considered 
differentially regulated when the magnitude of change was >1.4 and the 
adjusted p-value was < 0.15. 
Differences and similarities in gene expression between the groups were 
determined for each sample set. Compared to the control group, cartilage 
constructs treated with IL-1 alone contained 152 differentially expressed 
genes and IL-1 in combination with OSM contained 187 differentially 
expressed genes (Fig. 5.9 A). Within the treatment groups, 37 genes were 
unique to the IL-1 only group and 72 genes were changed specifically when 
OSM was added. Both treatment groups had 115 differentially regulated genes 
in common. In dermal equivalents, expression of 101 genes changed when IL-
1 only was added and 182 changed when the dermal constructs were treated 
with IL-1 and OSM together (Fig. 5.9 B). A comparison of the two treatments 
revealed that 30 gene changes were unique to IL-1 treatment whereas 111 
were differentially expressed only in response to OSM stimulation. Both 
treatment groups had 71 changed genes in common. Therefore, the overall 
magnitude of changes induced by cytokine treatment is similar in cartilage and 
dermal constructs. Heat maps of the genes differentially expressed in 
response to treatment regimens in cartilage and dermal constructs are shown 
in Fig. 5.10. This illustrates the consistency of differential regulation of these 
genes across the repeat chip sets. 
In the following paragraphs, differentially expressed genes are grouped into 
different categories for more detailed discussion. These include inflammatory 
response genes, proteoglycans, CS/DS synthesis, heparin/HS, HA, KS 
synthesis and modification, and N-linked glycan synthesis and modification. 
This should help to give a better overview of the effects of inflammatory 
stimulation on each type of glycosylation. A table listing the gene name 
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abbreviations together with the full names of the corresponding proteins can 
be found in Table 5.6. 
 
Table 5.6 Abbreviations of gene names and their corresponding translated proteins with 
full names. Full names were obtained from the UniProt Knowledgebase database 
(www.uniprot.org). 
Abbreviation Full name of protein 
ACAN Aggrecan 
AGRN Agrin 
ALG9 Alpha-1,2-mannosyltransferase 9 
ALG10B Alpha-1,2-glucosyltransferase 10B 
ALG14 UDP-N-acetylglucosaminyltransferase subunit 
BGN Biglycan 
CCL2 Monocyte chemotactic and activating factor 
CCL20 Macrophage inflammatory protein 3 alpha 
CHGN Chondroitin sulfate N-acetylgalactosaminyltransferase 1 
CHPF Chondroitin polymerizing factor 
CHPF2 Chondroitin polymerizing factor 2 
CHST3 Chondroitin 6-O-sulphotransferase 1 
CHST6 N-acetylglucosamine 6-O-sulfotransferase 5 
CHST11 Chondroitin-4-O-sulphotransferase 1; C4ST-1 
CHST15 Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) 
sulphotransferase 15; GalNAc4S-6ST 
CHSY3 N-acetylgalactosaminyl-proteoglycan 3-beta-
glucuronosyltransferase 
COL9A2 Collagen type IX, alpha 2 
CXCL1 Neutrophil-activating protein 3 
CXCL3 Macrophage inflammatory protein 2-beta 
CXCL5 Epithelial-derived neutrophil-activating protein 78 
DDOST Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 
kda subunit 
ESM1 Endocan 
EXTL1 Glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-
acetylglucosaminyltransferase 
EXTL2 Glucuronyl-galactosyl-proteoglycan 4-alpha-N-
acetylglucosaminyltransferase 
FMOD Fibromodulin 
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Abbreviation Full name of protein 
FUT4 Alpha-(1,3)-fucosyltransferase 4 
GALNT1 Protein-UDP acetylgalactosaminyltransferase 1 
GCNT1 Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-
acetylglucosaminyltransferase 
GALNT2 Protein-UDP acetylgalactosaminyltransferase 2 
GALNT3 Protein-UDP acetylgalactosaminyltransferase 3 
GALNT4 Protein-UDP acetylgalactosaminyltransferase 4 
GALNT5 Protein-UDP acetylgalactosaminyltransferase 5 
GALNT6 Protein-UDP acetylgalactosaminyltransferase 6 
GALNT10 Protein-UDP acetylgalactosaminyltransferase 10 
GPC1 Glypican 1 
GPC3 Glypican 3 
GPC4 Glypican 4 
GPFPT2 Glutamine--fructose-6-phosphate aminotransferase 2 
HAS2 Hyaluronic acid synthase 2 
HAS3 Hyaluronic acid synthase 3 
HS2ST1 Heparan sulfate 2-O-sulfotransferase 1 
HS3ST1 Heparan sulfate glucosamine 3-O-sulfotransferase 1 
HS3ST3A1 Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 
HSPG2 Perlecan 
IL8 Interleukin 8 
JUNB Transcription factor jun-B 
LEPRE1 Leprecan-1 
LIF Leukemia inhibitory factor 
LUM Lumican 
OGN Osteoglycin 
PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 
PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 
POMT2 Protein O-mannosyl-transferase 2 
PRG4 Lubricin 
PTPRZ1 Phosphacan 
SDC1 Syndecan 1 
SDC2 Syndecan 2 
SDC4 Syndecan 4 
SRGN Serglycin 
ST3GAL1 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-
sialyltransferase 1 
UGCGL2 UDP-glucose:glycoprotein glucosyltransferase 2 
197 
 
Abbreviation Full name of protein 
UST Uronyl 2-sulfotransferase 
VCAN Versican 
XYLT1 Xylosyltransferase 1 
 
 
 
 
 
Figure 5.9 Venn diagrams showing differences in gene expression in response to 
cytokine stimulation. The diagrams show the number of transcripts found to be differentially 
expressed for either IL-1 alone (red) or IL-1 + OSM co-stimulation (blue) for cartilage 
constructs (A) or dermal equivalents (B). The number of genes which were responding to both 
treatments are shown as a overlapping area (purple). Diagrams were created using the 
Bioconductor software package together with the R software suite by Suzanne Papp and Lana 
Schaffer, Scripps Research Institute, La Jolla, CA, USA.   
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Figure 5.10 Heat maps of cartilage and dermal construct microarrays. The heat maps 
show the mean-scaled expression of individual transcripts which were identified to be 
differentially expressed in both treatments compared to control for cartilage samples (A) and 
dermal samples (B). Heat maps were generated using the dChip software package by 
Suzanne Papp and Lana Schaffer, Scripps Research Institute, La Jolla, CA, USA. Red shows 
increased and blue shows decreased expression relative to control. Colour shades reflect 
relative fold change over control based on log2 signal intensity values (see scale at bottom of 
panel). Samples are named as follows: Cart_Ctrl_1-3 = cartilage control samples 1-3, 
Cart_Treat1_1-3 cartilage = IL-1 alone samples 1-3, Cart_Treat2_1-3 = cartilage IL-1 + 
OSM samples 1-3, Skin_Ctrl_1-3 = skin control samples 1-3, Skin_Treat1_1-3 = skin IL-1 
alone samples 1-3, Skin_Treat2_1-3 = skin IL-1 + OSM samples 1-3. 
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5.3.4.1 Genes associated with inflammatory response 
Inflammatory stimulation resulted in the up-regulation of cytokines and 
chemokines in cartilage (Table 5.7) and dermal constructs (Table 5.8) as 
expected. The biggest changes in expression were observed for genes 
encoding the small chemokines CXCL1, 3 and 5. They are members of the 
CXC chemokine family and induce attraction of neutrophils and monocytes 
(Persson et al. 2003; Smith et al. 2005; Moser et al. 1990) by signaling through 
CXCR2. Furthermore, the chemokines CCL2 and CCL20 were highly up-
regulated. Likewise, a substantial increase in IL-8 and LIF gene expression 
was observed. These proteins are known to be up-regulated upon IL-1 
stimulation (Carlson et al. 1996; Campbell et al. 1993; Lotz, Moats, et al. 1992) 
and IL-8 and CCL20 expression was further investigated as a positive control 
of genes known to be highly up-regulated by IL-1. Q-PCR analysis of IL-8 and 
CCL20 gene expression confirmed the up-regulation of both genes, although 
the actual magnitude of change in expression determined in this more 
sensitive method was substantially higher compared to the data from 
microarrays (Table 5.6, 5.7). 
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Table 5.7 Inflammatory stimulation of cartilage constructs led to increased expression 
of chemokines and cytokines. Microarray results are shown as the magnitude (fold change) 
and adjusted p-value for each gene for treatment with IL-1 alone or in combination with OSM. 
Validation of changes in expression of selected genes was performed using SYBRgreen Q-
PCR. Here, data is shown as mean Ct ± SEM and corresponding fold change (2-Ct) ± SEM 
derived from three independent experiments with duplicates. P-values are based on Ct 
values. Statistically significant changes to untreated control samples were determined with 
one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison test. n.s. = not 
significant.  
Microarray IL-1 alone IL-1 + OSM 
Gene Accession 
no. 
Magnitude 
(FC) 
Adjusted  
p-value 
Magnitude 
(FC) 
Adjusted p-
value 
CXCL3 NM_002090 156.6 <0.001 84.0 <0.001 
CXCL1 NM_001511 154.3 <0.001 115.9 <0.001 
CXCL5 NM_002994 103.2 <0.001 122.9 <0.001 
CCL20 NM_004591 81.5 <0.001 78.2 <0.001 
CCL2 NM_002982 54.2 <0.01 58.0 <0.01 
IL8 NM_000584 54.9 <0.001 42.0 <0.001 
LIF NM_002309 21.1 <0.001 27.0 <0.001 
 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold change Ct p-value Fold 
change 
IL8 -13.0 ± 
2.0 
<0.01 46789.4 ± 
44689.6 
-10.4 ± 1.4 <0.01 2928.6 ± 
2131.4 
CCL20 -11.1 ± 
1.4 
<0.01 5392 ± 
4463.2 
-11.1 ± 0.4 <0.01 1190.0 ± 
318.2 
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Table 5.8 Inflammatory stimulation of dermal constructs led to increased expression of 
chemokines and cytokines. Microarray results are shown as the magnitude (fold change) 
and adjusted p-value for each gene for treatment with IL-1 alone or in combination with OSM. 
Validation of changes in expression of selected genes was performed using SYBRgreen Q-
PCR. Here, data is shown as mean Ct ± SEM and corresponding fold change (2-Ct) ± SEM 
derived from three independent experiments with duplicates. P-values are based on Ct 
values. Statistically significant changes to untreated control samples were determined with 
one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison test. n.s. = not 
significant. 
 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold change Ct p-value Fold 
change 
IL8 -10.9 ± 
0.6 
<0.001 2192.2 ± 
723.8 
-7.3 ± 0.8 <0.01 196.6 ± 
74.0 
CCL20 -2.9 ± 
0.9 
n.s. 11.2 ± 6.6 -0.9 ± 0.6 n.s. 2.2 ± 0.9 
 
  
Microarray IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude 
(FC) 
Adjusted 
p-value 
Magnitude 
(FC) 
Adjusted p-
value 
CXCL5 NM_002994 132.4 <0.001 120.5 <0.001 
CXCL3 NM_002090 125.0 <0.001 495 <0.001 
CXCL1 NM_001511 83.5 <0.001 46.7 <0.001 
IL8 NM_000584 61.9 <0.001 37.1 <0.001 
CCL2 NM_002982 11.2 <0.05 2.1 <0.15 
CCL20 NM_004591 2.9 <0.05 - - 
LIF NM_002309 2.9 0.06 - - 
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5.3.4.2 Proteoglycans 
Stimulation of cartilage constructs with IL-1 in the presence and absence of 
OSM affected the expression of various proteoglycans (Table 5.9). The biggest 
change in gene expression was observed for serglycin, being up-regulated 17-
fold (IL-1 alone) and 14-fold (IL-1/OSM). Genes encoding endocan, agrin, 
perlecan and lumican were moderately up-regulated (up to about 4-fold). 
Down-regulation was observed for genes involved in maintaining the 
chondrocyte phenotype (aggrecan, lubricin, collagen type IX 2 chain) as well 
as versican which belongs like aggrecan to the large aggregating 
proteoglycans present in cartilage. Moreover, proteoglycans not known to be 
associated with articular cartilage, osteoglycin and phosphacan, were 
identified and found to be down-regulated. Several proteoglycans were only 
identified as changed in one of the two treatments. Endocan (ESM1) and 
perlecan (HSPG2) were only up-regulated when IL-1 alone was added, 
whereas lumican and collagen type IX 2-chain were only changed in the 
presence of both IL-1 and OSM. 
Validation of the microarray results was performed for serglycin and lumican. 
The results showed that serglycin was even more substantially up-regulated 
than expected from the microarray data. The expression was 130-fold 
increased for IL-1 alone and 51-fold increased for IL-1 in combination with 
OSM (Table 5.9). The differences between the two methods were not as big 
for lumican. It was 6-fold increased for IL-1 alone and 4-fold increased for IL-
1 together with OSM (Table 5.9). 
In the dermal constructs, serglycin was only marginally up-regulated during IL-
1 treatment (Table 5.10). Moreover, in contrast to cartilage, lumican was 
down-regulated by treatment of dermal equivalents with IL-1. Mostly 
syndecans and glypicans were differentially expressed in dermal samples 
(Table 5.10). In addition, fibromodulin expression increased with both 
treatments and biglycan expression increased 2-fold when IL-1 and OSM 
were added to the medium. 
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Table 5.9 Effect of inflammatory stimulation on cartilage proteoglycan gene expression. 
Microarray results are shown as the magnitude (fold change) and adjusted p-value for each 
gene for treatment with IL-1 alone or in combination with OSM. Validation of changes in 
expression of selected genes was performed using SYBRgreen Q-PCR. Here, data is shown 
as mean Ct ± SEM and corresponding fold change (2-Ct) ± SEM derived from three 
independent experiments with duplicates. P-values are based on Ct values. Statistically 
significant changes to untreated control samples were determined with one-way ANOVA with 
post hoc analysis using Tukey‘s multiple comparison test. n.s. = not significant. 
Microarray IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude (FC) Adjusted 
p-value 
Magnitude 
(FC) 
Adjusted 
p-value 
SRGN NM_002727 17.6 <0.01 14.1 <0.01 
ESM1 NM_007036 3.1 <0.05 - - 
AGRN NM_198576 3.1 <0.05 2.1 <0.15 
HSPG2 NM_005529 1.6 <0.05 - - 
LUM NM_002345 - - 1.5 <0.15 
LEPRE1 NM_022356 -1.8 <0.05 -2.41 <0.01 
PRG4 NM_005807 -2.0 <0.15 -3.0 <0.05 
COL9A2 NM_001852 - - -3.0 <0.15 
ACAN NM_001135 -3.1 <0.15 -6.4 <0.01 
VCAN NM_004385 -3.7 <0.05 -2.5 <0.15 
OGN NM_024416 -4.4 <0.01 -5.5 <0.01 
PTPRZ1 NM_002851 -6.0 <0.01 -8.4 <0.001 
 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold change Ct p-value Fold 
change 
SRGN -6.0 ± 
1.2 
< 0.05 127.8 ± 64.7 -4.6 ± 1.3 < 0.05 51.2 ± 
22.4 
LUM -1.7 ± 
1.1 
n.s. 5.8 ± 3.4 -1.4 ± 0.8 n.s. 3.9 ± 1.7 
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Table 5.10 Effect of inflammatory stimulation on dermal proteoglycan gene expression. 
Microarray results are shown as the magnitude (fold change) and adjusted p-value for each 
gene for treatment with IL-1 alone or in combination with OSM.  
Microarray IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude 
(FC) 
Adjusted p-
value 
Magnitude 
(FC) 
Adjusted p-
value 
SRGN NM_002727 3.3 <0.15 - - 
SDC1 NM_002997 - - 2.4 <0.01 
FMOD NM_002023 2.3 <0.01 3.1 <0.01 
BGN NM_001711 - - 2.2 <0.05 
GPC3 NM_004484 1.8 <0.15 - - 
LEPRE1 NM_022356 1.5 <0.01 - - 
LUM NM_002345 -1.4 <0.05 - - 
GPC1 NM_002081 - - -1.4 <0.05 
ESM1 NM_007036 - - -1.5 <0.15 
GPC4 NM_001448 -1.7 <0.05 -1.8 <0.15 
SDC2 NM_002998 -1.8 <0.05 -2.2 <0.01 
SDC4 NM_002999 - - -1.9 <0.05 
OGN NM_024416 -1.9 <0.01 -1.9 <0.01 
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5.3.4.3 Genes associated with CS/DS biosynthesis 
The expression of enzymes involved in the synthesis and modification of 
CS/DS chains was influenced by inflammatory stimulation of cartilage 
constructs. XYLT1 (xylosyltransferase 1) is responsible for the initiation of the 
chain synthesis by adding a xylose to serine/threonine. It was down-regulated 
2 and 3-fold for IL-1 alone and in combination with OSM, respectively (Table 
5.11). CHPF (chondroitin polymerizing factor) and CHSY3 (chondroitin 
sulphate synthase 3), both glycosyltransferases involved in the synthesis of 
the repeating GlcA/GalNAc disaccharide subunits, were down-regulated by 
both treatments. Besides GAG chain synthesis, also enzymes involved in the 
sulphation of CS chains were affected (Table 5.11). PAPSS1 was down-
regulated about two fold by each treatment. This enzyme is responsible for the 
synthesis of PAPS which serves as the donor molecule for sulphate groups 
used by sulphotransferases. Expression of CHST3 and CHST15, both 
sulphotransferases with different specificity, was changed by inflammatory 
treatment. CHST3 is adding a sulphate group to the C6-atom of GalNAc and 
CHST15 is adding a sulphate group on the C6-atom of GalNAc-4-sulphate. In 
contrast to all other genes being down-regulated during inflammation, CHST15 
was up-regulated when IL-1 and OSM were added to the medium at the same 
time (Table 5.11). Q-PCR analysis subsequently revealed that an increase in 
expression also occurred for treatment with IL-1 alone. CHST11 expression 
was also further investigated as it was reported to be up-regulated in OA 
cartilage compared to normal cartilage (Karlsson et al. 2010). However, data 
obtained from Q-PCR analysis showed that its expression was unchanged in 
both treatment groups. Taken together, these data indicate reduced CS 
synthesis combined with increased GalNAc4,6diS content. 
Interestingly, the CS/DS synthesis machinery in dermal constructs was not as 
negatively affected by cytokine stimulation as in cartilage constructs (Table 
5.12). While XYLT1 expression levels were essentially unchanged, CHGN and 
CHPF2 expression levels were increased for each treatment. Similar to CHPF, 
both proteins are glycosyltransferases which are involved in the synthesis and 
elongation of CS/DS chains (Mikami and Kitagawa 2013). CHPF2 up-
regulation was confirmed by Q-PCR, showing that its expression was about 3-
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fold (IL-1 alone) and 5-fold (IL-1/OSM) increased (Table 5.12). In contrast 
to cartilage, microarray and follow up Q-PCR data also showed that CHST11, 
encoding a chondroitin 4-O sulphotransferase, was highly up-regulated. Its 
expression was more than 7-fold (IL-1 alone) and 35-fold (IL-1/OSM) 
increased compared to control (Table 5.12). 
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Table 5.11 Effect of inflammatory stimulation on CS/DS synthesis and modification in 
cartilage constructs. Microarray results are shown as the magnitude (fold change) and 
adjusted p-value for each gene for treatment with IL-1 alone or in combination with OSM. 
Validation of changes in expression of selected genes was performed using SYBRgreen Q-
PCR. Here, data is shown as mean Ct ± SEM and corresponding fold change (2-Ct) ± SEM 
derived from three independent experiments with duplicates. P-values are based on Ct 
values. Statistically significant changes to untreated control samples were determined with 
one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison test. n.s. = not 
significant. 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold change Ct p-value Fold 
change 
CHST15 -1.5 ± 
0.6 
n.s. 4.2 ± 0.6 -2.2 ± 0.5 <0.5 6.6 ± 1.0 
XYLT1 -0.2 ± 
0.6 
n.s. 1.3 ± 0.4 -1.2 ± 0.8 n.s. 0.6 ± 0.3 
CHST11 -0.2 ± 
0.3 
n.s. 1.2 ± 0.2 0.2 ± 0.6 n.s. 1.0 ± 0.4 
CHSY3 1.6 ± 
0.4 
n.s. 0.4 ± 0.1 2.5 ± 0.7 <0.5 0.2 ± 0.1 
 
  
Microarray IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude 
(FC) 
Adjusted p-
value 
Magnitude 
(FC) 
Adjusted p-
value 
CHST15 NM_015892 - - 3.2 <0.01 
CHPF NM_024536 -1.6 <0.15 -1.9 <0.15 
CHST3 NM_004273 - - -1.9 <0.15 
XYLT1 NM_022166 -2.4 <0.15 -3.7 <0.01 
PAPSS1 NM_005443 -2.4 <0.05 -2.0 <0.15 
CHSY3 NM_175856 -3.6 <0.01 -4.1 <0.001 
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Table 5.12 Effect of inflammatory stimulation on CS/DS synthesis and modification in 
dermal constructs. Microarray results are shown as the magnitude (fold change) and 
adjusted p-value for each gene for treatment with IL-1 alone or in combination with OSM. 
Validation of changes in expression of selected genes was performed using SYBRgreen Q-
PCR. Here, data is shown as mean Ct ± SEM and corresponding fold change (2-Ct) ± SEM 
derived from three independent experiments with duplicates. P-values are based on Ct 
values. Statistically significant changes to untreated control samples were determined with 
one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison test. n.s. = not 
significant. 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold 
change 
Ct p-value Fold 
change 
CHST11 -1.8 ± 1.3 n.s. 7.5 ± 6.0 -4.4 ± 1.1 <0.5 35.7 ± 23.1 
CHPF2 -0.1 ± 2.6 n.s. 2.9 ± 2.7 -1.74 ± 1.0 n.s. 4.9 ± 2.0 
XYLT1 -0.1 ± 1.8 n.s. 1.3 ± 0.4 1.8 ± 1.0 n.s. 0.6 ± 0.3 
 
  
Microarray IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude 
(FC) 
Adjusted p-
value 
Magnitude 
(FC) 
Adjusted    
p-value 
CHGN NM_018371 4.4 <0.05 4.5 <0.05 
CHST11 NM_018413 2.1 <0.05 5.1 <0.001 
XYLT1 NM_022166 - - 2.4 <0.001 
CHPF2 NM_019015 - - 1.5 <0.05 
PAPSS2 NM_001015880 - - 1.6 <0.05 
UST NM_005715 - - -1.6 <0.01 
PAPSS1 NM_005443 - - -2.1 <0.01 
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5.3.4.4 Genes associated with heparin/heparan sulphate and keratan 
sulphate biosynthesis 
In addition to changes observed in the expression levels of CS/DS chains, 
genes encoding for proteins involved in synthesis and modification of 
heparin/HS, HA and KS were affected by the inflammatory stimulations. 
However, the number of genes was more limited compared to CS/DS 
biosynthesis. For reasons of relevance to the main topic of the PhD, only 
changes in cartilage constructs are presented and discussed. 
Microarray results showed that except for HS2ST1, a sulphotransferase 
adding a sulphate group to the C-2 atom of iduronic acid in HS, all genes found 
to be differentially expressed were down-regulated (Table 5.13). This included 
EXTL2 which is a key enzyme that adds the first GlcNAc residue to the GAG 
linkage region and thereby initiates heparin/HS synthesis (Sugahara and 
Kitagawa 2000). EXTL1 is another glycosyltransferase involved in HS chain 
synthesis (Kim et al. 2001) and this was down-regulated as well.  
Two genes coding for enzymes known to modify KS were found to be affected 
by the inflammatory stimulation (Table 5.13). One was ST3GAL1, the 
expression of which was increased more than 4-fold by IL-1 alone and 3-fold 
by IL-1 together with OSM. Q-PCR analysis verified the microarray data, 
showing that the increase was about 9-fold for IL-1 and 2-fold for IL-1/OSM 
treatment (Table 5.13). This enzyme is a sialic acid transferase that transfers 
sialic acid to the non-reducing terminal end of KS. The other enzyme, CHST6, 
is a KS specific GlcNAc 6-O sulphotransferase which selectively acts on 
terminal GlcNAc residues in KS (Stanley and Cummings 2009). It was down-
regulated almost 5-fold by IL-1 and 3-fold by IL-1/OSM (Table 5.13). In 
addition to CHST6, sulphation in KS can also occur through CHST3 which 
sulphates chain internal galactose residues. CHST3 was down-regulated by 
IL-1/OSM but not by IL-1 alone as already discussed (Table 5.11). Taken 
together, this points towards an altered pattern of sulphation in KS upon 
inflammatory stimulation. 
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5.3.4.5 Genes involved in hyaluronic acid synthesis 
HA synthases (HAS) 2 and 3 were both differentially expressed upon 
inflammatory stimulation. Both enzymes are located in the plasma membrane 
and directly secrete HA chains into the extracellular space (Weigel and 
DeAngelis 2007). HAS2 is the major HA synthase in cartilage (Hiscock et al. 
2000). Microarray data showed that it was 2-fold down-regulated by IL-1 
stimulation (Table 5.13). HAS3 which has a low expression level in cartilage 
under normal conditions, was increased by IL-1 stimulation. In contrast to the 
other HAS enzymes, the chain synthesized by HAS3 has a lower molecular 
weight (Tammi et al. 2011; Oguchi and Ishiguro 2004). Such a change may 
affect average chain length of HA molecules synthesized. 
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Table 5.13 Effect of inflammatory stimulation on heparin/HS, HA, and KS synthesis and 
modification in cartilage constructs. Microarray results are shown as the magnitude (fold 
change) and adjusted p-value for each gene for treatment with IL-1 alone or in combination 
with OSM. Validation of changes in expression of selected genes was performed using 
SYBRgreen Q-PCR. Here, data is shown as mean Ct ± SEM and corresponding fold change 
(2-Ct) ± SEM derived from three independent experiments with duplicates. P-values are 
based on Ct values. Statistically significant changes to untreated control samples were 
determined with one-way ANOVA with post hoc analysis using Tukey‘s multiple comparison 
test. n.s. = not significant. 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold change Ct p-value Fold change 
ST3GAL1 -4.5 ± 1.3 <0.5 8.7 ± 2.5 -2.4 ± 1.4 n.s. 2.4 ± 0.5 
 
  
Microarray  IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude 
(FC) 
Adjusted p-
value 
Magnitude 
(FC) 
Adjusted p-
value 
Heparin/HS   
HS2ST1 NM_012262 1.5 <0.15 2.0 <0.05 
HS3ST3A1 NM_006042 -1.6 <0.15 -1.6 <0.15 
EXTL2 NM_001033025 -1.8 <0.05 -1.7 <0.05 
EXTL1 NM_004455 -3.2 <0.05 -3.3 <0.05 
HS3ST1 NM_005114 - - -1.5 <0.15 
      
KS   
ST3GAL1 NM_003033 4.7 <0.01 3.0 <0.05 
CHST6 NM_021615 -4.2 <0.05 -4.4 <0.05 
      
HA   
HAS3 NM_005329 1.5 <0.05 - - 
HAS2 NM_005328 -2.0 <0.15 - - 
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5.3.4.6 Genes involved in N- and O-linked glycosylation of proteins 
Not only GAG synthesis was affected by inflammatory stimulation, but also the 
synthesis and modification of N-linked glycans. N-linked glycans are attached 
to the core protein through asparagine residues. Several enzymes involved in 
the formation of N-linked oligosaccharide precursors were changed in their 
expression (Table 5.14). ALG genes are coding for glycosyltransferases 
involved in the build-up of the branched oligosaccharides consisting of 
GlcNAc, mannose and glucose. ALG14 and ALG10B which are involved in the 
initial and late stages of glycan precursor formation, respectively, were both 
down-regulated by IL-1/OSM co-stimulation. In contrast, the 
mannosyltransferase ALG9 was up-regulated by both treatments. Using Q-
PCR analysis, the down-regulation of ALG14 by IL-1/OSM treatment could 
be confirmed (Table 5.14). For IL-1 alone, the expression was unchanged. 
Furthermore, DDOST is unchanged by treatment with IL-1 alone and down-
regulated by IL-1/OSM. This is a key enzyme in the N-linked glycosylation 
pathway as it is responsible for the ‘en-bloc’ transfer of the oligosaccharide 
precursor to the asparagine residue of the protein. Taken together, these 
changes may lead to reduced N-glycosylation. 
 
O-linked glycans are attached to the core proteins through serine/threonine 
residues. Their synthesis occurs in the Golgi system and is initiated by the 
transfer of a GalNAc catalyzed by N-acetylgalactosaminyltransferases 
(GALNTs). Several of these enzymes were either down-regulated (GALNT1, 
3, 4, 5, 6, 10) or up-regulated (GALNT2, 4) upon inflammatory stimulation 
(Table 5.15). The increase in GALNT4 expression was confirmed by Q-PCR 
(Table 5.15). Moreover, the fucosyltransferase FUT4 was found to be 
increasingly expressed with both treatments (Table 5.15). O-linked glycans 
can be modified by sulphation, sialysation, fucosylation and acetylation (Van 
den Steen et al. 1998).  
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Table 5.14 Effect of inflammatory stimulation of cartilage constructs on expression of 
enzymes involved in N-linked glycosylation. Microarray results are shown as the 
magnitude (fold change) and adjusted p-value for each gene for treatment with IL-1 alone or 
in combination with OSM. Validation of changes in expression of selected genes was 
performed using SYBRgreen Q-PCR. Here, data is shown as mean Ct ± SEM and 
corresponding fold change (2-Ct) ± SEM derived from three independent experiments with 
duplicates. P-values are based on Ct values. Statistically significant changes to untreated 
control samples were determined with one-way ANOVA with post hoc analysis using Tukey‘s 
multiple comparison test. n.s. = not significant. 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold change Ct p-value Fold change 
ALG14 -0.1 ± 0.7 n.s. 1.2 ± 0.4 0.13 ± 0.5 n.s. 0.6 ± 0.01 
 
  
Microarray IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude 
(FC) 
Adjusted p-
value 
Magnitude 
(FC) 
Adjusted p-
value 
GFPT2 NM_005110 3.6 <0.05 2.6 <0.15 
ALG9 NM_024740 2.1 <0.05 1.6 <0.15 
ALG10B NM_032834 - - -1.4 <0.15 
ALG14 NM_144988 - - -1.5 <0.15 
DDOST NM_005216 - - -1.6 <0.05 
UGCGL2 NM_020121 -1.9 <0.05 -2.2 <0.05 
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Table 5.15 Effect of inflammatory stimulation of cartilage constructs on expression of 
enzymes involved in O-linked glycosylation. Microarray results are shown as the 
magnitude (fold change) and adjusted p-value for each gene for treatment with IL-1 alone or 
in combination with OSM. Validation of changes in expression of selected genes was 
performed using SYBRgreen Q-PCR. Here, data is shown as mean Ct ± SEM and 
corresponding fold change (2-Ct) ± SEM derived from three independent experiments with 
duplicates. P-values are based on Ct values. Statistically significant changes to untreated 
control samples were determined with one-way ANOVA with post hoc analysis using Tukey‘s 
multiple comparison test. n.s. = not significant. 
Q-PCR IL-1 alone IL-1 + OSM 
Gene Ct p-value Fold change Ct p-value Fold change 
GALNT4 -1.5 ± 0.7 n.s. 2.0 ± 0.2 -1.0 ± 0.5 n.s. 1.4 ± 0.04 
 
  
Microarray IL-1 alone IL-1 + OSM 
Gene Accession no. Magnitude 
(FC) 
Adjusted p-
value 
Magnitude 
(FC) 
Adjusted p-
value 
FUT4 NM_002033 3.1 <0.15 2.4 <0.15 
POMT2 NM_013382 2.0 <0.15 - - 
GALNT2 NM_004481 1.8 <0.15 - - 
GALNT4 NM_003774 1.4 <0.15 1.5 <0.05 
GALNT6 NM_007210 -1.5 <0.15 -1.9 <0.01 
GALNT10 NM_017540 -1.6 <0.15 -1.8 <0.15 
GALNT3 NM_004482 -1.8 <0.15 -1.8 <0.15 
GALNT1 NM_020474 -1.9 <0.15 -1.9 <0.15 
GCNT1 NM_001097634 -2.3 <0.15 -2.5 <0.15 
GALNT5 NM_014568 -5.0 <0.01 -4.2 <0.01 
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 Discussion 
In this chapter, cartilage and dermal constructs were stimulated with IL-1 
alone and in combination with OSM. The effects on gene expression were 
analyzed using GlycoChips developed by the International Consortium for 
Functional Glycomics. These are Affymetrix microarrays containing a probe 
set designed for investigating genes involved in glycosylation and related 
proteins. The aim of these experiments was to investigate changes in the 
expression of glycosyltransferases and sugar modifying enzymes established 
by an inflammatory environment in cartilage and dermal constructs to identify 
characteristic patterns that may aid development of biomarkers for OA.  
 
The importance of inflammation in early OA is now generally accepted 
(Goldring and Otero 2011). Previous studies used cartilage model systems to 
investigate the effects of catabolic factors, e.g. IL-1, TNF-, on cartilage 
metabolism (Barksby et al. 2006; Aigner et al. 2005; Sun et al. 2011; Vincenti 
and Brinckerhoff 2001). The microarray chips used in these studies contained 
probe sets for the whole human genome and essentially revealed increased 
expression of genes associated with the major catabolic pathways. In addition, 
the up and down-regulation of specific cartilage matrix proteins was observed. 
However, no fundamental new discoveries were made and no novel biomarker 
identified. The advantage of the chips used in this study compared to previous 
studies was the use of a restricted probe specifically designed to look only at 
a selected type of metabolic pathway, namely glycosylation. This was 
considered to be a promising approach to gain new insights into 
posttranslational modifications of GAG chains, and glycosylated proteins more 
generally in OA. Furthermore, the cell model employed here allowed for strict 
control of experimental conditions which is paramount in any microarray-based 
screening approach. As previously described (Barksby et al. 2006; Aigner et 
al. 2005), IL-1 alone and in combination with OSM resulted in the up-
regulation of IL-8, LIF, CCL2, and CXCL2, as well as other proteins involved 
in chemoattraction. No significant difference between cartilage and dermal 
constructs was observed in our study for most inflammatory mediators, 
indicating that the response to IL-1 through up-regulation of cytokines and 
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chemokines is not tissue specific. The combination of IL-1 and OSM had an 
even more severe effect on cartilage degradation compared to IL-1 alone 
(Fig. 5.4) in line with previous studies (Barksby et al. 2006; Gilbert et al. 2012). 
However, little mechanistic information on the reason for this synergy is 
published. By comparing the signaling pathways triggered by either IL-1 or 
OSM (Fig. 5.1) it becomes clear that an overlap exists. Both cytokines are 
known to also activate Erk1/2, p38 MAPK and Jnk1/2/3 signaling. Therefore, 
one explanation for the synergistic effect on cartilage degradation could be 
enhanced signaling through these alternative pathways. A different 
explanation could be the effect on IL-6 production. Using mouse synovial 
fibroblasts, Le Goff and coworkers could show that OSM induced IL-6 
expression even at low concentrations, and further enhanced IL-6 expression 
when combined with IL-1 or TNF (Le Goff et al. 2014). Furthermore, they 
showed that OSM increased IL-1R1 expression, and could therefore lead to 
increased or sustained sensitivity of synovial fibroblasts to IL-1. However, IL-
6 was not detectable in our microarray experiment even after IL-1 or 
continued IL-1/OSM stimulation. 
 
Proteoglycan expression was changed by the inflammatory stimulation. Down-
regulation of aggrecan and collagen type IX 2 chain after treatment with IL-
1 alone or in combination with OSM was recently described (Gilbert et al. 
2012), and therefore an additional control for the validity of our model system. 
Interestingly, serglycin showed the highest up-regulation in cartilage 
constructs and was several fold higher expressed in cartilage than in dermal 
constructs at baseline. Serglycin is a proteoglycan traditionally thought to be 
expressed by cells of the hematopoietic lineage. The GAG chains attached to 
serglycin can be of heparin, HS, or CS type. Only little information about 
serglycin in chondrocytes is available. Recently, Zhang and colleagues 
identified serglycin as a binding partner for MMP-13 C-terminal domain (Zhang 
et al. 2010). Using conditioned medium from human articular chondrocytes 
(isolated after joint arthroplasty) embedded in alginate beads, serglycin was 
isolated using an affinity column containing the MMP-13 C-terminal domain. 
217 
 
Immunocytochemical staining of serglycin in chondrocytes showed a granular 
distribution in the cytoplasm, similar to MMP-13 in the same cells. However, 
no co-localization was reported. In addition, the same observation was made 
when full-depth cartilage was stained for serglycin and MMP-13, but this time 
the two stainings did co-localize. Since serglycin is known to be involved in 
intracellular packaging and inactivation of proteases in secretory granules in 
hematopoietic cells (Stevens and Adachi 2007; Niemann et al. 2004), the 
authors suggested that serglycin may be involved in the regulation of MMP-13 
secretion in chondrocytes. Our observation of a >50-fold up-regulation of 
serglycin upon inflammatory stimulation of chondrocytes is novel and identifies 
this proteoglycan as a potentially important player in the context of OA. 
In addition to serglycin, lumican expression was increased in cartilage 
constructs upon inflammatory stimulation, although more modestly, whereas it 
was down-regulated in dermal equivalents. Lumican belongs to the group of 
small leucine-rich proteoglycans (SLRP) and carries a KS chain (Nikitovic et 
al. 2008). SLRPs in cartilage are known to be involved in growth factor binding, 
cell adhesion and proliferation, and organization of fibrillar collagens (Iozzo 
1999; Svensson et al. 2000). Using a lateral menisectomy sheep model of OA, 
Young and coworkers found a significant increase in lumican expression in 
induced OA compared to non-operated control. The magnitude of change in 
expression was the biggest increase of all investigated SLRPs (Young et al. 
2005). This result is in line with the increase in lumican expression found in 
this study. Lumican was recently also proposed as a potential novel biomarker 
for OA (Fernández-Puente et al. 2011). This was based on a study where the 
authors were analyzing proteins in synovial fluid of OA patients using mass 
spectrometry (Melrose et al. 2008). 
 
Analysis of gene expression changes in enzymes responsible for CS/DS 
synthesis and sulphation showed that in cartilage constructs, most of the 
genes were down-regulated. This involved chain initiation (XYLT1), elongation 
(CHPF, CHSY3) and sulphation (CHST3). In early OA, the cartilage tries to 
repair itself through increased anabolic activity of chondrocytes (Goldring and 
Goldring 2007). This is accompanied by an increased GAG chain synthesis, in 
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parts mediated by up-regulation of XYLT1. Venkatesan and coworkers (2012) 
found that XYLT1 expression in cartilage was increased by TGF-1. In 
addition, regulation of other CS/DS modifying enzymes by TGF-1, EGF, and 
PDGF has been described in human lung fibroblasts (Tiedemann et al. 2005). 
Furthermore, a recent study using a model of vascular calcification identified 
XYLT1-mediated GAG synthesis controls TGF-1 activity and thereby 
establishes a positive feedback loop controlling XYLT1 expression and TGF-
1 activity (J Yan et al. 2011). In contrast, IL-1 down-regulates XYLT1 
expression, leading to a decreased amount of GAG chains attached to 
cartilage proteoglycans (Venkatesan et al. 2012; Venkatesan et al. 2009), 
consistent with the findings here. 
Despite the likely reduction in overall GAG chain synthesis, changes in 
expression of individual sulphotransferases could lead to the generation of 
GAG chain modifications that could potentially serve as a biomarker. The 
increase of CHST15 (GalNAc4S-6ST) expression upon inflammatory 
stimulation in cartilage constructs was very interesting. GalNAc4S-6ST is a 
sulphotransferase that catalyzes the transfer of a sulphate group to the C-6 
atom of GalNAc-4S (Ohtake et al. 2003; Ohtake et al. 2001; Ito and Habuchi 
2000). This type of sulphation was first identified in squid cartilage CS and 
named CS-E (Suzuki et al. 1968). This CS species comprises significant 
biological activity. For example, it was shown that it enabled Lewis lung 
carcinoma cell metastasis (Mizumoto et al. 2013; Mizumoto et al. 2012). These 
cells express CS chains containing the CS-E motif on their surface which leads 
to binding of the receptor of advanced glycation end product (RAGE) 
expressed in pulmonary tissue. Administration of an anti-RAGE antibody into 
mice as well as gene knockdown of GalNAc4S-6ST resulted in a markedly 
lower colonization of the lungs by these carcinoma cells. An increase in 
GalNAc4S-6ST expression could potentially be a lead for a novel OA 
biomarker. The fact that GalNAc4S-6ST was the only sulphotransferase gene 
being up-regulated during inflammatory stimulation of cartilage constructs 
further highlights the potential of this. In addition, this was not found in dermal 
constructs, showing that the differential regulation could be tissue specific. 
Therefore, OA-specific CS epitopes may be generated by this enzyme. 
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However, more experimental evidence would be necessary to support such a 
notion. It was shown that GalNAc4S-6ST sulphates internal as well as terminal 
disaccharides on the non-reducing end (Mikami and Kitagawa 2013; Midura et 
al. 1995). Plaas and coworkers identified changes in the GAG chain fine 
structure in OA cartilage (Anna H Plaas et al. 2001). They observed a reduction 
in the amount of CS-4,6diS as the terminal disaccharide on the non-reducing 
end of CS chains from 60% in normal cartilage to 30% in OA cartilage. This is 
not consistent with to the observed up-regulation of GalNAc4S-6ST in our 
model system. A possible explanation for this observation could be that 
because the cartilage used by Plaas et al was obtained from knee 
arthroplasties, gene expression could have changed during the course of 
disease, with joint replacement reflecting end-stage disease. In this study, the 
early changes in gene expression directly after inflammatory stimulation was 
analyzed. Furthermore, it is possible that GalNAc4S-6ST showed a preference 
for internal rather than terminal chain disaccharides. Interestingly, previous 
studies also found that during mast cell maturation, GalNAc4S-6ST, C4ST-1 
(CHST11) and serglycin expression was increased at the same time (Duelli et 
al. 2009; Ohtake et al. 2008). A high degree of sulphation of GAG chains 
attached to serglycin, i.e. its strong negative charge, is necessary for 
maintaining the storage capacity for basic granule compounds (Pejler et al. 
2009). Furthermore, mast cells from GalNAc4S-6ST knockout mice showed 
reduced granule-associated protease activity (Ohtake-Niimi et al. 2010), 
possibly because protease storage in the granules was impaired. Similarly, 
mast cells from serglycin knockout mice also displayed defects in storage of 
various mast cell proteases (Abrink et al. 2004). Based on these observations, 
we hypothesize that serglycin CS/DS chains are the main target of GalNAc4S-
6ST in chondrocytes. Therefore, further studies are aimed at investigating 
changes in serglycin GAG chain structure associated with inflammation and 
OA.  
In addition to the possible connection between serglycin and GalNAc4S-6ST 
expression, a different plausible scenario for GalNAc4S-6ST up-regulation 
could be a role related to the ability of CS-4,6diS to bind growth factors. In a 
recent study by Kawamura and colleagues (2014), the effect of different CS 
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types (CS-4S, CS-6S, CS-4,6diS) on the chondrogenic differentiation of 
ATDC5 cells was investigated. They found that the addition of CS-4,6diS to 
the culture media increased the expression of aggrecan, collagen type II, Sox9 
during chondrogenic differentiation of the cells induced by insulin (Kawamura 
et al. 2014). For the other CS types, the expression levels remained 
unchanged compared to control. The authors suggested that the effect could 
be a result of enhanced retention of endogenously expressed BMP-4 which is 
an important growth factor involved in chondrogenic differentiation. The 
increased expression of GalNAc4S-6ST during cartilage inflammatory 
stimulation discovered here could possibly be involved in a similar mechanism. 
An increased secretion of CS-4,6diS attached to proteins could also lead to 
the retention of growth factors which have anabolic activity and this could 
therefore be an attempt of cartilage at repairing itself. 
 
The inflammatory stimulation of dermal constructs had the opposite effect on 
the expression of genes involved in CS/DS synthesis and sulphation. Several 
glycosyltransferases responsible for GAG chain elongation (CHPF2, CHGN) 
as well as XYLT1 which initiates GAG chain synthesis were up-regulated. 
Moreover, CHST11 expression was substantially increased which indicates 
that CS/DS chains are likely to contain a higher amount of GalNAc-4S. The 
altered CS/DS chain synthesis during inflammation could be associated with 
the wound healing response of the fibroblasts. Kuwaba and colleagues found 
that the CS/DS chain of decorin in fibroblasts was elongated in healing skin, 
allowing enlarged interfibrillar gaps between collagen fibrils to form (Kuwaba 
et al. 2001).  
 
Besides CS/DS, also the expression of enzymes involved in heparin/HS 
synthesis or modification was changed by inflammatory stimulation of cartilage 
constructs. Two glycosyltransferases involved in heparin/HS synthesis were 
down-regulated. This may not imply necessarily that heparin/HS synthesis was 
down-regulated as the expression of major glycosyltransferases involved in 
chain elongation, EXT1 and EXT2 (Esko et al. 2009), was apparently 
unchanged (not shown). HS2ST-1, a sulphotransferase responsible for the 
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sulphation on the C-2 atom of iduronic/glucuronic acid, was modestly up-
regulated during inflammatory stimulation. This could potentially result in an 
increased 2-O sulphation in heparin/HS. 
 
KS synthesis was not apparently changed by IL-1 or IL-1/OSM, but 
expression of enzymes known to modify KS were affected. CHST6 expression 
was more than 4-fold decreased which could have an effect on the degree of 
KS sulphation and therefore change the properties of proteoglycans containing 
KS, e.g. lumican. The increase in ST3GAL1 expression could affect the degree 
of sialic acid content of KS. However, KS is not the only substrate for this 
enzyme (Rao et al. 2009).  
 
In terms of N-glycosylation, mostly enzymes responsible for the build-up of the 
glycan precursor were affected, namely ALG9, 10B, 14 and DDOST by 
inflammatory stimulation of the cartilage model. However, there was no 
uniform up- or down-regulation of gene expression that would clearly indicate 
a generalizable change in glycan structure. In addition, the changes were only 
modest, leading to the assumption that N-linked glycosylation might not be 
overtly altered by inflammatory stimulation. The only gene which was 
increased by both treatments more than 2-fold was GFPT2. This protein is 
known to protect cells against reactive oxygen species (ROS) induced 
cytotoxicity (Zitzler et al. 2004) which could occur as a consequence of 
inflammatory stimulation. 
 
Otherwise, no general tendency for a reduction or increase in the amount of 
O-linked glycans attached to proteins in response to inflammatory stimulation 
of cartilage was observed. Interestingly, an increase in the expression of the 
fucosyltransferase FUT4 was observed for both treatments which could 
indicate that O-linked glycans contain more fucose residues than in normal 
cartilage. Increased fucosylation was found in synovial proteins from patients 
with arthritis (Ferens-Sieczkowska et al. 2007) which supports this finding. 
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In summary, analysis of gene expression of cartilage and dermal constructs 
stimulated with IL-1 alone or IL-1 together with OSM showed that genes 
involved in the glycosylation of proteins are effected in different ways. 
Importantly for our overall aims, some of these alterations appear to be tissue 
specific. Our data show that many different types and aspects of glycosylation 
are influenced, from synthesis of basic sugar units, synthesis of precursors, 
build-up of glycan structures to post-synthesis modifications of glycans by 
various enzymes. Such changes can dramatically affect the physiological 
properties of glycosylated proteins. Most importantly, several interesting 
candidate genes were found, including serglycin, lumican, and GalNAc4S-
6ST. Further analysis will need to confirm that the observed gene expression 
changes translate to the protein level. This could then lead the way for potential 
experiments using the identified proteins or specific epitopes thereof, or 
products of respective enzyme activity as markers in patient samples.  
 
 
 
 
 
 
 
 
 
Chapter 6: 
 
Characterization of changes 
induced in tissue models by 
inflammatory mediators 
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6 Characterization of changes induced in tissue 
models by inflammatory mediators 
 Introduction  
In the previous chapter, cartilage constructs generated from human 
chondrocyte progenitor cells were stimulated with pro-inflammatory cytokines 
and expression of genes involved in glycan synthesis and modification were 
analyzed using microarray and Q-PCR. In addition, dermal constructs based 
on human skin fibroblasts were stimulated with the same treatment. This 
identified changes in the cytokine response that are solely found in 
chondrocytes. Many different genes were differentially regulated during 
inflammatory stimulation. Although not all of them were highly up- or down-
regulated, one has to keep in mind that also small changes in expression can 
make a huge difference. 
 
In this chapter, it should be analyzed whether selected changes in gene 
expression observed in the microarray experiments translated to changes in 
the ECM of stimulated cartilage constructs on a protein level. This was very 
important with respect to a potential use of these markers for the diagnosis of 
early OA in the future. It would strengthen the scientific case to justify further 
development, and ultimately it would enable analysis of changes in cartilage 
homeostasis resulting from inflammation in chondrocytes using common 
clinical tools like ELISAs.  
 
Two proteoglycans, serglycin and lumican, were identified to have an 
increased expression as a result of inflammatory stimulation. These two 
proteins were chosen for further analysis in the following experiments. While 
lumican expression and function in cartilage is well characterized (Grover et 
al. 1995; Roughley 2006), little is known about the role of serglycin in cartilage. 
It is predominantly found in cells derived from the hematopoietic lineage, e.g. 
monocytes, macrophages, megakaryocytes, platelets, lymphocytes, mast 
cells, and neutrophils (Scully et al. 2012). It plays a major role in the genesis 
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and homeostasis of intracellular granules and secretory vesicles in these cells. 
More recently, serglycin was also found in chondrocytes (Zhang et al. 2010), 
endothelial cells (Meen et al. 2011), and smooth muscle cells (Lemire et al. 
2007).  
The core protein of serglycin contains a characteristic region rich in Ser-Gly 
repeats, which gave rise to the name “serglycin” (Bourdon et al. 1985). The 
GAG chains attached to the serine residues can be either of heparin, HS or 
CS type. These are so densely packed, that the whole molecule is resistant to 
proteolytic degradation (Kolset and Pejler 2011). Interestingly, inflammatory 
mediators have been shown to substantially alter serglycin modification with 
glycans (Chang et al. 2012). 
 
 Aims for this chapter: 
1. Investigate changes in expression and composition of serglycin and 
lumican in cartilage constructs stimulated with inflammatory factors at 
the protein level to substantiate results from gene expression analysis. 
 
2. Investigate whether inflammatory stimulation impacts on 
posttranslational modification of decorin in line with expected changes 
in carbohydrate biosynthesis from gene expression screening in the 
absence of changes in expression of decorin itself. 
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 Materials and methods 
 
 Inflammatory stimulation of cartilage constructs 
Cartilage constructs were treated with 1 ng/ml IL-1 alone or in combination 
with 10 ng/ml OSM as described in chapter 5 (section 5.2.1). Constructs were 
cultured for a total of 6 days in medium containing cytokines, with replacing 
the medium every day. The conditioned medium was collected from the inside 
of the transwell and from the bottom well during media change, pooled for each 
construct and stored at -20°C. GAG content of the media was determined 
using the DMMB assay described in chapter 3 (section 3.2.8). For histological 
analysis, constructs were collected at day 2, 4 and 6. At the time of harvest, 
the constructs were washed in PBS and fixed in 4% paraformaldehyde (PFA) 
in PBS for 24 h at 4°C. Prior to that, the wet weight was determined. 
Processing of the sample for histology was performed as described in chapter 
3 (section 3.2.5). For protein extraction, constructs were harvested at day 2, 4 
and 6. At the end of the experiment, the cartilage constructs were removed 
from the transwell culture inserts, washed with PBS and subsequently snap 
frozen in liquid N2. The constructs were stored at -80°C until further processing. 
Each condition was analyzed in triplicate with one construct used per 
experiment. 
 
 OA cartilage tissue samples 
Osteochondral knee joint specimens were obtained from patients undergoing 
total knee arthroplasty. Specimens were dissected from macroscopically 
undamaged areas of cartilage using an 8 mm disposable biopsy punch and 
subsequently fixed in 4% PFA in PBS for 24 h, followed by embedding in 
paraffin. 5 µm sections were cut from the specimens and used for histological 
staining and immunohistochemistry as described in chapter 3 (section 3.2.5) 
and chapter 4 (section 4.3.3).  
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 Extraction of ECM proteins from cartilage constructs 
For the extraction of ECM proteins, the constructs were placed into a 1.5 ml 
tube and immediately mixed with 200 µl extraction buffer (6 M guanidine HCl, 
50 mM sodium acetate, 100 mM EDTA, pH 5.8) containing protease inhibitors 
(100 mM aminohexanoic acid, 10 mM benzamidine, 1 mM PMSF, 1 mM NEM). 
The constructs were crushed with a disposable plastic pestle on ice into a 
homogenous solution. The tubes were sealed and incubated at 4°C for 16 h 
on a rotary shaker to maximize efficiency of extraction. Afterwards, the 
samples were centrifuged at 12,000 x g for 5 min to remove residual insoluble 
material. The supernatant was collected. The protein concentration was 
determined using the Pierce™ BCA assay kit (Thermo Scientific) as described 
(chapter 2, section 2.2.11). 
 
 Analysis of cartilage extracts and conditioned media using 
Western blotting 
Proteins extracted from the cartilage constructs were precipitated by mixing 
one volume of sample with 9 volumes of ice-cold ethanol, followed by 
incubation for 16 h at 4°C. Afterwards, the precipitated protein was recovered 
by centrifugation at 14,000 x g for 30 min at 4°C. The resulting pellet was 
dissolved in 7 µl 8 M Urea and 7 µl SDS sample buffer (2x stock, containing -
mercaptoethanol) and boiled for 5 min. 20 µg protein from each sample were 
separated on a 4-20% Tris-glycine gel (Life Technologies). For the analysis of 
proteins released into the conditioned medium during inflammatory 
stimulation, 100 µl from each time point were used. The samples were dried 
using a vacuum concentrator (RVC 2-25 CDplus), and the resulting pellet was 
resuspended in urea and sample buffer as above, and boiled for 5 min. After 
electrophoresis and transfer to nitrocellulose/PVDF membranes, the 
membrane was blocked with 5% skimmed milk in PBS and probed with 
antibodies (Table 6.1) as previously described (chapter 2, section 2.2.15). For 
detection of lumican, a nitrocellulose membrane was used for Western blotting 
as normal, whereas for detection of serglycin, a PVDF membrane was used 
as this protein was reported to bind poorly to nitrocellulose. For digestion of 
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the samples with chABC or heparinase 2 prior to electrophoresis, 20 µg protein 
from each sample were dried using a vacuum concentrator. The resulting 
pellet was either resuspended in 100 µl of 50 mM Tris-HCl, pH 8.0, 60 mM 
sodium acetate containing 10 mU chABC (Seikagaku, Associates of Cape 
Cod, East Falmouth, MA, USA) or resuspended in 100 µl of 20 mM sodium 
acetate, pH 7.0, 2 mM calcium acetate containing 10 mU heparinase 2 (Sigma 
Aldrich) and incubated for 1 h at 37°C. Note, heparinase 2 can cleave both 
heparin and HS. Afterwards, the reaction mixture was heated to 100°C for 5 
min to inactivate the enzyme. The samples were dried using a vacuum 
concentrator and mixed with Urea and SDS sample buffer for SDS-PAGE and 
Western blotting as before. 
 
 Immunohistochemical analysis of cartilage constructs after 
inflammatory stimulation 
The tissue was embedded in paraffin and 5 µm sections were prepared. 
Deposition of lumican and serglycin within the extracellular matrix was 
visualized as described (chapter 4, section 4.3.3). The antibodies used are 
described in Table 6.1. 
 
 
Table 6.1 Antibodies used for Western blotting (WB) and immunohistochemical staining of 
cartilage sections (IHC) 
Antigen Antibody name, type and dilution Reference 
Lumican LUM-1, mouse monoclonal, 1:500 in 5% skimmed 
milk/TBS (WB), 1:20 in 1% BSA/TBS (IHC) 
Bruce Caterson, 
Cardiff University 
Serglycin Ab76512, mouse monoclonal, 1:500 in 5% 
skimmed milk/TBS (WB), 1:100 in 1% BSA/TBS 
(IHC) 
Abcam 
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 Inflammatory stimulation of human skin fibroblasts and analysis 
of changes in decorin GAG chain disaccharide composition 
Bonacker cells were cultured in monolayer culture as described (chapter 2, 
section 2.2.8). When approx. 70% confluency was reached, the serum 
concentration was reduced to 4% and cytokine treatment was started. Cells 
were cultured with medium containing either 1 ng/ml IL-1 alone or in 
combination with 10 ng/ml OSM. The cells were cultured for 72 h without 
medium change. Afterwards, the medium was collected and centrifuged at 500 
x g for 5 min to remove any cells or cell debris. The medium was supplemented 
with Tris-HCl pH 7.5 to a final concentration of 5 mM and stored at -20°C until 
further use. Decorin was purified from the conditioned medium as described 
(chapter 2, section 2.2.9). Afterwards, the disaccharide composition of CS/DS 
chains of decorin was analyzed using AMAC-labelling and reversed phase 
HPLC as described (chapter 2, section 2.2.5, 2.2.7).  
 
 Deglycosylation of decorin samples using PNGase F 
Peptide-N-glycosidase F (PNGase F) is a protein isolated from Flavobacterium 
meningosepticum which allows for specific removal of N-linked glycans from 
proteins. 2 µl PNGase F (corresponding to 1000 U, New England Biolabs, 
Ipswich, MA, USA), 2 µl NP40 (10% v/v) and 2 µl G7 buffer (10X stock) were 
added to 14 µl sample and incubated for 2 h at 37°C. For Western blotting, the 
reaction mixture was afterwards dried using a vacuum concentrator and 
reconstituted in 7 µl 8 M urea and 7 µl SDS sample buffer (from 2X stock, 
containing -mercaptoethanol).  
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 Results 
 Changes associated with inflammatory stimulation of cartilage 
constructs: Wet weight and GAG release 
In the previous chapter, gene expression changes of cartilage constructs upon 
stimulation with IL-1 alone or in combination with OSM was analyzed. To 
follow up on these experiments, similar fully differentiated constructs were here 
stimulated with both treatments, the difference to the previous experiments 
being that the inflammatory stimulation was carried out for 6 days. The reason 
for this was to get a better picture of the more long-term effects of the 
inflammatory stimulation on cartilage constructs and to allow for the changes 
in gene expression to have enough time to become detectable on a protein 
level. A set of constructs was collected every 2 days to monitor the progression 
of the catabolic events and conditioned medium collected every day for 6 days 
(Fig. 6.1 A). Analysis of the wet weight showed that no obvious changes were 
present after 2 or 4 days of stimulation. After 6 days, tissue loss was evident 
for constructs treated with IL-1/OSM in that they were lighter compared to 
untreated and IL-1 only treated constructs (Fig. 6.1 B). Analysis of the amount 
of GAG chains released into the conditioned media showed that for both 
treatment groups, release was increased already within the first day of 
stimulation (Fig. 6.1 C). In line with previous observations (Fig. 5.4), constructs 
treated with IL-1/OSM substantially showed enhanced GAG chain release 
compared to IL-1 alone. GAG chain release peaked during the first 2 days. 
Thereafter, the GAG release by the constructs treated with IL-1/OSM or IL-
1 gradually returned to a similar level as observed for control. As GAG release 
differed substantially between the IL-1/OSM and IL-1only groups, GAG 
depletion from the tissue was not the main reason for the reduced GAG release 
seen in the later phases of the experiment, at least for IL-1 only treated 
constructs. 
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Figure 6.1 Inflammatory stimulation of cartilage constructs 
Fully differentiated cartilage constructs (35 days) were cultured for 3 days in medium without 
differentiation factors prior to stimulation with IL-1 (1 ng/ml) alone or in combination with OSM 
(10 ng/ml) for a total of 6 days. Medium was replaced every day and fresh cytokines were 
added. Cartilage constructs were collected for analysis after 2, 4 and 6 days in culture (A). 
The wet weight was determined immediately after removing the constructs from the transwell 
inserts (B). Released total GAG from the conditioned media was measured using the DMMB 
assay (C). Data is presented as mean ± SEM of two independently grown constructs. 
Statistically significant changes compared to control samples were determined with one-way 
ANOVA with post hoc analysis using Tukey‘s multiple comparison test. **P<0.01, ***P<0.001.  
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 Histological analysis of cartilage constructs stimulated with 
inflammatory cytokines 
To analyze the effects of inflammatory stimulation of cartilage constructs on a 
histological level, constructs collected after 2, 4 and 6 days of treatment were 
stained with H&E and toluidine blue and also used for immunohistochemical 
staining for serglycin and lumican. Histological analysis of untreated control 
constructs showed a cartilaginous tissue morphology and high amount of GAG 
chains as indicated by toluidine blue staining (Fig. 6.2 B). Using a monoclonal 
antibody raised against serglycin and lumican showed that both proteins were 
present. Serglycin staining was strong directly around or associated with 
chondrocytes throughout all layers of the construct but not in the ECM. Staining 
for lumican was faint and was found pericellularly around chondrocytes as well 
as in the matrix proper in the upper half of the construct. 
 
 
Figure 6.2 Histological analysis of an untreated control cartilage construct at day 6 
5 µm paraffin sections of a cartilage construct cultured without inflammatory cytokines were 
stained with H&E (A) and toluidine blue (B) to visualize tissue morphology and matrix content. 
Sections were also stained with antibodies raised against serglycin (C) or lumican (D). Non-
specific mouse IgG was used as a control (E). Bar = 100 µm. 
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The detrimental effect of adding IL-1 to the culture medium of cartilage 
constructs was visible after staining of the constructs with H&E and toluidine 
blue (Fig. 6.3). Toluidine blue staining of cartilage constructs stimulated with 
IL-1 alone showed that the GAG chains within the ECM were gradually lost 
over time. At day 2, GAG depletion was restricted to the superficial layer (Fig. 
6.3). After 4 days, bands of weak (top) and strong (bottom) toluidine blue 
staining ECM were observed, which showed that the release of GAG chains 
proceeded slowly from the surface layer to the inside of the construct. After 6 
days, the ECM was substantially depleted of GAG chains throughout all layers 
of the construct. Also, the resilience to mechanical challenge of the construct 
was much reduced at this stage (not shown). Immunostaining for serglycin 
showed that there was an increase in staining over the treatment period. While 
at day 2, the staining was relatively evenly distributed across the construct, 
staining in the GAG depleted top area was increased at day 4 and further 
enhanced after 6 days. At day 6 and to a lesser extent at day 4, the very 
superficial layer of the construct was staining particularly strongly for serglycin, 
which indicated that serglycin may have a unique role in superficial zone cells. 
Immunostaining for lumican did not show similar changes. On day 2, staining 
was comparable to control. Staining of the superficial layer ECM was 
increased marginally on day 4, but did not further increase by day 6.  
It would have been expected from the measurement of the released GAG 
chains into the conditioned medium that the ECM lost the bulk of its GAG 
chains on day 1 and 2. Strangely, the cartilage ECM after 2 days was still rich 
in GAG chains. This may indicate that intact GAG chains are released initially 
but at later stages broken down into smaller components that are not detected 
in the DMMB assay. 
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Figure 6.3 Histological analysis of cartilage constructs stimulated with IL-1 alone 
5 µm paraffin sections of a cartilage construct cultured with 1 ng/ml IL-1 alone for 2, 4 and 6 
days were stained with H&E, toluidine blue, and antibodies raised against serglycin and 
lumican. Non-specific mouse IgG was used as a control. Bar = 100 µm.  
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Stimulation of cartilage constructs with IL-1 in combination with OSM showed 
an even more pronounced catabolic effect on tissue architecture (Fig. 6.4). 
Very weak toluidine blue staining was observed already after 2 days of 
treatment indicating almost complete GAG depletion. Similarly, constructs 
cultured for 4 days in IL-1/OSM had the same weak staining. Interestingly, 
there was a slight increase in toluidine blue staining around cells in the upper 
part of the construct after 6 days. A reason for this could potentially be an 
increased GAG chain synthesis of the chondrocytes as an attempt to repair 
the ECM. Similar to the construct stimulated with IL-1 alone, serglycin staining 
was substantially increasing during the inflammatory treatment. However, by 
day 6 a general increase throughout the construct was observed in addition to 
very strong staining in the superficial zone (Fig. 6.4). Lumican staining was 
observed mainly in the superficial layer on day 2 and 4 (Fig. 6.4). On day 6, 
this staining was marginally enhanced. A notable observation was that the 
constructs collected after 6 days of IL-1/OSM treatment were very fragile. 
This showed that the ECM integrity was completely lost as a result of the 
catabolic events triggered by the cytokine stimulation. 
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Figure 6.4 Histological analysis of cartilage constructs stimulated with IL-1 and OSM 
5 µm paraffin sections of a cartilage construct cultured with 1 ng/ml IL-1 and 10 ng/ml OSM 
for 2, 4 and 6 days were stained with H&E, toluidine blue, and antibodies raised against 
serglycin and lumican. Non-specific mouse IgG was used as a control. Bar = 100 µm.  
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Human cartilage isolated from waste tissue of total knee arthroplasty was used 
to compare the expression of serglycin and lumican in patient OA cartilage with 
that observed in the in vitro model. Samples were collected from 
macroscopically intact areas of joint cartilage plate and were left attached to 
the subchondral bone plate for processing.  
Patient #1 was an 88 year old male, and Patient #2 was a 76 year old female. 
Both samples showed some degree of tissue degradation in the superficial 
layers (Fig. 6.5). These regions showed reduced toluidine blue staining, 
indicating GAG chain loss likely as a result of progression of OA. 
Immunostaining for serglycin showed a similar pattern as observed in the in 
vitro model with increased staining of the superficial zone as well as staining 
of chondrocytes in deeper layers (Fig. 6.5). Lumican staining was faint but 
nevertheless present in the same region, although only few chondrocytes were 
positive (Fig. 6.5). These distributions are remarkably similar to the ones 
observed for cartilage constructs stimulated with IL-1 alone (Fig. 6.3). 
Unfortunately, no healthy control cartilage was available which would have 
been useful for comparison with the OA cartilage samples. Therefore, it 
remains unclear whether these proteins are increased in OA knee cartilage or 
not. 
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Figure 6.5 Analysis of human OA-cartilage specimens 
5 µm paraffin sections from knee cartilage of two patients with OA were stained with H&E, 
toluidine blue and antibodies raised against serglycin and lumican. Mouse IgG was used as a 
control. Bar = 100 µm.  
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 Analysis of changes in serglycin and lumican caused by 
inflammatory stimulation of cartilage constructs 
In addition to immunostaining of cartilage sections, matrix proteins were 
extracted from cartilage constructs treated with pro-inflammatory cytokines for 
2, 4, and 6 days. The samples were used for Western blotting followed by 
staining with an antibody raised against serglycin (Fig. 6.6) and lumican (Fig. 
6.7). For the analysis of serglycin, samples were digested with chABC (Fig, 
6.6 A), heparinase 2 (Fig. 6.6 B) or with both enzymes at the same time (Fig. 
6.6 C, D, E) prior to SDS-PAGE. This was done because serglycin can carry 
CS and HS chains. Probing of the Western blots with an anti-serglycin 
monoclonal antibody resulted in multiple bands for all conditions (Fig. 6.6 A, 
B, C). After chABC digestion, a high molecular weight band larger than 
100 kDa showed the strongest signal (Fig. 6.6 A [1]). After digestion of the 
samples with heparinase 2, a predominant band with a molecular weight of 
around 80 kDa appeared (Fig. 6.6 B [2]). Again, multiple smaller bands were 
observed, whereby the lowest band had a molecular weight of ~30 kDa. 
However, this was not consistent with the calculated molecular mass of the 
serglycin core protein which is approx. 17 kDa. Interestingly, after digesting 
the samples with both chABC and heparinase 2, both bands seen before 
appeared at the same time (Fig. 6 C [1] and [2]). Assuming that the monoclonal 
antibody was specific for serglycin as stated by the manufacturer, two different 
forms of serglycin with either CS or HS were present in cartilage. On the other 
hand, given that the molecular mass is not consistent with serglycin, it is also 
possible that the antibody cross-reacts with another CS/HS proteoglycan and 
this requires further investigation. 
Western blot analysis of the conditioned media collected during inflammatory 
stimulation of the constructs over 6 days showed that a ~25 kDa protein 
detected by the anti-serglycin antibody was highly up-regulated after 
stimulation with IL-1 alone from day 1 to 4 (Fig. 6.6 D). The migration position 
of this band is consistent with that reported for de-glycanated serglycin in the 
literature (Chang et al. 2012). This band was not observed in the control 
samples. Surprisingly, Western blot analysis of the conditioned media from 
constructs stimulated with IL-1/OSM did not reveal a similar up-regulation of 
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the respective protein. Only weak bands that corresponded in size to the 
intense bands from Fig. 6.6 D were observed after 1 and 2 days of treatment. 
This could indicate differential regulation of serglycin by the different 
inflammatory regimens, or more likely, indicate that secreted serglycin is 
rapidly undergoing proteolytic degradation (personal communication, Prof. 
Niels Borregaard, University of Copenhagen, Denmark) given that it is up-
regulated by both treatments as determined by Q-PCR (Table 5.9) and by 
immunohistochemistry (Fig. 6.3, 6.4). Enhanced proteolysis is also consistent 
with the more rapid breakdown of cartilage after IL-1/OSM treatment 
compared to IL-1 alone (Fig. 6.3, 6.4).  
In the control samples, a band >100 kDa was reproducibly observed at day 0 
(before starting the treatment). The nature of this band is unclear but it may be 
related to band 1 previously discussed in the cartilage extracts. 
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Figure 6.6 Western blot analysis of cartilage matrix and conditioned media for serglycin 
after inflammatory stimulation 
Guanidine HCl-extracts of cartilage constructs (A – C) cultured for up to 6 days under 
inflammatory stimulation (20 µg per lane) or respective conditioned media (D – E) were probed 
with a monoclonal antibody raised against serglycin. Proteins were digested with chABC (A), 
heparinase 2 (B) or chABC and heparinase 2 (C, D, E) prior to SDS-PAGE separation and 
Western blotting. Migration of molecular weight markers is indicated on the left.  
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Western blot analysis of lumican extracted from cartilage constructs showed 
that there was a small increase in band intensity (around 66 kDa) observed 
between control samples and samples from cartilage stimulated with 
cytokines. Lumican was detected as a broad band of ~50 - 75 kDa as it is 
substituted with KS. By day 4, the bands of samples from both inflammatory 
treatments had a similar intensity but were more intense than the one from 
control (Fig. 6.7 A). By day 6, no signal was present in the IL-1/OSM sample, 
whereas the band detected in control and IL-1 samples had a similar intensity. 
As samples prepared from the cartilage construct ECM contained also newly 
synthesized matrix proteins, this could suggest that lumican expression was 
increased as a result of inflammatory stimulation in line with gene expression 
data (Table 5.9). 
Analysis of the conditioned media showed that lumican release was increased 
in cartilage constructs stimulated with IL-1 only on day 1, 2 and 3 (Fig. 6.7 B). 
The release decreased on day 4 and no lumican could be detected on day 5 
and 6. Similarly, conditioned media from constructs stimulated with both IL-
1/OSM also showed increased release on day 2 and 3, which was reduced 
on day 4 and 5 and was absent on day 6 (Fig. 6.7 C). Unfortunately, the 
intensity of the signal was suboptimal in this experiment and therefore requires 
repetition. 
 
HPLC-based disaccharide analysis of cartilage extracts prepared from papain-
digested samples was unfortunately not successful. The reason for this was 
that the background of the samples was unexpectedly high and no conclusive 
data could be obtained. This was unfortunate as it would have been interesting 
to see whether there would be a difference in the disaccharide compositions 
of GAG chains after inflammatory stimulation, especially as it was known from 
the microarray and Q-PCR analysis that CHST15 (GALNAC4S-6ST) was up-
regulated by cytokine treatment. It would have been important to confirm 
differences in the relative amounts of its reaction product (GlcA-
GalNAc4,6diS). However, it is also possible that such changes would have 
been masked due to the massive release of GAG chains immediately after 
addition of cytokines.  
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Figure 6.7 Western blot analysis of cartilage matrix and conditioned media for lumican 
after inflammatory stimulation 
Guanidine HCl-extracts of cartilage constructs (A) cultured for up to 6 days under inflammatory 
stimulation (20 µg per lane) or respective conditioned media (B, C) were probed with a 
monoclonal antibody raised against lumican. Proteins were digested with chABC prior to SDS-
PAGE separation and Western blotting. Migration of molecular weight markers is indicated on 
the left.  
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 Effects of inflammatory stimulation on decorin secreted by skin 
fibroblasts 
 
Decorin purified from the conditioned media of human skin fibroblasts 
stimulated with IL-1 alone or in combination with OSM was analyzed to 
investigate changes that may have occurred in its CS/DS chain. This should 
be considered separately from the cartilage inflammatory stimulation and the 
search for biomarkers and be seen more as a general investigation of the 
hypothesis that GAG chain synthesis and modification can be affected by 
inflammatory factors. After SDS-PAGE of the samples followed by silver 
staining, a difference in the molecular weight between decorin purified from 
untreated and treated cells was observed (Fig. 6.8 A). Decorin purified from 
untreated cells showed a smear with a molecular weight around 97 kDa (see 
also Fig. 2.6 A). Addition of IL-1 resulted in a higher molecular weight of 
decorin compared to untreated control and addition of IL-1/OSM resulted in 
an even larger decorin molecule than when IL-1 was added alone (Fig. 6.8 
A). Furthermore, each sample contained a high molecular weight band, the 
size of which was increasing correspondingly. Western blotting using a 
polyclonal antibody raised against decorin (described in Table 2.3) showed 
that both bands were decorin. The higher molecular weight band are likely to 
be a decorin dimer as discussed previously (Fig. 2.6 B).  
To investigate whether the increase in molecular weight was resulting from 
alterations in the GAG chain attached to the decorin core protein, the N-linked 
glycans attached to decorin or the core protein itself, each sample was 
digested with chABC alone (as described in chapter 2, section 2.2.10) or in 
combination with PNGase F. Depolymerization of the GAG chain by chABC 
showed that all decorin core proteins had a similar molecular weight of 
~44 kDa independent of the treatment (Fig. 6.8 B). Further digestion with 
PNGase F showed that the size of decorin core protein was unchanged across 
the conditions (Fig. 6.8 C). Taken together, this indicates that there is no 
difference in the amount of N-linked glycans. From this experiment it was 
concluded that cytokine stimulation only affected the length of the CS/DS chain 
of decorin.  
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Figure 6.8 Inflammatory stimulation of skin fibroblasts leads to increased GAG chain 
size on secreted decorin 
Human skin fibroblasts (Bonacker cells) were cultured in monolayer with medium 
supplemented with IL-1 alone or in combination with OSM for 72h. Decorin was purified from 
the conditioned medium and analyzed using SDS-PAGE and silver staining (A, left) or Western 
blotting (A, right) using the polyclonal antibody raised against decorin. The asterisk marks an 
immunoreactive band that likely corresponds to a decorin dimer. Digestion of the samples with 
chABC alone and in combination with PNGase F (B) showed that there was no difference in 
the amount of N-linked glycans attached to the core protein between the different culture 
conditions.  
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The previous experiment showed that the GAG chain length was increased 
after inflammatory stimulation of human skin fibroblasts. To further investigate 
changes in the GAG chain composition, CS/DS chains derived from decorin 
were analyzed using AMAC-labelling followed by reversed phase HPLC (Fig. 
6.9). This showed that there was a difference in the amount of 4S, 6S and 
0S disaccharides between the different samples after complete GAG chain 
depolymerization with chABC (Fig. 6.9 A). While the relative amount of 4S 
increased from 74.6% in control samples to 81.8% in IL-1 only and 85.7% in 
IL-1/OSM stimulated samples, the amount of 2S, 6S and 0S decreased 
from 2.8%/12.8%/5.7% in control samples to 1.3%/9.2%/4.1% in IL-1 only 
and 0.7%/7.6%/3.6% in IL-1/OSM stimulated samples, respectively. 
Differences in the relative amount of di- and tri-sulphated disaccharides 
between the different treatments were much smaller. Digestion of the CS/DS 
chains using chAC-I showed only little difference in the relative amounts of 
4S, 6S and 0S (Fig. 6.9 B). In contrast, chB-digestion showed that decorin 
from cells stimulated with IL-1/OSM had a 4% higher content of 4S, which 
was made up of DS (Fig. 6.9 C). Differences were also observed for the 
disulphated 2,4diS, which was increased for IL-1 only and decreased in IL-
1/OSM co-stimulation compared to control. 
Taken together, these results suggest that stimulation of skin fibroblasts with 
IL-1 alone or in combination with OSM affected the length of GAG chains and 
also influenced the sulphation of disaccharide subunits. In both, chABC or chB 
digestion of GAG chains, an increase in 4S disaccharides was detected. 
Furthermore, these disaccharides appear to be largely made of DS. 
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Figure 6.9 Quantitative analysis of the disaccharide composition of decorin isolated 
from human skin fibroblasts stimulated with 1 ng/ml IL1- alone or in combination with 
10 ng/ml OSM. 
From each sample, 4 µg protein was digested using chondroitinases ABC (A), AC-I (B) or B 
(C), followed by labelling with AMAC and reversed phase HPLC analysis. Data is shown as 
mean ± SEM from three independent experiments. Statistical significance of changes 
compared to control samples were determined with one-way ANOVA with post hoc analysis 
using Tukey‘s multiple comparison test. None of the changes was large enough to reach 
significance with the confidence interval set to 95%  
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 Discussion 
In this chapter, the effect of inflammatory stimulation of cartilage constructs 
using 1 ng/ml IL-1 alone or in combination with 10 ng/ml OSM was analyzed 
using histological methods and Western blotting as well as HPLC-based 
disaccharide analysis. The results from the experiments showed that serglycin 
was up-regulated in cartilage constructs upon stimulation with IL-1 alone or 
together with OSM. Additionally, lumican protein expression was also 
increased by both treatments, although to a lesser extent. Analysis of decorin 
CS/DS chains purified from human skin fibroblasts cultured in media 
containing inflammatory factors showed that GAG chain length was increased 
as well as disaccharide sulphation changed as a result of the cytokine addition. 
Most of the changes observed in this chapter can be directly linked to the 
changes in gene expression identified using the microarray and Q-PCR 
analysis in the previous chapter 5. 
This chapter shows in some instances preliminary data, which may not fully 
support a final conclusion and some aspects clearly need to be further 
investigated. This work was still in progress at the end of this PhD project, but 
should not be omitted from the thesis in order to provide a comprehensive 
overview on the work that has been carried out and the direction of future work 
that was enabled by it. 
It was shown previously (chapter 5, Fig. 5.4) that the combination of 1 ng/ml 
IL-1 and 10 ng/ml OSM had an even more dramatic effect on cartilage ECM 
integrity than addition of IL-1 alone as determined from GAG release. This 
was confirmed here by toluidine blue staining of cartilage constructs (Fig. 6.4), 
showing that the ECM was almost completely depleted of GAG chains already 
after 2 days. This was not surprising as it is known that the combination of IL-
1 and OSM results in a much higher expression and activity of matrix 
degrading enzymes, for example MMP13, ADAMTS-4, ADAMTS-5 (Barksby 
et al. 2006; Gilbert et al. 2012), than IL-1 alone. Nevertheless, it confirmed 
that our model faithfully reproduced the expected sequence of events 
associated with OA. 
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The staining intensity of serglycin in the immunohistochemical analysis of 
cartilage constructs seemed to be time dependent rather than influenced by 
the addition of OSM, because the staining increased in both treatment groups 
at a similar rate over time. The strongest staining was observed in the 
superficial layer of the constructs, which could be explained by the fact that 
this layer was directly exposed to the cytokines. The discreteness of the 
labeling, i.e. what appears to be a single cell layer, could also indicate a 
specific role of serglycin in these cells that are clearly distinct and have a 
unique role in cell communication between cartilage proper and the fluid phase 
(culture medium/synovium). Lumican staining was weak in the cartilage 
constructs and did not give a conclusive impression whether it was increased 
or not. Given that lumican was abundantly expressed as determined from 
cartilage extracts, it is possible that a keratanase digestion would have 
improved immunolocalization. 
Immunostaining of patient OA cartilage showed that there was an increased 
amount of serglycin and lumican present in the top region. This was similar to 
the observations made with cartilage constructs after 6 days of inflammatory 
stimulation. However, a proper control was not available to compare staining 
in OA cartilage with normal cartilage. Little is known about serglycin expression 
in cartilage or OA. The only publication we are aware of (Zhang et al. 2010) 
provides very limited information on how serglycin is involved in inflammatory 
processes in cartilage. From the information obtained by the staining of the 
patient cartilage, it can be speculated that lumican and serglycin is more 
abundant in areas which show reduced toluidine blue staining. It is likely that 
a high expression of matrix degrading enzymes can be found in these regions. 
If this was caused by the presence of inflammatory cytokines in the synovial 
fluid during development of OA, which cannot be definitely confirmed, it would 
be in line with the results derived from the experiments with cartilage 
constructs and could relate to IL-1signaling. However, it is also possible that 
antigenic epitopes are more available in these regions and actual protein levels 
not altered. 
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Western blot analysis of serglycin from cartilage construct extracts was not 
conclusive. Firstly, there were many bands present which indicated that either 
the antibody showed some cross-reactivity with other proteins or that serglycin 
was present with various different and extensive posttranslational 
modifications, potentially with different amounts of GAG chains attached to it. 
Only after chABC or heparinase 2 digest, predominant discrete bands were 
observed. However, these did not apparently relate to the same protein 
species as determined from soluble digests. Serglycin expressed by activated 
macrophages and mucosal mast cells contains CS but not heparin/HS (Kolset 
and Tveit 2008). However, heparinase 2 and chABC digestion here indicated 
that HS (and possibly heparin) and CS are present in cartilage derived 
serglycin. Without digestion prior to Western blotting, no band was observed 
at all (not shown). This indicated that the molecular mass of fully intact 
serglycin extracted here from cartilage was either too high to enter the 
separation gel in the SDS-PAGE or the epitopes were masked by the GAG 
chains. The two different band sizes observed after chABC and heparinase 2 
digest on their own could be explained when serglycin contains both CS and 
HS type chains. But then, a combined digest with both enzymes should have 
resulted in a complete removal of GAG chains from the serglycin core protein. 
Neither of the bands was consistent with the molecular mass of the core 
protein. Further experiments should repeat the Western blot analysis using a 
different antibody against serglycin to substantiate the specificity of these 
findings in a first instance. It is possible that besides carbohydrate addition, 
serglycin also undergoes some form of covalent cross-linking, either through 
the core protein such as transglutaminase cross-linking, or involving GAGs as 
observed in inter--inhibitor (Zhuo et al. 2004; Chang et al. 2012), and this 
may explain the observed high molecular mass components apparently 
containing serglycin. 
 
Although lumican immunostaining of cartilage sections was relatively weak, 
Western blotting of the cartilage extracts showed that there was an increase 
in extractable lumican as a result of inflammatory stimulation and incubation 
time. Digestion of the samples with keratanase would clarify whether lumican 
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protein expression is increased, as it removes the KS chains attached to the 
lumican core protein and therefore would separate core protein changes from 
differential glycosylation. However, keratanase was unavailable at the time 
when the experiments were performed and could not be repeated due to time 
restraints. The strongest band was observed at around 66 kDa, but further 
bands running below and above were also observed. This could be explained 
by lumican containing KS with different chain length, or different modifications 
of the KS chain, for example incorporation of sialic acid (Esko et al. 2009). 
Western blot analysis of lumican present in the conditioned media showed 
firstly, that there was increased release following inflammatory stimulation and 
secondly, that intact protein appeared to be released. This was most likely the 
result of matrix degradation triggered by the cytokine treatment. 
 
In chapter 5, an increase in expression of the GALNAC4S-6ST after 
inflammatory stimulation of cartilage constructs was identified. This was 
interesting as it indicated that specific changes in GAG chain sulphation in an 
inflammatory environment were likely to occur. To confirm the increase of 
GALNAC4S-6ST expression on a protein level, Western blot analysis using a 
monoclonal antibody raised against the sulphotransferase was performed 
using the cartilage extract samples. However, there was no protein detectable, 
probably because the expression levels were too low or the antibody not 
suitable (not shown). Attempts to purify proteoglycans from the cartilage 
constructs for further analysis was not successful. One of the reasons was that 
the cartilage material was not available in a sufficient amount. A more sensitive 
method which would have been useful to analyze the composition of newly 
synthesized GAG chains employs 35S labeled sulphate. This was previously 
used by researchers to quantify newly synthesized GAG chains (Carney et al. 
1985). Unfortunately, this was not possible to be performed in our laboratory 
because of safety concerns and the lack of an extraction hood in the radiation 
laboratory. 
 
The observation that the CS/DS chain attached to decorin from skin fibroblasts 
was larger after addition of IL-1 and also IL-1/OSM (Fig. 6.8 A) can be 
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directly related to changes in gene expression observed after microarray and 
Q-PCR analysis of dermal constructs stimulated with the same cytokines. The 
increase in GAG chain length likely be the result of the increased expression 
of the CS-glycosyltransferases CHGN and potentially CHPF2. HPLC analysis 
of the GAG chain composition showed that there was an increase in the 
relative proportion of 4S disaccharides in decorin isolated from skin 
fibroblasts stimulated with cytokines (Fig. 6.9). This was probably caused by 
the increased expression of CHST11, which was about 8-fold up regulated in 
cells treated with IL-1 alone and about 36-fold with IL-1/OSM. In addition, a 
reduction in the amount of 2S, 6S and 0S was observed, which was 
possibly because of a reduced amount of free disaccharide subunits available 
for other sulphotransferases. 
This result showed that the GAG chain synthesis and modification machinery 
is sensitive to inflammatory conditions. Furthermore, it confirmed that changes 
in expression affecting oligosaccharide biosynthesis as determined by gene 
expression analysis indeed translate into altered posttranslational modification 
of proteins, albeit demonstrated here for a fibroblast culture rather than 
cartilage constructs. The resulting changes could influence the biological 
activity of GAG chains, for example to bind and retain growth factors or 
influence cell signaling.  
 
 
 
 
 
 
 
 
 
Chapter 7: 
 
General discussion 
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7 General discussion 
 Summary of the results 
The hypothesis to be investigated in this thesis was whether the glycosylation 
of secreted proteoglycans changes as a result of inflammatory processes in 
cartilage. The resulting alterations in glycosylation may lead to specific 
carbohydrate epitopes that could be utilized as novel biomarkers for 
degenerative joint diseases like osteoarthritis (OA). 
The results presented in this thesis show that substantial changes in the 
expression of genes involved in glycosylation and glycan modification are 
observed after applying inflammatory conditions. This was demonstrated using 
a novel 3D human cartilage model system, which served as a model for human 
articular cartilage and was stimulated with inflammatory factors present in 
osteoarthritis. In addition, dermal constructs based on human skin fibroblasts 
were treated with the same inflammatory cytokines. This served as a reference 
model to identify tissue specific changes in cartilage. The data showed that the 
expression of serglycin and GalNAc4S-6ST were strongly increased in 
cartilage constructs and much lower or absent in dermal constructs. 
Immunohistochemical analysis of stimulated cartilage confirmed an increase 
in expression of serglycin in the tissue upon inflammatory stimulation.  
As a follow-on to experiments using tissue models, GAG chain analysis was 
performed of decorin purified from conditioned medium of human skin 
fibroblast. Culturing the cells in medium containing inflammatory cytokines 
resulted in an increased GalNAc4S content within the GAG chain. Moreover, 
the chain length was increased after inflammatory stimulation. 
In summary, the combined results show that glycosylation in general and 
especially GAG chain synthesis and modification is highly sensitive for 
changes in cell metabolism and that identification of novel epitopes generated 
during pathological conditions could be used as markers for diagnosis as well 
as monitoring disease progression and treatment efficiency. 
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 Conclusions 
 Formation of cartilage constructs using human chondrocyte 
progenitor cells: a valuable new model for study of OA 
pathogenesis and pharmacological intervention 
For the investigation of changes in cartilage GAG chain synthesis under OA-
like conditions, a supply of normal human articular cartilage was an essential 
requirement to perform all necessary experiments, e.g. microarray and Q-PCR 
analysis, protein extraction, or GAG analysis. However, completely normal 
human cartilage is rarely available and the relatively limited amount of normal 
cartilage which would be obtainable from patients undergoing joint 
replacement without having degraded cartilage (and therefore OA) would 
make experiments difficult. Furthermore, every normal or OA cartilage sample 
has different properties depending on the patient’s genomic background, age, 
gender or secondary diseases, and tissue derived from an individual with OA 
is likely affected by the inflammatory environment even if macroscopically 
normal. 
To solve the issue regarding the cartilage supply for the experiments, a model 
system was established which could deliver the necessary amount of normal 
cartilage. Human chondrocyte progenitor cells (Dowthwaite et al. 2004; 
Williams et al. 2010) were used to generate cartilage constructs in vitro. The 
results showed that it was important to grow the cells in serum-free medium 
with a combination of TGF-2, BMP-2, and insulin to achieve chondrogenic 
differentiation. Both TGF-2 and BMP-2 are described to induce chondrogenic 
differentiation on their own (Johnstone et al. 1998; Murdoch et al. 2007; 
Shintani et al. 2013), but cartilage formation with only one of the two growth 
factors was not successful. The chondrogenic effect of growth factors seems 
to be strongly dependent on the cell type and needs to be determined each 
time when a so far untested cell type is used for generating cartilaginous 
tissue. Culturing human chondrocyte progenitor cell strains isolated from knee 
articular cartilage of different patients using the same chondrogenic medium 
formulation resulted in the formation of cartilaginous tissue thereby confirming 
that the optimized medium formulation could work for any other chondrocyte 
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progenitor cell strain derived in the future. It is important to note, however, that 
no similar path of differentiation was observed when progenitor cells were 
derived from an OA affected joint. 
The advantage of this model over other established model systems, e.g. 
bovine cartilage explants (Hui et al. 2003; Gilbert et al. 2012; Sauerland and 
Steinmeyer 2007; Sauerland et al. 2003; M Durigova et al. 2008) or cartilage 
constructs based on stem cells derived from other tissues (bone marrow, fat 
tissue) (Mendelson et al. 2011; Im et al. 2005; Johnstone et al. 1998; Murdoch 
et al. 2007), is first of all that the model is based on cells of human origin. This 
is an important prerequisite to study the potentially species specific 
biochemical changes that take place in human osteoarthritis or other 
degenerative joint diseases. Secondly, the cells are derived from the correct 
tissue site and therefore carry appropriate epigenetic information. The 
chondrocyte progenitor cells are derived from articular cartilage and therefore 
seem to be predetermined for the formation of cartilaginous extracellular 
matrix. For example, the cells have a constitutively high expression of the 
important chondrogenic transcription factor Sox9 (Williams et al. 2010), which 
regulates the expression of collagen type II, IX, XI, and aggrecan (de 
Crombrugghe et al. 2000).  
Following development and optimization of the cartilage model system, the 
biochemical and histological properties of the constructs were thoroughly 
analyzed. This was important to determine the baseline properties of the 
cartilaginous tissue. Biochemical, histological and gene expression analysis 
revealed that after 35 days in culture, the constructs showed properties that 
were similar to fully differentiated articular cartilage. Q-PCR analysis showed 
that during chondrogenesis, expression of cartilage-specific genes (collagen 
type II, aggrecan, matrilin-3, GDF-5, chondromodulin-1) increased. Moreover, 
markers of mesenchymal condensation (N-cadherin, tenascin-C) that were 
increased initially, but then decreased during progression of differentiation. 
This suggests that the progenitor cells were undergoing an accelerated 
embryonic development. Furthermore, a switch to expression of collagen type 
II B indicated the presence of progressively increasing numbers of mature 
chondrocytes in the cartilage constructs (Zhu et al. 1999; Sandell et al. 1994; 
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Johnstone et al. 1998). Likewise, GAG amount increased to a level consistent 
with cartilage and after 35 days, approached a level of C-6-S typically seen in 
articular cartilage. Hypertrophic differentiation of tissue engineered cartilage 
constructs is a big issue, especially when bone marrow-derived MSCs are 
used (Johnstone et al. 1998). No overt sign of hypertrophic differentiation was 
found in the cartilage constructs after 35 days. Although gene expression of 
collagen type X increased during differentiation, no collagen X deposition in 
the ECM was observed. Conversely, terminal differentiation was observed 
after inducing chondrocyte hypertrophy on purpose using triiodothyronine 
(Mueller and Tuan 2008). Based on these results, one might speculate that 
cartilage constructs generated from chondrocyte progenitor cells do not 
undergo terminal differentiation spontaneously, although this would need to be 
confirmed in more long-term experiments. This is a very important feature, 
because it indicates that constructs generated from autologous progenitor cells 
from patients could be used to generate functional cartilage constructs for re-
implantation using the protocol described in this thesis. 
The cartilage model system developed here has a lot of potential for being 
used to further study the effects of different conditions on OA development and 
progression. For example, it could be used to analyze the effect of anti-
inflammatory drugs to prevent cartilage degradation. Another aspect would be 
to use the model for investigating the effect of aberrant mechanical load on 
cartilage metabolism. Although bovine cartilage is heavily used for this 
purpose already, cartilage constructs based on human cells might provide 
additional data that could be more useful for human OA research. In addition, 
the influence of specific components on formation of ECM or chondrogenic 
differentiation could be studied using the model, for example through a 
knockdown approach using shRNA. As a specific example, it would be 
interesting to investigate the effect of various sulphotransferase knockdowns 
in chondrocytes. Sulphation of CS plays an important role in cartilage 
formation, and studies by Klüppel and colleagues found that knockdown of 
chondroitin-4-O-sulphotransferase 1 leads to severe chondrodysplasia 
(Klüppel et al. 2005). 
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 Stimulation of cartilage constructs with inflammatory factors 
alters the expression of genes involved in GAG chain synthesis 
Based on the work described above, sufficient amounts of cartilage constructs 
could be generated for the analysis of genes involved in protein glycosylation, 
with and without inflammatory stimulation. Microarray analysis was performed 
using a custom-designed chip (GlycoChipv4), detecting only genes relevant to 
glycosylation. Among the many interesting observations, the data showed that 
genes responsible for GAG chain synthesis were generally down-regulated in 
cartilage. However, it also showed that the proteoglycan serglycin was highly 
up-regulated after addition of inflammatory cytokines and that GalNAc4S-6ST 
expression was substantially increased, which is a sulphotransferase specific 
for CS chains. Both these findings were novel. This was a promising result 
because the GalNAc4,6diS modification was reported to have potent biological 
activity (Mizumoto et al. 2013; Ohtake-Niimi et al. 2010). Subsequent Q-PCR 
analysis confirmed the up-regulation of both proteins, and some data on 
protein expression, although preliminary, revealed interesting new 
observations.  
Further investigation should look at the purification of serglycin from 
conditioned medium of cartilage constructs. This would reveal changes 
associated with inflammatory stimulation, and the proteins could then be used 
to analyze the serglycin-specific GAG chain disaccharide composition. 
Serglycin contains a large amount of GAG chains and is therefore an 
interesting target to identify changes in GAG chain modification in response to 
inflammation. It would be interesting to see whether there is an increase in 
GalNAc4,6diS in one of its CS chains as a result of the up-regulation of 
GalNAc4S-6ST, or whether the modification is made on a CS chain of a 
different proteoglycan (e.g. aggrecan, decorin, or biglycan). Clearly, serglycin 
itself or an associated GAG epitope could be a new lead in the search for novel 
biomarkers for OA. However, further analysis on the potential of serglycin as 
a marker for OA needs to be carried out. For this, a sample bank containing 
synovial fluid, urine, and plasma from patients with joint disease is currently 
being assembled in our laboratory and could be utilized to identify serglycin or 
its GAG component in biological fluids. Furthermore, the link to and biological 
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role of GalNAc4,6diS in OA needs to be investigated. This might serve together 
with serglycin as a potential biomarker. However, an antibody which is specific 
for this particular sulphation motif would need to be developed. 
In conclusion, the results from the gene expression screening experiments 
provide novel insight into changes in glycosylation during inflammatory 
stimulation of cartilage, an area which is thus far under-investigated. 
 
 Stimulation of human skin fibroblasts with inflammatory cytokines 
leads to up-regulation of genes involved in CS chain synthesis 
Dermal constructs generated by human skin fibroblasts were stimulated with 
inflammatory cytokines similar to cartilage constructs. The reason why dermal 
constructs were chosen as a reference model to compare changes in gene 
expression with human cartilage was because these cells are also producing 
abundant extracellular matrix, but of a different type (mainly collagen type I). 
Similar to chondrocytes, they are also secreting proteoglycans and have 
therefore a similar repertoire of glycosyl- and sulphotransferases. In addition, 
the fibroblast model and protocols to isolate decorin, a proteoglycan of interest 
here, from culture media were already established in our laboratory. 
Microarray analysis showed that stimulation of dermal constructs with IL-1 
alone or in combination with OSM resulted in an increase in the expression of 
several glycosyltransferases involved in the elongation of CS/DS chains. 
Moreover, chondroitin-4-O-sulphotransferase 1 was up-regulated after 
addition of the cytokines. Both observations translated into corresponding 
changes in the decorin GAG chain as discussed below, thereby validating the 
gene expression screening approach for identification of changes in 
carbohydrate biosynthesis in response to cell stimulation. This was in contrast 
to the data obtained after cartilage construct inflammatory stimulation, where 
a general down-regulation of GAG chain synthesis was observed. The up-
regulation of GAG chain synthesis or increased length of GAG chains could 
play a role in wound healing as proposed by others (Kuwaba et al. 2001). The 
observation that the expression of glycosyl- and sulphotransferases in dermal 
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constructs was so different from the gene expression in chondrocytes points 
to an important and tissue-specific role of glycosylation during inflammation. 
 
 Decorin GAG chain composition varies between different cell 
types 
For the analysis of GAG chain composition, several HPLC analysis methods 
were evaluated for their sensitivity. Fluorescent labeling of disaccharides with 
2-aminoacridone (AMAC) (Deakin and Lyon 2008; A H Plaas et al. 2001; 
Jackson 1994; Kitagawa et al. 1995) followed by separation using reversed 
phase HPLC provided the highest sensitivity of about 10 pg per disaccharide. 
Decorin isolated from human skin fibroblast conditioned media was used as a 
model protein because it has a relatively simple structure containing a single 
CS/DS chain. In addition, the decorin CS/DS chain composition is sensitive to 
changes in cell metabolism (J Yan et al. 2011) and could therefore be a 
sensitive indicator for changes in GAG biosynthesis. Disaccharide analysis of 
decorin from different sources (skin fibroblasts, human chondrocyte progenitor 
cells, and recombinantly expressed by HEK293 cells) showed that the CS/DS 
chain composition varied between different cell types in line with previous 
reports (Laremore et al. 2010; Nomura 2006; Zhao et al. 2013). This highlights 
that the GAG chain is “tailored” within each tissue to suit its biological function, 
e.g. binding of growth factors (Seidler et al. 2005), cytokines (Tufvesson and 
Westergren-Thorsson 2002), or cell signaling (Schönherr et al. 2005; Santra 
et al. 2002). These results show that the composition of decorin’s CS/DS chain 
is highly versatile and is therefore a good model to investigate changes 
resulting from different stimuli, e.g. inflammatory conditions. 
 
 Decorin GAG chain length and disaccharide composition are 
changed by inflammatory cytokines 
By comparing the different decorin preparations, an increase in GAG chain 
length could be observed that was occurring in response to inflammatory 
stimulation of fibroblasts. This was in line with an increased expression of the 
CS chain polymerases ChGn and ChPF2.  
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Disaccharide analysis showed that also the composition of decorin’s CS/DS 
chain was altered after culturing cells in the presence of cytokines. Compared 
to untreated control, cytokine addition resulted in an increased amount of 
GalNAc4S and reduced amount of GalNAc6S and non-sulphated GalNAc. 
This could be a result of the observed increased expression of chondroitin-4-
O-sulphotransferase 1.  
These results demonstrate a direct link between changes in gene expression 
in a biosynthesis pathway and the respective end product at the protein level. 
In addition, they show that medium supplementation with IL-1 alone or 
together with OSM has a direct influence on the length and sulphation pattern 
of GAG chains. This opens up the possibility that specific sulphation motifs in 
GAG chains are generated as a consequence of inflammatory processes. 
These novel structures could be used for the generation of specific antibodies 
which would improve diagnosis of pathological conditions. Furthermore, 
additional research is required to investigate the role of altered GAG chain 
composition and its influence on the biochemical properties of the 
proteoglycan, for example facilitating growth factor binding or regulation of cell 
signaling pathways. An emerging body of evidence indicates that SLRPs like 
decorin or biglycan play an important role as signaling molecules in innate 
immunity (Frey et al. 2013). This would provide a better understanding on how 
cells are responding to an inflammatory environment. 
 
In conclusion, the work presented in this thesis has advanced knowledge first 
of all in the field of cartilage tissue engineering, demonstrating that a so far 
unexplored cell type known as chondrocyte progenitor cells is well suited for 
the formation of cartilaginous tissue when cultured in an optimized 
chondrogenic medium. In addition, the gene expression analysis of cartilage 
constructs stimulated with inflammatory cytokines showed that disease-
specific alterations in protein glycosylation are likely to exist.  
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Appendix II: Application to the Consortium of 
Functional Glycomics (microarray studies) 
 
Understanding inflammation-mediated changes in protein glycosylation 
in cartilage 
 
Context 
The Arthritis Research UK Centre of Excellence in Cardiff has been 
established to address the ‘big’ questions in joint disease. Osteoarthritis (OA) 
is the most common form of joint disease. However, diagnosis of OA is still 
confirmed by x-ray (or MRI), yet this detects gross structural changes, which 
occur late in the disease process, and there are no reliable diagnostic or 
prognostic biochemical markers that would enable early OA diagnosis or 
patient stratification. An OARSI/FDA consensus document [1] laid out the need 
for progress in this area and pointed out that developing new prognostic 
indicators will not only have an impact on patient diagnosis but is crucial for 
development of future disease modifying therapeutic agents.  
Background 
OA is no longer considered as mainly a degenerative disorder as it is 
associated with both local (synovial) and also low-level systemic inflammation 
[2]. For example, elevated levels of markers for inflammation such as AGE and 
HMGB1 were found in the synovium of the STR/ort mouse model of 
spontaneous OA and positively correlated with increased serum levels of IL-
1β [3]. We believe that disease-specific protein modifications are likely to 
provide a sensitive qualitative indicator of early OA as has been seen in various 
immune-mediated conditions including rheumatoid arthritis [4].  
Objective 
This project will analyse changes in the pattern of glycosylation of specific 
proteins with the aim of identifying signature patterns in the carbohydrate 
chains that characterize disease states and therefore can be used to develop 
biomarker assays. 
Outline 
A major problem in OA biomarker studies is patient-to-patient variability. To 
avoid this, we have established a human cartilage in vitro model. 
Chondroprogenitor cells were isolated from normal superficial zone knee 
cartilage [5]. These cells keep their chondrogenicity even after extensive 
expansion in monolayer [6]. Cells are seeded into transwells at high density in 
serum-free medium containing a cocktail of growth factors to induce 
differentiation, forming cartilage disks of 6 mm diameter and 1 mm height 
within 28 days. These constructs have biomechanical properties similar to 
articular cartilage explants. This approach allows us to produce a large number 
of samples in a reproducible way for experimental manipulation. 
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The glyco-chip provided by the CFG is optimally suited to identify changes in 
gene expression of enzymes that play a role in posttranslational modification 
during protein biosynthesis. Constructs have been treated with inflammatory 
cytokines to mimic OA conditions or were left untreated. Total RNA from 
multiple samples was pooled and the experiment repeated 3 times. 
Additionally, we have selected an unrelated tissue model in which 
proteoglycans we are particularly interested in are expressed. This model was 
treated with the same cytokine regimen as the cartilage model. The purpose 
is to differentiate the changes that are a generic response to the cytokine 
challenge from those which are a cartilage-specific response. In total, our 
experimental setup therefore requires 18 microarrays (2 tissues, 3 conditions, 
3 replicates). Differential expression of selected proteins as identified in 
microarray analysis will subsequently be confirmed in tissue from OA patients. 
Based on the identified altered expression of enzymes we can subsequently 
analyze carbohydrates for specific structural changes in a targeted fashion 
using a mass-spectrometry-based micro sequencing approach [7]. 
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